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Mesenchymal	  stem	  cells	  (MSCs)	  are	  multipotent	  stromal	  stem	  cells	  with	  the	  capacity	  to	  differentiate	  
into	  mesodermal	  lineages	  and	  immunomodulatory	  properties.	  MSCs	  have	  been	  isolated	  from	  several	  
fetal	   and	   adult	   tissue	   sources	   with	   some	   distinct	   phenotypic	   and	   functional	   profiles.	   The	   clinical	  
benefits	   exerted	   by	   MSCs	   upon	   transplantation	   are	   due	   to	   the	   release	   of	   paracrine	   factors	   and	  
biologically	   relevant	   molecules	   to	   the	   diseased	   or	   injured	   tissue.	   The	   so-­‐called	   MSC	   secretome	  
influences	   the	   microenvironement	   following	   injury,	   promoting	   endogenous	   regeneration	   of	   the	  
injured	  tissue	  environment	  via	  cytoprotection	  and	  angiogenesis.	  Therefore,	  the	  interest	  in	  MSCs	  for	  
clinical	  applications	  has	  constantly	  increased	  over	  the	  last	  decade,	  mainly	  for	  cell-­‐based	  therapies	  but	  
also	   for	   cardiovascular	   tissue	   engineering.	   Here,	   the	   combination	   of	   MSCs	   with	   biodegradable	  
scaffold	  materials	  enables	  enhanced	  extracellular	  matrix	  production	  and	  in	  vivo	  tissue	  formation.	  
In	  the	  presented	  thesis,	  different	  human	  and	  animal-­‐derived	  MSCs	  were	  isolated	  and	  characterized.	  
Human	   adult	  MSCs	   from	   the	   adipose	   tissue	   (hADSCs),	   bone	  marrow	   (hBMSCs)	   and	   umbilical	   cord	  
Wharton’s	   jelly	   (hWJSCs)	   demonstrated	   distinct	   chemoattractive	   and	   angiogenic	   potential.	   Mass	  
spectrometry	   analyses	   revealed	   that	   hBMSC	   and	   hWJSC	   secretome	   possess	   a	   more	   retained	   pro-­‐
angiogenic	  and	  inflammatory	  profile	  compared	  to	  hADSCs.	  On	  the	  other	  hand,	  fetal	  MSCs	  from	  the	  
amniotic	   fluid	   (AFSCs)	  were	   evaluated	   in	   the	   ovine	   developmental	  model,	  which	   uniquely	   enables	  
investigation	   of	   prenatal	   cells.	   In	   contrast	   to	   humans	   the	   ovine	   model	   maintains	   two	   separate	  
extraembryonic	  cavities,	  the	  amniotic	  and	  the	  allantoic	  fluid	  cavity.	  Therefore,	  several	  parameters	  for	  
discrimination	   of	   the	   two	   fetal	   fluids	   over	   gestation	   have	   been	   defined	   and	   isolated	   cells	   were	  
systematically	  compared.	  Higher	  expression	  of	  pluripotency-­‐related	  genes	  was	  found	  in	  ovine	  AFSCs	  
compared	   to	   cells	   isolated	   from	   the	   allantoic	   fluid,	   pointing	   toward	   a	  more	   pronounced	   stem	   cell	  
phenotype.	  Finally,	  new	  scaffolds	  for	  cardiovascular	  tissue	  engineering	  applications	  were	  evaluated.	  
A	   jet	  spinning	  process	   for	   the	  rapid	  and	  automated	   fabrication	  of	   fibrous	  heart	  valve	  scaffolds	  was	  
established.	  Tissue	  engineered	  heart	  valves	  were	  minimally-­‐invasively	  deployed	  into	  the	  pulmonary	  
valve	   position	   in	   the	   ovine	  model	   and	   shown	   to	   be	   functional	   for	   15	   hours.	   However,	   the	   in	   situ	  
remodeling	  was	  shown	  to	  be	  low	  in	  long-­‐term	  follow	  up.	  Therefore	  the	  incorporation	  of	  either	  MSCs	  






Mesenchymale	   Stammzellen	   (MSCs)	   sind	  multipotente	   Stammzellen	   des	   Bindegewebes,	   welche	   in	  
verschiedene	  mesodermale	  Gewebe	  differenzieren	  können	  und	  immunomodulierende	  Eigenschaften	  
besitzen.	  MSCs	  können	  aus	  verschiedenen	  fetalen	  und	  adulten	  Gewebequellen	   isoliert	  werden,	  mit	  
jeweils	  unterschiedlichen	  phänotypischen	  und	  funktionellen	  Merkmalen.	  Die	  klinischen	  Vorteile	  nach	  
MSC	  Transplantation	  beruhen	  auf	  der	  Freisetzung	  von	  parakrinen	  Faktoren	  und	  biologisch	  relevanten	  
Molekülen,	  welche	  auf	  das	  erkrankte	  oder	  verletzte	  Gewebe	  Einfluss	  ausüben.	  Das	  sogenannte	  MSC	  
Sekretom	   beeinflusst	   die	   Mikroumgebung	   nach	   Verletzung	   und	   fördert	   die	   körpereigene	  Wieder-­‐
herstellung	   des	   verletzten	   Gewebes	   durch	   Zellschutz	   und	   der	   Bildung	   neuer	   Blutgefässe	   (Angio-­‐
genese).	  Dementsprechend,	  stieg	  das	  Interesse	  an	  MSCs	  für	  die	  klinische	  Anwendung	  in	  den	  letzten	  
Jahrzehnten	   stetig,	   insbesondere	   für	   Zelltherapie	   aber	   auch	   für	   die	   kardiovaskuläre	   Gewebe-­‐
rekonstruktion	   (Tissue	   Engineering).	   Hierbei,	   stellt	   die	   Kombination	   aus	   MSCs	   und	   biologisch	  
abbaubarem	  Zellträger	  (Scaffold)	  eine	  Möglichkeit	  dar	  die	  Produktion	  von	  extrazellulärer	  Matrix	  und	  
Gewebebildung	  in	  vivo	  zu	  fördern.	  
In	  der	   folgenden	  Arbeit	  wurden	   verschiedene	  MSCs	   von	  Mensch	  bzw.	  dem	  Tiermodell	   isoliert	   und	  
charakterisiert.	   Humane	   adulte	  MSCs	   vom	   Fettgewebe	   (hADSCs),	   Knochenmark	   (hBMSCs)	   und	   der	  
Wharton-­‐Sulze	   der	   Nabelschnur	   (hWJSCs)	   zeigten	   unterschiedliches	   Potential	   hinsichtlich	   Chemo-­‐
attraktion	  und	  Angiogenese.	  Massenspektrometrie	   zeigte	  deutlich,	  dass	  die	  Sekretome	  von	  hBMSC	  
und	   hWJSC	   im	   Vergleich	   zu	   hADSC	   ein	   stärker	   ausgeprägtes	   pro-­‐angiogenes	   und	   entzündliches	  
Potential	  aufweisen.	  Zudem	  wurden	  die	  fetalen	  MSC	  vom	  Fruchtwasser	  (AFSC)	  im	  fetal	  Schafmodell	  
untersucht.	  Im	  Gegensatz	  zum	  Menschen	  verbleiben	  im	  Schafmodell	  zwei	  separate	  extraembryonale	  
Flüssigkeitsräume,	  das	  Fruchtwasser	  und	  die	  Allantois-­‐Kavität.	  Es	  wurden	  Parameter	  zur	  spezifischen	  
Diskriminierung	  der	  zwei	   fetalen	  Flüssigkeiten	  während	  der	  Schwangerschaft	  analysiert	  und	  dessen	  
Zellen	   systematisch	   charakterisiert.	   Ovine	   AFSC	   zeigten	   im	   Gegensatz	   zu	   Zellen	   aus	   der	   Allantois-­‐
Flüssigkeit	   eine	   erhöhte	   Expression	   von	   mehreren	   Pluripotenz-­‐assoziierten	   Genen,	   was	   auf	   einen	  
stärker	  ausgeprägten	  Stammzell-­‐Phänotyp	  schliessen	  lässt.	  Zudem	  wurde	  ein	  neuer	  Scaffold	  für	  das	  
kardiovaskuläre	  Tissue	  Engineering	  untersucht.	  Ein	  Gerät	  für	  die	  schnelle,	  automatisierte	  Herstellung	  
von	  Herzklappengeweben	  wurde	  entwickelt.	  Tissue	  engineerte	  Herzklappen	  wurden	  minimal	  invasiv	  
in	   die	   pulmonale	   Position	   des	   Schafmodels	   implantiert	   und	   zeigten	   15	   Stunden	   Funktionalität.	  
Allerdings,	  war	  der	  in	  situ	  Gewebeumbau	  langfristig	  niedrig.	  Jedoch	  könnte	  die	  Einarbeitung	  von	  den	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  matrix	  	   ECM	   poly(glycerol	  sebacate)	   	   PGS	  
endothelial-­‐to-­‐mesenchymal	  transformation	  	   EMT	   placental	  growth	  factor	   	   PIGF	  
embryonic	  stem	  cell	   ESC	   poly(lactic	  acid)	   	   PLA	  
food	  and	  drug	  administration	   FDA	   region	  of	  interest	   	   ROI	  
false	  discovery	  rate	   FDR	   stromal	  cell-­‐derived	  growth	  factor	   	   SDF	  
fibroblast	  growth	  factor	   FGF	   scanning	  electron	  microscopy	  	   	   SEM	  
fourier	  transform	  infrared	  spectroscopy	   FTIR	   smooth	  muscle	  cell	   	   SMC	  
good	  manufacturing	  practice	   GMP	   tissue	  engineering	   	   TE	  
generation	  time	   GT	   tissue	  engineered	  heart	  valve	  	   	   TEHV	  
graft-­‐versus-­‐host	  disease	   GVHD	   tissue	  engineered	  venous	  valve	  	   	   TEVV	  
hematoxylin	  and	  eosin	  	   H&E	   transforming	  growth	  factor	  beta	   	   TGF-­‐β	  
hexfluoroispropanol	  	   HFIP	   tumor	  necrosis	  factor	  alpha	   	   TNF-­‐α	  
hepatocyte	  growth	  factor	   HGF	   total	  protein	   	   TP	  
human	  leucocyte	  antigen-­‐DR	   HLA-­‐DR	   thrombospondin-­‐1	   	   Tsp-­‐1	  
human	  peripheral	  mononuclear	  cells	   hPBMC	   upper	  control	  limit	  	   	   UCL	  
human	  platelet	  lysate	   hPL	   vascular	  endothelial	  growth	  factor	   	   VEGF	  
human	  umbilical	  vein	  endothelial	  cells	   HUVEC	   von	  giesson-­‐elastin	   	   VG-­‐EL	  
interferon	  gamma	   IFN-­‐γ	   valvular	  interstitial	  cell	  	   	   VIC	  
insulin	  growth	  factor	   IGF	   von	  kossa	   	   VK	  
interleukin	   IL	   Wharton's	  jelly	  derived	  MSC	   	   WJSC	  
induced	  pluripotent	  stem	  cell	   iPSC	   alpha	  smooth	  muscle	  actin	   	   αSMA	  
international	  society	  for	  cellular	  therapy	   ISCT	   β-­‐tricalcium	  phosphate	   	   β-­‐TCP	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Valvular	  heart	  disease	  remains	  to	  be	  a	  major	  cause	  of	  death	  worldwide	  with	  increasing	  prevalence,	  
mortality,	   and	  morbidity.	   Current	   heart	   valve	   replacements	   are	   associated	  with	   several	   limitations	  
due	  to	  their	  nonviable	  nature.	  In	  this	  regard,	  heart	  valve	  tissue	  engineering	  has	  shown	  to	  represent	  a	  
promising	  concept	   in	  order	  to	  overcome	  these	   limitations	  and	  replace	  diseased	  cardiac	  valves	  with	  
living,	   autologous	   constructs.	   These	   bioengineered	   valves	   hold	   potential	   for	   in	   situ	   remodeling,	  
growth,	   and	   repair	   throughout	   the	   patient's	   lifetime	   without	   the	   risk	   of	   thromboembolic	  
complications	  and	  adverse	  immune	  responses.	  For	  the	  fabrication	  of	  tissue-­‐engineered	  heart	  valves,	  
several	   concepts	  have	  been	  established,	   the	   "classical"	   in	   vitro	   tissue	  engineering	  approach,	   the	   in	  
situ	   tissue	   engineering	   approach,	   and	   alternative	   approaches	   including	   three-­‐dimensional	   printing	  
and	   electrospinning.	   Besides	   first	   attempts	   have	   been	   conducted	   in	   order	   to	   produce	   a	   tissue-­‐
engineered	  venous	  valve	  for	  the	  treatment	  of	  deep	  venous	  valve	  insufficiency.	  Here	  we	  review	  basic	  
principals	   and	   current	   scientific	   status	   of	   valvular	   tissue	   engineering,	   including	   a	   critical	   discussion	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Valvular	  heart	  disease	   is	  responsible	  for	  a	  high	  disease	   load	  worldwide,	  affecting	  people	  of	  all	  ages	  
and	   origins.	   In	   industrialized	   countries	   increasing	   aging	   of	   the	   population	   is	   the	   major	   cause	   of	  
degenerative	  valve	  disease,	  while	  in	  developing	  countries	  the	  problem	  of	  rheumatic	  cardiac	  diseases	  
is	   still	   prevalent,	   resulting	   in	   increased	   mortality	   and	   morbidity	   each	   year	   1,2.	   Although	   medical	  
progress	  has	  been	  outstanding	  over	   the	  past	   few	  decades,	   the	  annual	  number	  of	  people	   requiring	  
heart	   valve	   replacements	   is	   expected	   to	   triple	   globally	   from	   currently	   approximately	   290,000	  
interventions	  per	  year	  to	  850,000	  in	  2050	  2.	  
Surgical	  replacement	  of	  the	   insufficient	  valves	   is	  the	  most	  commonly	  used	  treatment	  for	  end	  stage	  
valvular	   heart	   disease.	   Nowadays,	   either	   mechanical	   or	   biological	   prostheses	   are	   used	   for	   the	  
replacement	   of	   dysfunctional	   valves.	   Although	   dramatically	   improving	   the	   life	   expectancy	   of	   the	  
patients	   all	   currently	   available	   prostheses	   are	   associated	  with	   substantial	   limitations	   including	   the	  
principal	   lack	   of	   growth,	   repair	   and	   remodeling	   capacities.	   The	   non-­‐adaptive	   non-­‐viable	  materials	  
show	  substantial	  surface	  thrombogenicity	  (mechanical	  valves)	  and	  progressive	  calcific	  degeneration	  
(bioprostheses).	   Lifelong	   anticoagulation	   therapies	   and	   repeated	   reoperations	   are	   therefore	  
indispensable,	  especially	  for	  pediatric	  applications.	  
Besides	   also	   chronic	   venous	   insufficiency	   (CVI)	   represent	   a	   major	   global	   health	   problem	   with	  
increasing	   prevalence,	   morbidity	   and	   socioeconomic	   impact	   3.	   Over	   long	   term,	   increased	   blood	  
pressure	  within	  the	  lower	  extremities	  and	  venous	  return	  to	  the	  heart	   is	   impaired.	  This	  results	  from	  
valvular	  incompetence,	  perforated	  veins,	  venous	  tributaries,	  venous	  obstruction	  or	  a	  combination	  of	  
theses	  mechanisms	  3.	  Insufficient	  valves	  are	  associated	  with	  venous	  blood	  reflux,	  obstruction,	  stasis	  
and	   distal	   venous	   hypertension	   3.	   As	   in	   the	   cardiac	   field	   current	   therapeutic	   applications	   are	  
suboptimal	  with	  short	  lasting	  results	  using	  palliative	  conventional	  techniques	  and	  highly	  invasive	  vein	  
reconstructions.	  Recently	  bioprosthesis	  have	  been	  investigated,	  so	  far	  with	  no	  success	   in	   long-­‐term	  
evaluations	  4.	  
Taken	  together,	  current	  prostheses	  for	  valvular	  disease	  are	  suboptimal	  and	  new	  approaches	  need	  to	  
be	  considered	  as	  alternative	  therapies.	  In	  this	  regard,	  tissue	  engineering	  has	  shown	  promising	  results	  
by	   creating	   bioengineered,	   living	   autologous	   replacements	   with	   the	   ability	   for	   somatic	   growth,	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1.1.2	  BASIC	  PRINCIPLE	  OF	  HEART	  VALVE	  TISSUE	  ENGINEERING	  
Tissue	   engineering	   is	   an	   emerging	   field	   of	   research	   with	   the	   goal	   to	   improve	   and/or	   restore	  
tissue/organ	  functionality	  via	  the	  development	  of	  engineered,	  living	  substitutes.	  Several	  strategies	  of	  
heart	  valve	   tissue	  engineering	  have	  been	   followed:	   the	   in	  vitro	   and	   the	   in	   situ	   approach	  as	  well	  as	  
alternative	   approaches	   including	   three-­‐dimensional	   (3D)	   printing	   and	   electrospinning.	   For	   the	  
traditional	   in	   vitro	   approach,	   autologous	   cells	   are	   isolated	   from	   individual	   patients,	   seeded	   onto	  
biodegradable	   scaffolds,	   pre-­‐conditioned	   and	   matured	   in	   a	   bioreactor	   system	   to	   induce	   native-­‐
analogous	  neo-­‐tissue	  formation	  ex	  vivo,	  followed	  by	  implantation	  of	  a	  living,	  autologous	  engineered	  
valve	   into	   the	   diseased	  patients.	   This	   strategy	   is	   referred	   to	   as	   in	   vitro	   tissue	   engineering	   and	  has	  
been	  the	  principal	  experimental	  approach	  for	  heart	  valve	  tissue	  engineering	  over	  the	  last	  years.	  The	  
second	   approach,	   referred	   to	   as	   in	   situ	   tissue	   engineering,	   aims	   at	   stimulating	   the	   bodies	   own	  
regenerative	  capacity	  in	  order	  to	  induce	  tissue	  formation	  in	  vivo	  (in	  situ),	  instead	  of	  generating	  tissue	  
ex	   vivo.	   Although	   the	   design	   of	   the	   scaffold	   and	   the	   potential	   seeding	   of	   isolated	   cells	   are	   still	  
performed	  ex	  vivo,	  no	  extensive	  and	  regulatory	  complex	  in	  vitro	  cell	  expansion	  and	  conditioning	  in	  a	  
bioreactor	   system	   are	   required	   prior	   to	   implantation.	   This	   approach	   is	   taking	   advantage	   of	   the	  
intrinsic	  regenerative	  potential	  of	  the	  body	  itself	  inducing	  autologous	  host	  cell	  repopulation	  followed	  
by	   tissue	   remodeling	   and	   potentially	   regeneration	   and	   growth.	   It	   represents	   a	   simplified	   strategy,	  
without	  the	  need	  of	  extensive	   in	  vitro	  cell	  expansion	  techniques.	  Using	  this	  approach	  higher	  clinical	  
feasibility	   of	   the	   tissue	   enginnered	   heart	   valve	   (TEHV)	   technology	   seems	   possible.	   Cell-­‐mediated	  
leaflet	  thickening,	  retraction	  and	  fibrosis	  induced	  by	  the	  mechanical	  conditioning	  of	  the	  seeded	  cells	  
in	  the	  bioreactor	  might	  be	  circumvented	  and	  in	  vitro	  cellular	  manipulation	  reduced	  5.	  However	  it	  is	  of	  
note	  that	  this	  approach	  substantially	  depends	  on	  the	  regenerative	  capacity	  of	  the	  host,	  which	  might	  
be	  a	  critical	  issue	  in	  patients	  with	  metabolic	  diseases	  or	  immunologic	  defects.	  Therefore	  over	  the	  last	  
years	  great	  effort	  has	  been	  made	  in	  the	  inclusion	  of	  bioactive	  compounds	  into	  the	  scaffolds	  to	  guide	  
in	  situ	  tissue	  remodeling.	  In	  this	  regard	  the	  development	  of	  novel	  simplified	  and	  fast(er)	  technologies	  
have	   been	   intensively	   studied.	   3D-­‐printing	   and	   electrospinnig	   with	   their	   different	   settings	   and	  
modalities	  enable	  to	  approximate	  the	  constructs	  to	  the	  requirements	  of	  the	  ideal	  valvular	  substitute	  
on	  the	  macro-­‐	  to	  microscopic	   level	  –	   including	  an	   ideal	  heart	  valve	  anatomy	  and	  bioactivity.	   Ideally	  
the	  release	  of	  bioactive	  molecules	  is	  coupled	  with	  the	  degradation	  of	  the	  polymer	  fibers,	  while	  new	  





Figure	  1:	  Main	   strategies	  of	  heart	   valve	   tissue	  engineering.	   (B)	  The	  concept	  of	   in	  vitro	  heart	  valve	  tissue	  engineering	  compromises	  the	  
harvest	  of	  autologous	  cells	  from	  the	  patient	  which	  are	  subsequently	  expanded	  to	  high	  cell	  numbers	  in	  vitro	  (1),	  seeded	  onto	  biodegradable	  
scaffolds	   (2)	  and	  conditioned	   in	  a	  bioreactor	  system	   (3).	  After	  3-­‐4	  weeks	  new	  tissue	  has	   formed	  and	  the	   tissue	  engineered	  heart	  valves	  
(TEHV)	  (4)	  can	  be	  implanted	  into	  the	  particular	  patient	  (5).	  (A)	  In	  order	  to	  store	  TEHV,	  the	  concept	  of	  decellularization	  enables	  the	  removal	  
of	  cellular	  components	  by	  detergent	  solutions	  (6)	  to	  create	  decellularized	  starter	  matrices	  (7)	  with	  long-­‐term	  availability	  (8).	  These	  off-­‐the-­‐
shelf	  constructs	  can	  subsequently	  be	  implanted	  (9)	  for	  the	  in	  situ	  host	  cell	  repopulation.	  (C)	  This	  concept	  of	  in	  situ	  tissue	  engineering	  takes	  
advantage	  of	  the	  intrinsic	  remodeling	  capacity	  of	  the	  body.	  The	  implantation	  of	  starter	  matrices	  triggers	  autologous	  host	  cell	  recruitment,	  
vascular	  remodeling	  and	  tissue	  formation	  in	  vivo	  (10).	  (D)	  By	  seeding	  bone	  marrow	  mononuclear	  cells	  (BMMCs)	  onto	  such	  starter	  matrices	  
the	  intrinsic	  remodeling	  capacity	  of	  the	  body	  can	  be	  further	  enhanced.	  Therefore,	  bone	  marrow	  is	  obtained	  by	  sternal	  puncture	  at	  the	  day	  
of	  implantation	  (11),	  BMMCs	  are	  isolated	  by	  density	  gradient	  centrifugation	  (12,13)	  and	  seeded	  onto	  heart	  valve	  starter	  matrices	  (14).	  
	  
1.1.2.1	  IN	  VITRO	  HEART	  VALVE	  T	  ISSUE	  ENGINEERING	  –	  CURRENT	  STATUS	  
The	  requirements	   for	  an	   in	  vitro	   tissue	  engineered	  heart	  valve	  compromise	   I)	  an	  autologous,	  easily	  
accessible	  cell	   source,	   II)	  a	  biodegradable	  scaffold	  material,	  designed	   in	  the	  shape	  of	  a	  heart	  valve,	  
and	   III)	   an	   in	   vitro	   bioreactor	   system	   for	   the	   mechanical	   and	   biochemical	   conditioning	   of	   the	  
construct.	   The	   quality	   of	   the	   tissue	   depends	   highly	   on	   the	   individual	   cell	   source	   chosen.	   In	   the	  
attempt	   to	   define	   the	   best	   suitable	   cell	   source,	   characteristics	   like	   their	   expansion	   potential,	   their	  
capability	   to	   produce	   extracellular	   matrix	   (ECM)	   and	   their	   regenerative	   potential	   are	   of	   critical	  
importance.	   Therefore,	   several	   promising	   cell	   sources	   isolated	   from	   different	   donor	   tissues	   have	  
already	  been	  used	  for	  the	  in	  vitro	  generation	  of	  TEHV	  such	  as	  adipose	  tissue-­‐derived	  cells	  6,	  amniotic	  
fluid-­‐derived	   cells	   7,8,	   bone	  marrow-­‐derived	   cells	   9-­‐11,	   chorionic	   villi-­‐derived	   cells	   12,	   umbilical	   cord-­‐
derived	  cells	  13,14	  and	  dermal	  fibroblasts	  15.	  In	  particular,	  vascular	  myofibroblasts	  and	  endothelial	  cells	  
(ECs)	   have	   been	   used	   for	   the	   fabrication	   of	   TEHV.	   After	   in	   vitro	   expansion	   of	   these	   cells	   to	   high	  
numbers,	   myofibroblasts	   are	   seeded	   on	   fully	   degradable	   scaffold	   materials	   –	   either	   synthetic	   or	  
natural	   –	   in	   its	   particular	   design.	   Ideally,	   scaffold	   materials	   must	   be	   biocompatible,	   supporting	  
cellular	  ingrowth	  and	  interaction	  for	  the	  formation	  of	  a	  continuous	  tissue	  layer,	  and	  biodegradable,	  
allowing	   for	   cellular	   expansion	   and	   matrix	   formation	   while	   the	   extrinsic	   material	   is	   gradually	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degraded.	  Seeded	  scaffolds	  are	  firstly	  pre-­‐incubated	  under	  static	  conditions	  before	  they	  are	  placed	  
into	  a	  bioreactor	  system	  for	  mechanical	  conditioning	  through	  pulsatile	  flow	  and	  pressure	  gradients.	  
These	  physiological	  conditions	  are	  responsible	  for	  the	  production	  of	  ECM	  from	  the	  seeded	  cells	  and	  
therefore	  ultimately	  enhance	  neotissue	  formation	  in	  vitro.	  Finally	  the	  constructs	  are	  seeded	  with	  ECs	  
to	  prevent	  thrombogenicity	  and	  resemble	  a	  native-­‐like	  structure	  with	  a	  confluent	  luminal	  EC	  layer.	  At	  
this	  point	  the	  constructs	  are	  ready	  for	  implantation.	  This	  technology	  has	  been	  investigated	  by	  several	  
independent	  studies.	  Its	  principle	  feasibility	  has	  been	  demonstrated	  for	  the	  first	  time	  in	  1995	  with	  an	  
in	  vitro	  engineered	  single	  pulmonary	  leaflet	  implanted	  into	  a	  lamb	  model	  16.	  Since	  then,	  the	  creation	  
of	  a	  complete	  trileaflet	  TEHV	  based	  on	  synthetic	  scaffold	  material	  has	  shown	  to	  be	  feasible	  17,18,	  with	  
in	  vivo	  functionality	  up	  to	  120	  days	  19	  and	  the	  ability	  of	  in	  vivo	  growth	  and	  remodeling	  20.	  Significant	  
increase	  in	  diameter	  and	  length	  demonstrated	  the	  ability	  of	  tissue-­‐engineered	  constructs	  to	  grow	  20.	  	  
Besides	  the	  use	  of	  vascular	  derived	  cells,	  several	  different	  stem	  cells	  have	  been	  investigated	  for	  their	  
use	   in	   tissue	  engineering	  approaches.	   In	  particular,	  mesenchymal	  stem	  cells	   (MSCs)	  have	  shown	  to	  
be	  an	  attractive	   alternative	   cell	   source	  due	   to	   their	   unique	   characteristics	   including	   I)	  multilineage	  
differentiation	   potential,	   II)	   extensive	   in	   vitro	   proliferation,	   III)	   privileged	   immunological	  
characteristics,	  and	  IV)	  paracrine	  mechanisms	  inducing	  host	  cell	  recruitment.	  In	  direct	  comparison	  to	  
vascular	  derived	  cells	   there	   is	  no	  need	  to	  sacrifice	   intact	  vascular	  tissue.	  MSCs	  are	  easily	  accessible	  
via	  low	  risk	  procedures	  in	  a	  wide	  variety	  of	  tissues,	  including	  tissues	  of	  fetal	  origin.	  This	  makes	  them	  
suitable	   for	   pediatric	   in	   vitro	   heart	   valve	   tissue	   engineering	   that	   aims	   at	   the	   fabrication	   of	   an	  
autologous,	  growing	  heart	  valve	  for	  the	  repair	  of	  congenital	  malformations	  prior	  to	  birth	  21.	  Besides	  
the	   use	   of	   the	  most	   frequent	   synthetic	   biomaterials	   including	   poly(glycolic	   acid)	   (PGA),	   poly(lactic	  
acid)	  (PLA),	  poly(ε-­‐caprolactone)	  (PCL)	  and	  poly(4-­‐hydroxybutyrate)	  (P4HB),	  also	  natural	  biomaterials	  
such	   as	   collagen	   and	   fibrin	   have	   been	   widely	   used	   in	   TE	   applications.	   Fibrin-­‐based	   heart	   valves	  
seeded	   with	   ovine	   carotid	   artery-­‐derived	   cells	   in	   an	   ovine	   model	   showed	   remarkable	   tissue	  
remodeling	  22,23.	  Even	  augmented	  collagen	  production	  and	  enhanced	  retention	  of	  glycoaminoglycans	  
within	  the	  developing	  ECM	  were	  detected	  by	  the	  use	  of	  fibrin	  in	  TEHV	  24.	  Recently,	  fibrin-­‐based	  heart	  
valve	  with	  a	  tubular	  leaflet	  design	  have	  been	  reported	  as	  an	  alternative	  to	  the	  conventional	  design	  of	  
TEHV	  25,	  including	  their	  principal	  feasibility	  for	  minimally	  invasive	  implantation	  techniques	  using	  self-­‐






Figure	  2:	  In	  vitro	  tissue	  engineered	  heart	  valves.	  (A)	  Distal	  view	  of	  a	  TEHV	  based	  on	  vascular-­‐derived	  cells.	  (B)	  The	  crimped	  TEHV,	  integrated	  
into	   a	   nitinol	   stent	   (b),	   is	   loaded	   into	   the	   delivery	   system	   and	   inserted	   transapically	   into	   the	   right	   ventricle	   (a).	   Deployment	   into	   the	  
pulmonary	  position	  is	  conducted	  by	  slowly	  advancing	  the	  inner	  pusher	  (c)	  into	  the	  sheath	  system	  (d).	  Adapted	  and	  reprinted	  from	  Schmidt	  
et	  al.,	  2010.	  
	  
However	   as	   the	   process	   of	   in	   vitro	   tissue	   engineering	   is	   logistically	   complex	   and	   highly	   time	  
consuming,	  the	  establishment	  of	  new	  strategies	  where	  heart	  valves	  could	  be	  provided	  with	  unlimited	  
supply	   at	   every	   required	   time	   point	   have	   been	   initiated.	   In	   this	   regard,	   the	   removal	   of	   cellular	  
components	   by	   combinations	   of	   detergents	   and	   biological	   agents	   results	   in	   cell-­‐derived	   starter	  
matrices	  composed	  of	  ECM	  and	  proteins.	  Minimal	  criteria	  for	  effective	  decellularization	  consist	  of	  I)	  
<50	  ng	   dsDNA/mg	   ECM	   (dry	  weight),	   II)	   <200	  bp	  DNA	   fragment	   length,	   and	   III)	   the	   lack	   of	   nuclear	  
material	   in	   histological	   sections	   (e.g	   H&E	   and	   DAPI)	   27.These	   homologous	   decellularized	   starter	  
matrices	   are	   subsequently	   implanted	   for	   the	   in	   situ	   host	   cell	   repopulation.	   The	   decellularization	  
process	   counteracts	   acute	   rejection	   of	   the	   implant	   by	   reducing	   the	   immune	   response.	   The	   use	   of	  
allogeneic	   and	   xenogenic	   decellularized	   heart	   valves	   has	   been	   reported	   with	   long	   term	   animal	  
models	   28-­‐30	   and	   commercially	   available	   heart	   valve	   substitutes,	   including	   the	   allograft	   Cryolife’s	  
SynerGraft	   ®	   or	   xenografts	   AutoTissue	   GmbH	  Matrix	   P	   plus	   NTM,	  with	   highly	   variable	   efficacy	   and	  
outcomes.	   These	   initial	   investigations	   have	   led	   to	   the	   combination	   of	   in	   vitro	   tissue	   engineering	  
strategies	  with	  decellularization	  techniques.	  Such	  decellularized	  TEHV	  (dTEHV)	  have	  shown	  principal	  
feasibility	  in	  different	  animal	  models	  including	  non-­‐human	  primate	  31	  and	  ovine	  models	  15,32,33,	  either	  
using	  synthetic	  PGA/P4HB	  31,33	  or	  natural	  fibrin	  gels	  in	  a	  tubular	  design	  15,32.	  Interestingly	  dTEHV	  have	  
shown	   to	   exhibit	   reduced	   risk	   of	   insufficiency	   through	   leaflet	   retraction,	   cellular	   repopulation	   and	  
matrix	   remodeling.	   Nevertheless,	   further	   enhancement/guidance	   of	   the	   leaflet	   recellularization	  
seems	   crucial	   to	   prevent	   adverse	   remodeling	   and	   provide	   adequate	   long-­‐term	   functionality	   of	   the	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1.1.2.2	  IN	  SITU	  HEART	  VALVE	  TISSUE	  ENGINEERING	  –	  CURRENT	  STATUS	  
In	  situ	  tissue	  engineering	  holds	  great	  promise	  due	  to	  the	  simplified	  fabrication	  protocols	  and	  reduced	  
immunogenicity.	   As	   scaffolds	   are	   directly	   implanted	   without	   any	   prior	   in	   vitro	   incubation,	   this	  
involves	   benefits	   such	   as	   no	   extensive	   in	   vitro	   cell	   expansion	   and	   manipulation	   as	   well	   as	   no	  
conditioning	   of	   the	   constructs	   in	   a	   bioreactor	   requiring	   complex	   infrastructure	   and	   logistics	   (also	  
involving	   time	  consuming	   regulatory	  approvals).	  The	  principal	   strategy	  of	   in	   situ	   tissue	  engineering	  
aims	  at	   implantation	  of	  a	  cell-­‐seeded	   ‘starter	  matrix’	   that	   triggers	  autologous	  host	  cell	   recruitment	  
with	  subsequent	  vascular	  remodeling/tissue	  formation	  in	  vivo.	  
In	   1999,	   the	   in	   situ	   tissue	   engineering	   approach	   has	   been	   used	   for	   a	   first	   in-­‐man	   trial	   for	   tissue	  
engineered	  grafts,	  where	  human	  cells	  harvested	   from	   the	  peripheral	   vein	  were	  directly	   seeded	  on	  
synthetic	   PCL	   reinforced	  with	  woven	   PGA	   and	   implanted	   successfully	   34.	   In	   2011,	   clinical	   trials	   for	  
tissue	  engineered	  vascular	  grafts	  have	  been	  initiated	  in	  the	  U.S.	  35	  using	  the	  in	  situ	  tissue	  engineering	  
approach.	  This	  milestone	   in	   the	   field	  of	  cardiovascular	   tissue	  engineering	  raised	  great	  hope	  for	   the	  
extrapolation	   of	   this	   concept	   to	   the	  more	   complex	   field	   of	   heart	   valve	   tissue	   engineering.	   At	   the	  
same	   time,	   this	  procedure	  was	   introduced	   to	   the	   field	  of	  heart	   valve	   in	   situ	   tissue	  engineering.	   Its	  
principal	   feasibility	  has	  been	  shown	   in	  a	  non-­‐human	  primate	  model	   34,36	  as	  well	  as	   in	   the	  adult	   37,38	  
and	   fetal	   39	   sheep	   model.	   In	   particular,	   scaffolds	   pre-­‐seeded	   with	   autologous	   bone	   marrow	  
mononuclear	  cells	  (BMMCs)	  have	  shown	  to	  enhance	  in	  situ	  remodeling.	  A	  higher	  cellularity	  indicative	  
for	   an	   early	   cellular	   infiltration	   in	   the	   acute	   phase,	   followed	   by	   enhanced	   layered,	   endothelialized	  
tissue	   formation	   on	   chronic	   survival	   have	   been	   reported	   using	   the	   bone	   marrow-­‐derived	  
mononuclear	  cell	  approach	  36.	  Similar	  results	  have	  been	  obtained	   in	  first	   investigations	  of	  the	  high-­‐
pressure	  system	  (aortic	  valve	  position)	  with	  acute	  and	  chronic	  survival	  37,38.	  	  
As	  cell	  harvest	  and	  delivery	  can	  be	  performed	  within	  the	  same	   intervention	  using	  the	   in	  situ	   tissue	  
engineering	   strategy,	   the	   combination	   with	   novel	   minimally	   invasive	   transcatheter-­‐based	  
implantation	   technologies	   could	   provide	   the	   opportunity	   of	   single-­‐step	   minimally	   invasive	  
procedures.	   In	   this	   regard,	   in	   a	   first	   large-­‐scale	   ovine	   animal	   model,	   trileaflet	   heart	   valves	   have	  
successfully	   been	   implanted	   using	   minimally	   invasive	   transapical	   procedures	   40.	   Furthermore,	   the	  
prenatal	  minimally	   invasive	   implantation	  of	   autologous	   amniotic	   fluid	   stem	   cell-­‐based	   TEHV	   in	   the	  
ovine	   fetal	   model	   using	   an	   in-­‐utero	   closed-­‐heart	   hybrid	   single-­‐step	   intervention	   has	   shown	   to	   be	  
feasible	  39.	  This	  was	  performed	  in	  order	  to	  mimic	  the	  prenatal	  implantation	  of	  heart	  valves	  in	  fetuses	  
with	  congenital	  heart	  valve	  malformations	  routinely	  detected	  by	  ultrasound	  examinations.	  	  
These	   results	   also	   uniquely	   exemplified	   that	   further	   characterization	   of	   the	   exact	   host	   remodeling	  
cascade	   initiated	   by	   seeded	   BMMCs	   needs	   to	   be	   defined	   to	   guide	   in	   situ	   remodeling	   /	   tissue	  
formation	  and	  to	  finally	  enable	  a	  clinical	   translation	  of	  the	  technology.	   Initially	   it	  was	  believed	  that	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the	   seeded	   cells	   directly	   contribute	   to	   the	   formation	   of	   tissue	   41.	   However,	   recent	   studies	   have	  
measured	  a	   rapid	   loss	  of	   the	   cells	   after	   implantation	   as	   the	   scaffold	  became	   repopulated	  by	  host-­‐
derived	  cells	  42,43.	  No	  integration	  of	  seeded	  cells	  into	  the	  scaffold	  could	  be	  detected,	  pointing	  towards	  
the	   fact	   that	   the	   seeded	  cells	  do	  not	  directly	   contribute	   to	   the	   cellular	   infiltration	  and	   subsequent	  
tissue	   formation.	   Nevertheless,	   seeded	   cells	   have	   shown	   to	   release	   paracrine	   factors	   initiating	   a	  
cascade	  of	   tissue	  remodeling	  defined	  by	  an	  early	  monocyte/macrophage	  attraction	  (inflammation),	  
followed	   by	   the	   recruitment	   of	   ECs	   and	   smooth	   muscle	   cells	   (SMCs)	   and	   finally	   leading	   to	   tissue	  
formation	   in	  vivo	   44,45.	  The	  seeded	  cells	   therefore	  seem	  to	  create	  a	  microenvironment	  of	   cytokines	  
and	  growth	   factors	  enhancing	   the	   intrinsic	   remodeling	  capacity	  of	   the	  body,	   in	  particular	  a	  healing	  
response	  with	  a	  rapid	  influx	  of	  inflammatory	  cells.	  Using	  a	  novel	  rat	  model,	  where	  cellular	  ingrowth	  
from	  the	  adjacent	   tissue	   is	   inhibited,	   the	   in	   situ	   regenerative	  potential	  of	  circulatory	  cells	   could	  be	  
attributed	  to	  peripheral	   immune	  cells	  46.	   Infiltrating	  monocytes	  support	  this	  remodeling	  cascade	  by	  
the	  additional	  release	  of	  multiple	  pro-­‐angiogenic	  and	  immunomodulatory	  factors	  such	  as	  monocyte	  
chemoattractant	   protein-­‐1	   (MCP-­‐1),	   interleukin	   6	   (IL-­‐6)	   and	   vascular	   endothelial	   growth	   factor	  
(VEGF).	   Interestingly,	   a	   similar	   host	   cell	   response	   has	   been	   described	   when	   comparing	   unseeded	  
scaffolds	   releasing	   MCP-­‐1	   with	   those	   seeded	   with	   BMMCs	   45.	   MCP-­‐1	   is	   suggested	   to	   burst/guide	  
circulating	  host	  cells	  from	  the	  bloodstream	  for	  tissue	  formation,	  regeneration	  and	  angiogenesis	  45-­‐48.	  
Besides	  BMNCs,	  other	  cell	  sources	  have	  been	  investigated	  on	  their	  pro-­‐angiogenic	  secretome	  for	  the	  
use	  in	  TE	  applications,	  including	  MSCs	  49,	  with	  first	  promising	  results.	  This	  implies	  that	  the	  cells	  could	  
be	  replaced	  completely	  in	  the	  future.	  Fast	  degrading	  cell-­‐free	  scaffolds	  by	  itself	  50	  or	  integrated	  with	  
a	  drug	  delivery	  system	  releasing	  a	  specific	  composition	  and	  concentration	  of	  cytokines	  51	  might	  be	  a	  
‘ready	   to	  use’	   solution	   for	   future	   tissue	  engineering	  approaches.	  Taken	   in	  mind	   that	  effective	  host	  
remodeling	   is	   required	   for	   the	   success	   of	   any	  medical	   implant,	   further	   investigations	  will	   need	   to	  





Figure	   3:	   In	   situ	   tissue	   engineered	   heart	   valves.	   (A)	   Bone	  
marrow-­‐derived	  TEHV.	   Isolated	   bone	  marrow	  mononuclear	  
cells	   were	   seeded	   on	   stented	   polyglycolic	   acid	   scaffold	  
matrices	   (a,b)	   using	   fibrin	   as	   a	   cell	   carrier	   (c,d).	   (B)	  
Macroscopic	  view	  of	  a	  decellularized	  TEHV	  for	  implantation	  
in	  a	  non-­‐human	  primate	  model.	  Adapted	  and	  reprinted	  from	  
Weber	  et	  al.,	  2011	  and	  2013.	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1.1.2.3	  ALTERNATIVE	  AND	  ADJUNCTIVE	  APPROACHES	  FOR	  HEART	  VALVE	  TISSUE	  	  
ENGINEERING	  
Three-­‐dimensional	   (3D)	   printing	   represents	   a	   rapid	   manufacturing	   technique	   that	   allows	   the	  
construction	  of	  a	  fully	  customized	  TEHV	  with	  the	  patient’s	  specific	  anatomy.	  Shortly,	  a	  3D	  scan	  of	  the	  
heart	  valve	  is	  acquired	  via	  X-­‐ray	  or	  MRI,	  converted	  into	  a	  stereolithography	  file	  for	  the	  3D	  printer	  and	  
subsequently	  printed	  to	  generate	  either	  a	  cell-­‐free	  or	  cell-­‐encapsulated	  biological	  heart	  valve.	  In	  this	  
regard,	   the	  group	  of	  Butcher	  has	  demonstrated	  that	  3D	  hydrogel	  printing	  can	   fabricate	  anatomical	  
heterogeneous	  valve	  conduits	  within	  45min	  with	  accuracy	  up	  to	  93%	  52.	  To	  better	  mimic	  the	  distinct	  
mechanical	   properties	   between	   root	   and	   leaflets,	   different	   types	   of	   photocrosslinkable	   hydrogels	  
were	  used	  accordingly	  52.	  The	  fabricated	  heart	  valve	  showed	  anatomically	  specific	  features,	  including	  
the	   coronary	   ostium	   and	   sinuses	   52.	   By	   crosslinking	   different	   striped	   of	   PEG	   hydrogels,	   varying	   in	  
stripe	  width	  and	  spacing,	  the	  anisotropic	  degree	  between	  the	  circumferential	  and	  radial	  orientation	  
of	  a	  native	  valve	  leaflet	  could	  be	  mimic	  53.	  Furthermore,	  3D	  printing	  allows	  to	  directly	  engineer	  heart	  
valves	  with	   the	  desired	  cell	   types	   to	  promote	   in	   situ	  remodeling	  and	  deposition	  of	  ECM	  within	   the	  
construct	  54-­‐56.	  In	  particular,	  human	  aortic	  valvular	  interstitial	  cells	  (VICs)	  encapsulated	  within	  bioprint	  
heart	   valves	   maintained	   cellular	   viability	   and	   promoted	   deposition	   of	   collagen	   and	  
glycosaminoglycans	   57.	   Also	   the	   adhesion	   behavior,	   morphology,	   protein	   secretion	   and	   activation	  
state	   of	   encapsulated	   VICs	   was	   modulated	   by	   specific	   bioactive	   peptides	   incorporated	   into	   the	  
polymer	  networks	  53.	  
Not	  only	  3D	  printing	  but	  also	  electrospinning	  has	  raised	  great	  attention	  over	  the	  last	  years	  due	  to	  its	  
simplified	  and	   fast	  manufacturing	  process.	  Electrospinning	  uses	  a	  high-­‐voltage	  electrostatic	   field	   to	  
generate	   fine	   fibers	   (micro	   to	   nano	   scale)	   through	   the	   ejection	   of	   the	   conductive	   polymer	   from	   a	  
needle.	  Electrospun	  poly-­‐(glycerol	   sebacate):poly(caprolactone)	   (PGS:	  PCL)	   scaffolds	  have	  shown	  to	  
resemble	  the	  ECM	  of	  native	  heart	  valve	  leaflets	  and	  their	  mechanical	  properties	  58,59.	  While	  the	  PGS	  
component	  of	  these	  hybrid	  polyester	  scaffolds	  accelerates	  the	  degradation	  rate	  of	  the	  scaffold,	  the	  
seeded	  VICs	  remodel	  and	  deposit	  new	  ECM	  to	  consequently	  maintain	  the	  mechanical	  properties	  of	  
the	   leaflet	   60.	   Native-­‐like	   leaflet	   behaviour	   has	   also	   been	   described	  with	   electrospun	   PEGdma-­‐PLA	  
scaffolds	  seeded	  with	  VICs/ECs	  under	  physiological	  conditions	  in	  a	  bioreactor	  61.	  Besides	  electrospun	  
scaffolds	  composed	  of	  poly(ester	  urethane)ureas	   (PEUU)	  have	  also	   the	  ability	   to	  mimic	  heart	  valve	  
anisotrophic	  mechanical	  properties	   62,63.	  Besides,	  adjunctive	  approaches	  where	  multiple	   techniques	  
are	  combined	  have	  been	  initiated	  for	  next	  generation	  TEHV.	  For	  instance,	  fibroblast	  cell	  sheets	  have	  
been	   produced	   using	   the	   self-­‐assembly	   method	   and	   subsequently	   assembled	   and	   molded	   to	  
generate	  a	  stented	  TEHV	  64,65.	  Furthermore	  the	  combination	  of	  hydrogels	  with	  electrospinning	  might	  
integrate	   the	   advantages	   of	   both	   technologies	   and	   improve	   the	   mechanical	   properties,	   scaffold	  
composition,	  material	  strength	  and	  cellular	  compatibility	  of	  future	  TEHV	  66,67.	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1.1.3	  BASIC	  PRINCIPLE	  OF	  VENOUS	  VALVE	  TISSUE	  ENGINEERING	  
In	  comparison	  to	  the	  field	  of	  heart	  valve	  tissue	  engineering	  only	  few	  attempts	  have	  been	  conducted	  
in	  order	  to	  produce	  a	  tissue	  engineered	  venous	  valve	  (TEVV)	  for	  the	  treatment	  of	  deep	  venous	  valve	  
insufficiency.	  So	   far	  only	   few	  clinical	  applications	  have	  been	   initiated	   for	  venous	  valves	  with	  either	  
cryopreserved	  allografts	  68	  or	  glutaraldehyde-­‐preserved	  xenografts	  4.	   In	  spite	  of	  initial	  good	  valvular	  
performance,	  cryovalve	   insertion	  has	  been	  associated	  with	  high	  morbidity	  and	  high	  occlusion	  rates	  
68.	   In	   a	   long-­‐term	   follow-­‐up,	   also	   the	   xenogenic	   glutaraldehyde-­‐fixed	   valves	   resulted	   in	   valve	  
incompetence	   and/or	   valvular	   stenosis	   related	  with	   excessive	   neo-­‐intimal	   hyperplesia	   and	   fibrotic	  
transformation	   4.	  Besides	  also	   surface	   thrombogenicity	  mainly	  owing	   to	   the	   low	  pressure	  and	   flow	  
environment	  involving	  static	  flow	  phases	  in	  the	  venous	  circulation	  branch	  has	  been	  a	  major	  issue	  in	  
valve	   implants.	   In	  summary,	  no	  durable	  and	  thrombus-­‐resistant	  venous	  valvular	  replacements	  have	  
been	   introduced	   to	   routine	   clinical	   use	   so	   far.	   A	   tissue	   engineered	   venous	   valve	   solution	   could	  
overcome	   these	   limitations	   and	   mainly	   allow	   for	   autologous	   thromboresistant	   (endothelialized)	  
implants.	  In	  a	  first	  experimental	  in	  vitro	  trial,	  tri-­‐	  and	  bicuspid	  TEVVs	  have	  been	  generated	  based	  on	  
the	   in	  vitro	   tissue	  engineering	  approach	  69.	  TEVVs	  were	  engineered	  from	  autologous	  bone	  marrow-­‐
derived	   MSCs	   and	   subsequently	   endothelialized	   showing	   layered	   tissue	   formation	   analogous	   to	  
native	  valvular	  tissues	  69.	  The	  feasibility	  of	  using	  the	  tissue	  engineering	  technique	  for	  the	  generation	  
of	  future	  TEVVs	  for	  the	  treatment	  of	  CVI	  has	  been	  demonstrated	  as	  part	  of	  this	  first	  study.	  However,	  
future	   in	   vivo	   studies	   seem	   mandatory	   in	   order	   to	   evaluate	   their	   functionality	   in	   physiological	  
conditions	  and	  their	  long-­‐term	  durability.	  	  	  
	  
1.1.4	  LIMITATIONS	  AND	  FUTURE	  PERSPECTIVES	  	  
Even	  if	  still	  limited	  to	  the	  experimental	  phase,	  heart	  and	  venous	  valve	  tissue	  engineering	  has	  shown	  
to	  be	  a	  potential	  future	  alternative	  therapeutic	  option	  for	  the	  replacement	  of	  diseased	  valves.	  Taking	  
in	   consideration	   the	  demographic	  development,	   the	  prevalence	  of	  heart	   and	   venous	   valve	  disease	  
will	  remain	  to	  be	  on	  the	  rise	  as	  the	  global	  population	  increases	  in	  age.	  Besides	  there	  is	  still	  no	  ideal	  
therapy	   for	   congenital	   disease	   as	   the	   currently	   available	   prostheses	   lack	   the	   potential	   of	   growth.	  
Since	   the	   introduction	   of	   vascular	   tissue	   engineering	   technologies,	   significant	   improvements	   have	  
been	  made.	  First	  clinical	  trials	  on	  tissue-­‐engineered	  vascular	  grafts	  have	  been	  initiated,	  the	  transition	  
from	  animal	  models	  to	  the	  clinical	  reality	  on	  a	  broader	  scale	  seems	  within	  our	  grasp.	  
Nevertheless,	   several	   questions	   have	   to	   be	   addressed	   before	   a	   clinical	   application	   of	   tissue	  
engineering	   will	   be	   feasible.	   For	   the	   in	   vitro	   tissue	   engineering	   approach	   the	   most	   favorable	   cell	  
source	  needs	  to	  be	  defined.	  Therefore	  an	  exact	  characterization	  of	  the	  cells	  is	  indispensable,	  taking	  
their	  proliferation	  capacity	  and	  cell	  survival	   in	  account.	  The	   impact	  of	  the	  ex	  vivo	  expansion	  on	  the	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cells	   has	   to	   be	   defined,	   given	   that	   their	   ex	   vivo	  manipulation	  might	   result	   in	   adverse	   biochemical,	  
genomic	  and	   immunological	   characteristics.	   In	  addition,	  xenogenic	   factors,	   such	  as	   fetal	   calf	   serum	  
within	  the	  proliferation	  medium,	  need	  to	  be	  replaced	  for	  a	  safe	  clinical	  application.	  For	  the	  design	  of	  
the	   valves,	   in	   all	   tissue	   engineering	   approaches,	   further	   adaptations	  will	   have	   to	   be	   considered	   in	  
order	   to	  minimize	  radial	   shortening	  of	   the	   leaflets	  and	  central	  valvular	   regurgitation.	   In	   this	   regard	  
TEHV	  need	  to	  better	  resemble	  the	  complex	  geometry	  of	  native	  heart	  valves,	  which	  includes	  sinuses,	  
ostia,	   individual	   layers	   of	   valve	   leaflets	   (ventricularis,	   fibrosa	   and	   spongiosa)	   and	   a	   heterogeneous	  
cellular	  composition	  70.	  Another	  important	  aspect	  concerns	  the	  scaffold	  material.	  Exact	  definition	  of	  
degradation	  rates,	  mechanical	  properties,	  thrombogenicity	  and	  surface	  interaction	  with	  cells	  (cellular	  
adhesion	  and	  ingrowth)	  need	  to	  be	  specified.	  Ultimately,	  cellular	  ECM	  production	  needs	  to	  be	  exactly	  
timed	  with	  degradation	  of	  the	  actual	  scaffold	  to	  maintain	  structural	  integrity	  and	  counteract	  chronic	  
inflammation,	  which	  might	  result	  in	  fibrosis	  and	  inappropriate	  functional	  behavior	  of	  the	  valve.	  This	  
chronic	   inflammation	   is	   characterized	   by	   an	   accumulation	   of	   macrophages	   in	   the	   attempt	   to	  
phagocytize	   the	   foreign	   biomaterial.	   Interestingly,	   the	   balance	   between	  M1	   and	  M2	  macrophages	  
has	  shown	  to	  influence	  the	  remodeling	  capacity	  following	  implantation.	  In	  this	  regard	  several	  groups	  
have	  established	  composite	  scaffolds	   for	   the	  controlled	  release	  of	  active	  biomolecules	   to	   influence	  
macrophage	  phenotype.	  As	  to	  the	  in	  situ	  tissue	  engineering	  approach	  particular	  concerns	  have	  been	  
raised	  given	  the	  highly	  heterogeneous	  in	  vivo	  remodeling	  responses	  among	  different	  individuals.	  This	  
implies	   the	   definition	   of	   clinical	   guidelines	   for	   the	   use	   of	   tissue	   engineering	   technologies,	   where	  
exact	   inclusion	  and	  exclusion	   criteria	   are	  of	   central	   importance.	  Moreover	   it	   requires	  an	   improved	  
understanding	   of	   the	   cellular	   cascades	   evident	   throughout	   the	   in	   vivo	   remodeling	   phase.	  
Summarized,	  improved	  outcomes	  for	  valve	  tissue	  engineering	  will	  require	  a	  systemic	  understanding	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The	   development	   of	   novel	   biomaterials	   for	   regenerative	  medicine	   applications	   requires	   improving	  
our	   understanding	  of	   the	  underlying	  biological	   processes	   that	   occur	   after	   implantation.	   Identifying	  
the	   multitude	   of	   biological	   interactions	   that	   take	   place	   during	   the	   different	   phases	   of	   the	   tissue	  
response	   to	   a	   biomaterial	   is	   essential.	   The	   healing	   following	   implantation	   is	   a	   complex	   process	   in	  
which	  effective	  tissue	  clearance,	  vascularization	  and	  matrix	  reconstruction	  are	  essential	  for	  achieving	  
complete	   biomaterial	   integration.	   These	   dynamic	   events	   depend	   on	   the	   crosstalk	   between	  
macrophages	   and	   other	   cells	   such	   as	   fibroblasts,	   endothelial	   cells	   and	  mesenchymal	   stem	   cells.	   In	  
this	   review,	   we	   summarize	   the	   current	   knowledge	   of	   the	   interactions	   between	  macrophages	   and	  
healing-­‐associated	  cells.	  The	  impact	  of	  this	  crosstalk	  between	  cells	  on	  cell-­‐material	  interaction,	  tissue	  
regeneration	  and	  ultimate	  biomaterial	  integration	  are	  highlighted.	  The	  use	  of	  in	  vitro	  macrophage	  co-­‐
cultures	   and	   their	   potential	   role	   as	   a	   predictive	   tool/model	   for	   assessing	   host-­‐biomaterial	  
interactions	   and	   the	   functionality	   of	   tissue-­‐engineered	   constructs	   are	   presented.	   Further,	   the	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  with	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   chapters:	   1.2.5	   Endothelial	   cells	   and	   their	   role	   in	   healing;	  










The	  emerging	  field	  of	  biomaterials	  research	  has	  changed	  drastically	  over	  the	  last	  several	  years.	  Until	  
recently,	  it	  was	  believed	  that	  a	  biomaterial	  should	  be	  inert	  and	  not	  interfere	  with	  body	  homeostasis.	  
However,	  most	  contemporary	  efforts	  focus	  on	  developing	  bioactive	  biomaterial-­‐based	  systems	  that	  
promote	   and	   guide	   specific	   biological	   responses,	   such	   as	   tissue	   regeneration,	   remodeling	   or	  
vascularization.	   The	   development	   of	   such	   biomaterials	   requires	   an	   in-­‐depth	   understanding	   of	   the	  
underlying	  biological	  processes	   that	  occur	   following	  biomaterial	   implantation,	  down	   to	   the	   cellular	  
level.	   In	   this	   regard,	   in	   vitro	   models	   play	   a	   key	   role	   in	   biomaterials	   research	   by	   allowing	   the	  
systematic	   study	  of	   the	   interactions	  of	   different	   cell	   types	  with	   a	   candidate	  biomaterial.	  However,	  
while	   in	   vitro	   models	   provide	   excellent	   means	   to	   learn	   about	   principle	   molecular	   and	   cellular	  
interactions,	  they	  cannot	  not	  accurately	  mimic	  the	  complexity	  of	  the	  native	  inflammatory	  response.	  
The	  challenges	  in	  these	  studies	  include	  selection	  of	  the	  appropriate	  cell	  types,	  appropriate	  analytical	  
tools	   as	   well	   as	   cultivation	   methodologies	   for	   the	   in	   vitro	   evaluation	   and	   development	   of	   novel	  
candidate	  biomaterials.	  
Macrophages	  (MΦs)	  are	  one	  of	  the	  main	  cell	  types	  involved	  in	  the	  initial	  host-­‐biomaterial	  interaction	  
after	  implantation	  1.	  This	  interaction	  starts	  with	  the	  direct	  response	  of	  MΦs	  to	  the	  implant,	  followed	  
by	   the	   recruitment	  of	  other	  cell	   types	  such	  as	   fibroblasts,	  endothelial	   cells	   (ECs)	  and	  mesenchymal	  
stem	  cells	   (MSCs).	  Crosstalk	  among	  all	  of	   these	  cell	   types	   in	   living	  tissues	  will	  determine	  the	  future	  
integration	  or	  rejection	  of	  the	  implanted	  biomaterial	  and	  therefore	  the	  development	  of	  predictive	  in	  
vitro	  models	  to	  simulate	  and	  understand	  this	  response	  is	  highly	  relevant.	  
The	  aim	  of	  this	  review	  is	  to	  critically	  discuss	  the	  interactions	  between	  MΦs	  and	  fibroblasts,	  ECs	  and	  
MSCs	   in	  both	   in	   vivo	   and	   in	   vitro	  models.	   The	  benefits,	   limitations	   and	   challenges	  of	   the	   currently	  
used	  MΦ	  co-­‐culture	  in	  vitro	  models	  are	  also	  discussed.	  
It	   is	  well	  established	  that	  cues	  presented	  by	  biomaterials	  play	  a	  determining	  role	  in	  modulating	  the	  
response	  of	  cells.	  The	  implantation	  of	  any	  type	  of	  construct	  or	  biomaterial	  for	  tissue	  engineering	  (TE)	  
invariably	  damages	  the	  tissue	  and	  its	  vasculature	  at	  the	  site	  of	  implantation.	  This	  tissue	  injury,	  affects	  
the	  local	  environment	  of	  the	  foreign	  material	  and	  triggers	  the	  initial	  response	  to	  the	  material,	  which	  
can	   be	   amplified	   or	   also	   dramatically	   altered	   by	   the	   characteristics	   of	   the	   material	   itself.	  
Subsequently,	   a	   cascade	   of	   events	   is	   initiated	   that	   can	   be	   broadly	   divided	   into	   four	   distinct,	   but	  
overlapping	   phases	   which	   have	   been	   originally	   described	   by	   Anderson	   1	   as	   shown	   in	   Figure	   1:	   I)	  
hemostasis,	  II)	  inflammation,	  III)	  proliferation	  and	  IV)	  repair.	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Figure	   1.	   Graphic	   (top)	   and	   schematic	   (bottom)	   of	   the	   different	   healing	   stages	   and	   the	   respective	   cells	   involved	   in	   the	   foreign	   body	  
response	  to	  a	  material.	  The	  intensity,	  time	  variables	  and	  repair	  mechanism	  (regeneration	  or	  fibrosis)	  developed	  depend	  on	  the	  extent	  of	  
injury	   created	   during	   implantation	   and	   the	   size,	   shape,	   topography,	   and	   chemical,	   physical,	   and	   degradation	   properties	   of	   the	   implant	  
material.	  Dashed	  lines	  in	  the	  graph	  represent	  situations	  leading	  to	  fibrosis,	  where	  an	  increasing	  and	  persistent	  number	  of	  myofibroblasts	  
and	  foreign	  body	  giant	  (FBG)	  cells	  are	  typically	  found.	  Graph	  adapted	  from	  (Anderson,	  1993).	  	  
	  
Much	  progress	  has	  been	  made	  in	  understanding	  the	  interactions	  of	  somatic	  cells	  and	  stems	  cells	  with	  
biomaterials	   2,	   however,	   much	   less	   is	   known	   about	   the	   response	   of	   immune	   cells,	   especially	  
macrophages,	  to	  biomaterial	  cues.	  Macrophages	  can	  either	  circulate	  in	  peripheral	  blood	  or	  reside	  in	  
tissues;	  both	  types	  originate	  from	  different	  sources.	  It	  has	  been	  suggested	  that	  some	  tissue	  resident	  
macrophages	  may	   arise	   in	   utero	   during	   embryological	   development	   2,3.	  Many	  examples	  have	  been	  
reported	   in	   which	   tissue-­‐specific	   factors	   steer	   very	   specific	   macrophage	   functions	   irrespective	   of	  
their	  ontological	  origin,	  indicating	  a	  high	  degree	  of	  plasticity	  in	  the	  monocyte/macrophage	  system	  4,5.	  
Organ-­‐specific	   tissue-­‐resident	   macrophages	   and	   circulating	   monocytes	   play	   essential	   roles	   in	   the	  
mammalian	   response	   to	   injury	   in	   a	   number	   of	   organs	   such	   as	   liver,	   intestine,	   heart	   and	   skeletal	  
muscle	   5,6.	   A	   recent	   review	   summarized	   the	   current	   knowledge	   on	   how	   dysregulated	  macrophage	  
function	  impairs	  wound	  healing	  and	  contributes	  to	  the	  development	  of	  fibrosis	  in	  these	  tissues	  5.	  
Bleeding	  at	  a	  wound	  site	  induces	  adhesion	  and	  degranulation	  of	  platelets	  and	  the	  rapid	  formation	  of	  
a	   fibrin	  clot	  via	  various	  paths	  of	  activation	  of	   the	  blood	  coagulation	  cascade.	  This	  clot	   represents	  a	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provisional	   matrix	   and	   is	   thought	   to	   constitute	   a	   major	   factor	   during	   the	   following	   inflammation	  
phase	  7.	  Inflammatory	  cells	  initially	  populate	  this	  matrix:	  first	  neutrophils,	  and	  later,	  typically	  within	  
1–2	  days	   after	  wounding,	  MΦs.	  During	   the	   subsequent	   proliferation	  phase,	   fibroblasts,	  MSCs,	   and	  
ECs,	   together	  with	   other	   tissue-­‐specific	   cell	   types,	   are	   recruited	   to	   the	  wound	   site.	  Under	   optimal	  
conditions,	   these	   cells	   work	   in	   synchrony	   to	   regenerate	   the	   damaged	   tissue.	   However,	   the	   initial	  
acute	   inflammation	   frequently	   develops	   into	   chronic	   inflammation	   in	   which	   activated	   MΦs	  
accumulate	  at	  the	  implant	  surface	  in	  an	  attempt	  to	  phagocytize	  the	  foreign	  material.	  The	  persistent	  
inflammatory	   state	   results	   in	   the	   fusion	  of	   the	   frustrated	  macrophages,	   giving	   rise	   to	   foreign	  body	  
giant	  (FBG)	  cells	  1.	  Meanwhile,	  the	  fibroblasts	  continue	  to	  produce	  the	  extensive	  amounts	  of	  collagen	  
that	  is	  often	  associated	  with	  their	  differentiation	  into	  the	  highly	  contractile	  myofibroblast	  phenotype	  
8.	   Over	   time,	   this	   results	   in	   fibrotic	   encapsulation	   caused	   by	   the	   dense	   layer	   of	   collagenous	  
connective	  tissue	  produced	  by	  the	  fibroblasts	  and,	  ultimately,	  the	  non-­‐integration	  of	  the	  implant.	  It	  is	  
thought	  that	  recruited	  monocytes,	  monocyte-­‐derived	  macrophages	  and	  tissue-­‐resident	  macrophages	  
control	   cell	   number	   through	   cell	   proliferation	   4.	   It	   is	   unclear	   to	   what	   extend	   the	   presence	   of	  
biomaterials	   interferes	   with	   the	   normal	   physiological	   process	   during	   healing.	   Recently,	   it	   was	  
reported	   that	   FBG	   cells	   express	   both,	   markers	   classically	   described	   as	   inflammatory	   markers	   and	  
markers	  associated	  with	  the	  healing	  state	  of	  macrophages	  9.	  This	  goes	  in	  line	  with	  recent	  studies	  that	  
highlight	   that	  macrophages	   can	  present	   in	   a	   continuum	  of	   inflammatory/non-­‐inflammatory	   stages,	  
rather	  than	  in	  a	  clearly	  unidirectional	  state	  10-­‐14	  (see	  also	  below	  section	  on	  macrophages).	  	  
TE	   strategies	   typically	  use	  degradable	  materials	  because	   the	  goal	   is	   for	   the	  material	   to	  degrade	  as	  
neo-­‐tissue	   formation	   proceeds.	   Ideally,	   this	   would	   result	   in	   the	   complete	   regeneration	   of	   the	  
damaged	   tissue	   through	   regenerative	  mechanisms.	  However,	   scar	   tissue	   formation	  often	  occurs	   in	  
real	   systems.	   The	   development	   of	   scar	   tissue	   can	   lead	   to	   interfacial	   problems	   because	   of	   the	  
differences	  in	  the	  biomechanical	  properties	  between	  the	  healthy	  and	  the	  scar	  tissues.	  Furthermore,	  
fibrotic	  encapsulation	  affects	  cell	  survival,	   the	  diffusion	  of	  bioactive	  molecules	  and	  the	  degradation	  
rate	  of	  constructs	  for	  TE.	  
The	  type	  of	  implanted	  material	  influences	  the	  repair	  mechanisms	  initiated	  in	  the	  host.	  For	  example,	  
biological	   degradable	  materials	   favor	   repair	   through	   regeneration.	  However,	   this	   is	   not	   always	   the	  
case,	  and	  non-­‐degradable	  synthetic	  materials	  do	  not	  always	  lead	  to	  severe	  fibrosis.	  Thus,	  the	  repair	  
mechanism	  depends	  on	  a	  variety	  of	  both	  known	  and	  unknown	   factors.	  The	  manufacturing,	  macro-­‐
architecture	  and	  surface	  properties	  of	  the	  final	  implant	  can	  all	  alter	  the	  host	  response.	  For	  example,	  
whereas	   decellularized	   extracellular	  matrix	   is	   one	   of	   the	   closest	   analogues	   to	   native	   tissue	   and	   is	  
indeed	   in	  many	  ways	   an	   ideal	   biomaterial	   for	   regeneration,	   it	   can	   still	   elicit	   a	   severe	   foreign	  body	  
response	   and	   the	   development	   of	   fibrosis	   15	   because	   of	   its	   immunogenicity	   or	   the	  manufacturing	  
methodologies	   used	   (e.g.,	   the	   use	   of	   crosslinking	   agents).	   Recent	   studies	   have	   reported	   that	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crosslinking	  has	  an	   impact	  on	   the	   severity	  of	   the	  host	   response	   16	  which	  was	   reviewed	  by	  Aamodt	  
and	  Grainger	   17.	   	   It	   has	   further	   been	   suggested	   that	   unnatural	   crosslinking	   leads	   to	   an	   increase	   of	  
foreign	  body	  formation,	  probably	  due	  to	  the	  formation	  of	  difficult-­‐to-­‐break-­‐down	  molecules	  16.	  
In	   contrast,	   titanium	   implants	   applied	   directly	   in	   contact	   with	   bone	   often	   show	   impressive	  
osseointegration	   without	   fibrosis	   or	   chronic	   inflammation	   18.	   However,	   osseointegration	   of	  
biomaterials	   might	   be	   inflammation-­‐triggered	   through	   an	   alternative	   pathway	   of	   host	   response	  
involving	  neutrophils	  and	  prostaglandins	  19.	  	  
Kzhyshkowska	   et	   al.	   even	   propose	   that	   the	   detailed	   understanding	   of	   the	   immune	   response	   from	  
macrophages	  to	  biomaterials	  can	  help	  to	  develop	  personalized	  biomaterials	  through	  developing	  new	  
materials	   and	   material	   coatings	   that	   allow,	   to	   some	   extend,	   immune	   engineering	   of	   a	   specific	  
response	   20.	   A	   very	   recent	   study	   provides	   evidence	   that	   cytokine	   delivery	   systems	  might	   shift	   the	  
early-­‐stage	  macrophage	   response	  at	   the	   tissue-­‐implant	   interface	  of	  a	  non-­‐degradable	  material	  and	  
suggests	  that	  modulation	  of	  the	  immune	  reaction	  at	  early	  stages	  of	  the	  host	  response	  21.	  This	  work	  
demonstrated	   that	   the	   tuned	   release	   of	   IL-­‐4	   resulted	   in	   a	   reduced	   formation	   of	   fibrotic	   capsule	  
surrounding	   the	   functional	   implant	   and	   that	   such	   immune	   engineering	   strategy	   may	   represent	   a	  
feasible	  recipe	  for	  promoting	  biomaterial	  integration	  and	  success.	  
The	   detailed	   mechanisms	   determining	   the	   host	   response	   to	   a	   biomaterial	   following	   implantation	  
have	   not	   been	   fully	   understood.	   Ultimately,	   this	   lack	   of	   information	   may	   lead	   to	   insufficient	  





Monocytes/macrophages	   (M/MΦ)	   are	   amongst	   the	   first	   responding	   cells	   after	   implantation	   of	   a	  
biomaterial.	   They	   are	   attracted	   to	   the	   wound	   site	   by	   complement	   factors,	   transforming	   growth	  
factor	   (TGF-­‐β),	   platelet-­‐derived	   growth	   factor	   (PDGF),	   platelet	   factor	   4	   (PF4),	   macrophage	  
chemoattractant	  proteins	  1-­‐4	  (MCP-­‐1,2,3,4),	  RANTES,	  macrophage	  inflammatory	  protein	  1a	  (MIP-­‐1a)	  
and	  MIP-­‐1b	  7,22-­‐24.	  Ubiquitous	  to	  most	  implantation	  sites,	  MΦs	  are	  responsible	  for	  the	  degree	  of	  the	  
inflammatory	  response	  and	  tissue	  repair	  in	  the	  body.	  They	  are	  a	  terminally	  differentiated	  population	  
of	  blood-­‐circulating	  monocytes.	  	  
MΦs	   are	   monocyte-­‐derived	   myeloid	   cells	   that	   develop	   from	   a	   common	   myeloid	   progenitor	   cell	  
residing	  in	  the	  bone	  marrow;	  they	  are	  released	  into	  the	  blood	  stream	  upon	  maturation	  11.	  Circulating	  
monocytes	  are	  generally	  non-­‐proliferative,	   though	  some	  exceptions	  have	  been	   identified	   25,	  with	  a	  
short	  half-­‐life	  of	  approximately	  1–3	  days.	  Here	  they	  are	  thought	   to	  provide	  a	  continuous	  source	  of	  
MΦs	   in	   tissues	   by	   migrating	   across	   the	   endothelium	   and	   locally	   differentiating	   into	   functionally	  
distinct	  MΦs	  (e.g.	  microglia	  cells	  in	  the	  brain,	  Kupffer	  cells	  in	  the	  liver	  and	  alveolar	  MΦs	  in	  the	  lung).	  
While	   extravasation	   occurs	   as	   part	   of	   normal	   body	   homeostasis,	   their	   migration	   across	   the	  
endothelium	  is	  enhanced	  in	  response	  to	  an	  inflammatory	  event.	  Recently,	  the	  role	  of	  tissue-­‐resident	  
macrophages	  in	  some	  organs	  has	  been	  highlighted	  in	  a	  review	  4	  and	  in	  this	  work	  it	  was	  emphasized	  
that	   the	   relative	   contributions	   of	   tissue	   niche	   versus	   ontological	   origin	   to	   the	   regulation	   of	  
macrophage	   function	   during	   steady	   state	   and	   healing/	   inflammation	   will	   be	   of	   major	   interest	   for	  
future	  studies.	  
Depending	   on	   the	   microenvironment	   encountered,	   MΦs	   may	   become	   activated	   and	   release	  
proinflammatory	   factors	   and	   chemoattractants	   that	   recruit	   additional	   monocytes	   from	   the	  
circulating	   blood,	   thus	   creating	   amplification	   loop	   of	   inflammation	   11.	   The	   MΦs	   recruited	   to	   the	  
inflammatory	   site	   are	   a	   heterogeneous	   cell	   population	   with	   high	   plasticity,	   capable	   of	   acquiring	  
distinct	   phenotypes.	   These	   phenotypes	   can	   be	   generally	   categorized	   into	   two	   major	   groups:	   I)	  
classically	   activated,	   proinflammatory	   MΦs	   (M1-­‐like)	   and	   II)	   alternatively	   activated	  
immunomodulatory	  MΦs	  (M2-­‐like)	  (Fig.	  2).	  
The	   MΦ	   phenotype	   transition	   from	   M1-­‐like	   to	   M2-­‐like	   correlates	   with	   changes	   in	   the	   cytokine	  
secretion	  profile	  of	  T	  cells,	  from	  type	  1	  (Th1)	  to	  type	  2	  (Th2).	  Indeed,	  the	  in	  vitro	  development	  of	  M1-­‐
like	   MΦs	   can	   be	   achieved	   by	   exposing	   naïve	   MΦs	   to	   interferon	   gamma	   (IFN-­‐γ),	   the	   main	   Th1	  
cytokine,	  alone	  or	  in	  combination	  with	  lipopolysaccharide	  (LPS,	  endotoxin)	  or	  tumor	  necrosis	  factor	  
alpha	  (TNFα),	  whereas	  M2-­‐like	  MΦs	  are	  formed	  by	  exposure	  to	  interleukin-­‐4	  (IL-­‐4),	  interleukin-­‐13	  (IL-­‐
13)	  or	  interleukin-­‐10	  (IL-­‐10),	  which	  are	  typical	  Th2-­‐type	  cytokines.	  M2-­‐like	  MΦs	  encompass	  a	  range	  
of	  well-­‐recognized	  subtypes	  (M2a,	  M2b,	  and	  M2c),	  all	  of	  which	  have	  distinct	   inducers,	  markers	  and	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functions.	  The	  inducers,	  markers	  and	  function	  of	  both,	  M1-­‐like	  and	  M2-­‐like	  MΦs,	  including	  the	  M2-­‐
subtypes,	  have	  been	  reviewed	  in	  detail	  elsewhere	  13,26-­‐28.	  MΦs	  are	  capable	  of	  adjusting	  their	  cytokine	  
release	   profile,	   metabolism	   and	   mobility	   in	   response	   to	   autologous	   and/or	   exogenous	   stimuli,	  
allowing	   them	   to	   respond	   as	   needed	   in	   different	   stages	  of	   the	  healing	  or	   disease	  progression.	   For	  
example,	   the	   binding	   of	   pathogen-­‐associated	   molecular	   cues	   such	   as	   LPS	   to	   the	   cell	   membrane	  
signals	  MΦs	   to	   the	   presence	   of	   invaders.	   This	   recognition	   of	   danger	   induces	   the	   activation	   of	   the	  
hostile	  M1-­‐like	  MΦ	  phenotype	  with	   the	  main	   function	  of	   stopping	   the	   threat.	   To	  do	   that,	   the	   cell	  
employs	  mechanisms	  of	   pathogen	   clearance,	   such	   as	   increased	   release	  of	   inflammatory	   cytokines,	  
reactive	  oxygen	  species	  and	  expression	  of	  complement-­‐mediated	  phagocytic	  receptors,	  and	  prevents	  
pathogen	   proliferation	   and	   growth	   by	   depleting	   iron	   from	   the	   extracellular	   matrix	   (ECM)	   by	  
increasing	   their	   intracellular	   storage	   levels	  of	   ferritin.	   In	  contrast,	   in	   the	  absence	  of	  pathogens	  and	  
presence	   of	   cytokines	   such	   as	   IL-­‐4	   or	   IL-­‐13,	   MΦs	   can	   decrease	   inflammation	   and	   promote	   tissue	  
regeneration.	   They	   release	   anti-­‐inflammatory	   cytokines,	   iron,	   and	   endothelial	   and	   fibroblastic	  
chemokines	   such	  as	  TGF-­‐β	  and	  vascular	  endothelial	   growth	   factor	   (VEGF),	  all	  of	  which	   support	   cell	  
proliferation,	  angiogenesis	  and	  matrix	  reconstruction.	  
	  
	  
Figure	  2.	  Schematic	  of	  the	  main	  specific	  markers	  and	  functions	  of	  M1	  and	  M2	  polarized	  macrophages.	  Note:	  Different	  sets	  of	  M2	  markers	  
are	   typical	   for	   different	   subsets	   of	   M2	   macrophages.	   These	   markers	   are	   representative	   of	   human	   and	   murine	   species.	   Information	  





MΦs	   present	   dynamic	   and	   plastic	   phenotypes	   that	   continuously	   change	   with	   time	   and	   local	  
microenvironmental	  signals	  29-­‐32.	  Examination	  of	  the	  MΦ	  population	  at	  any	  given	  time	  point	  shows	  a	  
mixture	  of	  MΦ	  phenotypes	  or	  MΦs	  in	  a	  state	  of	  transition	  that	  express	  marker	  subsets	  of	  both	  M1-­‐
like	   and	  M2-­‐like	   phenotypes.	   In	   fact	  macrophages	   can	   present	   in	   a	   continuum	   of	  M1-­‐like/M2-­‐like	  
stages	  10-­‐14.	  
Evidence	   suggests	   that	   the	   cell	   number	   ratio	  between	  M1-­‐like	  and	  M2-­‐like	  MΦs	  and	  with	   this	   the	  
ratio	   of	   inflammatory/anti-­‐inflammatory	   marker	   molecules	   significantly	   affect	   tissue	   remodeling	  
following	  biomaterial	  implantation	  11,33,34.	  Cellular	  events	  such	  as	  inflammation,	  tissue	  clearance,	  cell	  
recruitment	  and	  vascularization	  require	  an	  interplay	  between	  the	  different	  MΦ	  phenotypes.	  Because	  
the	   behavior	   and	   recruitment	   of	   other	   cells	   from	   the	   surrounding	   tissue	   appear	   to	   be	   largely	  
dependent	  on	  the	  environment	  created	  and	  sustained	  by	   the	  MΦs,	  a	  deeper	  understanding	  of	   the	  
influence	  of	  MΦs	  on	  the	  behavior	  of	  the	  other	  cell	  types	  and	  on	  the	  host-­‐biomaterial	   interaction	  is	  
needed	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1.2.3	  MESENCHYMAL	  STEM	  CELLS	  AND	  THEIR	  ROLE	  IN	  HEALING	  
MSCs	  are	  a	  heterogeneous	  group	  of	  plastic	  adherent	  cells	  that	  exhibit	  self-­‐renewal	  and	  multi-­‐lineage	  
differentiation	   capacities.	   They	   were	   first	   observed	   in	   the	   bone	   marrow	   by	   Friedenstein	   and	  
colleagues	   in	   the	   1970s	   35.	   Since	   then,	  MSCs	   have	   also	   been	   successfully	   isolated	   from	   alternative	  
adult	   and	   fetal	   adnexal	   tissues.	   The	   commonly	   used	   definition	   for	   human	  MSCs	   described	   by	   the	  
International	   Society	   for	   Cell	   Therapy	   36	   is	   based	   on	   their	   I)	   plastic	   adherence	   in	   standard	   culture	  
conditions,	   II)	   in	   vitro	   tri-­‐lineage	   differentiation	   potential	   into	   osteoblasts,	   adipocytes	   and	  
chondrocytes	   and	   III)	   specific	   surface	   antigen	   expression	   positive	   for	   CD105,	   CD73	   and	   CD90,	   but	  
negative	  for	  CD45,	  CD34	  and	  CD14;	  CD11b	  and	  CD79alpha;	  or	  CD19	  and	  HLA-­‐DR.	  
MSCs	   have	   been	   considered	   for	   a	   wide	   variety	   of	   clinical	   applications	   to	   promote	   healing,	  
regeneration	  and	  remodeling	  of	   injured	   tissues	  by	   transplantation	  with	  or	  without	  a	  carrier	   for	  TE.	  
On-­‐going	   clinical	   trials	   are	   testing	   MSC	   treatments	   for	   autoimmune,	   cardiovascular,	   liver,	   graft-­‐
versus-­‐host	   disease	   (GVHD)	   and	   neuronal	   diseases,	   as	   well	   as	   orthopedic	   injuries	   and	   cancer	   37.	  
However,	  the	  underlying	  mechanisms	  involved	  in	  the	  functional	  restoration	  of	  diseased	  structures	  by	  
MSCs	  have	  not	  yet	  been	  fully	  elucidated,	  largely	  because	  of	  the	  lack	  of	  a	  specific	  single	  marker	  that	  
can	  be	  used	  to	  identify	  and	  trace	  them	  in	  the	  body.	  Alternative	  methods	  for	  studying	  MSC	  behavior	  
in	  vivo	  involve	  the	  use	  of	  intravenously	  injected	  labeled	  cells.	  Although	  these	  methodologies	  involve	  
certain	  technical	  challenges	  (reviewed	  in	  38),	  they	  have	  been	  successfully	  applied	  to	  demonstrate	  that	  
MSCs	  are	  indeed	  actively	  recruited	  to	  sites	  of	  tissue	  injury	  where	  they	  contribute	  to	  an	  acceleration	  
of	   the	  healing	  process	   39,40.	   In	   this	   regard,	   the	   release	  of	  anti-­‐apoptotic	  and	   tropic	   factors	  by	  MSCs	  
has	   been	   demonstrated	   to	   initiate	   cellular	   protection	   and	   repair	   through	   the	   recruitment	   of	   host	  
cells.	   Furthermore,	   the	   role	   of	  MSCs	   in	   healing	  may	  be	   related	   to	   an	   immunomodulatory	   function	  
(reviewed	  in	  41).	  Taken	  together,	  MSCs	  are	  considered	  to	  be	  a	  versatile	  cell	  source	  for	  regenerative	  
medicine	   applications,	   either	   through	   direct	   administration/implantation	   as	   an	   element	   of	   a	   TE	  
strategy	  or	  through	  their	  endogenous	  presence	  at	  wound	  sites.	  
	  
1.2.3.1	  MΦ-­‐MSC	  CROSSTALK	  
Initially,	  interest	  in	  MSCs	  for	  clinical	  applications	  focused	  on	  their	  capability	  to	  replace	  damaged	  cells.	  
However,	  that	  focus	  changed	  in	  2004,	  when	  MSCs	  were	  considered	  for	  the	  treatment	  of	  acute	  GVHD	  
because	   of	   their	   immunomodulatory	   potential	   42.	   The	   majority	   of	   the	   publications	   on	   the	  
immunomodulatory	   function	   of	   MSCs	   that	   followed	   focused	   on	   their	   ability	   to	   inhibit	   T-­‐cell	  
proliferation.	   Conversely,	   in	   2009,	   Nemeth	   et	   al.	   43	   demonstrated	   in	   vivo	   that	   MSC	   modulation	  
following	  sepsis,	  a	  generalized	  and	  excessive	  inflammatory	  state,	  was	  not	  attributed	  to	  their	  role	  in	  T-­‐
cell	   inhibition,	   as	   demonstrated	   using	  mice	   genetically	   lacking	  mature	   T	   cells.	   Instead,	   they	   found	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that	  depletion	  of	  M/MΦ	  eliminated	  the	  efficacy	  of	  MSC	  treatment	  on	  survival	  in	  the	  murine	  model.	  
Furthermore,	  by	  combining	   in	  vivo	  and	   in	  vitro	  data,	   the	  authors	  showed	  that	  MSCs	  primed	  by	  the	  
inflammatory	   environment	   increase	   their	   synthesis	   of	   prostaglandin	   E2	   (PGE2),	   resulting	   in	   the	  
induction	  of	  anti-­‐inflammatory	  IL-­‐10	  production	  by	  MΦs.	  To	  test	  the	  mechanism	  of	  interaction,	  three	  
different	  types	  of	  co-­‐cultures	  were	  employed:	  I)	  direct	  culture	  in	  which	  MSCs	  and	  MΦs	  were	  seeded	  
in	  a	  mixed	  monolayer	  allowing	  direct	  cell-­‐cell	  physical	  contact;	   II)	   transwell	  cultures	   in	  which	  MSCs	  
were	   seeded	   on	   the	   transwell	   membrane	   insert	   and	   MΦs	   were	   seeded	   on	   the	   well	   bottom,	  
preventing	  direct	  cell	  contact;	  and	  III)	  conditioned	  medium	  (CM)	  co-­‐culture	  experiments	  in	  which	  the	  
culture	  media	  from	  the	  MSCs	  was	  mixed	  1:1	  into	  the	  MΦ	  culture	  media.	  Using	  these	  strategies,	  the	  
authors	  were	  able	  to	  suggest	  that	  direct	  contact	  between	  the	  two	  cell	  types	  is	  necessary	  to	  stimulate	  
IL-­‐10	   production.	   However,	   recent	   research	   has	   also	   reported	   MSC-­‐mediated	   suppression	   of	   MΦ	  
inflammation	   in	   transwell	   and	   CM	   experiments	   44-­‐46.	   Taken	   together,	   while	   the	   exact	   signaling	  
pathway	  between	  MSCs	  and	  M/MΦs	  has	  not	  yet	  been	  elucidated,	  their	  communication	  appears	  to	  
be	  based	  on	  both	  direct	  contact	  and	  paracrine	  interactions.	  
Focusing	   on	   the	   paracrine	   mechanism,	   the	   effect	   of	   MSC-­‐secreted	   factors	   on	   MΦs	   seems	   to	   be	  
enabled	  by	  the	  release	  of	  PGE2,	  in	  both	  murine	  and	  human	  MSCs,	  but	  the	  release	  of	  indoleamine	  2,3-­‐
dioxygenase	   in	   vitro	   47	   and	   tumor	  necrosis	   factor-­‐inducible	   gene	  6	   in	   vitro	  and	   in	   vivo	   48	   have	  also	  
been	   implicated	   in	   the	   immunosuppressive	   effects	   of	   MSCs.	   Furthermore,	   the	   suppression	   and	  
control	  of	   inflammation	  by	  MSCs	  is	  not	  only	  achieved	  by	  the	  release	  of	  selected	  cytokines,	  but	  also	  
by	  their	  capacity	  to	  induce	  a	  shift	  in	  the	  macrophage	  phenotype	  from	  M1	  towards	  M2	  as	  reported	  by	  
numerous	   papers	   in	   both	   direct	   and	   indirect	   cultures	   in	   vitro	   and	   in	   vivo	   36,44-­‐55.	   However,	   it	   is	  
important	  to	  understand	  that	  MSCs	  must	  be	  pre-­‐exposed	  to	  a	  proinflammatory	  environment	  before	  
becoming	   immunosuppressive	   56,	   and	   thus	   depend	   on	   the	   immune	   cells	   themselves	   to	   exert	   their	  
immunomodulatory	  functions.	  
MΦs	  are	  major	  contributors	  to	  the	  inflammatory	  microenvironment	  and,	  therefore,	  influence	  MSCs	  
as	  much	  as	   they	  are	   influenced	  by	  MSCs.	  While	   the	  effects	  of	  MΦs	  on	  MSCs	  has	  not	   received	   the	  
same	   attention	   as	   the	   reciprocal	   relationship,	   MΦs	   have	   been	   shown	   to	   influence	   not	   only	   the	  
viability	  and	  growth	  of	  MSCs	  57,	  but	  also	  their	  chondrogenic	  58,59,	  osteogenic	  38,60,61	  and	  myogenic	  62	  
differentiation	   potential.	   In	   general,	   the	   effects	   of	   MΦs	   appear	   to	   be	   dependent	   on	   the	  
activation/polarization	   state	   of	   the	   MΦs.	   Accordingly,	   MΦs	   activated	   by	   IL-­‐1β	   promote	   the	  
differentiation	   of	   human	   adipose	   tissue-­‐derived	  MSCs	   into	   smooth	  muscle	   cells	   62,	  while	  M1	  MΦs	  
inhibit	   58,	   whereas	   M2	   MΦs	   promote	   59,	   chondrogenesis.	   Furthermore,	   MΦs	   have	   been	  
demonstrated	  to	  be	  essential	  for	  osteogenesis	   in	  general	  63.	  Contradictory	  data	  regarding	  the	  exact	  
MΦ	  phenotype	  involved	  in	  osteogenic	  differentiation	  of	  MSCs	  have	  been	  published.	  Nicolaidou	  et	  al.	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61	  claim	  that	  all	  M/MΦs	  possess	  the	  capability	  to	  induce	  osteogenesis,	  while	  other	  groups	  report	  that	  
osteogenesis	  is	  only	  promoted	  by	  either	  M1-­‐like	  64	  or	  M2-­‐like	  60	  MΦs.	  
	  
1.2.3.2	  MΦ-­‐MSC	  INTERACTIONS	  WITH	  BIOMATERIALS	  
The	  clinical	   interest	   in	  MSCs	   in	   the	  context	  of	  biomaterials	   research	  has	  grown	  drastically	  over	   the	  
last	   decade	  because	  of	   their	   endogenous	  presence	   at	   the	   implantation	   site	   and	   their	   regenerative	  
potential	  across	  a	  broad	  spectrum	  of	  therapeutic	  applications,	  including	  TE	  strategies.	  As	  mentioned	  
in	  the	  previous	  section,	  MSCs	  both	  influence	  and	  are	  influenced	  by	  MΦs.	  This	  interaction	  affects	  the	  
disease	  progression	  of	   sepsis	  and	  GVHD,	   for	  example.	  Therefore,	   the	  crosstalk	  between	  these	  cells	  
can	   influence	   the	   body’s	   healing	   process	   and	   also	   tissue	   remodeling	   in	   response	   to	   implanted	  
biomaterials.	  
In	   a	   recent	   paper,	   Chen	   et	   al.	   60	   identified	   the	   advantages	   of	   using	   in	   vitro	   co-­‐culture	   models	   to	  
investigate	  β-­‐tricalcium	  phosphate	  (β-­‐TCP)-­‐induced	  osseointegration.	  The	  osteoconductive	  nature	  of	  
β-­‐TCP	  is	  well	  recognized	  in	  vivo,	  but	  the	  mechanism	  behind	  the	  osteogenic	  potential	  of	  the	  material	  
has	  not	  yet	  been	  fully	  explained.	  By	  exposing	  MSCs	  to	  CM	  from	  MΦs	  cultured	  in	  direct	  contact	  with	  
β-­‐TCP,	   the	  authors	  were	  able	  to	  correlate	  the	  detected	  osteogenic	  effect	  of	  β-­‐TCP	  with	  a	  material-­‐
induced	   switch	   in	   MΦ	   polarization	   towards	   M2	   and	   an	   activation	   of	   calcium-­‐sensitive	   pathways.	  
Other	   studies	   using	   both	   direct	   and	   transwell	   co-­‐culture	   models	   have	   investigated	   the	  
immunomodulatory	   characteristics	   of	   MSCs	   in	   TE	   strategies.	   MSCs	   encapsulated	   in	   polyethylene	  
glycol	   (PEG)	   hydrogel	   induced	   a	   reduction	   in	   the	   amount	   of	   tumor	   necrosis	   factor	   alpha	   (TNF-­‐α)	  
released	   by	   MΦs	   in	   direct	   in	   vitro	   co-­‐culture,	   which	   was	   further	   correlated	   in	   vivo	   to	   a	   reduced	  
foreign	  body	  response	  to	  the	  implanted	  PEG	  gel	  65.	  This	  paracrine	  interaction	  was	  also	  described	  by	  
Valles	  et	  al.	  66,	  who	  monitored	  the	  effects	  of	  MSCs	  cultured	  either	  on	  two-­‐dimensional	  (2D)	  or	  three-­‐
dimensional	   (3D)	   surfaces	   in	   vitro	   on	   the	   behavior	   of	   MΦs.	   Compared	   with	   conventional	   2D	  
cultivation,	   MSCs	   cultured	   on	   3D	   substrates	   produced	   more	   anti-­‐inflammatory	   PGE2	   and	   tumor	  
necrosis	  factor-­‐inducible	  gene	  6,	  but	  less	  monocyte	  chemoattractant	  protein-­‐1	  (MCP-­‐1)	  and	  IL-­‐6.	  This	  
resulted	   in	   a	   reduction	   in	   monocyte	   chemotaxis	   in	   response	   to	   CM	   from	   MSCs	   cultured	   on	   3D	  
substrates	  in	  an	  in	  vitro	  transwell	  assay.	  Taken	  together,	  the	  results	  of	  these	  studies	  highlight	  the	  role	  
of	   the	   biomaterial	   in	   the	   overall	   cellular	   cascades	   involved	   in	   healing	   and	   suggest	   that	   further	  




1.2.4	  FIBROBLASTS	  AND	  THEIR	  ROLE	  IN	  HEALING	  
Fibroblasts	  are	  the	  majority	  cell	  type	  in	  connective	  tissue	  and	  are	  derived	  from	  primary	  mesenchymal	  
cells.	   They	   are	   a	   heterogeneous	   dynamic	   cell	   population	   that	   displays	   phenotypic	   and	   functional	  
diversity	   based	   on	   their	   anatomical	   origin.	   Fibroblasts	   play	   key	   roles	   in	   various	   processes,	   such	   as	  
tissue	   regeneration,	   ECM	   production	   and	   inflammation	   67.	   However,	   their	   main	   functions	   are	  
synthesizing	   and	   remodeling	   ECM	  molecules	   including	   collagen,	   glycosaminoglycans,	   glycoproteins	  
and	  elastic	   fibers	   68-­‐70.	  However,	  excessive	  deposition	  and	  synthesis	  of	  ECM	  molecules	  may	   lead	   to	  
the	  formation	  of	  scar	  tissue	  or	  a	  fibrous	  capsule	  around	  an	  implant.	  This	  fibrotic	  process	  is	  caused	  by	  
the	  inflammatory	  and	  immunological	  crosstalk	  between	  fibroblasts	  and	  the	  innate/adaptive	  immune	  
system	   through	   the	   expression	   of	   various	   cytokines,	   growth	   factors	   and	   enzymes	   71.	   During	   this	  
process,	   the	   resident	   fibroblasts	   in	   the	   tissue	   are	   activated	   and	   differentiated	   into	  myofibroblasts	  
that	   synchronize	   angiogenesis	   and	   ECM	   formation.	   Thus,	   one	   major	   mediator	   of	   fibrotic	   tissue	  
remodeling	  and	  wound	  healing	   is	   the	  activation	  of	   the	  ECM-­‐producing	  myofibroblasts	   (Wynn	  et	  al.	  
2012,	   Klingberg	   et	   al.	   2014).	   In	   the	   initial	   stage,	   the	   formation	   of	   fibrous	   tissue	   enhances	   the	  
integration	   of	   the	   implant	   with	   the	   surrounding	   tissue.	   Further,	   it	   controls	   and	   modulates	   the	  
inflammatory	   responses	   by	   isolating	   the	   damage	   caused	   by	   the	   implant.	  However,	   over-­‐growth	   of	  
the	  fibrous	  capsule	  can	  interfere	  with	  the	  functionality	  of	  the	  implant,	  which	  may	  lead	  to	  insufficient	  
or	  deteriorating	  implant	  integration	  into	  the	  tissue	  and	  hence	  malfunction	  of	  the	  device.	  
	  
1.2.4.1	  MΦ-­‐FIBROBLAST	  CROSSTALK	  
MΦs	   and	   fibroblasts	   concurrently	   synchronize	   and	   react	   to	   foreign	   materials.	   Crosstalk	   between	  
fibroblasts	   and	  MΦs	   occurs	   via	   complex	   synergistic	   autocrine	   and	   paracrine,	   as	  well	   as	   juxtacrine,	  
signaling	   72.	   These	   cells	   act	   cooperatively	   in	   various	   processes	   related	   to	   cell	   migration,	   implant	  
degradation,	   fibrosis,	   healing	   and	   inflammation.	   Fibroblasts	   and	  MΦs	   secrete	   numerous	   enzymes,	  
growth	  factors,	  ions,	  chemokines	  and	  cytokines	  to	  coordinate	  the	  host	  response	  to	  a	  foreign	  material	  
73.	   Some	   of	   the	   most	   effective	   cytokine	   and	   chemokine	   inflammatory	   signals,	   which	   remain	   up-­‐
regulated	   in	   the	   presence	   of	   a	   foreign	   material,	   include	   TNF-­‐α,	   IL-­‐1,	   macrophage	   inflammatory	  
proteins	   (MIP-­‐1α,	   MIP-­‐1β),	   MCP-­‐1	   and	   the	   Regulated	   on	   Activation,	   Normal	   T	   cell	   Expressed	   and	  
Secreted	   (RANTES)	   chemokine	   12,74-­‐77.	   Specifically,	   activated	  MΦs	  express	   IL-­‐1,	   IL-­‐4,	   IL-­‐10,	   IL-­‐13	  and	  
TNF-­‐α,	  which	  leads	  to	  further	  fibroblast	  activation	  and	  overexpression	  of	  ECM	  molecules.	  
MΦs	  play	  a	  substantial	  role	  in	  remodeling	  and	  fibrosis.	  Signals	  from	  the	  recruited	  and	  locally	  resident	  
MΦs	   promote	   ECM	   synthesis	   by	   fibroblasts	   68-­‐70.	   Deposition	   and	   degradation	   of	   ECM	   requires	   an	  
delicate	  balance	  between	  matrix	  metalloproteinases	  (MMPs)	  and	  tissue	  inhibitors	  of	  MMPs	  (TIMPs),	  
which	   are	   expressed	   by	   MΦs	   71.	   For	   example,	   MMP9	   is	   a	   dominant	   pro-­‐fibrotic	   MMP;	   inhibiting	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MMP9	  can	  suppress	  fibrosis	  78,79.	  Besides	  MMPs,	  TGF-­‐β	  is	  also	  produced	  mainly	  by	  MΦs	  and	  plays	  a	  
fundamental	  pro-­‐fibrotic	  role	   in	  chronic	   fibrotic	  disease	   80.	  TGF-­‐β	  stimulates	  the	  expression	  of	  ECM	  
genes	  and	  down	  regulates	  the	  expression	  of	  ECM	  degrading	  MMPs	  81.	  Overall,	  fibroblasts	  and	  MΦs	  
induce	   both	   chemical	   and	   physical	   modifications	   to	   the	   microenvironment	   that	   regulate	   cell	  
recruitment/proliferation	   and	   the	   production	   of	   ECM,	   proteins	   and	   enzymes	   68,69,74.	   Clarifying	   this	  
intricate	  cross-­‐communication	  between	  the	  fibroblasts	  and	  MΦs	  may	  assist	  in	  material	  selection	  for	  
developing	  a	  fully	  functional	  implant.	  
The	  type	  of	  communication	  and	  signaling	  routes	  between	  fibroblasts	  and	  MΦs,	  as	  well	  as	  the	  source	  
of	   the	   cells	   (primary	   or	   secondary),	   play	   key	   roles	   in	  models	   of	   the	   foreign	   body	   reaction	   in	   vitro.	  
These	   cells	   communicate	   through	   various	   signaling	   routes	   including	   autocrine,	   paracrine	   (indirect	  
cell-­‐cell	   signaling)	  and	   juxtacrine	   (direct	   cell-­‐cell	   signaling).	  Holt	  et	  al.	   72	   cultured	  both	  primary	  and	  
secondary	   cells	   in	   mono-­‐	   and	   co-­‐culture	   formats	   to	   model	   different	   cell-­‐cell	   communication	  
conditions.	  The	  presence	  of	  both	  an	   inflammatory	  cell	  activator	  and	  an	  exogenous	  activating	  agent	  
such	   as	   LPS,	   IFN-­‐γ	   or	   phorbol	   esters	   are	   necessary	   to	   recreate	   the	   expressive	   cell	   inflammatory	  
response.	  The	  morphologies	  of	   the	  primary	  and	  secondary	  cells	  under	  paracrine	  and	   juxtacrine	  co-­‐
culture	   conditions	   were	   both	   similar	   to	   their	   respective	   monocultures.	   However,	   the	   LPS-­‐treated	  
MΦs	   in	  mono-­‐	  and	  co-­‐culture	  displayed	  a	  highly	  activated	  morphology	   that	  normally	   results	   in	   the	  
formation	  of	  FBG	  cells.	  LPS-­‐stimulated	  MΦs	  expressed	  more	  inflammatory	  cytokines,	  such	  as	  IL-­‐6	  and	  
TNF-­‐α,	   compared	  with	   the	   non-­‐stimulated	   cells,	   and	   this	   effect	   was	  more	   pronounced	   in	   primary	  
cells.	  Other	  groups	  have	  reported	  that	  stimulated	  fibroblasts	  in	  monoculture	  express	  more	  IL-­‐6	  than	  
non-­‐stimulated	  fibroblasts	  82.	  
Several	  cytokines	  and	  soluble	  factors,	  such	  as	  PGE2,	  released	  by	  fibroblasts	  can	   limit	  the	  release	  of	  
MIP-­‐1b,	   MIP-­‐1a	   and	   TNF-­‐α	   by	   MΦs	   83,84.	   Paracrine	   and	   juxtacrine	   co-­‐culture	   systems	   showed	   a	  
decrease	   in	   the	  expression	  of	   these	   cytokines	   compared	  with	  monocultures.	  However,	   it	   has	  been	  
reported	  that	  IL-­‐6	  and	  RANTES	  are	  downregulated	  only	  in	  primary	  MΦ	  co-­‐cultures,	  not	  in	  secondary	  
MΦ	  co-­‐cultures.	  This	  effect	  may	  be	  caused	  by	  mutual	  cytokine	  down-­‐regulation	  that	  only	  occurs	   in	  
primary	  cells	  72.	  Upregulation	  of	  TNF-­‐α	  increases	  the	  expression	  of	  MCP-­‐1,	  which	  is	  a	  mitogenic	  factor	  
for	   fibroblasts	   85.	   Paracrine	   and	   juxtacrine	   signaling	   in	   co-­‐cultured	   primary	   MΦs	   induced	   a	   large	  
increase	  in	  MCP-­‐1	  expression	  compared	  with	  that	  in	  monocultures	  72.	  
	  
1.2.4.2	  MΦ-­‐FIBROBLAST	  INTERACTIONS	  WITH	  BIOMATERIALS	  
Together,	  MΦs	  and	   fibroblasts	   can	  orchestrate	   the	  degradation	  of	   natural	   biomaterials	   and	  native	  
tissues,	  especially	  connective	   tissue.	  The	   first	   two	   innate	  events	   that	  occur	   in	  host-­‐cell	   interactions	  
are:	  1)	  stimulation	  of	  MΦs,	  and	  2)	  MΦ-­‐enhanced	  fibroblast	  recruitment	  and	  their	  cooperative	  effects	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on	   the	   implant	   86.	  Activated	  MΦs	  attach	  directly	   to	  a	  biomaterial	  and	  FBG	  cells	   secrete	  mediators,	  
such	   as	   degradative	   enzymes,	   superoxide	   anions,	   oxygen	   free	   radicals	   and	   reactive	   oxygen	  
intermediates,	  which	   facilitate	   the	  degradation	  of	   the	  biomaterial.	   The	  maximum	  concentration	  of	  
these	  degradative	  agents	  is	  found	  at	  the	  implant-­‐host	  interface.	  However,	  the	  chemical	  composition	  
of	  the	   implant	   is	  the	  key	  determinant	  of	  the	  probability	  that	  an	   implant	  will	  degrade.	  For	  example,	  
polyethylene	   and	   polypropylene	   polymers	   are	   susceptible	   to	   surface	   oxidation.	   Polyesters	   such	   as	  
polycaprolactone,	  poly(glycolic	  acid)	  and	  poly(lactic	  acid)	   can	  be	  enzymatically	  degraded	   into	   small	  
monomers	   that	   are	   metabolized	   through	   the	   Krebs’	   cycle.	   A	   few	   studies	   exist	   showing	   that	  
fibroblasts	   are	   also	   capable	   of	   releasing	   hydrolases	   and,	   therefore,	   contribute	   to	   the	   degradation	  
process	   through	   phagocyte-­‐like	   functionality.	   After	   adhering	   to	   an	   implant,	   fibroblasts	   synthesize	  
ECM.	   These	   ECM	  molecules	   stimulate	   the	   production	   of	   degradative	   enzymes,	   inducing	   hydrolytic	  
reactions.	   They	   may	   also	   further	   increase	   the	   degradation	   of	   fibrous	   electrospun	   scaffolds	   by	  
inducing	   stress	   on	   the	   structure	   after	   attachment.	   In	   addition,	  MΦs	   and	   fibroblasts	   synergistically	  
facilitate	   the	   degradation	   of	   dextran-­‐poly(lactic-­‐co-­‐glycolic	   acid)	   (PLGA)	   scaffolds	   67.	   Dextran-­‐PLGA	  
scaffolds	   seeded	  with	  MΦ-­‐fibroblast	   co-­‐cultures	  were	   degraded	   faster	   than	   scaffolds	   seeded	  with	  
only	   one	  particular	   cell	   type.	  However,	  MΦs	   alone	   are	  more	  degradative	   than	   fibroblasts	   because	  
they	  release	  a	  wider	  range	  of	  enzymes	  and	  oxidative	  agents	  67.	  
Chronic	  inflammation	  typically	  results	  in	  damage	  to	  and	  degradation	  of	  connective	  tissue	  caused	  by	  
the	  elimination	  of	  collagen	  or	  proteoglycans.	  The	  presence	  of	  MΦs	  and	  fibroblasts,	  along	  with	  T	  and	  
B	   lymphocytes	   in	   the	  chronic	   inflammatory	  environment	   suggests	   that	   these	  cells	  play	   roles	   in	   the	  
degradation	   of	   connective	   tissues,	   such	   as	   cartilage.	   Huybrechts-­‐Godin	   et	   al.	   87	   reported	   that	  
mitogen-­‐stimulated	   and	   proteinase-­‐secreting	   MΦs	   cooperate	   with	   fibroblasts	   and	   enhance	   their	  
capacity	   for	  collagenase	  synthesis,	  subsequently	   leading	  to	  collagen	  degradation	  87.	  The	  addition	  of	  
lymphocyte	   factors	   has	   been	   observed	   to	   increase	   the	   crosstalk	   between	  MΦs	   and	   fibroblasts	   in	  
direct	   co-­‐cultures,	   but	   has	   no	   direct	   effect	   on	   fibroblasts	   alone	   87.	   This	   finding	   confirms	   that	   the	  
production	  of	  collagenase	  by	  fibroblasts	  is	  partially	  controlled	  by	  communication	  between	  fibroblasts	  
and	  the	  various	  other	  cellular	  and	  humoral	  components	  of	  the	  immune	  system.	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1.2.5	  ENDOTHELIAL	  CELLS	  AND	  THEIR	  ROLE	  IN	  HEALING	  
Endothelial	   cells	   (ECs)	   line	   the	   entire	   vasculature,	   forming	   an	   inner	   cell	   layer	   that	   serves	   as	   a	  
multifunctional	  barrier	  between	  the	  bloodstream	  and	  the	  surrounding	  tissues.	  Consequently,	  ECs	  are	  
involved	  in	  a	  wide	  variety	  of	  different	  functions	  important	  for	  physiological	  homeostasis	  of	  the	  body.	  
Being	  in	  direct	  contact	  with	  the	  blood,	  ECs	  function	  as	  a	  semi-­‐permeable	  barrier	  that	  controls	  solute	  
and	   macromolecule	   transfer	   through	   the	   endothelium.	   ECs	   have	   multifunctional	   paracrine	   and	  
endocrine	   characteristics,	   including	   involvement	   in	   1)	   immune	   and	   inflammatory	   reactions	   by	  
regulating	  leukocyte	  migration	  into	  the	  tissue;	  2)	  the	  formation	  of	  a	  non-­‐thrombogenic	  vessel	  lumen	  
by	  regulating	  thrombosis,	  coagulation,	  platelet	  adherence,	  fibrinolysis,	  vascular	  tone	  and	  blood	  flow;	  
3)	   angiogenesis,	   the	   sprouting	   of	   new	   blood	   vessels	   from	   pre-­‐existing	   vascular	   tubes	   and	   4)	  
vasculogenesis,	   the	   formation	  of	  new	  blood	  vessels	  via	   the	  migration,	  assembly	  and	  maturation	  of	  
ECs	  88.	  These	  last	  two	  EC	  functions,	  the	  formation	  and/or	  expansion	  of	  new	  functional	  blood	  vessels	  
for	   tissue	   vascularization,	   regeneration	   and	   growth,	   are	   of	   particular	   interest	   to	   the	   field	   of	  
biomaterials	   and	   the	   development	   of	   regenerative	   therapies,	   which	   includes	   wound	   healing,	   cell	  
transplantation	  approaches	  and	  TE	  strategies.	  Angiogenesis	  at	   the	   implantation	  site	   is	  necessary	  to	  
improve	   the	   integration	   of	   the	   scaffold	   into	   the	   native	   host	   tissue	   89.	   This	   process	   has	   long	   been	  
understood	   to	   involve	   dynamic	   and	   bidirectional	   interactions	   between	  M/MΦs	   and	   ECs	   90,91.	   The	  
expansion	   of	   blood	   vessels	   is	   divided	   into	   two	   phases:	   vessel	   sprouting	   and	   vessel	   anastomosis.	  
Following	  an	  angiogenic	  stimulus,	  vessel	  sprouting	  occurs,	  which	  includes	  the	  transition	  of	  ECs	  from	  a	  
quiescent	  to	  an	  active	  state	  and	  proteases	  are	  secreted	  to	  open	  the	  basal	  lamina	  and	  enable	  vascular	  
growth	  92.	  Here,	  M/MΦs	  directly	  regulate	  the	  patterning	  of	  the	  local	  ECM	  degradation,	  consequently	  
influencing	  the	  distribution	  of	  neovessel	  formation	  and	  their	  branch	  points	  93	  94.	  Anastomoses	  occur	  
when	   two	   angiogenic	   sprouts	  meet	   and	   connect	   to	   form	   a	   new	   closed	   vascular	   tube.	   In	   this	  way,	  
complex	  vascular	  networks	  can	  be	  assembled	  for	  the	  (re)vascularization	  of	  ischaemic	  tissue,	  wounds	  
or	  biomaterials	   introduced	   for	  TE	  applications.	   It	  was	   shown	   that	  MΦs	   interact	  physically	  with	  ECs	  
during	   the	   process	   of	   anastomosis	   formation	   to	   promote	   tip	   cell	   fusion	   during	   development	   95,96.	  
Recent	   studies	   investigating	   materials	   for	   TE	   have	   further	   emphasized	   the	   important	   role	   of	  
infiltrating	  inflammatory	  cells	  (primarily	  M/MΦs)	  for	  vascular	  host	  cell	  recruitment,	  tissue	  formation	  
and	  maturation	  97,98.	  Consequently,	  MΦ	  depletion	  can	  inhibit	  neovessel	  formation,	  as	  demonstrated	  
by	  the	  absence	  of	  cellular	  infiltration	  and	  incomplete	  endothelialisation.	  In	  summary,	  the	  interactions	  
between	  M/MΦs	  and	  ECs	  during	   these	  angiogenic	  processes	  are	  based	  on	  direct	  bidirectional	  cell-­‐
cell	  interaction;	  the	  secretion	  of	  classic	  pro-­‐angiogenic	  factors,	  including	  inflammatory	  cytokines	  and	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M/MΦs	   significantly	   support	   EC	   growth	   and	   proliferation	   when	   the	   cells	   are	   cultured	   in	   direct	  
contact.	   Such	  direct	   co-­‐culture	   of	  monocytes	   and	  human	  umbilical	   vein	   endothelial	   cells	   (HUVECs)	  
revealed	  increased	  BrdU	  incorporation	  in	  HUVECs	  and	  a	  higher	  cell	  density	  in	  co-­‐culture	  99.	  Increased	  
proliferation	  also	  occurs	  with	  either	  a	  subset	  of	  pro-­‐angiogenic	  CD14+,	  CD16+	  and	  CD163+	  M/MΦs	  
100	  or	  VEGF-­‐stimulated	  MΦs	  101	  co-­‐cultured	  with	  dermal	  microvascular	  ECs.	  In	  most	  cases,	  a	  confluent	  
monolayer	  of	  ECs	  can	  be	  found	  in	  the	  co-­‐culture,	  but	  not	  monoculture,	  conditions	  100,102.	  In	  fact,	  the	  
numerical	   ratio	   between	   the	   (co-­‐)cultured	   cells	   significantly	   influences	   this	   proliferative	   effect.	  
Further,	   monocytes	   also	   exhibit	   higher	   proliferation	   rates	   when	   exposed	   to	   HUVECs	   in	   direct	   co-­‐
culture	   conditions	   103,104.	   All	   of	   these	   findings	   highlight	   the	   positive	   correlation	   between	   the	   pro-­‐
angiogenic	   effects	   of	  MΦs	   and	   the	   actual	   number	   of	   ECs	   in	   the	   co-­‐culture	   systems	   101,104.	   Similar	  
results	  have	  been	  obtained	  from	  classic	   in	  vitro	  scratch/wound	  healing	  assays,	   in	  which	  a	  scratch	  is	  
made	  on	  an	  EC	  monolayer	  to	  test	  and	  quantify	  EC	  migration	  into	  the	  denuded	  areas.	  The	  presence	  of	  
monocytes	  in	  this	  assay	  accelerates	  the	  re-­‐endothelialisation	  process	  99.	  Apart	  from	  this	  bidirectional	  
proliferative	  effect,	  the	  time-­‐dependent	  transformation	  of	  monocytes	   into	  endothelial-­‐like	  cells	  has	  
been	   described	   following	   their	   adherence	   to	   a	   pre-­‐existing	   endothelium	   105,106,	   interaction	   with	  
biomaterials	  107	  and	  exposure	  to	  an	  angiogenic	  environment	  108,109.	  The	  ability	  of	  M/MΦs	  to	  promote	  
angiogenesis	   has	   been	   associated	   with	   the	   secretion	   of	   classic	   pro-­‐angiogenic	   factors	   as	  
demonstrated	  with	   experiments	  using	   indirect	   co-­‐culture	   systems,	   both	   through	  CM	  exposure	   and	  
membranes	   filters	   that	   prevent	   direct	   cell	   contact.	   These	   co-­‐culture	   systems	   are	   suitable	   tools	   for	  
studying	   the	   expression	   of	   soluble	   factors	   such	   as	   VEGF,	   basic	   fibroblast	   growth	   factor	   (bFGF),	  
placental	  growth	  factor	  (PIGF),	  angiopoietin	  (Ang-­‐1,	  Ang-­‐2)	  and	  IL-­‐8.	  EC	  proliferation	  is	  enhanced	  by	  
exposure	   to	   CM	   from	   activated	   monocytes	   in	   a	   concentration-­‐dependent	   manner	   110.	   Indeed,	  
neutralizing	   antibodies	   against	   bFGF,	   VEGF	   and	   IL-­‐8	   partially	   reverse	   this	  mitogenic	   effect	   110.	   The	  
stimulating	  effects	  of	  bFGF	  and	  VEGF	  on	  the	  formation	  of	  capillary-­‐like	  structures	  by	  ECs	  were	  larger	  
if	  they	  were	  co-­‐cultured	  with	  THP-­‐1	  monocytic	  cells	  111.	  Furthermore,	  pleiotrophin	  enhances	  both	  the	  
migration	   and	   pro-­‐angiogenic	   response	   of	   ECs	   and	   the	   expression	   of	   angiogenic	   molecules	   by	  
monocytes	  112.	  	  
Taken	   together,	   these	   data	   indicate	   that	   the	   bidirectional	   interaction	   between	   M/MΦs	   and	   ECs	  
involves	   both	   the	   release	   of	   a	   broad	   spectrum	   of	   pro-­‐angiogenic	  mediators,	   as	   well	   as	   the	   direct	  
physical	  interaction	  of	  the	  two	  cell	  types.	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1.2.5.2	  MΦ-­‐EC	  INTERACTION	  WITH	  BIOMATERIALS	  
There	  is	  very	  strong	  evidence	  that	  the	  composition	  of	  polymers	  in	  scaffolds	  alters	  the	  activation	  state	  
of	  M/MΦs,	  which	  ultimately	  affects	  the	  angiogenic	  response	  to	  the	  biomaterial.	  In	  activated	  M/MΦs,	  
the	  mRNA	  expression	  of	   angiogenic	   genes	   and	   the	   release	  of	   angiogenic	  mediators	   such	  as	  Ang-­‐1,	  
thrombospondin-­‐1	  (Tsp-­‐1)	  and	  VEGF,	  are	  dependent	  on	  the	  polymer	  material	  used	  113-­‐115.	  M/MΦs	  in	  
direct	   contact	   with	   various	   polymeric	   materials,	   such	   as	   poly(L-­‐lactic	   acid)	   and	   PLGA,	   exhibit	   a	  
different	  release	  profile	  of	  inflammatory	  cytokines	  such	  as	  RANTES,	  TNF-­‐α,	  IL-­‐α/β,	  IL-­‐3,	  IL-­‐8	  and	  IL-­‐10	  
114.	   In	   addition,	   the	  medium	   conditioned	   by	  M/MΦs	   in	   contact	  with	   different	   polymeric	  materials	  
may	  alter	  the	  proliferation,	  viability	  and	  capillary	  sprouting	  ability	  of	  ECs	  113,114.	  Significantly	  improved	  
in	   vitro	  wound	   closure	  has	  been	  detected	  on	  EC	  monolayers	  using	   such	  CM	   in	   studies	  of	  different	  
polymeric	   materials,	   pointing	   towards	   paracrine	   mediators	   as	   important	   signals	   for	   guiding	  
regeneration	   114.	   Thus,	   vascularization	   and	   the	   long-­‐term	   integration	   of	   implanted	   scaffolds	   with	  
native	   tissue	   can	   be	   promoted	   by	   incorporating	   active	   paracrine	   agents	   116.	   For	   example,	   pro-­‐
angiogenic	  C16	  peptides	  and	  anti-­‐inflammatory	  Ac-­‐SDKP	  peptides	  were	  incorporated	  into	  a	  collagen	  
gel	   that	  was	   then	   loaded	   into	   porous	   scaffolds	   to	   evaluate	   their	   controlled	   release	   in	   HUVEC	   and	  
M/MΦ	   co-­‐cultures	   116.	   A	   high	   degree	   of	   interdependence	   between	   angiogenesis,	   assessed	   by	   the	  
tubologenesis	  of	  the	  ECs,	  and	  inflammation,	  assessed	  by	  the	  phagocytic	  activity	  of	  the	  M/MΦs,	  was	  
detected	   116.	   Furthermore,	   incorporation	   of	   the	   proinflammatory	   molecule	   fibrinogen	   into	   the	  
chitosan	  biomaterial	  clearly	  decreased	  the	  expression	  of	  inflammatory	  cytokines	  while	  increasing	  the	  
secretion	  of	  growth	   factors	  and	  mediators	   involved	   in	  wound	  healing	  and	  angiogenesis	   115.	   Several	  
other	  studies	  have	  also	  reported	  enhanced	  vascularization	  and/or	  wound	  healing	   in	  vitro	  and/or	   in	  
vivo	   by	   incorporating	   VEGF	   117,	   PDGF-­‐BB/FGF2	   118,	   laminin-­‐5	   119,	   phytochemically-­‐stabilized	   gold	  
nanoparticles	   120,	  bFGF	   121	  and	  calcium	  phosphate	   122	   into	  different	  biomaterials.	  The	  phenotype	  of	  
the	  MΦs	  plays	  a	  key	  role	  in	  the	  induction	  of	  angiogenesis.	  Spiller	  et	  al.	  showed	  that	  not	  only	  the	  M2	  
phenotype,	   but	   also	   the	   coordinated	   transition	   from	   the	   M1	   to	   M2	   phenotype	   promotes	  
angiogenesis	  in	  TE	  scaffolds	  123.	  For	  example,	  decellularized	  bone	  scaffolds	  that	  sequentially	  released	  
the	  M1-­‐promoting	   cytokine	   IFN-­‐γ	   and	   then	   the	  M2-­‐promoting	   cytokine	   IL-­‐4,	   promoted	   sequential	  
polarization	   from	  M1	   to	  M2	   as	   defined	   by	   their	   gene	   expression	   profile	   and	   cytokine	   release	   124.	  
Interestingly,	  these	  scaffolds	  exhibited	  in	  vivo	  a	  higher	  vascularization	  capacity,	  suggesting	  that	  both	  
M1	  and	  M2	  MΦs	  are	  necessary	  to	  achieve	  scaffold	  vascularization.	  That	  result	  is	  in	  agreement	  with	  
the	   findings	   of	  Oliveira	  et	   al.,	  who	   reported	   that	   the	   density	   of	  MΦs	   and	   not	   their	   polarization	   is	  
responsible	  for	  improving	  in	  vivo	  angiogenesis	  122.	  
In	   addition	   to	   polymer	   composition	   and	   exogenously	   incorporated	   mediators,	   the	   fiber,	   pore	  
dimensions	   and	   size	   of	   the	   interconnected	   pores	   influence	   the	   resulting	   vascularization	   125,126.	  
Polydioxanone	   scaffolds	   with	   larger	   pore	   sizes	   and	   fiber	   diameters	   induce	   higher	   expression	   of	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angiogenic	   cytokines	   by	   MΦs	   co-­‐cultured	   with	   the	   scaffolds.	   Further,	   this	   angiogenic	   cytokine	  
secretion	  increased	  the	  length	  and	  density	  of	  the	  EC	  sprouts	  125.	  Taken	  together,	  all	  of	  these	  studies	  
demonstrate	  that	  TE	  scaffolds	  can	  be	  designed	  to	  maximize	  the	  angiogenic	  response	  of	  the	  MΦs	  to	  
the	  implanted	  biomaterial.	  However,	  it	  should	  be	  noted	  that	  a	  balanced	  expression	  of	  both	  pro-­‐	  and	  
anti-­‐angiogenic	  factors	  is	  necessary	  to	  inhibit	  tumor	  growth	  and	  enable	  physiological	  performance	  of	  
biomaterials	  in	  future	  TE	  applications.	  
	  
1.2.6	  MACROPHAGE	  CO-­‐CULTURE	  MODELS:	  BENEFITS	  AND	  LIMITATIONS	  
Healing	  following	  implantation	  of	  a	  construct	  or	  biomaterial	  for	  TE	  is	  a	  complex	  event	  that	  involves	  
the	  interplay	  between	  different	  cell	  types.	  Therefore,	  the	  current	  standard	  for	  evaluating	  graft-­‐host	  
interactions	   is	  the	  use	  of	   in	  vivo	  models.	  However,	  these	   investigations	  are	  expensive,	  raise	  several	  
ethical	   questions	   and	   the	   results	   are	   not	   always	   fully	   predictive	   of	   the	   human	   physiology	   due	   to	  
significant	   inter-­‐species	  variability.	  The	  development	  of	  new	  drugs	  perfectly	  exemplifies	   the	   lack	  of	  
consistency	   between	   animal	   and	   clinical	   studies.	   Clinical	   trials	   for	   new	   drugs	   are	   only	   conducted	  
following	   substantial	   evidence	   for	   efficacy	   and	   safety	   in	   animals.	   However,	   in	   spite	   of	   their	   initial	  
success	  in	  animal	  models,	  85%	  of	  new	  drugs	  fail	  during	  early	  clinical	  trials	  and,	  of	  those	  that	  survive	  
through	  to	  phase	  III,	  only	  half	  are	  approved	  for	  clinical	  use	  127.	  Creating	  predictive	  in	  vitro	  evaluation	  
systems	  using	  human	  cells	  would	  reduce	  the	  need	  for	  in	  vivo	  animal	  experiments	  and	  may	  decrease	  
the	   time	   for	  drug	  development.	   In	  addition,	   it	  may	  allow	   for	  mechanistic	  analyses	  and	  also	   reduce	  
costs.	   However,	   there	   are	   also	   several	   limitations	   associated	  with	   the	   use	   of	   in	   vitro	  models.	   The	  
majority	   of	   cell-­‐based	   in	   vitro	  models	   are	   limited	   to	   the	   use	   of	   a	   single	   cell	   type,	  which	   does	   not	  
correspond	   to	   the	   complex	   interactions	   that	   occur	   in	   vivo	   72.	   Therefore,	   co-­‐culture	  models	   usually	  
better	   capture	   the	   dynamic	   cellular	   interactions	   and	   biomaterial-­‐associated	   signaling	   than	   mono-­‐
culture	  based	  assays.	  As	  previously	  mentioned,	  the	  presence	  of	  MΦs	  can	  modulate	  the	  behavior	  of	  
various	  cell	  types	   including	  MSCs,	  ECs	  and	  fibroblasts	  during	  biomaterials	  evaluation	  testing.	   In	  this	  
regards	   the	   development	   of	   an	   in	   vitro	   co-­‐culture	  model	   including	  macrophages	   that	   successfully	  
mimics	  the	  complex	  healing	  process	  evident	  in	  vivo	  still	  faces	  a	  series	  of	  challenges:	  
First,	  an	  appropriate	  in	  vitro	  model	  must	  be	  selected	  for	  each	  application.	  Various	  cells	  can	  be	  used	  
for	   MΦ-­‐based	   immunological	   studies	   (Table	   1),	   and	   an	   appropriate	   cell	   type	   should	   be	   carefully	  
selected	  based	  on	  the	  experimental	  setup.	  Although	  human	  cells	  are	  superior	  to	  murine	  models	  with	  
regards	   to	   clinical	   translation	   a	   plethora	   of	   groups	   still	   use	   cells	   of	   murine	   origin,	   notably	   the	  
transformed	   cell	   line	   RAW	   264.7.	   Although	   the	   use	   of	   these	   murine	   lines	   is	   commonly	   accepted,	  
substantial	   differences	   between	   the	   immunobiology	   of	   humans	   and	   mice	   have	   been	   clearly	  
demonstrated	   128.	   In	   addition,	   significant	   variation	   has	   been	   observed	   between	   the	   responses	   of	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primary	   versus	   transformed	   murine	   macrophages	   to	   biomaterials,	   which	   may	   lead	   to	   misleading	  
conclusions	  129.	  Human	  cell	  lines,	  such	  as	  THP-­‐1,	  do	  not	  entirely	  mimic	  the	  behavior	  of	  primary	  cells	  
either,	  even	  if	  they	  are	  useful	  alternative	  models	  given	  their	  homogeneous	  genetic	  background.	  The	  
consistent	   behavior	   of	   cell	   lines	   helps	   in	   the	   identification	   of	  mechanisms	   involved	   in	   the	   cellular	  
response	   to	   particular	   culture	   conditions	   130.	   Compared	   with	  murine	   and	   human	   transformed	   cell	  
lines,	   primary	   cells	   isolated	   from	   blood	   donors	   usually	   show	   high	   inter-­‐patient	   variability	   and	   low	  
proliferative	   potential	   in	   vitro.	   Furthermore,	   different	   isolation	   and	   culturing	   procedures	  may	   limit	  
the	  experimental	  reproducibility	  and	   it	  would	  therefore	  be	   important	  to	  establish	  standardized	  cell	  
cultivation	   and	   analytical	   protocols,	   which	   could	   facilitate	   comparability	   of	   different	   studies.	   The	  
selection	   of	   primary	   MSCs	   poses	   similar	   challenges	   because	   of	   their	   inherent	   heterogeneity.	   In	  
addition,	   the	   immunomodulatory	   capability	   of	  MSCs	   is	   also	   affected	   by	   the	   cell	   source	   55,	   passage	  
number	  131	  and	  exposure	  time	  132.	  Likewise,	  there	  are	  differences	  between	  ECs	  isolated	  from	  arterial,	  
dermal	  microvascular,	  umbilical	  vein	  and	  pulmonary	  microvascular	  tissues.	  
Other	  factors	  limiting	  the	  utility	  of	  in	  vitro	  macrophage	  co-­‐cultures	  are	  the	  absence	  of	  inflammatory	  
stimulators,	   such	   as	   LPS,	   IFN-­‐γ	   and	   TNF-­‐α,	   and	   other	   inflammatory	   cells,	   such	   as	   T	   and	   B	   cells	   75.	  
Exogenous	  inflammatory	  stimulators	  have	  been	  observed	  in	  the	  host-­‐biomaterial	  interface	  and	  thus	  
should	   be	   added	   to	   in	   vitro	   models.	   However,	   even	   the	   presence	   of	   these	   stimuli	   might	   not	   be	  
sufficient	   to	   reproduce	   in	  vivo	  events.	  Several	   studies	  have	  shown	  that	  MΦs	  stimulated	   in	  vitro	  do	  
not	  fully	  mimic	  the	  inflammatory	  behavior	  of	  cells	  stimulated	  in	  vivo	  75.	  For	  example,	  the	  expression	  
of	  IL-­‐6	  was	  not	  responsive	  to	  LPS	  stimulation	   in	  vitro,	  whereas	  LPS	  stimulation	   in	  vivo	   increased	  the	  
expression	  of	  TNF-­‐α	  and	  other	  proinflammatory	  cytokines	   133,134.	   In	  vitro	  evaluations	  of	  biomaterial	  
biocompatibility	   should	   also	   determine	   the	   effects	   of	   the	   biomaterial	   on	   the	   innate	   and	   acquired	  
immune	  cells	  such	  as	  T	  cells,	  B	  cells,	  natural	  killer	  cells	  and	  granulocytes	  69,135.	  Consequently,	  in	  vitro	  
models	  lacking	  these	  inflammatory	  cells	  are	  limited	  in	  their	  ability	  to	  accurately	  represent	  the	  in	  vivo	  
cellular	   crosstalk.	   Together,	   the	   timing	   and	   microenvironment	   of	   cellular	   interactions	   between	  
macrophages	   and	   other	   cell	   types	   define	   the	   final	   host	   response;	   in	   vitro	   models	   that	   fail	   to	  
recapitulate	  the	   in	  vivo	  environment	  are	  of	   limited	  value	  for	  predicting	  the	  tissue	  response	   in	  vivo.	  
For	   example,	   the	   immunomodulatory	   capacity	   of	   MSCs	   depends	   on	   the	   presence	   of	   the	  
inflammatory	   environment	   created	   by	  MΦs,	   while	   the	   inflammatory	   state	   created	   by	   the	  MΦs	   is	  
likewise	   affected	   by	   the	   presence	   of	  MSCs.	   Furthermore,	   the	   challenge	   of	   tracking	  MSCs	   and	   the	  
plasticity	   of	   the	   MΦ	   phenotype	   makes	   it	   difficult	   to	   establish	   cause-­‐and-­‐effect	   timelines	   of	   their	  
interactions	   in	   vivo.	   For	   example,	   one	   in	   vitro	   MФ-­‐MSC	   co-­‐culture	  model	   failed	   to	   show	   that	   the	  
degree	   of	   MSC	   differentiation	   when	   encapsulated	   in	   a	   PEG	   gel	   was	   linearly	   correlated	   with	   an	  
increase	  in	  capsule	  formation	  in	  vivo	  65.	  This	  suggests	  that	  in	  vitro	  co-­‐culture	  models	  alone	  are	  not	  yet	  
sufficient	  for	  predicting	  the	  many	  possible	  outcomes	  following	  biomaterial	  implantation.	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Another	   challenge	   for	   in	   vitro	   co-­‐culture	   models	   is	   replicating	   the	   in	   vivo	   mechanical	  
microenvironment.	   All	   tissues	   and	   organs	   within	   the	   body	   are	   exposed	   to	   continuous	   or	   pulsatile	  
mechanical	  stimuli.	  Static	  in	  vitro	  co-­‐culture	  models	  typically	  do	  not	  consider	  this	  biologically	  relevant	  
aspect	  of	  tissue	  healing.	  The	  endothelium	  in	  the	  native	  environment	  in	  particular	  is	  exposed	  to	  shear	  
stress	  and	  dynamic	   fluid	   flow.	  Therefore,	   investigations	  of	  monocyte	  extravasation	  and	  endothelial	  
activation	  may	  find	  different	  results	   in	  static	  and	  dynamic	  cultures.	  In	  fact,	  static	  culture	  models	  do	  
not	   induce	   the	   same	   EC	   phenotype	   as	   cultures	   under	   flow,	   and	   differences	   between	   steady	   and	  
physiological	  pulsatile	  flow	  have	  been	  observed	  136,137.	  To	  address	  this,	  an	  increasing	  effort	  has	  been	  
invested	   in	   creating	   vascularized	   grafts	   using	   TE	   technologies	   that	   more	   closely	   resemble	   native	  
vessel	  structures.	  Microfluidic	  devices	  and	  bioreactors	  may	  enable	  more	  detailed	  examinations	  of	  the	  
interplay	  between	  M/MΦs	  and	  ECs	  under	  flow	  conditions.	  
Overall,	  the	  use	  of	   in	  vitro	  co-­‐culture	  models	  is	  indispensable	  to	  further	  understand	  and	  predict	  the	  
tissue	   responses	   following	   biomaterial	   implantation.	   However,	   the	   culture	   conditions	   such	   as	   cell	  
origin,	  the	  type	  of	  co-­‐culture	  model	  and	  the	  cell	  culture	  protocols	  may	  limit	  the	  utility	  of	  the	  model	  
and	  should	  be	  chosen	  carefully.	  Future	  work	  exploring	  and	  defining	  these	  limiting	  factors	  should	  be	  
directed	   to	   further	   enable	   predictive	   in	   vitro	   experiments	   mimicking	   relevant	   steps	   in	   the	   cell-­‐
material	  response	  cascade.	  This	  might	  ultimately	  help	  to	  reduce	  the	  number	  of	  animal	  experiments	  
as	  well	  as	  the	  time	  invested	  for	  the	  preclinical	  phase	  of	  research.	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1.2.7	  SUMMARY	  
The	  healing	  of	  tissues	  following	  implantation	  is	  a	  complex,	  dynamic	  and	  time-­‐dependent	  process	  that	  
involves	  a	  wide	  variety	  of	  different	  cell	  types.	  Successful	  healing	  depends	  on	  the	  interplay	  between	  
inflammatory	  and	  regenerative	  mechanisms,	  including	  cell	  migration,	  angiogenesis,	  ECM	  production	  
and	   remodeling.	   The	   present	   review	   has	   highlighted	   the	   multiple	   ways	   in	   which	   macrophages	  
interact	  with	   endothelial	   cells,	  mesenchymal	   stem	   cells	   and	   fibroblasts	   during	   the	   healing	   process	  
(Fig.	   3).	   Specific	   molecules	   and	   signaling	   pathways	   that	   modulate	   the	   cellular	   responses	   and,	  
consequently,	   the	   healing	   process	   have	   been	   described.	   However,	   further	   investigations	   are	  
necessary	  to	  identify	  the	  precise	  cellular	  crosstalk	  between	  macrophages	  and	  MSCs,	  ECs,	  fibroblasts	  
and	  biomaterials.	   In	   this	   regard,	   the	  development	  of	  more	  sophisticated	   in	  vitro	   co-­‐culture	  models	  
that	   better	  mimic	   the	   in	   vivo	   physiological	   environment	  would	  enable	  more	  precise	   studies	  of	   the	  
complex	  healing	  process.	  
Figure	   3.	   Schematic	   of	  macrophage	   crosstalk	  with	  MSCs,	   fibroblasts	   and	   ECs	   highlighting	   the	   processes	   and	  molecules	   that	   have	   been	  
implicated	   in	   cell-­‐cell	   interactions.	   Arrows	   show	   the	   cellular	   processes	   that	   are	   affected	   by	   cell-­‐to-­‐cell	   communication.	   Arrow	  direction	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CHAPTER  1 . 3   
	  
Thesis	  outlook	  
A	  comprehensive	  overview	  of	  the	  state	  of	  art	  in	  cardiovascular	  tissue	  engineering	  is	  provided	  within	  
this	  first	  introductory	  chapter	  (Chapter	  1.1).	  In	  addition,	  the	  importance	  of	  the	  host	  immune	  system	  
–	   and	   its	   first	   cellular	   attraction	   of	   monocytes/macrophages	   –	   is	   pointed	   out	   in	   response	   to	   any	  
implant	   for	   regenerative	   applications	   (Chapter	   1.2).	   In	   this	   regard,	   particularly	  MSCs	   have	   shown	  
clinically	  and	  experimentally	  to	  support	  the	   in	  situ	  tissue	  remodeling	  after	  biomaterial	   implantation	  
via	  an	  inflammation-­‐mediated	  cellular	  cascade.	  Therefore,	  two	  chapters	  of	  this	  thesis	  are	  focusing	  on	  
the	  characterization	  of	  MSCs	  from	  different	  tissue	  origins	  such	  as	  the	  bone	  marrow	  (BMSCs),	  adipose	  
tissue	   (ADSCs),	  umbilical	  cord	  Wharton’s	   jelly	   (WJSCs)	  and	  amniotic	   fluid	   (AFCs)	   (Chapter	   2	   and	  3),	  
followed	   by	   a	   section	   on	   biodegradable	   scaffold	   matrixes	   for	   cardiovascular	   tissue	   engineering	  
applications	   (Chapter	   4).	   Combining	  MSCs	  with	   certain	  polymer	  matrices	  may	  allow	  may	  allow	   for	  
new	  delivery	  routes	  and	  specific	  tissue	  properties	  of	  bioengineered	  materials	  in	  the	  future.	  	  
Therefore,	   a	   better	   understanding	   of	   the	   phenotype,	   origin	   and	   underlying	   mechanisms	   of	   MSCs	  
seems	  mandatory.	  Given	  that	  not	  the	  MSCs	  themselves	  but	  their	  secretome	  initiates	  first	  attraction	  
of	   host	   cells	   to	   the	   transplant	   site,	   a	   systematic	   comparison	   of	   different	   therapeutically	   relevant	  
MSCs	  enabled	  to	  define	  the	  most	  potent	  secretome	  composition	  for	  host	  immune	  cell	  attraction	  and	  
angiogenesis	  (Chapter	  2.1).	  In	  the	  future	  these	  knowledge	  might	  be	  used	  to	  create	  “synthetic,	  non-­‐
cellular	   factors”	   that	   could	   be	   implemented	   within	   biodegradable	   scaffolds	   for	   in	   situ	   tissue	  
engineering	  applications.	  AFCs	  were	  investigated	  in	  the	  standard	  ovine	  developmental	  model,	  which	  
uniquely	   enables	   investigation	   of	   prenatally	   harvested	   fetal	   (stem)	   cells	   without	   any	   ethical	   and	  
medical	   restrictions	   (Chapter	   3).	   Species	   differences	   were	   first	   evaluated	   to	   assure	   accurate	  MSC	  
isolation	   from	   the	   anatomical	   different	   ovine	   fetal	   fluid	   cavities	   (Chapter	   3.1).	   Subsequently	   the	  
“broadly	   multipotent”	   state	   of	   AFCs	   was	   investigated	   to	   exemplify	   that	   MSC	   origin	   influence	  
expression	   levels	  of	  pluripotency	   related	  genes	  and	  ultimately	   cellular	  phenotype	   (Chapter	   3.2).	   In	  
chapter	   4,	   biodegradable	   scaffolds	   for	   the	   in	   situ	   tissue	   engineering	   approach	   were	   evaluated	  
(Chapter	   4).	   The	   feasibility	   of	   a	   rapid	   and	   automated	   fabrication	   of	   extracellular	  matrix	   for	   in	   situ	  
heart	  valve	  tissue	  engineering	  was	  tested	  in	  vitro	  and	  in	  the	  ovine	  animal	  model	  (Chapter	  4.1).	  At	  the	  
end,	  the	  results	  of	  all	  studies	  are	  critically	  discussed	  with	  the	  focus	  on	  the	  clinical	  translation	  of	  MSCs	  




      2   
	  





















The	  content	  of	  this	  chapter	  is	  based	  on:	  
	  
Kehl	   D,	   Mallone	   A,	   Generali	   M,	   Uldry	   AC,	   Heller	   M,	   Gantenbein	   B,	   Hoerstrup	   SP,	   Weber	   B.	   A	  
proteomic	   approach:	   hWJSC	   secretome	   retains	   the	   highest	   inflammation-­‐mediated	   angiogenesis	  





CHAPTER  2 . 1   
A	  proteomic	  approach:	  hWJSC	  secretome	  retains	  the	  
highest	  inflammation-­‐mediated	  angiogenesis	  potential	  	  
	  
Debora	  Kehl1,	  Anna	  Mallone1,	  Melanie	  Generali1,	  Anne-­‐Christine	  Uldry2,	  
Manfred	  Heller2,	  Benjamin	  Gantenbein3,4,	  Simon	  P.	  Hoerstrup1,3,5,	  Benedikt	  
Weber1,3,5	  
	  
1	  Institute	  for	  Regenerative	  Medicine	  (IREM),	  Center	  for	  Therapy	  Development	  and	  Good	  
Manufacturing	  Practice,	  University	  of	  Zurich,	  Zurich,	  Switzerland	  
2	  Mass	  Spectrometry	  and	  Proteomics	  Core	  Facility,	  Department	  of	  Clinical	  Research,	  University	  of	  
Bern,	  Bern,	  Switzerland	  
3	  Center	  for	  Applied	  Biotechnology	  and	  Molecular	  Medicine	  (CABMM),	  University	  of	  Zurich,	  Zurich,	  
Switzerland	  
4	  Tissue	  and	  Organ	  Mechanobiology,	  Institute	  for	  Surgical	  Technology	  and	  Biomechanics,	  University	  
of	  Bern,	  Switzerland	  
5	  Zurich	  Center	  for	  Integrative	  Human	  Physiology	  (ZHIP),	  University	  of	  Zurich,	  Zurich,	  Switzerland	  
	  
Abstract	  
Mesenchymal	   stem	   cells	   (MSCs)	   secretome	   has	   shown	   to	   promote	   in	   vivo	   angiogenesis	   and	  
endogenous	   regeneration	   in	   an	   inflammation	   dependent	   way.	   Recent	   studies	   emphasize	   that	   the	  
secretome	   of	   MSC	   derived	   from	   different	   tissue	   sources	   have	   distinct	   profiles	   and	   ultimately	  
functional	   responses.	   In	   this	   regard,	   the	  presented	  study	  systematically	  compares	  MSC	  secretomes	  
from	  several	  donors	  from	  human	  adipose	  tissue	  (hADSCs),	  bone	  marrow	  (hBMSC)	  and	  umbilical	  cord	  
Wharton’s	   jelly	   (hWJSCs)	  on	   their	   chemoattractive	  and	  angiogenic	  potential.	   For	   this	   approach	   the	  
MSC	  secretomes	  have	  been	  derived	  using	  a	  GMP-­‐compliant	  protocol.	   LC/MS-­‐MS	  analyses	   revealed	  
that	   hBMSC	   and	   hWJSC	   secretomes	   possess	   a	   stronger	   pro-­‐angiogenic	   and	   inflammatory	   profile	  
compared	   to	   hADSCs	   secretome.	   In	   particular,	   hADSC	   secretome	   did	   not	   only	   lack	   crucial	   pro-­‐
angiogenic	  proteins	   (e.g	  AKT1	  and	  FGF2),	  but	  also	  expressed	  most	  of	   the	  proteins	   to	  a	  significantly	  
lower	  level	  compared	  to	  hBMSC	  and	  hWJSC.	  These	  results	  on	  the	  proteomic	  level	  were	  functionally	  
confirmed	   in	   vitro	  by	   a	   significantly	   higher	   CD14++	   CD16-­‐	  monocyte	  migration	   towards	   hBMSC	   and	  
hWJSC	  secretome.	  Both	  secretomes	  also	  induced	  a	  marked	  pro-­‐angiogenic	  phenotype	  of	  endothelial	  
cells	  in	  vitro	  indicated	  by	  a	  significantly	  higher	  expression	  of	  CD105,	  CD202b,	  CD144,	  CD31.	  Matrigel	  
plug	   assay	   did	   not	   found	   any	   differences	   in	   vivo.	   These	   results	   enable	   a	   broad	   overview	   of	   the	  
angiogenic	   potential	   of	   human	   MSCs	   from	   different	   tissue	   sources	   and	   will	   allow	   for	   a	   direct	  





Experimental	  contributions	  (Kehl	  D	  only):	  
Isolation	  and	  expansion	  of	  all	  cell	  lines,	  including	  hADSC	  (n=5),	  hBMSC	  (n=5),	  hWJSC	  (n=5)	  and	  HUVEC	  
(n=1).	  Characterization	  of	  MSC	  cell	  lines	  in	  terms	  of	  proliferation,	  trilineage	  differentiation	  potential	  
into	  adipogenic,	  osteogenic	   and	   chondrogenic	   lineages	  and	   common	  MSC	   surface	  markers	  by	   flow	  
cytometry.	   MSC	   conditioned	   media	   (CM)	   harvest	   and	   concentration	   for	   all	   cell	   lines.	   Isolation	   of	  
hPBMCs	  for	  transmigration	  assay.	  Flow	  cytometric	  analysis	  of	  hPBMC	  migration	  and	  staining	  of	  the	  
migratory	  subsets.	  Co-­‐incubation	  of	  MSC	  CM	  on	  HUVEC	  and	  the	  subsequent	  flow	  cytometry	  analysis	  
of	  pro-­‐angiogenic	  surface	  markers.	  Protein	  elution	  and	  separation	  using	  gel	  electrophoresis.	  
	  
Experimental	  contributions	  (Kehl	  D,	  together	  with	  co-­‐authors)	  
Analysis	   of	   flow	   cytometry	   data	   using	   bidimensional	   tSNE	   and	   PhenoGraph	   algorithms.	   In	   vivo	  
injection	  of	  MSC	  CM	  into	  mice	  and	  explant	  of	  matrigel	  plugs	  for	  evaluation	  of	  angiogenic	  response.	  
Mass	  spectrometry	  analysis,	  identifying	  proteins/pathways	  of	  interest.	  
	  
Non-­‐experimental	  contributions	  (Kehl	  D	  only):	  
Study	   design	   and	   planning	   of	   the	   study.	   Acquiring	   funding	   and	   ethical	   licenses	   for	   the	   isolation	   of	  
hMSCs	   from	   primary	   human	   material	   and	   the	   in	   vivo	   matrigel	   plug	   assay.	   Statistical	   analyses.	  
Analyzing	   all	   results	   and	   drafting	   all	   figures.	   Writing	   the	   entire	   manuscript.	   Correspondence	   with	  
collaborating	  partners.	  
	  
Steps	  contained	  in	  the	  published	  work	  (without	  personal	  contribution	  of	  Kehl	  D)	  
Alcian	  Blue	  PAS	  staining	  for	  the	  determination	  of	  chondrogenic	  differentiation	  potential.	  Generation	  
of	   bidimensional	   t-­‐SNE	   maps	   from	   multidimensional	   flow	   cytometry	   data	   and	   application	   of	  
PhenoGraph	   and	   FlowSOM	   algorithms.	   Mass	   spectrometry	   in	   collaboration	   with	   the	   Mass	  
Spectrometry	   Facility	   Bern,	   Manfred	   Heller	   and	   Anne-­‐Christine	   Uldry.	   Determination	   of	   serum	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2.1.1	  INTRODUCTION	  
Since	  the	   introduction	  of	  mesenchymal	  stem	  cells	   (MSCs)	  for	  the	  use	   in	  regenerative	  medicine,	  the	  
number	   of	   pre-­‐clinical	   and	   first	   clinical	   studies	   has	   constantly	   increased	   over	   the	   last	   decades	  
(ClinicalTrials.gov).	   Initial	  MSC	  research	  focused	  on	  the	  multilineage	  differentiation	  of	  cells	   towards	  
desired	  phenotypes,	   though	   it	  has	  become	  evident	   that	   functional	  benefits	   exerted	  by	  MSCs	  upon	  
transplantation	  are	  rather	  due	  to	  the	  release	  of	  paracrine	  factors	  and	  biologically	  relevant	  molecules	  
such	  as	  exosomes	  and	  microvesicles	   to	   the	  neighboring	  diseased	  or	   injured	  tissue	  1,2.	  The	  so-­‐called	  
MSC	   secretome	   or	   conditioned	   media	   (CM)	   influences	   the	   microenvironment	   following	   injury,	  
promoting	   cytoprotection	   and	   endogenous	   regeneration	   of	   the	   injured	   tissue	   environment.	   These	  
effects	   are	   particularly	   of	   interest	   for	   the	   treatment	   of	   ischemic	   diseases,	   where	   promoting	  
vascularization	   and	   reinstalling	   perfusion	   of	   the	   ischemic	   tissues	   via	   angiogenesis	   is	   crucial	   for	  
increasing	  the	  chances	  of	  tissue	  rescue	  and	  to	  prevent	  fibrosis.	  
Angiogenic	   factors	   produced	   by	  MSC	   include	   among	   others	   basic	   fibroblast	   growth	   factor	   (bFGF),	  
vascular	  endothelial	  growth	  factor	  (VEGF),	  transforming	  growth	  factor	  beta	  (TGF-­‐β),	  platelet-­‐derived	  
growth	  factor	  (PDGF),	  angiopoietin-­‐1	  (ANG-­‐1),	  placental	  growth	  factor	  (PIGF),	   interleukin	  6	  (IL-­‐6)	  ad	  
monocyte	   chemoattractant	   protein	   1	   (MCP-­‐1)	   3.	   The	   MSC	   secretome	   positively	   stimulated	  
angiogenesis	   in	   vitro	   and	   in	   vivo	   3	   and	   the	   angiogenic	   activity	   can	   be	   significantly	   inhibited	   by	  
neutralizing	  antibodies	  against	  VEGF,	  MCP-­‐1	  and	  IL-­‐6	  4.	  Exosomes	  may	  also	  mediate	  angiogenesis	  by	  
transferring	   genetic	  material	   and	  pro-­‐angiogenic	  molecules	   to	   the	  damaged	  areas	   and	   seem	   to	  be	  
key	  factors	  for	  angiogenesis	  5.	  Additionally,	  inflammatory	  cells	  have	  shown	  to	  migrate	  towards	  MSC	  
secretome	  and	  participate	  in	  the	  angiogenic	  process	  by	  secreting	  cytokines	  themselves	  that	  infuence	  
endothelial	   cell	   (EC)	   function,	   including	   their	   activation,	   proliferation	   and	   migration	   6.	   Moreover,	  
infiltrating	  monocytes/macrophages	  release	  proteases	  to	  regulate	  patterning	  and	   local	  degradation	  
of	   the	   extracellular	   matrix	   (ECM),	   influencing	   the	   distribution	   of	   neovessel	   formation	   and	   their	  
branch	  points	  7,8.	  
Although	   most	   isolated	   secretomes	   from	   different	   MSC	   sources	   revealed	   angiogenesis-­‐related	  
proteins,	   the	  secreted	   factors	  seem	  to	  be	  distinct	   in	  composition	  and	  amount.	   In	   this	   regard,	  mass	  
spectrometry	  analyses	  revealed	  higher	  secreted	  levels	  of	  hepatocyte	  growth	  factor	  (HGF),	  VEGF	  and	  
IL-­‐6	   in	   rat	  adipose	  derived	  MSC	   (ADSCs),	  whereas	   rat	  bone	  marrow	  derived	  MSC	   (BMSCs)	  secreted	  
higher	  amounts	  of	   cell	  migration-­‐related	   chemokine	   stromal	   cell-­‐derived	   factor	  1	  alpha	   (SDF-­‐1α)	   9.	  
On	   the	   other	   hand,	   human	   ADSCs	   expressed	   higher	   levels	   of	   insulin-­‐like	   growth	   factor	   1	   (IGF-­‐1),	  
VEGF-­‐D	  and	  IL-­‐8	  compared	  to	  human	  BMSCs,	  whereas	  other	  factor	  such	  as	  VEGF-­‐A,	  bFGF,	  SDF-­‐1	  and	  
angiogenin	  were	   expressed	   at	   similar	   levels	  without	   significant	   differences	   10.	   In	   the	   secretome	   of	  
human	  Wharton’s	   jelly	  derived	  MSCs	   (WJSCs)	  more	  secreted	   factors	   involved	   in	  angiogenesis	  were	  
MSC	  secretome	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found	   compared	   to	   human	   BMSCs,	   inducing	   better	   in	   vitro	   microvasculature	   formation	   and	  
endothelial	  cell	  migration	  11.	  Quantitative	  proteomics	  revealed	  an	  increased	  angiogenic	  profile	  within	  
the	   secretome	   of	   MSC	   isolated	   from	   fetal	   rather	   than	   from	   adult	   skin	   12.	   Thus,	   these	   studies	  
demonstrate	   that	  MSCs	   isolated	   from	   different	   tissue	   sources	   show	   dissimilarities	  with	   respect	   to	  
their	   transcriptional,	   proteomic	   and	   functional	   profile.	   A	   systematic	   comparative	   analysis	   of	   the	  
chemoattractive	  as	  well	  as	  angiogenic	  potential	  of	  MSC	  secretome	   isolated	   from	  different	  clinically	  
relevant	   MSC	   sources	   has	   not	   been	   performed	   yet.	   Moreover,	   mostly	   targeted	   proteomic	  
approaches	  have	  been	  used	  so	  far	  with	  only	  a	  fraction	  of	  angiogenic	  proteins	  identified.	  
Therefore,	  the	  presented	  study	  aimed	  to	  isolate	  and	  fully	  characterize	  MSCs	  secretomes	  from	  several	  
donors	  from	  human	  adipose	  tissue	  (hADSCs),	  bone	  marrow	  (hBMSCs)	  and	  umbilical	  cord	  Wharton’s	  
jelly	   (hWJSCs)	   in	   order	   to	   systematically	   compare	   their	   chemoattractive	   and	   angiogenic	   potential.	  
Importantly,	  MSC	   secretomes	  were	  obtained	  under	   standardized	  GMP-­‐compliant	   culture	  protocols	  
using	   human	   platelet	   lysate	   to	   replace	   xenogenic	   serum	   supplements.	   Firstly,	   we	   used	   high-­‐
resolution,	   two-­‐dimensional	   liquid	   chromatography	   tandem	   mass	   spectrometry	   (LC-­‐MS/MS)	   for	   a	  
broad	  proteomic	  profile	  of	  human	  MSC	  secretomes,	  with	  focus	  on	  proteins	  related	  to	  inflammation	  
and	  angiogenesis.	   Secondly,	  we	  differentially	   analyzed	   the	   functional	   response	  of	  MSC	   secretomes	  
from	   different	   origins	   to	   define	   which	   MSC	   source	   possesses	   the	   highest	   potential	   for	   inducing	  
inflammation	  mediated	  angiogenesis	  in	  vitro	  and	  in	  vivo.	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2.1.2	  MATERIAL	  AND	  METHODS	  
2.1.2.1	  hMSC	  ISOLATION	  FROM	  DIFFERENT	  HUMAN	  TISSUES	  
All	  hMSC	  were	  isolated	  as	  described	  below	  and	  cultured	  in	  standard	  proliferation	  medium	  consisting	  
of	   high-­‐glucose	  DMEM	   supplemented	  with	   10%	   human	   platelet	   lysate	   (hPL),	   1%	  Glutamax	   (Gibco,	  
USA),	   and	   an	   antibiotic-­‐antimycotic	   solution	   (Sigma,	   Switzerland).	   hPL	   was	   obtained	   from	   platelet	  
apheresis	   collection	   of	   donors	   compliant	  with	   local	   blood	   donation	   prerequisite	   (Center	   for	   Blood	  
Donation	  Zurich,	  Switzerland).	  Medium	  changes	  for	  all	  cell	  sources	  were	  performed	  every	  third	  day	  
and	   passaging	   was	   performed	   after	   reaching	   80%	   confluence	   using	   Accustase	   (Innovative	   Cell	  
Technologies	  Inc.,	  USA).	  
	  
HUMAN	  ADIPOSE	  DERIVED	  MESENCHYMAL	  STEM	  CELLS	  (hADSCs)	  
Adipose	   tissue	   (n=5)	   obtained	   from	   surgically	   performed	   liposuction	   procedure	   was	   used	   for	   the	  
isolation	  of	  hADSCs	  approved	  by	  the	  cantonal	  ethics	  committee	  (KEK-­‐ZH-­‐2010-­‐0476).	  Adipose	  tissue	  
was	  digested	  using	  collagenase	  type	  A	  (Roche	  Diagnostics	  GmbH,	  Switzerland)	  at	  37°C	  for	  1h	  under	  
constant	  gentle	  motion.	  The	  sample	  was	  filtered	  using	  a	  nylon	  cell	  strainer	  with	  70μm	  mesh	  size	  (BD	  
Bioscience,	   USA)	   and	   separated	   by	   histopaque-­‐1077	   density	   gradient	   centrifugation	   (Sigma,	  
Switzerland)	   for	   30min	   at	   600g.	   The	   interphase	   was	   plated	   in	   standard	   proliferation	   medium	   for	  
cellular	  attachment	  and	  growth.	  
	  
HUMAN	  BONE	  MARROW	  DERIVED	  MESENCHYMAL	  STEM	  CELLS	  (hBMSCs)	  
Human	  bone	  marrow	  aspirate	  (n=5)	  was	  collected	  in	  sterile	  heparinized	  tubes	  (BD	  Bioscience,	  USA)	  
after	   written	   informed	   consent	   from	   the	   patients.	   For	   isolation	   of	   hBMSCs	   the	   aspirate	   was	  
separated	  by	  histopaque-­‐1077	  density	  gradient	  centrifugation	  for	  25min	  at	  800g.	  Subsequently,	  the	  
mononuclear	  cell	  layer	  was	  collected,	  washed	  and	  plated	  in	  standard	  proliferation	  medium.	  
	  
HUMAN	  WHARTON’S	  JELLY	  DERIVED	  MESENCHYMAL	  STEM	  CELLS	  (hWJSCs)	  
Human	  umbilical	  cords	  (n=5)	  were	  obtained	  after	  full-­‐term	  births	  with	  written	   informed	  consent	  of	  
the	  patient	  (KEK-­‐ZH-­‐2009-­‐0095)	  and	  processed	  for	  isolation	  of	  hWJSC.	  Wharton’s	  jelly	  was	  dissected	  
from	   the	   umbilical	   cord	   and	   cut	   into	   small	   pieces	   (1mm2).	   After	   letting	   the	   tissues	   adhere	   to	   the	  
culture	  plate,	  standard	  proliferation	  medium	  was	  gently	  added.	  Tissue	  pieces	  were	  removed	  after	  a	  
first	  cellular	  outgrowth	  could	  be	  detected	  and	  cells	  were	  harvested.	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2.1.2.2	  hMSC	  CHARACTERIZATION	  
DIFFERENTIATION	  POTENTIAL	  
Multillineage	  differentiation	  was	  assessed	  by	   inducing	  differentiation	  to	  osteocytes,	  adipocytes	  and	  
chondrocytes.	  Therefore,	  hMSCs	  from	  adipose	  tissue	  (n=5),	  bone	  marrow	  (n=5)	  and	  Wharton’s	  jelly	  
(n=5)	  were	  either	  cultured	  in	  I)	  osteogenic	  medium:	  10nM	  glycerol	  2-­‐phosphate	  (Sigma,	  Switzerland),	  
50μm	  L-­‐ascorbic	  acid	  2-­‐phosphat	  (Sigma,	  Switzerland),	  100nM	  dexamethasone	  (Sigma,	  Switzerland)	  
and	  2nM	  L-­‐glutamine	  (Sigma,	  Switzerland)	  in	  low	  glucose	  DMEM	  (Sigma,	  Switzerland)	  with	  10%	  hPL	  
and	  an	  antibiotic-­‐antimycotic	  solution,	  II)	  adipogenic	  medium	  (GibcoTM,	  ThermoFisher	  Scientific,	  USA)	  
or	   III)	   chondrogenic	   medium:	   50μm	   L-­‐ascorbic	   acid	   2-­‐phosphate,	   0.5	   ug/ml	   insulin	   (Sigma,	  
Switzerland),	  10	  ng/ml	  transforming	  growth	  factor-­‐beta1	  (Preprotech,	  UK),	  2	  mM	  L-­‐glutamine	  in	  high	  
glucose	  DMEM	  with	  1%	  hPL	  and	  an	  antibiotic-­‐antimycotic	  solution.	  After	  3	  weeks,	  cells	  were	  fixed	  in	  
4%	  paraformaldehyde/PBS	  and	  subsequently	  stained	  with	  I)	  2%	  Alzarin	  Red	  S	  (Sigma,	  Switzerland),	  II)	  
3mg/ml	  Oil	  Red	  O	  (Sigma,	  Switzerland)	  or	  III)	  Alcian	  Blue	  PAS.	  	  
	  
PROLIFERATION	  PARAMETERS	  
Proliferation	  kinetics	  were	  assessed	  over	  12	  days	  for	  hADSC,	  hWJSC	  and	  hBMSC	  (n=5	  per	  cell	  source).	  
The	   amount	   of	   total	   cells	   after	   every	   third	   day	  was	  measured	   based	   on	   the	   absorbance	   of	   crystal	  
violet.	   In	   brief,	   cells	   were	   fixed	   with	   methanol	   (Sigma,	   Switzerland)	   for	   10min	   and	   subsequently	  
stained	   with	   0.1%	   crystal	   violet	   (Artechemis,	   Switzerland)	   for	   5min.	   After	   washing	   and	   air-­‐drying,	  
absorbed	  crystal	  violet	  was	  solubilized	  with	  Na-­‐deoxycholate	  (Sigma,	  Switzerland)	  while	  being	  heated	  
at	  60°C	  for	  10min.	  The	  absorbance	  was	  recorded	  at	  550nm	  using	  a	  standard	  ELISA	  reader	  Synergy	  HT	  
(Bio	   TEK,	   USA).	   Quantitative	   data	   was	   obtained	   using	   a	   standard	   curve	   with	   serial	   dilutions.	  
Cumulative	   population	   doubling	   (PD)	   rate	   and	   generation	   time	   (GT)	   were	   calculated	   according	   to	  
previous	  described	  formula	  13.	  
	  
MSC	  MARKER	  EXPRESSION	  BY	  FLOW	  CYTOMETRY	  
Isolated	   hMSCs	   (n=5	   per	   tissue	   source)	   were	   characterized	   for	   common	  MSC	   markers	   using	   flow	  
cytometry.	  2.5	  x	  105	  MSCs	  were	  stained	  for	  20min	  at	  4°C	  according	  to	  standard	  procedures	  with	  the	  
following	  antibodies:	  Pacific	  Blue	  mouse-­‐anti	  human	  CD73	  (clone	  AD2;	  Biolegend,	  USA),	  PerCP-­‐Cy5.5	  
mouse	   anti-­‐human	   CD90	   (clone	   5E10;	   BD	   Bioscience,	   USA),	   APC	  mouse	   anti-­‐human	   CD105	   (clone	  
266;	  BD	  Bioscience,	  USA),	  FITC	  mouse	  anti-­‐human	  CD14	  (clone	  MφP;	  BD	  Bioscience,	  USA),	  PE	  mouse	  
anti-­‐human	  CD34	  (clone	  581;	  BD	  Bioscience,	  USA),	  BV605	  mouse	  anti-­‐human	  CD45	  (clone	  HI30;	  BD	  
Bioscience,	  USA)	  and	  Zombie	  Aqua	  fixable	  viability	  kit	  (Biolegend,	  USA).	  Antibodies	  have	  been	  used	  in	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saturating	  conditions	  defined	  by	  serial	  dilutions.	  50’000	  events	  were	  acquired	  using	  a	  LSR	  Fortessa	  
(BD	   Bioscience,	   USA)	   and	   the	   datasets	   were	   analyzed	   by	   FlowJo	   software	   (Tree	   Star,	   Inc.,	   USA).	  
Bidimensional	  t-­‐SNE	  maps	  were	  generated	  from	  multidimensional	  flow	  cytometry	  data	  sets	  using	  the	  
open	  source	  R	  platform	  and	  the	  Cytokit	  package	  (http://bioconductor.org).	  Firstly,	  2000	  events	  were	  
randomly	   selected	   from	   the	   analyzed	   sample.	   Secondly,	   the	   selected	   events	   were	   clustered	   using	  
PhenoGraph	   algorithm	   (k=42).	   PhenoGraph	   arranged	   all	   events	   in	   the	   multidimensional	   space	  
according	   to	   similarities	   in	   surface	   marker	   expression	   levels	   and	   allowed	   to	   plot	   the	   data	   in	   two	  
dimensions	  using	  bi-­‐dimensional	  visual	  stochastic	  neighbor	  embedding	  (vi-­‐SNE)	  graphs.	  We	  used	  the	  
wi-­‐SNE	  graphs	  to	  analyze	  and	  detect	  subset	  differences	  in	  MSC	  marker	  expression	  profile.	  
	  
2.1.2.3	  hMSC	  CONDITIONED	  MEDIA	  HARVEST	  
For	  hMSC	  conditioned	  media	  (CM)	  harvest,	  all	  hMSC	  lines	  (n=5	  per	  tissue	  source)	  were	  cultured	  until	  
80%	  confluence	  in	  standard	  proliferation	  medium,	  washed	  with	  PBS	  and	  subsequently	  transferred	  to	  
serum	   free	   conditions	   (basal	  medium	  only)	   for	   16	  hours.	   Collected	  CM	  was	   filtered	  using	   a	   0.2μm	  
filter,	  concentrated	  using	  centrifugal	  filter	  units	  with	  a	  3-­‐kDA	  cutoff	  at	  4°C	  (Amicon	  Ultra	  Centrifugal	  
filters,	  Millipore,	  USA)	  and	  stored	  at	  80°C	  for	  further	  analysis.	  Exact	  number	  and	  viability	  of	  starved	  
cells	  was	  obtained	  using	  a	  NucleoCounter	  NC-­‐200	   (CHemoMetec,	  Denmark).	  Aliquots	  of	  stored	  CM	  
were	  always	  derived	   from	  1x106	   cells	   in	  200μl.	   Possible	   serum	   leftover	  of	   the	  primarily	   added	  hPL	  
was	  assessed	  by	  quantitative	  evaluation	  of	  platelet	   factor	  4	   (PF-­‐4)	  using	  a	  multiplex	  particle-­‐based	  
flow	  cytometric	  cytokine	  assay	  14.	  
	  
2.1.2.4	  MASS	  SPECTROMETRY	  ANALYSIS	  
Proteins	   of	  MSC	   CM	   derived	   from	   1x106	  cells	   (not	   concentrated	  with	   centrifugal	   filter	   units)	   were	  
gained	   using	   5μl	   Strata	   Clean	   resin	   beads	   per	   ml	   of	   CM	   (Agilent	   Technologies,	   USA).	   Beads	   were	  
incubated	   for	  30min	  by	   rotation	  at	   room	  temperature	  and	  subsequently	   centrifuged	  with	  230g	   for	  
2min.	  Proteins	  were	  eluted	  from	  bead	  pellets	  by	  the	  addition	  of	  Laemmli	  buffer	  and	  boiling	  at	  95°C	  
for	  5min.	  Eluted	  proteins	  of	  all	  MSC	  CM	  and	  their	  corresponding	  controls	  were	  loaded	  onto	  12%	  SDS-­‐
Page	   gels	   (Sigma-­‐Aldrich,	   Switzerland)	   and	   subsequently	   digested	   as	   described	   elsewhere	   15.	   An	  
aliquot	   of	   5μl	   peptide	   extract	   was	   analyzed	   by	   LC-­‐MS/MS	   on	   an	   EASY-­‐nLC1000	   chromatograph	  
connected	  to	  a	  QExactive	  HF	  mass	  spectrometer	  (ThermoFisher	  Scientific)	  using	  a	  Pepmap100	  Trap	  
C18	  300	  mm	  x	  5	  mm	  (Thermo	  Fisher	  Scientific)	  and	  a	  C18	  separation	  column	  (3μm,	  100	  Å,	  75μm	  x	  15	  
cm,	  Nikkyo	  Technos,	  Tokyo,	  Japan)	  by	  applying	  a	  40	  min	  gradient	  as	  previously	  described	  16.	  
LC-­‐MS/MS	   data	   was	   processed	   with	   MaxQuant	   (version	   1.5.4.1)	   using	   default	   settings	   for	   peak	  
detection,	  strict	  trypsin	  cleavage	  rule	  allowing	  for	  up	  to	  three	  missed	  cleavages,	  variable	  oxidation	  on	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methionine,	   deamidation	   of	   asparagine	   and	   glutamine,	   and	   acetylation	   of	   protein	   N-­‐termini	   with	  
strict	  carbamidomethylation	  of	  cysteines.	  Match	  between	  runs	  was	  used	  within	  each	  sample	  group	  
with	   a	   retention	   time	  window	  of	  1min.	   The	   fragment	   spectra	  were	   interpreted	  with	   the	   SwissProt	  
Homo	   sapiens	   database	   (version	   2016_04)	   accepting	   only	   protein	   identifications	  with	   at	   least	   two	  
razor	  peptides	  at	  a	  1%	  false	  discovery	  rate	  (FDR)	  cutoff.	  	  
	  
2.1.2.5	  IMMUNE	  CELL	  RESPONSE	  
Heparinized	   human	   peripheral	   blood	   was	   obtained	   from	   randomly	   selected	   healthy	   donors	   (n=3)	  
(KEK-­‐ZH-­‐2014-­‐0430).	  Human	  peripheral	  blood	  mononuclear	  cells	   (hPBMCs)	  were	   isolated	  according	  
to	  standard	  protocols	  by	  ficoll	  density	  gradient	  centrifugation	  (Histopaque-­‐1077;	  Sigma,	  Switzerland).	  
Migration	  of	  3x106	  hPBMCs	   in	  300μl	  basal	  medium	  supplemented	  with	  0.5%	   fetal	   calf	   serum	   (FCS)	  
(Sigma,	  Switzerland)	  towards	  the	  lower	  compartment	  containing	  either	  I)	  0.1ml	  MSC	  CM	  +	  0.5%	  FCS	  
(n=5	  per	  tissue	  source),	  II)	  basal	  medium	  +	  0.5%	  FCS	  or	  II)	  5ng/ml	  monocyte	  chemoattractant	  protein	  
1	  (MCP-­‐1)	  +	  0.5%	  FCS,	  was	  evaluated	  through	  a	  PET	  membrane	  with	  3μm	  pores	  (Corning,	  USA)	  after	  
3	   hours.	   The	   amount	   of	  migrated	   cells	   was	   determined	   by	   recording	   cell	   counts	   over	   1	  min	   on	   a	  
FACSCanto	   II	   (BD	   Bioscience,	   USA).	  Monocyte	   subpopulations	  were	   differentiated	   by	   staining	  with	  
FITC	  mouse-­‐anti	  human	  CD14	  (clone	  MφP9,	  BD	  Bioscience,	  USA)	  and	  PerCP-­‐Cy5.5	  mouse-­‐anti	  human	  
CD16	  (clone	  3G8,	  BD	  Bioscience,	  Switzerland).	  
	  
2.1.2.6	  ENDOTHELIAL	  CELL	  RESPONSE	  
IN	  VITRO	  ENDOTHELIAL	  CELL	  ACTIVATION	  ASSAY	  
Endothelial	  cells	  were	  harvested	  from	  human	  umbilical	  cords	  with	  written	   informed	  consent	  of	  the	  
patient	   (KEK-­‐ZH-­‐2009-­‐0095).	   Briefly,	   human	   umbilical	   cord	   vein	   endothelial	   cells	   (HUVEC)	   were	  
dissociated	  from	  the	  venous	  lumen	  by	  incubating	  a	  collagenase	  solution	  (2mg/ml	  collagenase	  type	  A,	  
Roche	  Diagnostics	  GmBH,	  Switzerland)	  for	  30min	  in	  a	  humidified	  incubator	  at	  37°C	  and	  obtained	  in	  
endothelial	   growth	   medium	   (EGM-­‐2;	   Lonza,	   Switzerland).	   After	   several	   passages,	   HUVEC	   were	  
starved	   in	   endothelial	   basal	  medium	   (EBM-­‐2;	   Lonza,	   Switzerland)	  with	  1%	  FCS	   for	   4	  hours	   and	   co-­‐
incubated	   for	   16h	  with	   either	   I)	   0.2ml	  MSC	  CM	  +	   0.5%	   FCS	   (n=5	  per	  MSC	   group),	   II)	   0.2ml	   EGM-­‐2	  
(n=5)	  or	  III)	  0.2ml	  basal	  DMEM	  +	  0.5%	  FCS	  (n=5)	  per	  100’000	  HUVEC.	  Harvested	  HUVEC	  were	  stained	  
20min	  at	  4°C	  with	  the	  following	  surface	  antibodies:	  V450	  mouse-­‐anti	  human	  CD31	  (clone	  WM59,	  BD	  
Bioscience,	  USA),	  FITC	  mouse-­‐anti	  human	  CD105	  (clone	  43A3,	  Biolegend,	  USA),	  PerCP-­‐Cy5.5	  mouse-­‐
anti	   human	   CD144	   (clone	   55-­‐7H1,	   BD	   Bioscience,	   USA)	   and	   PE	  mouse-­‐anti	   human	   CD202b	   (clone	  
33.1,	   Biolegend,	   USA).	   50’000	   events	   were	   acquired	   using	   a	   LSR	   Fortessa	   and	   the	   datasets	   were	  
Chapter	  2.1	  	  
71	  
analyzed	  by	  FlowJo	  software.	  Bidimensional	  t-­‐SNE	  maps	  were	  generated	  from	  multidimensional	  flow	  
cytometry	  (5000	  events)	  and	  PhenoGraph	  algorithm	  employed	  as	  previously	  described.	  
	  
IN	  VIVO	  MATRIGEL	  PLUG	  ASSAY	  
C57BL/l	   mice	   (female,	   7-­‐week	   old)	   were	   divided	   into	   four	   groups:	   control	   (n=5;	   basal	   medium),	  
hADSC	  CM	  (n=5;	  derived	  from	  1x106	  cells),	  hBMSC	  CM	  (n=5;	  derived	  from	  1x106	  cells)	  and	  hWJSC	  CM	  
(n=5;	  derived	   from	  1x106	  cells).	  For	  each	  condition	  0.2ml	  of	  medium	  was	  mixed	  with	  0.3ml	  phenol	  
red-­‐free,	   growth	   factor	   reduced	   basement	  membrane	  matrix	   (Corning,	  USA).	  Media	  were	   injected	  
subcutaneously	  into	  the	  left	  and	  right	  dorsal	  flank	  of	  mice	  (n=10	  per	  group).	  After	  14	  days,	  mice	  were	  
sacrificed	   and	   the	  matrigel	   plugs	  were	  harvested.	   For	   quantitative	   evaluation,	  matrigel	   plugs	  were	  
weighed	  and	  homogenized	  in	  cold	  PBS	  using	  a	  tissue	  homogenizer.	  The	  homogenate	  was	  centrifuged	  
at	   6000g	   for	   10min	   and	   the	   hemoglobin	   content	   of	   the	   supernatant	   measured	   using	   Drabkin’s	  
reagent	   kit	   525	   (Sigma-­‐Aldrich,	   Switzerland).	   The	   absorbance	  was	   read	   at	   540nm	  using	   a	   standard	  
ELISA	  reader	  Synergy	  HT.	  All	  animal	  experiments	  were	  approved	  by	  the	  Cantonal	  Ethics	  Committee	  
(State	  Veterinary	  Office	  of	  the	  Canton	  of	  Zurich,	  Switzerland;	  No.	  105/2016).	  	  
	  
2.1.2.7	  STATISTICAL	  ANALYSIS	  
Quantitative	  data	  are	  presented	  as	  mean±standard	  deviation	  (GraphPad	  Prism;	  Graph	  Pad	  Software,	  
Inc.).	  For	  statistical	  comparison	  either	  One-­‐Way	  ANOVA	  with	  Tukey	  multiple	  comparison	  test	  or	  Two-­‐
Way	   ANOVA	   with	   Sidak’s	   multiple	   comparisons	   test	   was	   used.	   P-­‐values	   <	   0.05	   were	   considered	  
statistically	  significant	  (*p<0.05,	  **p<0.01,	  ***p<0.001).	  
For	   MS	   data	   analysis,	   peptide	   feature	   intensities	   reported	   in	   the	   evidence	   file	   were	   group-­‐wise	  
median	  normalized	  and	   the	   intensities	  of	   the	   three	  most	   intense	  peptides	   summed	   to	   the	  protein	  
intensity.	  When	  a	  group	  had	  at	   least	  one	  positive	   identification,	  missing	  values	  were	   imputed	  from	  
the	   low	   end	   of	   the	   LOG2	   transformed	   intensity	   distribution	   from	   each	   individual	   sample	   using	  
Perseus	  (version	  1.5.5.3)	  as	  suggested	  by	  Lazar	  et	  al.	  17.	  Proteins	  identified	  in	  any	  of	  the	  three	  platelet	  
controls	   were	   not	   used	   for	   further	   statistical	   evaluations.	   With	   the	   remaining	   proteins,	   pairwise	  
Students	  T-­‐tests	  and	  a	  multi	  sample	  ANOVA	  test	  were	  performed,	  applying	  a	  permutation	  based	  FDR	  
of	   1%	   as	   an	   acceptation	   criteria	   for	   differentially	   expressed	   proteins	   and	   to	   correct	   for	   multiple	  
testing.	  The	  results	  of	  the	  two-­‐sample	  T-­‐tests	  is	  used	  to	  identify	  proteins	  that	  are	  significantly	  over-­‐	  
or	  under-­‐expressed	  in	  one	  group	  compared	  to	  another.	  Gene	  set	  enrichment	  analysis	  (GSEA)	  can	  be	  
applied	   to	   the	   selected	   over-­‐	   or	   under-­‐expressed	   proteins	   in	   order	   to	   detect	   pathways	   that	   occur	  
significantly	  more	   than	   they	  would	   by	   chance	   alone.	   In	   this	   study	   the	  GSEA	   tool	   SetRank	   18	   (open	  
source	  R	  package)	  was	  applied	  in	  its	  unranked	  form	  to	  all	  pairs	  of	  samples.	  In	  order	  to	  avoid	  sample	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source	  bias,	  the	  reference	  set	  of	  proteins	  was	  in	  each	  case	  the	  union	  of	  proteins	  of	  the	  two	  samples	  
under	  consideration.	  Unlike	  many	  other	  GSEA	  algorithms,	  SetRank	  avoids	  false	  positive	  hits	  by	  taking	  
into	  account	  gene	  sets	  overlap	  when	  calculating	  their	  significance.	  The	  decision	  whether	  a	  protein	  is	  
significantly	   over-­‐	   or	   under-­‐expressed	   was	   made	   by	   applying	   a	   cut-­‐off	   according	   to	   the	   FDR	  
acceptation	   criteria	   19.	   Gene	   sets	   containing	  more	   than	   100	   genes	  were	   ignored	   in	   order	   to	   avoid	  
generic,	   uninformative	   gene	   sets.	   The	   network	   analysis	   was	   performed	   with	   a	   p-­‐value	   cut-­‐off	   for	  
gene	  sets	  of	  0.01,	  and	  a	  false	  discovery	  rate	  cut-­‐off	  of	  0.05.	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2.1.3	  RESULTS	  
2.1.3.1	  hMSC	  CHARACTERIZATION	  
All	  primary	   isolated	  MSC	   from	  human	  adipose	   tissue	   (n=5),	  bone	  marrow	   (n=5)	  and	  umbilical	   cord	  
Wharton’s	   jelly	   (n=5)	  were	   successfully	   cultured	   in	   xenofree	  GMP-­‐compliant	   proliferation	  medium	  
based	   on	   human	   platelet	   lysate	   (hPL).	   These	   conditions	   are	   necessary	   for	   all	   further	   analyses	  
including	   immune	   cell	   activation	   and	   migration.	   hADSCs	   showed	   higher	   proliferation	   abilities	  
compared	   to	   hBMSCs	   and	   hWJSCs	   (Figure	   1B-­‐C).	   In	   detail,	   hADSCs	   showed	   a	   significantly	   higher	  
cumulative	  population	  doublings	  (CPD)	  and	  lower	  generation	  time	  compared	  to	  hBMSCs	  (Figure	  1C).	  
hBMSCs	   and	   hWJSCs	   showed	   similar	   proliferation,	   with	   significant	   higher	   GT	   compared	   to	   hADSC	  
(p<0.05)	  and	  a	  tendency	  of	  lower	  CPD.	  Therefore,	  subsequent	  CM	  harvest	  was	  performed	  based	  on	  
the	  exact	  amount	  of	  cells	  after	  serum	  free	  incubation.	  	  
Multipotent	  MSC	  nature	  of	  isolated	  cells	  was	  confirmed	  by	  trilineage	  differentiation	  into	  adipogenic,	  
osteogenic	   and	   chondrogenic	   lineages	   positively	   staining	  with	  Oil	   Red	  O,	   Alzarin	   Red	   S	   and	   Alcian	  
Blue	  PAS	   (Figure	  1A).	  Overall	   no	  differences	  were	  detected	   in	   the	  differentiation	  potential	   of	  MSC	  
from	  different	  tissue	  sources.	  	  
Multidimensional	   data	   from	   the	   flow	   cytometry	   analysis	   performed	   using	   common	   MSC	   markers	  
(CD14,	  CD34,	  CD45,	  CD74,	  CD90	  and	  CD105)	  were	  processed	  to	  generate	  bidimensional	  t-­‐SNE	  maps	  
(n=5	  donors	  per	  cell	  source)	  (Figure	  1D-­‐E).	  The	  distribution	  of	  the	  recorded	  events	  within	  the	  t-­‐SNE	  
maps	  was	  visualized	  with	  cumulative	  density	  plots	  (Figure	  1D).	  The	  expression	  profile	  of	  each	  marker	  
within	   each	   t-­‐SNE	   graph	   was	   described	   by	   cumulative	   marker	   expression	   level	   plots	   (Figure	   1D).	  
MSCs	  from	  all	  sources	  positively	  expressed	  CD73,	  CD90	  and	  CD105,	  and	  only	  a	  minimal	  proportion	  of	  
cells	  were	  positive	  for	  CD14,	  CD34	  and	  CD45.	  Interestingly,	  hADSCs	  and	  hWJSCs	  showed	  similar	  event	  
distribution	   in	   contrast	   to	   hBMSCs,	   which	   possesses	   a	  more	   condensed	   population.	   The	   recorded	  
events	   were	   subdivided	   into	   three	   sectors	   to	   compare	   I)	   sector-­‐dependent	   event	   density	   and	   II)	  
sector-­‐dependent	  median	  fluorescence	  intensity	  (MFI)	  of	  each	  particular	  marker.	  hBMSCs	  appeared	  
to	   be	   significantly	   more	   abundant	   in	   sector	   3	   (p<0.001)	   and	   less	   abundant	   in	   sector	   1	   (p<0.001),	  
whereas	  hADSCs	  and	  hWJSCs	  were	  distributed	  within	  all	   three	  sectors.	  Sector	  3	   is	  characterized	  by	  
higher	   MFIs	   of	   CD73,	   CD90	   and	   CD105	   as	   visualized	   in	   Figure	   1G	   compared	   to	   sector	   1	   and	   2.	  
Therefore,	   these	   results	   indicate	   that	   even	   if	   all	  MSC	   sources	   express	  CD73,	  CD90	  and	  CD105,	   the	  
amount	  of	  surface	  proteins	  is	  different	  among	  different	  cell	  sources	  and	  that	  hBMSCs	  have	  a	  stronger	  
MSC	   phenotype	   compared	   to	   hADSCs	   and	   hWJSCs.	   No	   differences	   were	   found	   for	   hADSCs	   and	  
hWJSCs.	  
	  




Figure	  1:	  Characterization	  of	  hMSCs	  from	  adipose	  tissue,	  bone	  marrow	  and	  umbilical	  cord	  Wharton’s	  jelly.	  (A)	  The	  capacity	  of	  hADSCs,	  
hWJSCs	  and	  hBMSCs	   to	  differentiate	   into	  adipogenic	   (left),	  osteogenic	   (middle)	  and	  chondrogenic	   lineages	   (right)	  was	  demonstrated	  by	  
positive	   staining	  with	   Oil	   Red	  O,	   Alzarin	   Red	   S	   and	   Alcian	   Blue	   PAS.	   Scale	   bar	   =	   100μm.	   (B)	   Proliferation	   capacities	   between	   all	   hMSC	  
sources	  were	   compared	  over	  12	  days	  by	  defining	   (F)	   the	  generation	   time	   (hours)	   and	   cumulative	  population	  doublings	   (CPD).	   (D-­‐E)	   For	  
phenotypic	   characterization,	   bidimensional	   t-­‐SNE	   maps	   were	   generated	   from	   multidimensional	   flow	   cytometry	   data	   of	   common	   MSC	  
markers	   CD73,	   CD90,	   CD105	   and	   CD14,	   CD34,	   CD45.	   The	   cellular	   distribution	   of	   5	   donors	   per	   cell	   source	   is	   visualized	  with	   cumulative	  
density	  plots	   (D),	  whereas	   the	  expression	  profile	  of	  each	  marker	   is	  described	  by	  marker	  expression	   level	  plots	   (red	  =	  expressed,	  blue	  =	  
absent)	  (E).	  Recorded	  cells	  were	  distributed	  into	  three	  sectors	  to	  compare	  median	  fluorescence	  intensities	  (MFI).	  Percentage	  of	  events	  (F)	  
and	  MFI	  (G)	  in	  each	  sector	  revealed	  that	  hBMSCs	  are	  significantly	  more	  abundant	  in	  sector	  3,	  whereas	  hADSCs	  and	  hWJSCs	  are	  distributed	  
within	  all	  three	  sectors.	  Sector	  3	  is	  defined	  by	  higher	  MFIs	  of	  CD73	  (orange),	  CD90	  (green)	  and	  CD105	  (blue)	  as	  visualized	  by	  the	  mean	  lines	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Supplementary	  Figure	  1:	  Multilineage	  differentiation	  potential	  of	  hMSC	  from	  adipose	  tissue,	  bone	  marrow	  and	  umbilical	  cord	  Wharton’s	  
jelly.	  Differentiation	  of	  hADSC,	  hBMSC	  and	  hWJSC	  (n=5	  per	  cell	  source)	  into	  adipogenic,	  osteogenic	  and	  chondrogenic	  lineages	  is	  visualized	  





Figure	  2:	  hMSC	  CM	  harvest.	  (A)	  Workflow	  for	  hMSC	  CM	  harvesting.	  Quality	  criteria	  have	  been	  defined,	  which	  consists	  of	  cellular	  viability	  
and	   human	   platelet	   lysate	   (hPL)	   serum	   contamination,	   defined	   as	   platelet	   factor-­‐4	   (PF-­‐4)	   leftover.	   (B-­‐C)	   For	   the	   detection	   of	   serum	  
contaminations,	  a	  serial	  dilution	  of	  10%	  hPL	  in	  standard	  culture	  medium	  was	  performed	  using	  multiplexed	  particle-­‐based	  flow	  cytometric	  
cytokine	  assay.	  (B)	  Left	  panel	  displayed	  the	  gating	  of	  PF-­‐4	  and	  its	  quantification	  was	  done	  according	  to	  the	  right	  low	  and	  high	  standards.	  (C)	  
At	  a	  dilution	  of	  3200	  no	  PF-­‐4	  could	  be	  detected,	  which	  demonstrates	  the	  baseline	  for	  subsequent	  functional	  assays	  and	  mass	  spectrometry	  
analyses.	  (D)	  Concentrated	  secretoma	  (n=5	  per	  cell	  source)	  revealed	  no	  significant	  differences	  in	  PF-­‐4	  leftover	  in	  all	  three	  MSC	  sources.	  (E)	  
Proteins	   in	   the	   secretomes	   were	   relatively	   quantified	   by	   label-­‐free	   proteomics	   approach.	   Red:	   protein	   not	   detected;	   Yellow:	   protein	  
detected.	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2.1.3.2	  hMSC	  CM	  HARVEST	  
hMSC	   secretome,	   respectively	   conditioned	   media	   (CM)	   was	   harvested	   according	   to	   the	   workflow	  
outlined	  in	  Figure	  2A.	  Quality	  criteria	  were	  defined,	  which	  consisted	  of	  cellular	  viability	  after	  serum	  
free	  incubation	  and	  remaining	  serum	  proteins	  in	  the	  incubating	  cells.	  Therefore,	  platelet	  factor	  4	  (PF-­‐
4),	  a	  protein	  of	  unique	  serum	  origin,	  was	  measured	  after	  incubation	  and	  further	  concentration	  of	  the	  
harvested	   CM.	   Serial	   dilutions	   of	   human	   platelet	   lysate	   (figure	   2B)	   allowed	   the	   comparison	   of	   the	  
initial	  amount	  of	  hPL	  in	  normal	  proliferation	  medium	  (approximately	  1ug/ml)	  with	  the	  one	  after	  the	  
CM	   harvest	   procedure	   of	   hADSC	   (4360	   ±	   2371	   pg/ml	   PF-­‐4),	   hBMSC	   (1214	   ±	   254	   pg/ml	   PF-­‐4)	   and	  
hWJSC	  (3840	  ±	  2429	  pg/ml	  PF-­‐4)	  (figure	  2C).	  This	  data	  demonstrates	  that	  presented	  results	  on	  MSC	  
CM	  are	  not	  biased	  by	  differences	  in	  leftover	  of	  hPL.	  
	  
2.1.3.3	  MASS	  SPECTROMETRY	  ANALYSIS	  
We	  focused	  on	  proteins	  involved	  in	  immune	  cell	  response	  (Figure	  3)	  and	  angiogenesis	  (Figure	  4)	  from	  
the	  overall	  proteome	  and	  compared	  their	   intensities	  measured	  by	  LC/MS-­‐MS.	  Proteins	   identified	  in	  
any	   of	   the	   platelet	   lysate	   controls	   were	   excluded	   from	   the	   analysis,	   in	   order	   to	   assure	   that	   the	  
proteins	  originated	  from	  the	  MSCs.	  Heat	  maps	  were	  generated	  according	  to	  protein	  intensities	  and	  
significance	  displayed	  by	  pairwise	  student	  t-­‐test.	  Location	  of	  the	  proteins	  was	  determined	  using	  the	  
Uniprot.org	  database.	  
81	  angiogenesis	  and	  endothelial	  cell	  function	  related	  proteins	  were	  detected	  in	  MSC	  secretome	  –	  17	  
of	  these	  were	  cellular	  (meaning	  either	  intracellular	  or	  membrane	  bound,	  but	  not	  released	  or	  actively	  
secreted	  into	  the	  extracellular	  space),	  22	  proteins	  were	  cellular	  with	  evidence	  of	  exosome	  and	  vesicle	  
function,	   and	  42	  proteins	  were	   secreted	   into	   the	  extracellular	   space	   (Figure	  4A).	   7	  of	   the	  proteins	  
have	   been	   associated	   with	   a	   negative	   effect	   on	   angiogenesis	   according	   to	   literature	   (Figure	   4A,	  
proteins	  in	  red	  letter).	  According	  to	  the	  heat	  maps,	  30	  proteins	  showed	  significantly	  higher	  levels	  in	  
hWJSC	   secretome	  compared	   to	  hBMSC	  and	  hADSC	  secretome.	  10	  proteins	  were	   significantly	  more	  
abundant	   in	   hBMSC	   secretome	   compared	   to	   hWJSC	   and	   hADSC	   secretome.	   13	   were	   equally	  
abundant	   in	   hBMSC	   and	   hWJSC	   secretome,	   but	   significantly	   higher	   than	   hADSCs.	   Only	   3	   proteins	  
showed	  significantly	  higher	  levels	  in	  hADSC	  secretome	  compared	  to	  hBMSC	  and	  hWJSC	  secretome.	  	  
45	   inflammation	   related	  proteins	  were	  detected	   in	  MSC	  secretome	  –	  13	  of	   these	  were	  cellular,	  18	  
proteins	  were	  cellular	  with	  evidence	  of	  exosome	  and	  vesicle	  function,	  and	  14	  proteins	  were	  secreted	  
into	  the	  extracellular	  space	  (Figure	  3G).	  According	  to	  the	  heat	  maps,	  18	  showed	  significantly	  higher	  
levels	  in	  hWJSC	  secretome,	  2	  in	  hBMSC	  secretome	  and	  2	  in	  hADSC	  secretome	  compared	  to	  the	  other	  
sources.	   7	   were	   equally	   abundant	   in	   hBMSC	   and	   hWJSC	   secretome,	   but	   significantly	   higher	   than	  
hADSCs.	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To	  display	  protein	  interactions,	  all	  angiogenesis-­‐related	  proteins	  were	  uploaded	  into	  String	  database	  
and	   evaluated	   using	   Cytoscape.	   Figure	   4B	   displays	   the	   interactions	   of	   all	   proteins	   related	   to	  
angiogenesis,	   except	   of	   the	   ones	   not	   being	   part	   of	   any	   interaction	   (includes	   18	   proteins).	   Node	  
size/color	  is	  based	  on	  the	  BetweennessCentrality	  defined	  by	  the	  combined	  score	  of	  String	  database.	  
High	   ranked	   proteins	   are	   those,	  which	   possesses	  more	   interactions	  within	   the	   network.	   AKT1	   and	  
FGF2	  were	  high	  ranked	  (blue	  in	  Figure	  4B),	  followed	  by	  IL-­‐6,	  PDGFRB,	  CTNNB1,	  PXN,	  VEGF-­‐C,	  WNT5A,	  
NOTCH3	   (green	   in	   Figure	   4B)	   and	   ENG,	   ANGPT1,	   TIMP2,	   PAX2,	   COL18A1,	   JAG1,	   EFNB2	   (yellow	   in	  
Figure	  4C).	  Interestingly,	  out	  of	  this	  protein	  selection	  AKT1,	  FGF2,	  NOTCH3,	  ENG,	  ANGPT1,	  JAG1	  and	  
EFNB2	   were	   not	   found	   in	   hADSC	   secretome,	   representing	   crucial	   angiogenic	   proteins	   within	   the	  
network.	  Also	  hBMSC	  secretome	  showed	  lack	  of	  fundamental	  angiogenic	  proteins,	  missing	  AKT1	  and	  
EFNB2,	   whereas	   hWJSC	   secretome	   retained	   the	   more	   complete	   pro-­‐angiogenic	   network	   by	   only	  
missing	  NOTCH3.	  hWJSC	  secretome	  possessed	  not	  only	  a	  higher	  number	  of	  angiogenic	  proteins,	  but	  
also	  specific	  pro-­‐angiogenic	  proteins	  to	  a	  higher	  extent.	  Interestingly,	  similar	  highly	  ranked	  proteins	  
such	   as	  AKT1,	   FGF2,	   IL6	   and	  WNT5A	  were	   also	   found	   in	   the	   network	   related	   to	   inflammation	   and	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Figure	  3:	  MSC	  CM	  induces	  immune	  cell	  response.	  (A)	  Concentration	  dependent	  migration	  of	  hPBMCs	  (n=3	  healthy	  blood	  donors)	  through	  
3μm	   pores	   of	   a	   transwell	   insert	   was	   evaluated	   after	   3hrs	   co-­‐incubation	  with	   5ng/ml,	   20ng/ml	   and	   50ng/ml	  MCP-­‐1.	   Only	   at	   a	   starting	  
amount	  of	  3x106	  hPBMCs	  (right)	  and	  not	  of	  1x106	  hPBMCs	  (left),	  significant	  differences	  in	  %	  of	  migration	  of	  total	  added	  monocytes	  could	  
be	  detected.	  (B)	  Using	  3x106	  hPBMCs,	  hMSC	  CM	  (n=5	  per	  cell	  source)	  revealed	  enhanced	  migration	  of	  monocytes,	  with	  significantly	  higher	  
migration	  of	  hBMSC	  CM	  and	  hWJSC	  CM	  in	  comparison	  to	  hADSC	  CM	  and	  5ng/ml	  MCP-­‐1	  control.	  (C)	  Three	  individual	  healthy	  blood	  donors	  
were	  used	   to	  define	   the	  chemoattractive	  potential	  of	  hMSC	  CM.	   (D)	  No	  essential	   lymphocyte	  migration	   (compared	   to	   initial	  population	  
seeded)	  was	  detected.	   (E-­‐F)	  MSC	  CM	   induced	  migration	  of	  mainly	   classical	   CD14++	   CD16-­‐	  monocytes,	   but	   not	   of	   intermediate	   and	  non-­‐
classical	  monocytes,	   as	   revealed	  by	  a	  CD14	  and	  CD16	   staining.	   (G)	  MSC	   secretome	  proteins	   involved	   in	   immune	  cell	   response.	  Pairwise	  
student	  t-­‐test	  were	  performed	  to	  detect	  differences	  between	  secretomes	  obtained	  from	  hADSCs	  (AD),	  hBMSCs	  (BM)	  and	  hWJSCs	  (WJ)	  (n=5	  
per	   cell	   source).	   Significantly	   changed	   secretion	   is	   indicated	   by	   +.	   Heat	  map	  was	   generated	   based	   on	   protein	   intensities	  measured	   by	  
LC/MS-­‐MS	   (red	   =	   not	   detected,	   green	   =	   detected).	   (H)	   All	   identified	   proteins	  were	   uploaded	   into	   String	   database	   and	   evaluated	   using	  
Cytoscape	   to	   define	   their	   interaction.	   Node	   size/color	   is	   based	   on	   the	   BetweennessCentrality	   defined	   by	   the	   combined	   score	   of	   String	  
database,	  whereas	  low	  values	  are	  small	  size	  and	  orange	  (color	  code	  from	  low	  to	  high:	  orange	  –	  yellow	  –	  green	  –	  blue).	  The	  same	  principle	  
was	  applied	  for	  map	  edge	  size/color.	  Proteins	  not	  being	  part	  of	  any	  interaction	  are	  not	  displayed.	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2.1.3.4	  IMMUNE	  CELL	  RESPONSE	  
The	   immune	   cell	   response	   induced	   by	   hMSC	   CM	   was	   tested	   by	   migration	   of	   hPBMCs	   from	   3	  
independent	  healthy	  donors	  towards	  a	  transwell	  insert.	  	  
To	  assure	  concentration	  dependent	  migration	  of	  hPBMCs,	   the	  assay	  was	  established	  using	  5ng/ml,	  
20ng/ml	   and	   50ng/ml	   MCP-­‐1.	   Only	   a	   starting	   amount	   of	   3x106	   hPBMCs	   and	   not	   1x106	   hPBMCs	  
showed	   significant	   differences	   in	   percentage	   of	   migration	   of	   total	   added	   monocytes	   by	   flow	  
cytometry	   (Figure	  3A).	  All	   results	  are	  displayed	  with	  subtracted	  control	  migration	  of	  basal	  medium	  
only.	  Using	  3x106	  hPBMCs	  MSC	  CM	  enhanced	  migration	  of	  particularly	  monocytes	  (Figure	  3B).	  	  
Significant	  higher	  monocyte	  migration	  to	  hBMSC	  CM	  (p	  <	  0.01)	  and	  hWJSC	  CM	  (p	  <	  0.001)	  compared	  
to	  hADSC	  CM	  was	  found	  (n=5	  per	  tissue	  source)	  (Figure	  3B).	  No	  differences	  were	  detected	  between	  
the	  CM	  of	  hBMSCs	  and	  hWJSC	  (p	  =	  0.14).	  Monocyte	  migration	  of	  the	  three	  individual	  blood	  donors	  is	  
displayed	  in	  figure	  3C.	  Interestingly,	  no	  significant	  difference	  was	  detected	  in	  lymphocyte	  migration	  
compared	  to	  the	  initial	  population	  seeded,	  supporting	  the	  immunomodulatory	  capacity	  of	  hMSC	  CM	  
(Figure	  3D).	  The	  original	  hPBMCs	  population	  consisted	  of	  91.96	  ±	  2.02	  %	  lymphocytes	  and	  8.04	  ±	  2.02	  
%	  monocytes,	  when	  neglecting	  the	  small	  amount	  of	  dendritic	  cells	  (below	  2	  %).	  After	  migration,	  the	  
following	  percentages	  of	   lymphocytes	  were	   found	  for	  hADSC	  CM	  9.62	  ±	  7.53	  %,	  hBMSC	  CM	  5.89	  ±	  
1.82	  %	  and	  hWJSC	  CM	  2.05	  ±	  1.24	  %	  compared	   to	  basal	  medium	  only	  24.58	  ±	  9.06	  %	  and	  5ng/ml	  
MCP-­‐1	  3.34	  ±	  4.32	  %,	  whereas	   the	  percentage	  of	  monocytes	   increased	  as	   followed	   for	   hADSC	  CM	  
90.38	   ±	   44.14	  %,	   hBMSC	  CM	  94.11	   ±	   27.93	  %	  and	  hWJSC	  CM	  97.95	   ±	   27.56	  %	   compared	   to	  basal	  
medium	   only	   75.42	   ±	   83.84	   %	   and	   5ng/ml	   MCP-­‐1	   96.66	   ±	   53.83	   %.	   To	   define	   the	   phenotype	   of	  
migrated	  monocytes,	   a	   CD14	   and	   CD16	   staining	   enabled	   to	   classify	   the	   cells	   into	   three	   subgroups	  
known	  as	  classical	  CD14++	  CD16-­‐	  monocytes,	  intermediate	  CD14++	  CD16+	  monocytes	  and	  non-­‐classical	  
CD14dim	  CD16+	  monocytes	   (Figure	  3E).	   The	  original	   seeded	  hPBMC	  population	   consisted	  of	  93.50	  ±	  
2.94	   %	   classical,	   2.04	   ±	   0.62	   %	   intermediate	   and	   4.51	   ±	   2.56	   %	   non-­‐classical	   monocytes	   of	   total	  
monocytes	  analyzed	  (Figure	  3E).	  After	  migration	  mainly	  classical	  hPBMCs	  prevailed	  with	  98.99	  ±	  0.12	  
%	  classical,	  0.47	  ±	  0.09	  %	  intermediate	  and	  0.54	  ±	  0.06	  %	  non-­‐classical	  for	  hADSC	  CM,	  98.87	  ±	  0.02	  %	  
classical,	  0.10	  ±	  0.02	  %	  intermediate	  and	  0.02	  ±	  0.01	  %	  non-­‐classical	  for	  hBMSC	  CM	  and	  99.79	  ±	  0.07	  
%	   classical,	   0.14	   ±	   0.05	   %	   intermediate	   and	   0.07	   ±	   0.03	   %	   non-­‐classical	   for	   hWJSC	   CM	   of	   total	  
monocytes	   migrated.	   Whether	   monocyte	   phenotype	   change	   over	   migration	   or	   only	   classical	  
monocytes	  migrate	  remains	  to	  be	  discussed.	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Figure	   4:	   The	  pro-­‐angiogenic	   proteome	  of	   hMSC	   secretome.	   (A)	  Proteins	   involved	   in	  angiogenesis	  and	  endothelial	  cell	   function	   in	  MSC	  
secretomes.	  Pairwise	  student	  t-­‐test	  were	  performed	  to	  detect	  differences	  between	  secretomes	  obtained	  from	  hADSCs	  (AD),	  hBMSCs	  (BM)	  
and	   hWJSCs	   (WJ)	   (n=5	   per	   cell	   source).	   Significant	   results	   are	   displayed	   by	   +.	   Heat	   map	   was	   generated	   based	   on	   protein	   intensities	  
measured	  by	  LC/MS-­‐MS	  (red	  =	  not	  detected,	  green	  =	  detected).	  For	  every	  protein	  related	  to	  angiogenesis,	  a	  reference	  has	  been	  added.	  
Proteins	   in	   red	   letter	   are	   known	   to	   exhibit	   negative	   effects	   on	   angiogenesis,	   whereas	   proteins	   in	   black	   letter	   are	   known	   to	   be	   pro-­‐
angiogenic.	  (B)	  All	  identified	  proteins	  were	  uploaded	  into	  String	  database	  and	  evaluated	  using	  Cytoscape	  to	  define	  their	  interaction.	  Node	  
size/color	  is	  based	  on	  the	  BetweennessCentrality	  defined	  by	  the	  combined	  score	  of	  String	  database,	  whereas	  low	  values	  are	  small	  size	  and	  
orange	  (color	  code	  from	  low	  to	  high:	  orange	  –	  yellow	  –	  green	  –	  blue).	  The	  same	  principle	  was	  applied	  for	  map	  edge	  size/color.	  Proteins	  not	  
being	  part	  of	  any	  interaction	  are	  not	  displayed	  (C)	  Proteins	  not	  found	  in	  the	  according	  secretome	  are	  displayed	  in	  red,	  demonstrating	  that	  
central	  proteins	  are	  missing	  in	  hADSC	  secretome	  compare	  to	  hBMSC	  and	  hWJSC	  secretome.	  
	  
2.1.3.5	  ENDOTHELIAL	  CELL	  RESPONSE	  
To	   analyze	   the	   pro-­‐angiogenic	   potential	   of	   hMSC	   CM	   in	   vitro,	   surface	   markers	   involved	   in	  
angiogenesis	  such	  as	  angiopoietin-­‐1	  receptor	  (CD202b),	  endoglin	  (CD105),	  VE-­‐cadherin	  (CD144)	  and	  
PECAM-­‐1	   (CD31)	   were	   analyzed	   after	   co-­‐incubation	   with	   either	   MSC	   CM,	   basal	   DMEM	   medium	  
(negative	   control)	   or	   original	   EGM-­‐2	  medium	   (positive	   control).	   Bidimensional	   t-­‐SNE	   density	  maps	  
were	   generated	   from	  multidimensional	   data	   obtained	   flow	   cytometry	   and	   showed	   unequal	   event	  
density	   distribution	   depending	   on	   the	   medium	   in	   which	   HUVEC	   were	   incubated	   (Figure	   5A).	  
Cumulative	  heat	  maps	  display	  scaled	  expression	  of	  the	  four	  surface	  markers	  (Figure	  5B).	  In	  order	  to	  
compare	  the	  effects	  of	  the	  different	  CM	  on	  HUVECs	  surface	  antigen	  profile,	  t-­‐SNE	  maps	  were	  divided	  
in	   three	   equal	   sectors.	   The	  %	  of	   events	   and	   the	  MFI	  was	   analyzed	   in	   each	   sector	   (Figure	   5A).	   The	  
three	  sectors	  were	  defined	  according	  to	  the	  MFI	  of	  all	  surface	  markers	  on	  HUVECs	  incubated	  under	  
standard	   EGM-­‐2	   condition	   as	   following:	   Sector	   1)	   CD105medium,	   CD202blow,	   CD144medium,	   CD31high	   ;	  
Sector	   2)	   CD105high,	   CD202bhigh,	   CD144high,	   CD31medium	   ;	   Sector	   3)	   CD105low,	   CD202blow,	   CD144low,	  
CD31low	  (Figure	  5C).	  
HUVECs	   treated	   with	   basal	   DMEM	  medium	   localize	   preferentially	   in	   sector	   3,	   with	   the	   significant	  
highest	   %	   of	   events	   (p<0.001)	   (Figure	   5D).	   Importantly,	   sector	   3	   is	   characterized	   by	   the	   lowest	  
expression	   all	   pro-­‐angiogenic	   surface	   markers.	   When	   HUVECs	   were	   treated	   with	   MSC	   CM	   major	  
event	   density	   shifts	   were	   observed.	   In	   detail,	   upon	   hBMSC	   and	   hWJSC	   CM	   treatment	   HUVECs	  
localized	  mainly	  in	  sector	  1	  and	  2;	  both	  sectors	  are	  characterized	  by	  higher	  surface	  expression	  level	  
of	   pro-­‐angiogenic	   surface	   markers.	   In	   particular,	   the	   CM-­‐dependent	   event	   density	   shift	   towards	  
sector	   1	   was	   significantly	   higher	   when	   HUVECs	   were	   treated	   with	   hBMSC	   CM	   and	   hWJSC	   CM	  
compared	  to	  hADSC	  CM,	  basal	  DMEM	  medium	  and	  original	  EGM-­‐2	  medium	  (p<0.001)	  (Figure	  5D).	  No	  
differences	  among	  all	  MSC	  CM	  were	  found	  in	  sector	  2	  (Figure	  5D).	  Overall	  these	  results	  demonstrate,	  
that	  hBMSC	  CM	  and	  hWJSC	  CM	   induce	  a	  more	  angiogenic	  HUVEC	  phenotype	   in	  vitro	   compared	   to	  
the	  pro-­‐angiogenic	   induction	   triggered	  by	  hADSC	  CM	  and	  are	  closer	   to	   the	  phenotype	  obtained	  by	  
treatment	  with	  original	  EGM-­‐3	  medium.	  Furthermore,	   the	  pro-­‐angiogenic	  effects	  of	  MSC	  CM	  were	  
tested	   in	   vivo	   angiogenesis	   by	   subcutaneously	   injection	   of	   matrigel	   mixed	   with	   MSC	   CM	   from	  
different	   sources	   (Figure	   6F).	   Vascularization	   of	   the	   matrigel	   plugs	   was	   quantitatively	   evaluated	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measuring	   the	   hemoglobin	   content.	   Significantly	   higher	   hemoglobin	   content	   was	   detected	   in	  
matrigels	  mixed	  with	  MSC	  CM	   compared	   to	   basal	  medium	   (Figure	   6G).	  However	   no	  differences	   in	  
angiogenic	  potential	  were	  detected	  between	  the	  three	  MSC	  sources	  in	  vivo.	  
	  
Figure	  5:	  hMSC	  secretome	  is	  pro-­‐angiogenic	  in	  vitro	  and	  in	  vivo.	  (A-­‐E)	  Stimulation	  of	  HUVEC	  with	  MSC	  CM	  induces	  phenotypic	  changes	  in	  
vitro,	   including	   the	   surface	  markers	  CD105,	  CD202b,	  CD144	  and	  CD31.	  Bidimensional	   t-­‐SNE	  maps	   show	   (A)	  unequal	   cellular	  distribution	  
depending	  on	  the	  incubation	  medium	  (basal	  =	  basal	  DMEM;	  original	  =	  EGM-­‐2)	  and	  (B)	  differences	  in	  expression	  pattern	  of	  surface	  markers.	  
(C)	  Cells	  were	  therefore	  distributed	  into	  three	  sectors	  which	  are	  defined	  based	  on	  median	  fluorescence	  intensity	  (MFI)	  of	  surface	  markers	  
of	   HUVEC	   under	   standard	   EGM-­‐2	   conditions.	   Sector	   1)	   CD105medium,	   CD202blow,	   CD144medium,	   CD31high	   ;	   Sector	   2)	   CD105high,	   CD202bhigh,	  
CD144high,	  CD31medium	  ;	  Sector	  3)	  CD105low,	  CD202blow,	  CD144low,	  CD31low.	  Percentage	  of	  events	  (D)	  and	  MFI	  (E)	  in	  each	  sector	  revealed	  that	  
hBMSC	   CM	   and	   hWJSC	   CM	   induce	   a	   more	   angiogenic	   phenotype	   in	   vitro	   compared	   to	   hADSC	   CM.	   (F-­‐G)	   In	   vivo	   matrigel	   plug	   assay	  
demonstrated	   significantly	   increased	   vascularization	   when	   using	   hMSC	   CM	   compared	   to	   basal	   medium	   only,	   as	   visualized	   with	   the	  
hemoglobin	  content	  in	  60mg	  matrigel.	  Scale	  bar	  =	  0.5	  cm.	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2.1.4	  DISCUSSION	  
The	  current	   study	  demonstrates	   that	  MSCs	  derived	   from	  different	   clinically	   relevant	   tissue	   sources	  
such	   as	   adipose	   tissue,	   bone	   marrow	   and	   umbilical	   cord	   Wharton’s	   jelly	   have	   distinct	  
chemoattractive	  and	  pro-­‐angiogenic	  potential.	  In	  particular,	  hBMSC	  and	  hWJSC	  secretomes	  retained	  
a	  higher	  inflammation	  mediated	  angiogenic	  profile	  and	  functional	  response	  compared	  to	  the	  hADSC	  
secretome.	   Protein	   maps	   generated	   by	   high	   resolution	   LC/MS-­‐MS	   demonstrated	   that	   angiogenic	  
proteins	  with	  high	  betweenness	   centrality/interactions	  were	  primarily	   found	   in	  hBMSC	  and	  hWJSC	  
secretome.	   These	   fundamental	   proteins,	   such	   as	   AKT1	   and	   FGF2,	   have	   strong	   control	   over	  
information	   flow	  within	   the	   pro-­‐angiogenic	   network	   and	   related	   signaling	   pathways.	   Interestingly,	  
these	   proteins	   not	   only	   influence	   the	   angiogenic	   process,	   but	   also	   mediate	   an	   inflammatory	  
response.	   These	   observations	   also	   further	   support	   the	   close	   interaction	   between	   the	   primary	  
inflammatory	  response	  and	  angiogenesis	  following	  tissue	  remodeling.	  
AKT1	  has	  shown	  to	  promote	  angiogenic	  related	  functions	  of	  BMSCs	  in	  vivo	  20	  and	  its	  overexpression	  
in	  MSCs	  of	  amniotic	   fluid	   21	  and	  bone	  marrow	  22,23	   supported	  the	  repair	  of	   ischemic	  heart	   tissue	   in	  
vivo.	   Endothelial	   AKT1	   enhances	   angiogenesis	   by	   phosphorylation	   of	   downstream	   angiogenic	  
substrates	   24	  and	  was	   reported	  as	  a	   regulator	   in	   the	  acute	   inflammatory	   response	   25.	  On	   the	  other	  
hand,	  FGF2	  is	  a	  potent	  inducer	  of	  angiogenesis	   in	  vitro	  and	   in	  vivo	  26	  and	  synergistically	  potentiates	  
inflammation	   mediated	   leukocyte	   recruitment	   27.	   Besides,	   the	   addition	   of	   FGF2	   has	   shown	   to	  
enhance	  the	  long-­‐term	  angiogenic	  efficacy	  of	  transplanted	  hADSCs	  into	  ischemic	  tissue	  28	  and	  induce	  
the	  production	  of	  MSC-­‐derived	  extracellular	  vesicles	  for	  vessel	  stabilization	  29.	  Exosomes	  have	  even	  
been	   proposed	   as	   key	   factors	   for	   angiogenesis,	   mediating	   through	   PDGFR,	   EGFR	   and	   NFkB	  
pathways30,	   given	   that	   MSC	   secretome	   depleted	   of	   exosomes	   exhibit	   an	   impaired	   pro-­‐angiogenic	  
function	  5.	  
Thus,	   it	   is	  not	   surprising	   that	  hADSC	  secretome	   induced	   lower	  monocyte	  migration	  and	  angiogenic	  
phenotype	  of	  HUVEC	  when	  considering	   the	  proteomic	   results.	  hADSC	   secretome	  did	  not	  only	  miss	  
crucial	   pro-­‐angiogenic	   proteins	   like	   AKT1	   and	   FGF2,	   but	   also	   expressed	  most	   of	   the	   proteins	   to	   a	  
significantly	   lower	   level	   compared	   to	   hBMSC	   and	   hWJSC	   secretome.	   Interestingly,	   surface	  marker	  
expression	   was	   identical	   between	   hADSCs	   and	   hWJSCs,	   not	   allowing	   any	   anticipated	   conclusion	  
about	  their	  functional	  response.	  Only	  hBMSCs	  demonstrated	  a	  different	  characterization	  profile	  with	  
significant	  higher	  expression	  of	  CD73,	  CD90	  and	  CD105,	  though	  did	  not	  exhibit	  better	  pro-­‐angiogenic	  
potential.	   However,	   hADSCs	   showed	   significant	   higher	   proliferation	   abilities	   compared	   to	   hBMSCs	  
and	  hWJSCs.	  Previous	  studies	  have	  described	  hADSCs	  as	  genetical	  and	  morphological	  more	  stable	  in	  
long-­‐term	  culture	  with	  lower	  senescence	  and	  higher	  proliferative	  capacities	  31.	  Here,	  identical	  cellular	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viability	  after	  secretome	  harvest	  was	  found,	  but	  higher	  proliferation	  might	  have	  influenced	  the	  pro-­‐
angiogenic	  potential	  of	  hADSCs.	  
Taken	   together,	   hWJSC	   secretome	   possesses	   a	   slightly	  more	   pro-­‐inflammatory	   and	   pro-­‐angiogenic	  
secretome	   compared	   to	   the	   intermediate	   phenotype	   of	   hBMSC	   secretome	   even	   if	   our	   functional	  
analyses	   failed	   to	   show	   statistically	   significant	   differences.	   In	   accordance	   to	   our	   study,	   recent	  
comparative	  studies	  have	  shown	  that	  hWJSC	  secretome	  possesses	  more	  secreted	  factors	  involved	  in	  
angiogenesis	  compared	  to	  hBMSC	  11.	  Ribeiro	  et	  al.	  proposed	  that	  hBMSC	  secretome	  might	  be	  most	  
potent	   to	   reduce	  oxidative	  stress,	  while	  hWJSC	  and	  hADSC	  secretome	  seem	  more	  beneficial	   in	   the	  
protection	   against	   excitotoxicity	   32.	   Furthermore,	   it	   was	   suggested	   that	   hWJSCs	   express	   more	  
stemness	   and	   growth	   related	   genes,	   whereas	   hBMSCs	   express	   more	   genes	   involved	   in	   skeletal	  
development	  33.	  	  
We	  therefore	  propose	  hWJSCs	  –	  and	  the	  hWJSC	  derived	  secretome	  –	  as	  the	  most	  potent	  MSC	  source	  
for	  clinical	  use.	  Prenatal	  hWJSCs	  can	  be	  obtained	   from	  healthy,	  young	  donors	  with	  minimal	  ethical	  
concerns	  in	  high	  quantities	  and	  with	  no	  risk.	  On	  the	  contrary,	  the	  amount	  of	  hBMSC	  obtained	  from	  a	  
bone	  marrow	  puncture	  is	  limited.	  hBMSCs	  are	  isolated	  from	  older	  patients,	  which	  are	  susceptible	  to	  
aging	   factors	   such	   as	   the	   accumulation	   of	   cellular	   damage,	   cell	   death/senescence	   and	   loss	   of	  
regenerative	  functions.	  	  
Nevertheless,	   patient	   variability	   has	   been	   detected	   in	   the	   presented	   study	   despite	   consistent	  
isolation	   and	   characterization	   procedures.	  One	   has	   to	   emphasize	   that	   different	   donors	   among	   the	  
tissue	   sources	   have	   been	   analyzed	   here,	   not	   allowing	   for	   direct	   comparison	  within	   one	   particular	  
patient.	   Furthermore	   no	   restriction	   on	   donor	   age,	   gender	   and	  medical	   history	   are	   available	   in	   the	  
current	   study.	   Therefore,	   5	   donors	   per	   cell	   source	   have	   been	   included	   into	   the	   study.	   However,	  
patient	   variability	   did	   not	   enable	   to	   find	   any	   significant	   differences	   in	   this	   in	   vivo	   investigation	  
conducted	   (Matrigel	   plug	   assay),	   in	   contrast	   to	   in	   vitro	   functional	   assays	   and	   mass	   spectrometry	  
analyses;	  this	  might	  particularly	  also	  due	  to	  the	  additional	  variability	   in	  angiogenic	  response	  among	  
different	  mice.	  Future	  studies	  will	  focus	  on	  a	  more	  reproducible	   in	  vivo	  angiogenic	  assay	  to	  confirm	  
the	  presented	  differences	  among	  tissue	  sources.	  
Overall	  the	  establishment	  of	  clinical	  treatments	  based	  on	  MSC	  secretomes	  has	  clear	  advantages	  for	  
clinical	  translation	  compared	  to	  autologous	  or	  homologous	  cells	  therapy,	  considering	  manufacturing	  
costs	  and	  logistics.	  In	  addition,	  the	  unlimited	  supply	  of	  the	  MSC	  secretome	  off-­‐the-­‐shelf	  without	  the	  
need	   for	   harvesting	   tissue	   from	   the	   affected	   patient	   would	   represent	   a	   major	   advantage	   over	  
currently	  used	  experimental	  and	  clinical	  cell	  therapy	  approaches.	  
However,	  major	  challenge	  of	   in	  vitro	  secretome	  studies	   lies	   in	  discriminating	  proteins	  that	  are	  truly	  
MSC-­‐secreted	   from	   those	   that	   are	   artifacts	   from	   cell	   culture	   media	   components	   (such	   as	   serum	  
Chapter	  2.1	  	  
85	  
proteins)	   or	   derived	   from	   non-­‐physiological	   stresses	   affecting	   the	   starving	   cells.	   In	   this	   regard,	  
intracellular	  proteins	  can	  be	  detected	   in	   the	  secretome	  due	   to	  cellular	  death	  or	   leakage.	  However,	  
there	  is	  now	  evidence	  that	  some	  of	  these	  proteins	  can	  also	  be	  released	  via	  nonclassical	  pathways	  via	  
vesicles	   and	   exosomes	   and	   exert	   extracellular	   functions	   that	   seem	   to	   be	   different	   from	   their	  
intracellular	  role	  34.	  Even	  if	  a	  subset	  of	  MSCs	  has	  entered	  apoptosis,	   it	  has	  been	  shown	  that	  factors	  
released	  from	  apoptotic	  MSCs	  can	  contribute	  to	  regeneration	  of	   ischemic	  tissues	  35,36.	   In	  particular,	  
Sun	   et	   al.	   highlighted	   the	   beneficial	   immunomodulatory	   roles	   of	   apoptotic	   stem	   cells	   by	  
demonstrating	  that	  combined	  therapy	  with	  apoptotic	  and	  healthy	  ADSCs	  is	  superior	  to	  either	  alone	  
36.	  Therefore,	  we	  believe	  that	  the	  complete	  secretome	  needs	  to	  be	  described	  in	  order	  to	  understand	  
their	   interaction	  and	   in	  vivo	   function.	  Unlike	  pharmaceutical	  treatments	  that	  deliver	  a	  single	  agent,	  
the	   MSC	   secretome	   provides	   several	   stimulatory	   and	   inhibitory	   bioactive	   factors	   at	   variable	  
concentrations	  that	  might	  sustain	  physiological	  pharmacokinetics	  in	  the	  local	  microenvironment.	  
Besides,	  secretome	  harvest	  procedures	  allow	  for	  the	  attachment	  of	  serum	  proteins	  that	  can	  later	  be	  
released	   into	   the	   MSC	   secretome	   34.	   This	   contamination	   with	   serum	   proteins	   might	   have	   been	  
neglected	   in	  many	  previous	   in	  vitro	   and	   in	  vivo	   studies,	  which	  might	   lead	   to	   incorrect	   conclusions.	  
Therefore,	  the	  presented	  work	  defined	  remaining	  serum	  proteins	  by	  the	  detection	  of	  PF-­‐4,	  a	  cytokine	  
uniquely	  released	  from	  activated	  platelets.	  No	  differences	  in	  PF-­‐4	  levels	  between	  the	  different	  MSC	  
sources	   confirmed	   that	   the	   results	   are	   not	   biased	   by	   differences	   in	   serum	   leftover.	   Furthermore,	  
serial	   dilutions	   allowed	   defining	   the	   detection	   limit	   of	   PF-­‐4	   and	   use	   this	   dilution,	   consisting	   of	   a	  
1:3200	  dilution	  of	  standard	  proliferation	  medium,	  as	  a	  suitable	  control	  for	  subsequent	  MS	  analysis.	  In	  
this	  way	  we	   could	   assure	   no	   culture	  medium	   artifacts	  within	   the	   presented	   data.	   However,	   some	  
proteins	  might	  have	  been	  masked	  by	   this	   procedure	   as	   they	   can	  be	  derived	   from	  both,	  MSCs	   and	  
hPL.	   Only	   by	   using	   standardized	   GMP-­‐compliant	   culture	   protocols,	   with	   hPL	   instead	   of	   xenogenic	  
components,	  we	  can	  increase	  in	  vivo	  safety	  for	  future	  clinical	  translation.	  
In	  conclusion,	  we	  have	  systematically	  compared	  MSC	  from	  hADSCs,	  hBMSCs	  and	  hWJSCs	  in	  order	  to	  
determine	   which	   cell	   source	   possesses	   the	   highest	   potential	   for	   angiogenesis	   and	   endogenous	  
regeneration.	  A	  GMP-­‐compliant	  xenofree	  approach	  towards	  generating	  MSC	  secretome	  and	  enabling	  
safe	   clinical	   translation	   has	   been	   established.	   MSC	   secretomes	   showed	   significant	   functional	   and	  
proteomic	  differences	  in	  inflammation-­‐mediated	  angiogenesis.	  Taken	  together,	  these	  results	  indicate	  
that	   hWJSC	   secretome	   might	   represent	   the	   most	   potent	   MSC	   source	   for	   clinical	   angiogenesis	  
induction.	   Compared	   with	   other	   tissue	   sources,	   hWJSCs	   have	   several	   advantages,	   such	   as	   their	  
noninvasive	   collection	   procedure,	   fetal	   origin	   and	   unlimited	   supply	   as	   leftover	   materials,	   which	  
emphasize	  their	  potential	  clinical	  utility	  for	  regenerative	  medicine	  in	  the	  future.	  
MSC	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The	  ovine	  developmental	  model	  represents	  the	  standard	  in	  vivo	  model	  for	  studies	  involving	  materno-­‐
fetal	  physiology,	  amniotic	  fluid	  research	  and	  fetal	  cell	  therapy	  prior	  to	  human	  clinical	  use.	  Although	  
being	   close	   to	   the	   human	   fetal	   anatomy,	   it	   maintains	   two	   separate	   extraembryonic	   fluid	  
compartments	  during	  gestation,	  known	  as	  the	  amnion	  and	  the	  allantois.	  A	  clear	  distinction	  between	  
amniotic	   fluid	   (AF)	   versus	   allantoic	   fluid	   (AL)	   is	   therefore	   indispensable	   for	   correct	   scientific	  
conclusions	  with	  regards	  to	  human	  translation.	  In	  the	  presented	  study,	  the	  biochemical	  composition	  
of	  AF	  and	  AL	  was	  evaluated	  in	  ovine	  gravid	  uteri	  post	  mortem	  (n=31).	  Four	  parameters,	  consisting	  of	  
Na+,	  Cl-­‐,	  Mg2+	  and	  total	  protein,	  have	  been	  found	  to	  allow	  for	  specific	  discrimination	  of	  the	  two	  fetal	  
fluids	  and	  as	  potential	  surrogate	  parameters	  for	  gestational	  age.	   In	  addition,	  volumetric	  changes	  of	  
the	  developing	  fetus	  and	  the	  two	  fetal	  fluid	  cavities	  were	  analyzed	  by	  contrast-­‐enhanced	  computed	  
tomography	   (n=12).	  AF	  showed	  a	  significant,	   linear	  volumetric	   increase	  over	  gestation,	  whereas	  AL	  
volume	   maintained	   relatively	   static	   independent	   of	   gestational	   age.	   These	   results	   may	   provide	   a	  
basis	   for	   future	   experimental	   studies	   in	   the	   ovine	   developmental	   model	   and	  may	   enable	   a	   more	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  and	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  published	  work	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Three-­‐dimensional	   computed	   tomography	   (CT)	   of	   ovine	   anatomy	   and	   fetal	   fluid	   cavities,	   including	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3.1.1	  INTRODUCTION	  
The	  ovine	  developmental	  model	  represents	  a	  standard	  in	  vivo	  model	  for	  the	  assessment	  of	  materno-­‐
fetal	  disease	  and	  fetal	  therapeutic	  applications	  prior	  to	  human	  clinical	  use.	  Even	  though	  it	  does	  not	  
completely	  recapitulate	  human	  pregnancy,	  several	  scientific	  questions	   involving	  the	  entire	  duration	  
of	   pregnancy	   cannot	   be	   addressed	   in	   the	   human	   situation	   given	   major	   ethical	   and	   medical	  
restrictions.	  Consequently,	  the	  ovine	  model	  is	  well	  accepted	  and	  regularly	  used	  as	  part	  of	  preclinical	  
fetal	  studies,	  such	  as	  fetal	  tracheal	  1,2	  and	  diaphragmatic	  3-­‐5	  reconstruction,	  heart	  valve	  replacement	  
6,	   wound	   healing	   7,	   materno-­‐fetal	   interactions	   (placenta	   development/function)	   8	   or	   cell	  
transplantations	  9.	  Also	  studies	  on	  ovine	  fetal	  adnexa-­‐derived	  (stem)	  cells	  10	  or	  ovine	  amniotic	  fluid-­‐
derived	  (stem)	  cells	  6,11	  have	  been	  conducted	  revealing	  cellular	  phenotypes	  largely	  comparable	  to	  the	  
human	  counterpart.	  
However,	   although	   being	   close	   to	   the	   human	   fetal	   anatomy,	   the	   ovine	   materno-­‐fetal	   model	  
maintains	   two	   separate	  extraembryonic	   fluid	   compartments	  during	   the	  entire	  gestation,	  which	  are	  
known	  as	  the	  amnion	  and	  the	  allantois.	  In	  humans	  only	  a	  single	  cavity,	  known	  as	  the	  amniotic	  fluid	  
cavity,	   is	   present	   after	   the	   3rd	   to	   5th	   week	   of	   conception	   where	   the	   transient	   allantoic	   fluid	  
compartment	   is	   lost	   12.	   As	   a	   consequence,	   when	   dealing	   with	   studies	   mimicking	   the	   human	  
physiology	   (such	   as	   fetal	   preclinical	   trials)	   this	   anatomical	   difference	   has	   to	   be	   appreciated.	   In	  
particular	   in	  studies,	  which	   involve	   the	  amniotic	   fluid	   (or	  cells	   thereof),	  a	  clear	  distinction	  between	  
amniotic	   versus	   allantoic	   fluid	   (AF	   vs.	   AL)	   harvest	   seems	   indispensable	   to	   allow	   for	   correct	  
interpretation	   of	   the	   data.	   This	   is	   even	   more	   exemplified	   by	   recent	   studies	   showing	   significant	  
differences	   in	   pluripotency-­‐related	   gene	   expression	   of	   cells	   isolated	   from	   the	   ovine	   AF	   versus	   AL	  
compartment	   13	   as	   well	   as	   proteomic	   analyses	   on	   both	   fluids	   14.	   Therefore,	   several	   groups	   have	  
investigated	   the	   biochemical	   composition	   of	   the	  AF	   and	  AL	   showing	   differences	   in	   electrolyte	   and	  
protein	   components	   between	   the	   two	   fetal	   fluids	   in	   mares	   15,	   sheep	   6,16,17	   and	   feline	   18.	   These	  
biochemical	  changes	  might	  be	  influenced	  by	  the	  fetal	  fluid	  metabolism	  and	  the	  significant	  volumetric	  
changes	  of	  the	  ovine	  fetal	   fluid	  compartments	  over	  the	  course	  of	  gestation	   16,19,20.	   In	  spite	  of	  these	  
first	   insights	   into	   the	   biochemical	   profiles	   and	   reports	   on	   the	   anatomical	   changes	   of	   the	   fetus	   in-­‐
utero,	   less	   is	   understood	   about	   the	   underlying	   mechanisms	   of	   fetal	   fluid	   regulation	   and	   solute	  
exchange.	   The	   establishment	   of	   temporal	   relationships	   would	   therefore	   not	   only	   enable	   a	   better	  
understanding	   of	   fetal	   fluid	  metabolism	   and	   gestational	   physiology	   for	   preclinical	   evaluations,	   but	  
also	  facilitate	  a	  more	  reliable	  harvest	  of	  fetal	  fluids	  (and	  biochemical	  verification	  thereof)	  in	  the	  ovine	  
animal	  model	  over	  gestation.	  
Therefore,	  the	  presented	  study	  analyzes	  volumetric	  changes	  of	  the	  fetus	  as	  well	  as	  the	  surrounding	  
fetal	  fluid	  cavities	  by	  computed	  tomography	  (CT)	  and	  correlates	  these	  findings	  with	  the	  biochemical	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profile	  obtained	  from	  both,	  the	  AF	  and	  AL,	  over	  the	  entire	  duration	  of	  ovine	  gestation.	  The	  analyses	  
should	  enable	  a	  better	  comparison	  of	  fetal	  fluid	  dynamics	  in	  the	  ovine	  versus	  the	  human	  situation	  for	  
future	  preclinical	  evaluations	  of	  materno-­‐fetal	  disease	  and	  fetal	  therapeutic	  applications.	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3.1.2	  MATERIAL	  AND	  METHODS	  
3.1.2.1	  HARVEST	  OF	  OVINE	  GRAVID	  UTERI	  
Ovine	   gravid	   uteri	   were	   provided	   post	  mortem	   by	   the	   slaughterhouse	   Hinwil,	   Switzerland	   (n=52).	  
Crown	   rump	   length	   (CRL)	  of	  each	   fetus	  was	  determined	   in	  order	   to	  allocate	   it	   to	  one	  of	   the	   three	  
gestational	   age	   groups	   according	   to	   previously	   published	   standards	   21.	   Gestational	   age	   group	   1	   is	  
defined	  by	  a	  CRL	  ≤	  10,	  group	  2	  by	  a	  CRL	  >	  10	  ≤	  20	  and	  group	  3	  by	  a	  CRL	  >	  20.	  For	  CT	  examination	  
(n=12),	   gravid	   uteri	   were	   directly	   stored	   at	   4-­‐8°C	   and	   measurements	   were	   performed	   within	   48	  
hours.	   Both	   fetal	   fluids,	   AF	   and	   AL,	   were	   harvested	   from	   the	   same	   animal	   (n=40)	   as	   previously	  
published	  11.	  In	  brief,	  the	  uterus	  and	  the	  fetal	  fluid	  cavities	  were	  opened	  surgically	  and	  the	  fetal	  fluids	  
were	   aspirated	   with	   a	   50ml	   syringe	   and	   a	   10	   Gauge	   needle	   under	   visual	   guidance.	   After	  
centrifugation	   for	   10	  minutes	   at	   1600	   RPM,	   the	   supernatant	   was	   stored	   overnight	   at	   4°C	   for	   the	  
subsequent	  differential	  fluid	  analyses.	  
	  
3.1.2.2	  IMAGING	  OF	  OVINE	  GRAVID	  UTERI	  
For	   CT	   imaging	   the	   uteri	   were	   placed	   in	   a	   supine	   position.	   The	   imaging	   was	   performed	   using	   a	  
multidetector	   CT	   scanner	   (Brilliance	   16,	   Philips	   AG,	   Zurich,	   Switzerland).	   Transverse	   slices	   of	   the	  
whole	  organs	  with	  a	  slice	  thickness	  of	  2mm	  were	  made	  using	  a	  voltage	  peak	  of	  120kVp	  and	  a	  current	  
of	   250mA.	   2-­‐20ml	   of	   contrast	  medium	   (Ioversol,	  Optiray	   300,	  Guerbet,	   Switzerland)	  were	   injected	  
into	   the	   amnion	   and	   allantois	   cavity	   under	   ultrasound	   guidance	   (MyLab	   One,	   Esaote,	   Maastricht,	  
8MHz	  Linear	  probe)	  depending	  on	  the	  particular	  size	  of	  the	  cavity.	  The	  fluid	  volumes	  were	  evaluated	  
in	   a	   soft	   tissue	   and	   bone	   window	  with	   a	   window	  width	   (W)	   of	   520	   Hounsfield	   Units	   (HU),	   and	   a	  
window	  level	  (L)	  of	  100	  HU.	  
	  
3.1.2.3	  VOLUMETRIC	  ASSESSEMENT	  OF	  OVINE	  FETAL	  FLUID	  CAVITIES	  
Volumetric	   measurements	   were	   performed	   with	   the	   Philips	   Intellispace	   Portal.	   Using	   the	   3D	  
Segmentation	  mode	  on	  the	  volume	  explorer,	  regions	  of	  interest	  (ROI)	  were	  selected	  according	  to	  the	  
injected	  contrast	  medium.	  ROI	  were	  verified	  on	  all	  planes.	  Volumina	  were	  calculated	  by	  the	  software	  
in	  cubic	  centimeter	  (cc)	  and	  the	  amount	  of	   injected	  contrast	  medium	  (ml)	  was	  subtracted	  from	  the	  
obtained	   results.	   Separate	   measurements	   were	   conducted	   for	   AF	   and	   AL	   compartments	   for	   each	  
animal.	   Fetal	   volume	   was	   determined	   by	   selecting	   the	   fetal	   body	   as	   ROI	   and	   calculating	   the	  
corresponding	   fetal	   volume.	   Extremities	   were	   not	   selected	   given	   their	   poor	   recognition	   at	   early	  
gestational	  ages.	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3.1.2.4	  DIFFERENTIAL	  OVINE	  FETAL	  FLUID	  ANALYSIS	  
To	  monitor	  gestational	  age	  differences	  in	  the	  composition	  of	  AF	  and	  AL,	  values	  of	  total	  protein	  (TP),	  
Albumin,	   Sodium	   (Na+),	  Chloride	   (Cl-­‐)	   and	  Magnesium	   (Mg2+)	  were	  defined	   in	  harvested	   fetal	   fluids	  
using	   the	   TP	   Gen.2	   (Ref.	   05171385190),	   the	   ISE	   indirect	   Na-­‐K-­‐Cl	   for	   Gen.2	   (Ref.	   108)	   and	   the	  Mg	  
Gen.2	  (Ref.	  05171911190)	  of	  Roche/Hitachi	  Cobas	  analyzer	  (Roche	  Diagnostics,	  Switzerland).	  	  
	  
3.1.2.5	  STATISTICAL	  ANALYSIS	  
Quantitative	  data	  are	  presented	  as	  mean	  ±	  standard	  deviation	  (GraphPad	  Prism,	  GraphPad	  Software	  
Inc.,	   USA).	   Receiver	   operating	   characteristic	   curves	   (ROC)	   were	   generated	   for	   visualization	   of	  
sensitivity	   (at	   a	   certain	   specificity)	   of	   parameters	   in	   the	   differential	   fetal	   fluid	   analysis	   (SPSS	   21.0,	  
IBM,	   USA).	   Differences	   in	   AF	   versus	   AL	   and	   gestational	   age	   groups	   were	   analyzed	   with	  Wilcoxon	  
signed-­‐rank	   test	   and	   p-­‐values	   <	   0.05	   or	   z-­‐values	   >	   ±1.96	   were	   considered	   statistically	   significant.	  
Correlations	  were	  analyzed	  with	  either	   the	  Pearson	   (ρ)	  or	  Spearman’s	  Rank	  Correlation	  Coefficient	  
(R)	  with	  the	  according	  significance	  level	  defined	  *p<0.05,	  **p<0.01,	  ***p<0.001,	  or	  additive	  Bayesian	  
networks	  for	  dependency	  structure	  discovery	  using	  graphical	  modeling	  (R	  Version	  3.3.3,	  Austria)	  22.	  
Overall,	  for	  statistical	  analyses	  values	  below	  detection	  level	  were	  set	  to	  zero	  (in	  TP	  and	  partially	  Cl-­‐).	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3.1.3	  RESULTS	  
3.1.3.1	  VOLUMETRIC	  ASSESSMENT	  OF	  OVINE	  FETAL	  FLUID	  CAVITIES	  –	  CORRELATION	  TO	  CRL	  
	  
Figure	  1:	  Computed	  tomography	  of	  ovine	   fetal	   fluid	  cavities	  over	  gestation.	  Computed	  tomography	  (CT)	  pictures	  of	  early,	  mid	  and	  late	  
gestation	  were	  obtained	  to	  measure	  fetal	  fluid	  volumes	  of	  amniotic	  (AF)	  and	  allantoic	  (AL)	  fluid.	  (A)	  Contrast	  agent	  (Ioversol,	  Opitray	  300)	  
was	  used	  to	  visualize	  both	  cavities.	  Three-­‐dimensional	  reconstruction	  of	  the	  ovine	  (B)	  amnion,	  (D)	  allantois	  and	  (D)	  merged,	  show	  in	  vivo	  
architecture	  of	  the	  fetal	  fluid	  cavities	  during	  pregnancy.	  Scale	  bar	  =	  4cm.	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Volumetric	  measurements	  of	  the	  fetus	  by	  CT	  (Figure	  1)	  revealed	  a	  significant	  correlation	  between	  the	  
CRL	  and	  the	  fetal	  volume	  over	  gestation	  (R=0.98,	  p	  <	  0.001)	  (Figure	  2A).	  Given	  that	  CRL	  is	  defined	  as	  
an	   indicator	   of	   the	   gestational	   age	   in	   this	   study,	   the	   volumetric	   assessment	   of	   the	   fetus	   further	  
exemplifies	   the	   fetal	  development	  over	   time	   (Figure	  2D).	  When	  analyzing	   the	  change	  of	  AF	  and	  AL	  
over	  either	  the	  fetal	  volume	  or	  the	  CRL,	  identical	  results	  were	  found.	  AL	  volume	  maintained	  relatively	  
static	  with	   a	  mean	   of	   157	   ±	   77ml	   and	   no	   correlation	   to	   gestational	   age,	   respectively	   fetal	   volume	  
(R=0.45,	  p=0.14)	  and	  CRL	  (R=0.46,	  p=0.13)	  (Figure	  2B).	  AF	  represented	  the	  major	  fluid	  within	  the	  fetal	  
cavity	  and	  significantly	   increased	  in	  a	   linear	  fashion	  over	  gestation,	  with	  positive	  correlations	  found	  
for	  fetal	  volume	  (𝜌=0.90,	  p	  <	  0.001)	  and	  CRL	  (𝜌=0.97,	  p	  <	  0.001)	  (Figure	  2B).	  Therefore,	  the	  total	  fetal	  
fluid	  is	  mainly	  influenced	  by	  the	  increase	  in	  AF	  and	  also	  significantly	  correlates	  with	  the	  fetal	  volume	  
(𝜌=0.89,	   p	   <	   0.001)	   and	   the	   CRL	   (𝜌=0.95,	   p	   <	   0.001).	   No	   significant	   differences	  were	   found	   in	   the	  
amount	  of	  AF	  and	  AL	  at	  early	  gestation	  (p=0.81),	  whereas	  there	  are	  some	  evidence	  for	  differences	  at	  
mid	  and	  late	  gestation	  (p=0.06	  and	  p=0.06)	  (Figure	  2C).	  The	  total	  fluid	  per	  fetal	  volume	  significantly	  
decreases	   over	   gestation	   (R=-­‐0.96,	   p<0.001)	   for	   AF	   (R=-­‐0.90p<0.001)	   and	   AL	   (R=-­‐0.90,p<0.001)	  
(Figure	  2E).	  In	  particular	  at	  early	  gestation	  (group	  1)	  a	  much	  higher	  fluid	  volume	  to	  fetal	  size/volume	  
was	  found,	  with	  equal	  amounts	  of	  AF	  and	  AL	  (group1:	  p=0.81).	  (Figure	  2F).	  At	  mid	  and	  late	  gestation	  
the	  fluid	  volume	  to	  fetal	  size/volume	  was	  found	  to	  be	  relatively	  static,	  however	  with	  weak	  evidence	  
showing	   higher	   AF	   amount	   compared	   to	   AL	   (group	   2:	   p	   =	   0.06,	   group	   3:	   p=	   0.06)	   (Figure	   2F).	  
Correlation	  analyses	   (Figure	  2G-­‐H)	   revealed	  strong	  dependence	  between	  fetal	   size,	  amnion	  volume	  
and	   fetal	   volume.	   However,	   correlation	   becomes	   independent	   when	   the	   effect	   of	   amnion	   is	  
removed,	   further	   underlying	   that	   the	   major	   cavity	   increasing	   over	   time	   is	   based	   on	   AF.	   The	  
independence	  of	  the	  allantois	  demonstrates	  its	  overall	  stable	  volume,	  not	  being	  in	  any	  relation	  with	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Figure	  2:	  Volumetric	  assessment	  of	  ovine	  amniotic	  and	  allantoic	  fluid	  cavities	  over	  gestation.	   (A)	  Crown	  rump	  length	  (CRL)	  significantly	  
correlates	  with	  fetal	  volume,	  (D)	  which	  is	  an	  indicator	  for	  gestational	  age.	  (B-­‐C)	  The	  total	  fetal	  adnexal	  fluid	  is	  mainly	  influenced	  by	  AF	  over	  
gestation	   increasing	   in	   a	   linear	   fashion,	  whereas	  AL	  maintains	   relatively	   static	   independent	  of	   gestational	   age.	   (E-­‐F)	  Overall	   higher	   fetal	  
adnexal	   fluid	  per	   fetal	  volume	   is	   found	  at	  early	  gestation.	  Over	  gestational	   time	  higher	  AF	  amount	  compared	  to	  AL	  are	  detected	  also	   in	  
relation	  to	   fetal	  volume.	   (G)	  Spearman’s	  rank	  correlation	  matrix	  display	  all	  correlation	  analyses	  conducted	  with	  each	  coefficient	  and	  the	  
according	  significance	  level	  (*p<0.05,	  **p<0.01,	  ***p<0.001),	  (H)	  demonstrating	  with	  graphical	  modeling	  that	  there	  is	  a	  strong	  dependence	  
between	  volume	  amnion	  and	  gestation,	  but	  not	  with	  volume	  allantois	  and	  gestation.	  
	  
3.1.3.2	  DIFFERENTIAL	  FETAL	  FLUID	  ANALYSIS	  
AF	  AND	  AL	  PURITY	  ASSESSMENT	  –	  CUT-­‐OFF	  VALUES	  OF	  ELECTROLYTES	  AND	  TOTAL	  PROTEIN	  
Harvested	  ovine	  fetal	  fluids	  (n=40)	  were	  compared	  to	  reference	  values	  from	  an	  existing	  database	  11,	  
including	  TP,	  Albumin,	  Na+,	  Cl-­‐	  and	  Mg2+,	  in	  order	  to	  assess	  the	  purity	  of	  the	  fetal	  fluids	  and	  exclude	  
possible	   collateral	   contamination.	   Using	   this	   reference	   pool	   11,	   receiver	   operating	   characteristic	  
curves	   (ROC)	   and	   cut-­‐off	   values	   (for	   AF:	   Na+-­‐Cutoff	   ≥	   117.5	  mmol/l,	   Cl-­‐-­‐Cutoff	   ≥	   95	  mmol/l,	  Mg2+-­‐
Cutoff	  ≤	  0.88	  mmol/l,	  TP-­‐Cutoff	  ≤	  1	  g/l)	  were	  established	  (Figure	  3A).	  At	  100%	  sensitivity	  levels,	  the	  
specificity	  values	  to	  detect	  inaccurate	  fluid	  harvest	  and	  contamination	  was	  100%	  for	  TP,	  90%	  for	  Na+	  
and	  Cl-­‐,	  86.7%	  for	  Mg2+.	  TP	  (z	  =	  -­‐4.646)	  and	  Mg2+	  (z	  =	  -­‐4.860)	  levels	  were	  significantly	  higher	  in	  the	  AL	  
compared	  to	  the	  AF,	  which	  confirms	  that	  they	  detect	  AL	  contamination	  with	  high	  sensitivity.	  On	  the	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other	  hand,	  Na+	  (z	  =	  -­‐4.860)	  and	  Cl-­‐	  levels	  (z	  =	  -­‐4.860)	  were	  significantly	  higher	  in	  the	  AF	  compared	  to	  
the	  AL,	  suggesting	  that	  they	  detect	  AF	  contamination	  with	  high	  sensitivity.	  Consequently,	  AF	  samples	  
with	  Mg2+	  and	  TP	  values	  over	  the	  defined	  cut-­‐off	  values	  and	  AL	  samples	  with	  Na+	  and	  Cl-­‐	  values	  over	  
the	  defined	  cut-­‐off	  values	  were	  excluded	  based	  on	  contamination	  according	  to	  our	  reference	  pool.	  
Hemorrhagic	  contamination	  of	   the	   fetal	   fluids	  potentially	  causing	  the	  differences	   in	   the	  TP	  amount	  
could	   be	   excluded	   by	   the	   lack	   of	   detection	   of	   albumin.	   If	   the	   amount	   of	   fetal	   fluid	   harvested	  was	  
insufficient	   for	   the	   differential	   fluid	   analysis,	   the	   respective	   fetuses	   were	   excluded	   from	   further	  
analyses	  (n=2).	  Taken	  together,	  9/40	  fetuses	  had	  to	  be	  excluded	  as	  their	  pure	  AF	  or	  AL	  origin	  could	  
not	   be	   confirmed,	   whereas	   fetal	   fluid	   samples	   included	   into	   the	   study	   are	   displayed	   on	   the	  
corresponding	  scatter	  plot	  (n=31)	  (Figure	  3B).	  	  
	  
Figure	  3:	  Differential	  analysis	  of	  ovine	  amniotic	  and	  allantoic	  fluid	  over	  gestation.	  	  (A)	  Receiver	  operating	  characteristic	  curve	  (ROC)	  show	  
sensitivity	  levels	  to	  detect	  inaccurate	  fetal	  fluid	  harvest	  and	  contaminations,	  consisting	  of	  100%	  for	  total	  protein	  (TP),	  90%	  for	  sodium	  (Na)	  
and	  chloride	   (Cl),	   86.7%	   for	  magnesium	   (Mg).	   (B)	   Scatterplots	  of	   fetal	   fluid	   samples	   included	   into	   the	   study.	  The	   red	   line	  demonstrated	  
cutoff	  values	  that	  have	  been	  established	  by	  the	  use	  of	  reference	  values	  from	  an	  existing	  database.	  (C)	  Photometric	  or	  colometric	  detection	  
of	  Na+,	  Cl-­‐,	  Mg2+	  and	  TP	  of	  harvested	   fetal	   fluids	   showed	   increasing/decreasing	  values	   throughout	  gestation	   (CRL	  =	  crown	  rump	   length).	  
Spearman’s	  ranks	  correlation	  matrices	  for	  AL	  (D)	  and	  AF	  (E)	  display	  all	  correlation	  detected,	  graphical	  modeling	  results	  are	  displayed	  for	  AL	  
(F)	  and	  AF	  (G).	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CORRELATION	  –	  ELECTROLYTES	  AND	  TOTAL	  PROTEIN	  VS	  CRL	  	  
Measurements	  of	  AF	  and	  AL	  biochemical	  components	  from	  gravid	  uteri	  post	  mortem	  (n=31)	  showed	  
several	  significant	  correlations	  with	  the	  CRL	  of	  the	  fetus	  (Figure	  3C),	  representing	  a	  surrogate	  marker	  
for	  the	  gestational	  age.	  Spearman’s	  rank	  correlation	  matrices	  display	  correlations	  for	  each	  fluid,	  AL	  
(Figure	  3D)	  and	  AF	  (Figure	  3E).	  While	  Na+-­‐levels	  of	  AF	  decreased	  significantly	  throughout	  pregnancy	  
(R=-­‐0.88,	  p	  <	  0.001),	  no	  significant	  correlation	  could	  be	  detected	  in	  AL	  (R=-­‐0.09,	  p=0.64).	  Cl-­‐-­‐levels	  of	  
AF	  (R=-­‐0.83,	  p	  <	  0.001)	  and	  AL	  (R=-­‐0.69,	  p	  <	  0.001)	  decreased	  significantly	  throughout	  pregnancy.	  On	  
the	   other	   hand,	  Mg2+	   showed	   a	   significant	   increase	   in	   AF	   (R=0.72,	   p	   <	   0.001)	   and	   AL	   (R=0.69,	   p	   <	  
0.001)	   fluid.	  TP	   levels	  only	  showed	  an	   increase	   in	   the	  AL	   throughout	  gestation	   (R=0.62,	  p	  <	  0.001),	  
while	  the	  values	  for	  AF	  were	  mostly	  below	  detection	  level	  (detection	  level:	  2g/l).	  	  
Correlation	   analyses	   using	   graphical	   modeling	   revealed	   strong	   dependence	   between	   Na+	   and	   Cl-­‐	  
levels	   in	   the	   amnion	   compartment,	   but	   not	  with	  Mg2+	   levels	   when	   corrected	   for	   fetal	   size.	   In	   the	  
allantois	   compartment,	   all	  measured	  electrolytes	   except	   for	  Na+	  depend	  on	   size.	  However,	  Mg2+	   is	  
independent	  of	  Cl-­‐	  given	  TP	  and	  independent	  of	  size	  given	  Cl-­‐	  and	  TP,	  whereas	  TP	  is	  independent	  of	  
size	  given	  Cl-­‐.	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3.1.4	  DISCUSSION	  
Amniotic	   fluid	   is	   a	   highly	   dynamic	   compartment	   that	   changes	   in	   volume	   and	   composition	   during	  
pregnancy.	   It	   not	   only	   provides	   mechanical	   cushioning,	   but	   also	   contains	   nutrients	   and	   growth	  
factors	   for	   fetal	   growth	   and	   development.	   AF	   volume	   results	   from	   a	   balance	   between	   fetal	   fluid	  
production	   (urination,	  expiration)	  and	  reabsorption	   (swallowing,	   intramembranous	  absorption)	   in	  a	  
defined	  pattern	  through	  pregnancy	  23.	   In	  humans,	  AF	  volume	  increases	   linear	  to	  fetal	  size	  until	  mid	  
gestation	   (~25	  weeks),	  where	  AF	  volume	   is	  no	   longer	   increasing	   in	  a	   linear	   fashion	  given	  complete	  
keratinization	  of	  the	  fetal	  skin.	  A	  plateau	  is	  reached	  near	  term	  gestation	  (~28	  weeks)	  and	  thereafter	  
its	   volume	  declines	   (~42	  weeks)	   23,24.	   In	   the	  ovine	  model	   this	  AF	  plateau	  and	  decline	  has	  not	  been	  
found	   in	  the	  presented	  study,	  consistent	  with	  previous	  reports	   17.	   In	   the	  ovine	  model	  AF	  showed	  a	  
significant	  increase	  over	  time	  in	  a	  linear	  fashion,	  whereas	  AL	  maintained	  relatively	  static	  with	  smaller	  
volumes	  compared	  to	  AF,	  as	  previously	  reported	  17.	  Interestingly,	  fluid	  dynamics	  described	  by	  Bazer	  
et	  al.	  did	  show	  the	  same	  AL	  behavior	  with	  a	  small	  decrease	  around	  gestational	  week	  7-­‐10,	  followed	  
by	   an	   increase	   afterwards	   17.	   These	   consistent	   findings	   suggest	   fluid	   control	   mechanisms	   in	   the	  
allantois.	  Its	  function	  consists	  of	  collecting	  liquid	  waste	  from	  the	  embryo	  and	  gas	  exchange.	  There	  are	  
also	  reports	  suggesting	  the	  allantois	  as	  a	  reservoir	  for	  nutrients,	  given	  its	  fusion	  with	  the	  chorion	  to	  
form	  the	  chorioallantoic	  placenta	  during	  placentation	  25.	  This	  independence	  of	  the	  AL	  compartment	  
has	   also	   been	   shown	   by	   the	   graphical	   modeling	   displayed	   in	   presented	   data,	   where	   a	   clear	  
anatomical	  independence	  of	  this	  compartment	  was	  shown.	  	  
In	  the	  presented	  study,	   three	  electrolytes	  and	  TP	  were	  selected	  based	  on	  their	  clear	  discriminative	  
potential	  between	  AF	  and	  AL.	  They	  represent	  hallmark	  biomarkers	  for	  the	  accurate	  isolation	  of	  fetal	  
fluids	   in	   the	  ovine	  developmental	  model	   11.	  By	   this	  manner	  collateral	   contaminations	  can	  be	  easily	  
excluded.	  This	  includes	  on	  one	  hand	  the	  evaluation	  of	  the	  fetal	  fluid	  function	  and	  composition	  during	  
fetal	   interventions,	   and	  on	   the	  other	  hand	  well-­‐defined	   isolation	  of	   fetal	   cells	   for	   cell	   based	   tissue	  
regeneration.	  In	  this	  regard,	  the	  presented	  work	  shows	  that	  not	  only	  the	  mean	  values	  of	  each	  fluid	  
show	   a	   sensitive	   and	   specific	   discrimination,	   but	   also	   changes	   over	   gestation	   still	   enable	   accurate	  
discrimination	   of	   AF	   and	   AL.	   These	   evaluations	   extending	   the	   entire	   gestation	   are	   mandatory	   for	  
future	   preclinical	   evaluations	   involving	   AF	   harvest	   in	   the	   ovine	  model	   and	   its	   translation	   into	   the	  
human	  counterpart.	  
Average	  Cl-­‐	  and	  Na+	  levels	  were	  significantly	  higher	  in	  the	  AF	  and	  showed	  a	  significant	  decrease	  over	  
pregnancy	   in	   the	   AF	   for	   both	   electrolytes	   but	   in	   the	   AL	   only	   for	   Cl-­‐.	   This	   is	   consistent	   with	  
independent	   studies	   in	  mares	   15,	   sheep	   20,26	   and	   feline	   18.	   The	   decrease	   in	  Na+	   and	   Cl-­‐	   in	   the	  AL	   is	  
suggested	   to	  be	  based	  on	   the	   increasing	   reabsorption	   ability	   of	   the	   fetal	   kidneys	  by	  means	  of	   the	  
Na+-­‐K+-­‐ATPase	   activity	   18	   and	   the	   increased	   renal	   responsiveness	   to	   plasma	   aldosterone	   27.	   In	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humans,	   lower	  Na+	   concentrations	  are	   found	  by	   the	  end	  of	  pregnancy	  given	  an	  almost	   completely	  
developed	   fetal	   kidney	  with	  Na+	  reabsorption	  of	  about	  85-­‐95%	  of	   the	   filtration	   load	   28.	   It	  has	  been	  
shown	   that	   the	  origin	  of	   the	  AF	   in	  humans	  varies	   through	  pregnancy.	  During	  early	  gestation,	  AF	   is	  
similar	  to	  fetal	  plasma	  and	  the	  production	  is	  due	  to	  diffusion	  of	  water	  and	  solutes	  between	  the	  fetus	  
and	   the	  not-­‐yet-­‐keratinized	   fetal	   skin	   and	   the	   surfaces	  of	   the	  amnion,	  placenta	  and	  umbilical	   cord	  
23,29.	  At	  late	  gestation,	  the	  majority	  of	  the	  fluid	  is	  produced	  by	  the	  fetus	  itself	  by	  secretion	  from	  the	  
respiratory	  tract	  or	  by	  production	  of	  urine	  23,29.	  Thus	  at	  late	  gestation	  only	  28%	  of	  ovine	  AL	  osmolality	  
is	   based	   on	   electrolyte	   contribution,	   given	   major	   developmental	   changes	   in	   metabolic	   activity	   30.	  
Interestingly,	  overall	  Na+,	  K+	  and	  Cl-­‐	  concentrations	  have	  shown	  to	  account	   for	  a	  significant	  greater	  
proportion	  of	  AF	  osmolality	  in	  humans	  (97%)	  as	  compared	  to	  ovine	  AF	  alone	  (86%)	  or	  hypothetically	  
combined	  with	   ovine	  AL	   31.	   These	   results	   demonstrated	   increased	   concentration	   of	   nonelectrolyte	  
solutes	  in	  the	  ovine	  model	  such	  as	  sugars	  and	  proteins	  compared	  to	  the	  human	  situation	  31.	  High	  TP	  
values	  were	   found	   in	   the	   AL,	   with	   increasing	   values	   over	   time,	   whereas	   TP	   below	   detection	   level	  
were	  measured	  for	  the	  AF.	  In	  pregnant	  sheep	  TP	  values	  only	  below	  1g/l	  have	  been	  detected	  in	  the	  AF	  
15,20,32,	  which	  would	  be	  below	  the	  detection	  threshold	  of	  the	  method	  used	  in	  the	  presented	  study.	  In	  
humans,	  AF	  proteins	  (0.2-­‐7g/l)	  are	  mainly	  of	  maternal	  origin	  and	  its	  principal	  clearance	  mechanism	  is	  
based	   on	   fetal	   swallowing	   33.	   Low	   level	   of	   TP	   in	   AF	   is	   necessary	   to	  maintain	   the	   osmotic	   pressure	  
between	   AF	   and	   maternal	   blood	   34.	   Among	   these	   proteins,	   proteomic	   analysis	   revealed	   peptides	  
involved	   in	   cellular	   movement,	   development	   of	   organs,	   cell-­‐to-­‐cell	   signaling,	   cellular	   growth	   and	  
proliferation	  35.	   In	  humans,	   these	  proteins	  get	   into	  the	  AF	  by	  different	  routes	  such	  as	  the	  maternal	  
uterine	  tissue,	  umbilical	  cord,	  AF	  cells,	  fetal	  urine,	  meconium	  and	  transudation	  through	  fetal	  skin	  33.	  
Accordingly,	   AF	   is	   not	   the	   result	   of	   simple	   filtration	   from	   the	   maternal	   blood,	   but	   independently	  
providing	  a	  pathway	  for	  the	  transport	  of	  regulatory	  proteins	  for	  fetal	  development	  34.	  However,	  one	  
has	   to	  emphasize,	   that	  all	   the	  measured	  values	   itself	  might	  differ	   from	  physiological	   values	  due	   to	  
post	  mortem	  harvest.	  As	  an	  example	  the	  meconium,	  which	  is	  usually	  retained	  in	  the	  fetus	  until	  after	  
birth,	  can	  be	  expelled	  in	  certain	  cases	  into	  the	  fetal	  cavities.	  However,	  Na+,	  K+	  and	  TP	  values	  detected	  
in	  living	  sheep	  17,31	  covered	  the	  same	  range	  as	  described	  in	  the	  presented	  study,	  suggesting	  minimal	  
compositional	  changes	  of	  the	  fetal	  fluids	  post	  mortem.	  Furthermore,	  Mg2+	  levels	  in	  human	  and	  ovine	  
AF	  were	  consistent,	  which	  has	  been	  hypothesized	  as	  an	  indicator	  for	  pregnancy	  complications	  such	  
as	   preeclampsia	   and	   diabetes	   36.	   Overall,	   changes	   in	   the	   composition	   along	   gestation	   represent	  
changes	   in	   metabolic	   and	   transport	   activity	   as	   well	   as	   different	   contributions	   of	   fetal	   and	   extra-­‐
embryonic	  tissues.	  
In	  summary,	  these	  results	  provide	   information	  on	  ovine	  fetal	   fluid	  dynamics	  and	  benchmark	  values	  
for	   preclinical	   studies	   examining	   volumetric	   and	   compositional	   changes	   of	   the	   AF	   as	   well	   as	   the	  
isolated	  cells	   thereof.	  Further	   this	   study	  highlights	   the	  necessity	  of	  a	  better	  characterization	  of	   the	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physiology	  of	  currently	  used	  animal	  models	  for	  more	  accurate	  extrapolation	  of	  gained	  knowledge	  to	  
the	   human	   situation,	   which	   also	   seems	   indispensable	   with	   regards	   to	   ethical	   principles	   in	   animal	  
research.	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Abstract	  
Amniotic	   fluid	   represents	   an	   abundant	   source	   of	   multipotent	   stem	   cells,	   referred	   as	   broadly	  
multipotent	   given	   their	   differentiation	   potential	   and	   expression	   of	   pluripotency-­‐related	   genes.	  
However,	   the	   origin	   of	   this	   broadly	   multipotent	   cellular	   fraction	   is	   not	   fully	   understood.	   Several	  
sources	  have	  been	  proposed	  so	  far,	  including	  embryonic	  and	  extra-­‐embryonic	  tissues.	  In	  this	  regard,	  
the	   ovine	  developmental	   model	   uniquely	   allows	   for	   direct	   comparison	   of	   fetal	   fluid-­‐derived	   cells	  
from	   two	   separate	   fetal	   fluid	   cavities,	   the	   allantois	   and	   the	   amnion,	   over	   the	   entire	   duration	   of	  
gestation.	  As	  allantoic	  fluid	  mainly	  collects	  fetal	  urine,	  cells	  originating	  from	  the	  efferent	  urinary	  tract	  
can	  directly	  be	  compared	  to	  cells	  deriving	  from	  the	  extra-­‐embryonic	  amniotic	  tissues	  and	  the	  fetus.	  
This	  study	  shows	  isolation	  of	  cells	  from	  the	  amniotic	  (oAFCs)	  and	  allantoic	  fluid	  (oALCs)	   in	  a	  strictly	  
paired	   fashion	  with	  oAFCs	  and	  oALCs	  derived	   from	  the	  same	  fetus.	  Both	  cell	   types	  showed	  cellular	  
phenotypes	   comparable	   to	   standard	  mesenchymal	   stem	  cells	   (MSC),	  with	   trilineage	  differentiation	  
potential	  and	  expression	  of	  common	  ovine	  MSC	  markers.	  However,	  the	  expression	  of	  MSC	  markers	  
per	   single	   cell	   was	   higher	   in	   oAFCSs	   as	   measured	   by	   flow	   cytometry.	   oAFCs	   exhibited	   higher	  
proliferative	   capacities	   and	   	   showed	   significantly	   higher	   expression	   of	   pluripotency-­‐related	   genes	  
OCT4,	  STAT3,	  NANOG	  AND	  REX1	  by	  qRT-­‐PCR	  compared	  to	  paired	  oALCs.	  No	  significant	  decrease	  of	  
pluripotency-­‐related	   gene	   expression	   was	   noted	   over	   gestation,	   implying	   that	   cells	   with	   high	  
differentiation	  potential	  may	  be	  isolated	  at	  the	  end	  of	  pregnancy.	  In	  conclusion,	  this	  study	  suggests	  
that	   cells	  with	  highest	   stem	   cell	   characteristics	  may	  originate	   from	   the	   fetus	   itself	   or	   the	   amniotic	  





Experimental	  contributions	  (Kehl	  D	  only):	  
Flow	  cytometry	  analysis	  of	  MSC	  markers	  in	  oAFCs,	  oALCs	  and	  oBMSCs.	  Differentiation	  of	  all	  three	  cell	  
types	  into	  adipogenic,	  osteogenic	  and	  chondrogenic	  lineages.	  Primer	  design	  and	  establishment.	  
	  
Experimental	  contributions	  (Kehl	  D,	  together	  with	  co-­‐authors)	  
Harvest	   of	   amniotic	   and	   allantoic	   fluid	   from	   gravid	   uteri	   post	   mortem.	   Isolation,	   expansion	   and	  
freezing	   of	   oAFCs,	   oALCs	   and	   oBMSCs.	   Phenotyping	   all	   cell	   types	   by	   immunohistochemistry	   for	  
common	  MSC	  and	  pluripotency-­‐related	  markers.	  	  	  
	  
Non-­‐experimental	  contributions	  (Kehl	  D	  only):	  
Study	   design	   and	   planning	   of	   the	   study.	   Acquiring	   funding	   for	   the	   entire	   project.	   Supervision	   and	  
teaching	  of	   two	  medical	  master	   students	   involved	   in	   the	  project.	  Analyzing	  all	   raw	  data.	   Statistical	  
analysis.	   Drafting	   all	   figures.	   Writing	   the	   entire	   manuscript.	   Submission	   and	   correspondence	   with	  
editorial	  office,	  including	  revision	  (R1).	  	  
	  
Steps	  contained	  in	  the	  published	  work	  (without	  personal	  contribution	  of	  Kehl	  D)	  
qPCR	   of	   pluripotency-­‐related	   markers.	   Three-­‐dimensional	   computed	   tomography	   (CT)	   of	   ovine	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3.2.1	  INTRODUCTION	  
Amniotic	   fluid	   represents	  an	  abundant	   source	  of	  multipotent	   stem	  cells,	  which	  are	  currently	  being	  
explored	  as	  a	  versatile	  cell	  source	  for	  autologous	  cell-­‐based	  therapies.	  These	  amniotic	  fluid-­‐derived	  
stem	   cells	   (AFSCs)	   have	   a	   phenotype	   similar	   to	   bone	  marrow-­‐derived	   (multipotent)	   mesenchymal	  
stem	  cells	   (BMSCs)	  37.	  However,	  human	  AFSCs	  are	  often	  referred	  to	  as	  “broadly	  multipotent”	  given	  
the	  expression	  of	  factors	  involved	  in	  the	  maintenance	  of	  pluripotency	  in	  embryonic	  stem	  cells	  (ESCs),	  
such	  as	  OCT4,	  NANOG	  and	  SSEA-­‐4	  38,39.	  AFSCs	  have	  also	  been	  differentiated	  into	  cell	  types	  of	  all	  three	  
germ	  layers,	  including	  adipogenic,	  osteogenic,	  myogenic,	  hepatic,	  neuronal	  and	  endothelial	  lineages	  
40,	   either	   using	   an	   unselected	   or	   a	   small	   pre-­‐selected	   population	   of	   c-­‐kit	   (CD117)	   positive	   cells	   38.	  
These	  characteristics	  make	  AFSCs	  highly	  amenable	   to	   reprogramming,	  which	   further	  supports	   their	  
higher	  “stemness”	  compared	  to	  postnatal	  multipotent	  stem	  cell	  sources	  41-­‐44.	  
So	  far,	  the	  origin	  of	  human	  AFSCs	  during	  intrauterine	  development	  in	  general	  as	  well	  as	  the	  origin	  of	  
this	  broadly	  multipotent	  cellular	  fraction	  in	  particular	   is	  not	   fully	  understood	  yet.	  AFSCs	   represent	  a	  
heterogeneous	   population	   of	   cells	   and	   ultimately	   several	   sources	   of	   origin	   have	   been	   proposed,	  
including	  embryonic	  (such	  as	  the	  urinary	  tract,	  the	  skin,	  the	  urogenital,	  respiratory	  or	  gastrointestinal	  
tract)	  as	  well	  as	  extra-­‐embryonic	  tissues	  (such	  as	  the	  placental	  tissue	  or	  the	  amniotic	  fetal	  adnexa)	  45.	  
Also	   the	   origin	   of	   the	   amniotic	   fluid	   itself	   varies	   with	   increasing	   gestational	   age,	   while	   at	   the	  
beginning	   the	   production	   is	   mainly	   due	   to	   active	   water	   and	   electrolyte	   transport	   across	   the	  
amniochorionic	   membrane	   and	   fetal	   skin,	   in	   the	   second	   half	   of	   gestation	   most	   of	   the	   fluid	   is	  
produced	  by	  the	  fetus	  itself,	  either	  by	  secretion	  from	  the	  respiratory	  tract	  or	  by	  production	  of	  urine	  
23,29.	   This	   further	   suggests	   that	   the	   origin	   of	   cells	  may	   also	   vary	  with	   different	   stages	   of	   gestation.	  
However,	  anatomical	  and	  ethical	  limitations	  prevent	  further	  studies	  concerning	  the	  origin	  of	  AFSCs	  in	  
humans.	  	  
On	   the	   contrary,	   the	   ovine	   developmental	   model	   uniquely	   enables	   investigation	   of	   prenatal	  
extraembryonic	  (stem)	  cell	  compartments	  11.	  Although	  being	  structurally	  and	  ontogenetically	  similar	  
to	  the	  human	  fetal	  anatomy	  8	  and	  thus,	  serving	  as	  a	  standard	   in	  vivo	  animal	  model	  for	  several	  fetal	  
therapeutic	   interventions	   involving	   AFSCs	   1-­‐7,11,46,	   it	   maintains	   two	   separate	  extraembryonic	   fluid	  
compartments	   over	   the	   entire	   duration	   of	   pregnancy,	  the	   allantoic	   and	   the	   amniotic	   fluid	   cavities	  
(Figure	   1).	   In	   human	   embryogenesis	   the	   allantois	   is	   only	   present	   in	   the	   first	   3	   to	   5	   weeks	   after	  
conception	  and	  afterwards	   it	   involutes	   to	   form	   the	   the	   intraembryonic	  urachus	   12.	   Interestingly,	   in	  
sheep	  the	  allantoic	  fluid	  compartment	  mainly	  collects	  fetal	  urine,	  which	  is	  drained	  from	  the	  urinary	  
bladder	  via	   the	  urachus	   [8].	   It	   therefore	   represents	  a	  model	   that	  allows	   for	  a	  direct	  comparison	  of	  
fetal	  fluid-­‐derived	  cells	  originating	  from	  the	  efferent	  urinary	  tract	  and	  the	  allantoic	  fetal	  adnexa	  with	  
cells	   derived	   from	   the	   fetus	   itself	   and	   amniotic	   fetal	   adnexa	   directly	   surrounding	   the	   fetus.	   A	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comparison	   of	   the	   pluripotency-­‐related	   gene	   expression	   of	   fetal	   fluid-­‐derived	   cells	   from	   different	  
compartments	  would	  shed	  some	  first	   light	  on	  the	  actual	  origin	  of	  the	  (broadly)	  multipotent	  cellular	  
component	  of	  human	  amniotic	  fluid	  cells,	  in	  particular	  on	  whether	  these	  cells	  seem	  to	  originate	  from	  
efferent	  urinary	  tissues	  or	  not.	  
Therefore,	   the	  present	  study	  compares	   the	  expression	  of	  pluripotency-­‐related	  genes	  between	  cells	  
isolated	   from	  the	  amniotic	  versus	   the	  allantoic	   fluid	  cavity	   in	   the	  ovine	  developmental	  model	  over	  
gestation	  in	  a	  strictly	  paired	  fashion.	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3.2.2	  MATERIAL	  AND	  METHODS	  
3.2.2.1	  POST	  MORTEM	  HARVEST	  OF	  OVINE	  FETAL	  FLUIDS	  
Ovine	   amniotic	   and	   allantoic	   fluids	   were	   harvested	   from	   gravid	   uteri	   post	  mortem	   from	   the	   local	  
slaughterhouse	  Zurich/Hinwil,	  Switzerland	  (n=9).	  The	  fetuses	  were	  selected	  according	  to	  crown	  rump	  
length	   (CRL)	   and	  allocated	   to	   three	   corresponding	  gestational	   age	  groups	   –	   group	  1:	  CRL	  ≤	  15	   cm;	  
group	  2:	  >15	  cm,	  ≤	  30	  cm	  CRL;	  group	  3:	  >	  30	  cm	  CRL	  21.	  For	   illustration	  purposes	  of	  the	  ovine	  fluid	  
cavities,	  a	  computer	  tomography	  (CT)	  (Brilliance	  16,	  Philips	  AG,	  Zurich,	  Switzerland)	  examination	  was	  
performed	  with	  different	  concentrations	  of	  contrast	  medium	  injected	  into	  each	  fluid	  cavity	  (Ioversol,	  
Optiray	  300,	  Guerbet,	  Switzerland)	  (Figure	  1).	  	  
	  
Figure	  1:	  The	  ovine	  developmental	  model	  and	  its	  corresponding	  fetal	  fluid	  cavities.	   (a-­‐b)	  The	  ovine	  fetus	  (A)	  is	  surrounded	  by	  the	  inner	  
amniotic	  fluid	  cavity	  (B),	  which	  is	  separated	  from	  the	  outer	  allantoic	  fluid	  cavity	  (C)	  drained	  via	  the	  umbilical	  cord	  (D).	  The	  fetal	  fluid	  cavities	  
are	  surrounded	  by	  the	  uterine	  wall,	  which	  is	  covered	  by	  single	  placentoma	  units	  (E).	  (c-­‐d)	  Three-­‐dimensional	  computed	  tomography	  (CT)	  
reconstruction	  of	  the	  ovine	  anatomy	  and	  the	  fetal	  fluid	  volumina	  (by	  the	  use	  of	  10ml	  Optiray	  300	  for	  amniotic	  fluid	  and	  20ml	  Optiray	  for	  
allantoic	  fluid)	  show	  in	  vivo	  architecture	  of	  the	  ovine	  fetal	  fluid	  compartments	  as	  previously	  described	  in	  the	  schematic.	  Scale	  bar	  =	  0.5	  cm.	  
	  
For	  the	  harvest	  of	  ovine	  fetal	  fluid,	  the	  uterus	  and	  the	  fetal	  fluid	  cavities	  were	  opened	  surgically	  and	  
the	  fetal	  fluids	  were	  aspirated	  with	  a	  50ml	  syringe	  and	  a	  10	  Gauge	  needle	  under	  visual	  guidance	  as	  
previously	   published	   11.	   In	   case	   of	   inaccurate	   surgical	   puncture	   or	   blood	   contamination,	   isolated	  
samples	   were	   excluded	   from	   the	   study.	   Following	   centrifugation	   for	   10	  minutes	   at	   300g,	   residual	  
cells	  were	  separated	  from	  their	  corresponding	  fetal	  fluid.	  For	  each	  animal,	  one	  aliquot	  of	  harvested	  
supernatant	   was	   stored	   overnight	   at	   4°C	   to	   verify	   the	   accuracy	   of	   fetal	   fluid	   harvest	   (and	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consequently	   accurate	   cell	   isolation)	   according	   to	   previous	   studies	   11.	   Therefore,	   values	   of	   total	  
protein,	   Albumin,	   Sodium,	   Chloride	   and	  Magnesium	   were	   compared	   to	   reference	   values	   from	   an	  
existing	  database	  previously	  published	  11.	  	  These	  parameters	  revealed	  a	  high	  discriminative	  power	  to	  
distinguish	   between	   the	   two	   fetal	   fluids.	   If	   selected	   values	   deviate	   from	   the	   reference	   values,	  
isolated	  cells	  were	  excluded	  from	  subsequent	  analysis,	  as	  their	  pure	  origin	  could	  not	  be	  proven.	  
	  
3.2.2.2	  ISOLATION	  AND	  EXPANSION	  OF	  CELLS	  
oAFCs	  AND	  oALCs	  
Ovine	   amniotic	   fluid	   cells	   (oAFCs;	   n=9)	   and	   allantoic	   fluid	   cells	   (oALCs;	   n=9)	   were	   isolated	   by	  
centrifugation	  of	  the	  fetal	   fluids	  at	  300g.	  The	  obtained	  cell	  pellet	  was	  seeded	   into	  standard	  culture	  
flasks	   and	   incubated	   in	   a	   humidified	   incubator	   at	   5%	  CO2	   at	   37	  °C.	   The	   proliferation	   medium	  
consisted	  of	  endothelial	  basal	  medium	  (EBMTM;	  Lonza,	  Switzerland)	  supplemented	  with	  10%	  fetal	  calf	  
serum	   (FCS,	   Sigma-­‐Aldrich,	   Switzerland),	   and	   growth	   factors	   (recombinant	   long-­‐insulin-­‐like	   growth	  
factor-­‐1	   (R3-­‐IGF-­‐1),	   human	   fibroblast	   growth	   factor	   (rhFGF-­‐B),	   human	   epidermal	   growth	   factor	  
(rhEGF)	  and	  ascorbic	  acid,	  as	  well	  as	  an	  antibiotic-­‐antimycotic	  solution	  containing	  100	  U/ml	  penicillin,	  
100	  μg/ml	  streptomycin	  and	  25	  ng/ml	  amphotericin	  B.	  	  
This	   medium	   has	   been	   used	   in	   previous	   studies	   11,41,47,48	   and	   demonstrated	   to	   prevent	   pre-­‐
differentiation	  of	  isolated	  fetal	  cells	  and	  maintain	  their	  stem	  cell	  phenotype	  over	  in	  vitro	  passaging.	  
Non-­‐adherent	   cells	   were	   removed	   by	   replacing	   the	   medium	   72-­‐96	   hours	   following	   the	   seeding	  
procedure.	  At	  80%	  confluency,	  cells	  were	  split	  using	  Accutase	  (GibcoTM,	  ThermoFisher	  Scientific,	  USA)	  
or	   Trypsin-­‐EDTA	   Solution	   (Sigma-­‐Aldrich,	   Switzerland).	   Cellular	   viability	   was	   assessed	   using	   a	   0.4%	  
trypan	  blue	  exclusion	  staining	  (GibcoTM,	  ThermoFisher	  Scientific,	  USA).	  A	  stock	  of	  frozen	  cells	  at	  every	  
passage	  was	   stored	   in	   liquid	   nitrogen	   (10%	  DMSO	   in	   FCS,	   Sigma-­‐Aldrich,	   Switzerland)	   until	   further	  
analysis.	  
CONTROL	  oBMSCs	  
The	  isolation	  of	  ovine	  bone	  marrow-­‐derived	  mesenchymal	  stem	  cells	  (oBMSCs;	  n=3)	  as	  control	  cells	  
was	  performed	  according	  to	  standard	  procedures.	  In	  brief,	  bone	  marrow	  aspirate	  was	  obtained	  from	  
the	   sternum	   or	   iliac	   crest	   of	   an	   adult	   sheep	   in	   oblique	   supine	   position	   under	   general	   aesthesia	  
according	  to	  the	  cantonal	  ethical	  permission	  No.	  9/14.	  Int.	  25040.	  Bone	  marrow	  aspirate	  was	  diluted	  
1:2	   with	   PBS	   for	   a	   histopaque	   (Histopaque-­‐1077,	   Sigma-­‐Aldrich,	   Switzerland)	   density	   gradient	  
centrifugation	   at	   400G	   for	   30min.	   The	   obtained	  mononuclear	   cell	   layer	  was	  washed	  with	   PBS	   and	  
seeded	   in	   above	  mentioned	  proliferation	  medium	   for	   further	   expansion.	   A	   stock	   of	   frozen	   cells	   at	  
every	  passage	  was	  stored	  in	  liquid	  nitrogen	  (10%	  DMSO	  in	  FCS)	  for	  further	  analysis.	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3.2.2.3	  PHENOTYPIC	  CHARACTERIZATION	  OF	  oAFCs,	  oALCs	  AND	  CONTROL	  oBMSCs	  
ANTIBODIES	  
Primary	   antibodies	   used	   were	   specific	   against	   CD11b	   (clone	   CC126,	   AbDSerotec,	   UK),	   CD29	  
(A.Zannettino,	   Adelaide,	   Australia)	   19,	   CD44	   (clone	   MAC329,	   LifeSpan	   BioSciences,	   USA;	   sc-­‐59758,	  
Santa	   Cruz	   Biotech,	   USA),	   CD166	   (clone	   3A6,	   Biolegend,	   USA),	   STRO-­‐4	   (A.Zannettino,	   Adelaide,	  
Australia)	   49,	   Desmin	   (clone	   D33,	   Dako,	   Denmark),	   Vimentin	   (clone	   Vim3B4,	   Dako,	   Denmark),	  𝛼-­‐
smooth	  muscle	   actin	   (𝛼SMA)	   (clone	   1A4,	   Dako,	   Denmark),	   NANOG	   (hNanog.2,	   eBioscience,	   USA),	  
OCT3/4	  (H-­‐134,	  Santa	  Cruz,	  USA)	  and	  STAT3	  (BD	  Transduction	  Laboratories,	  USA).	  All	  stainings	  were	  
accompanied	  by	  isotype	  controls	  for	  IgG1	  (clone	  MOPC-­‐21,	  Biolegend,	  USA)	  and	  IgG2a	  (clone	  MOPC-­‐
173,	  Biolegend,	  USA	  or	  AbDSerotec,	  UK),	  IgG2b	  (clone	  C.SW	  IgG2b,	  k,	  BD	  PharmingenTM,	  USA)	  as	  well	  
as	  secondary	  antibody-­‐only	  control	  stainings.	  For	  immunofluorescence	  stainings,	  primary	  antibodies	  
were	   detected	   with	   secondary	   goat-­‐anti-­‐mouse	   Cyanine-­‐2-­‐conjugated	   antibodies	   (Alexafluor	   488,	  
Jackson-­‐ImmunoResearch	   or	   Life	   Technologies,	   USA),	   donkey-­‐anti-­‐rat	   Cyanine-­‐2-­‐conjugated	  
antibodies	  (Alexafluor	  488,	  Jackson-­‐ImmunoResearch,	  USA)	  or	  goat-­‐anti-­‐rabbit	  Cyanine-­‐2-­‐conjugated	  
antibodies	   (Alexafluor	   488,	   Life	   Technologies,	   USA),	   phalloidin	   (AlexaFluor	   546,	   Invitrogen,	  
ThermoFisher	   Scientific,	   USA)	   and	   DAPI	   (Sigma-­‐Aldrich,	   Switzerland).	   For	   flow	   cytometry,	   primary	  
antibodies	  were	   detected	  with	   either	   a	   FITC-­‐conjugated	   goat-­‐anti-­‐mouse	   antibody	   (BD	   Bioscience,	  
USA)	  or	  a	  FITC-­‐conjugated	  goat-­‐anti-­‐rat	  antibody	  (Biolegend,	  USA).	  
	  
IMMUNOFLUORESCENCE	  STAINING	  
For	  immunofluorescence	  stainings,	  oAFCs	  (n=3),	  oALC	  (n=3)	  and	  oBMSC	  (n=3)	  were	  washed	  with	  PBS	  
and	  fixed	  with	  4%	  parafolmaldehyde/PBS	  for	  10min.	  Following	  a	  second	  washing	  step	  with	  PBS,	  cells	  
were	   permeabilized	   with	   0.2%	   Triton	   X-­‐100/PBS	   (Sigma-­‐Aldrich,	   Switzerland)	   for	   10min	   at	   room	  
temperature.	   After	   blocking	  with	   5%	   goat	   serum	   in	   1%	   BSA/PBS	   for	   30min	   at	   room	   temperature,	  
primary	   antibodies	   (diluted	   in	   5%	   goat	   serum/1%	   BSA/PBS)	   were	   added	   and	   incubated	   for	   1h	   or	  
overnight	   at	   room	   temperature.	   Cells	  were	  washed	   three	   times	   for	   5min	  with	   PBS	   and	   incubated	  
with	  the	  secondary	  antibodies	  for	  45min	  at	  room	  temperature.	  Again,	  three	  washing	  steps	  with	  PBS	  
were	   performed	   (3x	   5min)	   and	   samples	  were	  mounted	  with	   Aqua-­‐Poly/Mount	   (Polysciences,	   Inc.,	  
USA).	  Stained	  cells	  were	  visualized	  using	  an	  inverted	  fluorescence	  microscope	  equipped	  with	  a	  CCD	  
camera	  (Zeiss	  Axiovert	  II;	  Zeiss,	  Germany	  and	  Leica	  DM6000B).	  
	  
FLOW	  CYTOMETRY	  ANALYSIS	  
For	  flow	  cytometry	  analysis,	  2	  x	  105	  oAFCs	  (n=3),	  oALC	  (n=3)	  and	  oBMSC	  (n=3)	  were	  used	  per	  primary	  
antibody	  staining,	  each	  diluted	  in	  FACS-­‐buffer	  (2%	  FCS/PBS,	  5mM	  EDTA)	  and	  incubated	  for	  30min	  at	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4°C.	  After	   two	  washing	   steps	  with	   FACS-­‐buffer,	   the	   cells	  were	   incubated	   for	   another	  30min	  at	   4°C	  
with	   secondary	   FITC-­‐conjugated	   antibodies.	   Again,	   two	   washing	   steps	   with	   FACS-­‐buffer	   were	  
performed.	  Between	  50’000	  to	  100’000	  events	  were	  acquired	  using	  a	  FACSCanto	   II	   (BD	  Bioscience,	  
USA)	   and	   the	   datasets	   were	   analyzed	   with	   FlowJo	   software	   (Tree	   Star,	   Inc.,	   USA).	   Median	  
fluorescence	  intensity	  ratio	  (MFIR)	  was	  calculated	  relative	  to	  the	  unstained	  controls.	  Specificity	  of	  the	  
antibodies	  was	  verified	  using	  the	  corresponding	  isotype	  controls.	  
	  
3.2.2.4	  CELL	  PROLIFERATION	  KINETICS	  
Proliferation	   kinetics	  were	  monitored	   over	   the	   complete	   expansion	   period	   for	   every	   isolated	   fetal	  
fluid.	  Only	  paired	  cell	   lines	  were	   integrated	   into	   the	  analysis,	  meaning	   that	  oAFCs	   (n=9)	  and	  oALCs	  
(n=9)	   from	   the	   same	   fetus	  were	   expanded	   and	   compared.	   The	   population	   doubling	   (PD)	   rate	  was	  
determined	   by	   integrating	   the	   harvested	   viable	   cell	   number	   (following	   a	   trypan	   blue	   exclusion	  
staining)	  into	  the	  mentioned	  formula	  below	  50.	  N1	  is	  defined	  as	  the	  plated	  and	  NH	  the	  harvested	  cell	  
number.	  
𝑋 = log!" 𝑁! − log!" 𝑁!log!" 2 	  
To	  define	  the	  absolute	  number	  of	  times	  each	  cell	  has	  doubled	  since	  their	  first	   isolation	   in	  vitro,	  the	  
cumulative	  population	  doublings	   (CPD)	  were	  calculated	  up	  to	  passage	  3.	  Therefore,	   the	  PD	  of	  each	  
passage	  was	  summed	  up	  to	  the	  PD	  of	  the	  previous	  one.	  The	  generation	  time	  (average	  time	  between	  
two	  cell	  doublings)	  was	  calculated	  at	  all	  three	  passages	  using	  the	  following	  formula	  50:	  
𝑋 = log!"(2) ⋅ Δ𝑡log 𝑁! − log  (𝑁!)    	  
	  
3.2.2.5	  TRILINEAGE	  DIFFERENTIATION	  POTENTIAL	  
Multilineage	  differentiation	  was	  assessed	  by	  inducing	  differentiation	  of	  oAFCs	  (n=3),	  oALCs	  (n=3)	  and	  
oBMSCs	  (n=3)	  to	  osteogenic,	  adipogenic	  and	  chondrogenic	  lineages	  according	  to	  standard	  protocols.	  
Briefly,	  ovine	  cells	  were	  cultured	  in	  either	  I)	  osteogenic	  medium:	  10nM	  glycerol	  2-­‐phosphat	  (Sigma,	  
Switzerland),	  50um	  L-­‐ascorbic	  acid	  2-­‐phosphat	  (Sigma,	  Switzerland),	  100nM	  dexamethasone	  (Sigma,	  
Switzerland)	   and	   2nM	   L-­‐glutamine	   (Sigma,	   Switzerland)	   in	   low	   glucose	   Dulbecco’s	   Modified	   Eagle	  
Medium	   (DMEM;	   Sigma,	   Switzerland)	   with	   10%	   FCS	   and	   an	   antibiotic-­‐antimycotic	   solution,	   II)	  
adipogenic	   medium	   (GibcoTM,	   ThermoFisher	   Scientific,	   USA)	   or	   chondrogenic	   medium:	   50um	   L-­‐
ascorbic	   acid	   2-­‐phosphat,	   0.5	   ug/ml	   insulin	   (Sigma,	   Switzerland),	   10	   ng/ml	   transforming	   growth	  
factor-­‐beta1	   (Preprotech,	   UK),	   2	   mM	   L-­‐glutamin	   in	   high	   glucose	   DMEM	   with	   1%	   FCS	   and	   an	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antibiotic-­‐antimycotic	   solution.	   After	   3	  weeks,	   ovine	   cells	  were	   fixed	   in	   4%	  paraformaldehyde/PBS	  
and	  subsequently	  stained	  with	  either	  I)	  2%	  Alzarin	  Red	  S	  (Sigma,	  Switzerland),	   II)	  3mg/ml	  Oil	  Red	  O	  
(Sigma,	  Switzerland)	  or	  III)	  Alcian	  Blue	  PAS.	  
	  
3.2.2.6	  PLURIPOTENCY-­‐RELATED	  GENE	  EXPRESSION	  
Total	  RNA	  was	  extracted	  using	  RNeasy	  Mini	  Kits	  (Qiagen,	  Switzerland)	  and	  reverse	  transcription	  was	  
carried	   out	   using	   Superscript	   III	   RT	   (Invitrogen,	   Switzerland)	   according	   to	   the	   manufacturer’s	  
instructions.	  Quantitative	  real-­‐time	  PCR	  (qRT-­‐PCR)	  was	  performed	  using	  Rotor-­‐Gene	  SYBR	  Green	  PCR	  
Kit	  SYBR	  (Qiagen,	  Switzerland)	  and	  ovine	  pluripotent	  stem	  cell	  primers	  (Microsynth,	  Switzerland)	  for	  
OCT4,	  STAT3,	  NANOG,	  SOX2	  and	  REX1	  (Table	  1).	  Primers	  have	  been	  established	  and	  evaluated	  by	  the	  
use	  of	  a	  previously	  published	  ovine	  induced	  pluripotent	  stem	  cell	  (iPSC)	  line	  kindly	  provided	  by	  Paul	  
Verma	   and	   Jun	   Liu	   of	   the	   Stem	   Cell	   and	   Genetic	   Engineering	   Group,	  Monash	   University,	   Clayton,	  
Australia	   51.	  The	  expression	   levels	  were	  analysed	  twice	   in	  triplicates	  using	  standard	  conditions	  on	  a	  
Rotor-­‐Gene	  Q	   (Qiagen,	   Switzerland)	   for	  n=9	  oAFCs,	  n=9	  oALCs	  and	  n=3	  oBMSCs.	  GAPDH	  served	  as	  
housekeeping	   gene	   to	   quantify	   relative	   stemness	   expression	   levels	   using	   the	   ΔCT	   threshold	   cycle	  





Table	  1.	  Ovine	  primer	  sequences	  for	  quantitative	  real-­‐time	  polymerase	  chain	  reaction	  analysis	  of	  pluripotencyy-­‐related	  gene	  expression	  in	  
ovine	  amniotic	  fluid	  cells	  and	  ovine	  allantoic	  fluid	  cells	  	  
3.2.2.7	  STATISTICAL	  ANALYSIS	  
Quantitative	  data	  are	  presented	  as	  mean	  ±	  standard	  deviation	  (GraphPad	  Prism,	  GraphPad	  Software	  
Inc.,	  USA).	  For	  statistical	  comparison	  of	  the	  paired	  results	  on	  oAFCs	  and	  oALCs	  paired	  students-­‐t-­‐test	  
were	  performed	  and	  p-­‐values	  <	  0.05	  were	  considered	  statistically	  significant.	  Saphiro-­‐Wilk	  normality	  
test	  proved	  that	  the	  datasets	  were	  normally	  distributed	  (p	  >	  0.05).	  Grubbs’	  test	  determined	  whether	  
one	  of	  the	  data	  points	  represented	  a	  significant	  outlier	  from	  the	  rest	  (p	  <	  0.05).	  
Gene Forward primer Reverse primer 
OCT4 GTCACTGCTTGATCGTTTGC GTGAGAGGCAACCTGGAGAG 
STAT3 GACTGGAAGAGGCGACAACA CGTTGCTGGGCCCTGAG 
NANOG TGCAGAGGAGAGCACAGAGA CGTTGCTGGGCCCTGAG 
SOX2 ACCAGCTCGCAGACCTACAT GGTAGTGCTGGGACATGTGA 
REX1 CAAGGCAAGGAGGCGGAG AGCCGGCTGACTCCCT 
GAPDH GCGTGGACAGTGGTCATAAGT TGGCAAAGTGGACATCGTTG 
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3.2.3	  RESULTS	  
3.2.3.1	  CELL	  ISOLATION,	  PROLIFERATION	  AND	  PHENOTYPIC	  CELL	  CHARACTERIZATION	  
After	  harvest	  of	  fetal	  fluids,	  the	  origin	  and	  purity	  of	  the	  fetal	  fluids	  was	  verified	  using	  a	  biochemical	  
differential	   fluid	   analysis	   according	   to	   previously	   published	   protocols	   11	   prior	   to	   inclusion	   of	   the	  
samples	  into	  the	  present	  study.	  Cellular	  yield,	  cell	  attachment	  and	  phenotypes	  were	  analyzed	  using	  
light	  microscopy	  and	  compared	  between	  oAFCs	  (n=9),	  oALCs	  (n=9)	  and	  control	  oBMSCs	  (n=3)	  (Figure	  
2).	  Bacterial	  contamination	  and	  premature	  senescence,	  defined	  by	  stagnation	  of	  proliferation,	  high	  
granularity	  of	  the	  cells	  and	  cellular	  detachment,	  was	  equally	  distributed	  between	  oAFCs	  and	  oALCs.	  
Compared	  to	  oBMSCs,	  the	  oAFCs	  and	  oALCs	  showed	  a	  more	  heterogeneous	  intra-­‐	  and	  inter-­‐patient	  
phenotypic	  variability,	  including	  cell	  size	  and	  phenotype.	  	  
Three	  morphological	  cell	  types	  (Figure	  2a-­‐h)	  were	  predominantly	  evident	  in	  both	  oAFCs	  (Figure	  2a-­‐d)	  
and	  oALCs	  (Figure	  2e-­‐h):	  I)	  small	  spindle-­‐shaped	  cells	  (Figure	  2a-­‐b	  and	  2e-­‐f),	  II)	  cobblestone-­‐like	  cells,	  
resembling	  epithelioid	  cells	   (Figure	  2d,	  2h),	  and	  III)	   larger	  flattened	  fibroblastic	  cells	   (Figure	  2c,	  2g).	  
After	   direct	   plating,	   a	   highly	   heterogeneous	   population	   of	   cells	   was	   observed,	   whereas	   with	  
passaging,	   the	   cell	   population	  became	  more	  homogenous	  with	   either	  phenotype	   I	   or	   III.	   At	   higher	  
passages,	  a	  higher	  senescence	  rate	  was	  found	  with	  morphological	  changes	  of	  the	  cells	  and	  stagnated	  
proliferation.	  Concerning	  proliferation	  (Figure	  2j-­‐k),	  oAFCs	  showed	  a	  tendency	  for	   lower	  generation	  
times	  (GT)	  and	  higher	  cumulative	  population	  doublings	  (CPD)	  when	  compared	  to	  oALCs	  derived	  from	  
the	   same	  mother	   animal	   and	   fetus	   (n=9	   per	   source).	   Significant	   differences	   where	   predominantly	  
found	  at	  passage	  3	  (p	  <	  0.05).	  No	  differences	   in	  proliferation	  parameters	  were	  detected	  when	  cells	  




















Figure	  2:	  Morphology	  and	  proliferation	  capacity	  of	   isolated	  oAFCs	  and	  oALCs.	   Isolated	  oAFCs	  (n=9)	  (a-­‐d)	  and	  oALCs	  (n=9)	  (e-­‐h)	  showed	  
similar	   initial	  heterogeneous	  cell	  phenotypes,	   including	  small	   spindle-­‐shaped	  cells	   (a,	  b,	  e,	   f),	   larger	   flattened	   fibroblastic	  cells	   (c,	  g)	  and	  
cobblestone-­‐like	  cells,	   resembling	  epithelioid	  cells	   (d,	  h).	  After	   longer	  cultivation	  periods,	  a	  more	  homogenous	  cell	  population	  of	  mostly	  
spindle-­‐shaped	  and	  fibroblast-­‐like	  cells	  prevailed.	  oAFCs	  (grey	  whiskers)	  exhibit	  a	  higher	  proliferation	  capacity	  then	  oALCs	  (white	  whiskers),	  
given	  (j)	  the	  higher	  cumulative	  population	  doublings	  (CPD)	  and	  (k)	  the	  lower	  generation	  times.	  *	  =	  p<0.05	  
	  
3.2.3.2	  MSC	  SURFACE	  MARKER	  EXPRESSION	  AND	  TRILINEAGE	  DIFFERENTIATION	  OF	  oAFCs	  
VERSUS	  oALCs	  
Immunofluorescence	   stainings	   (passage	  3-­‐5)	  of	   representative	  paired	  oAFCs	   (n=3)	  and	  oALCs	   (n=3)	  
from	   the	   same	   fetus	   revealed	   a	   positive	   expression	   of	   common	   ovine	  MSC	  markers	   CD29,	   CD44,	  
STRO-­‐4	   as	   well	   as	   Vimentin	   and	   alpha-­‐smooth	   muscle	   actin	   (α-­‐SMA)	   (Figure	   3).	   A	   myogenic,	  
mesodermal	   phenotype	   is	   supported	   by	   the	   positive	   expression	   of	   the	   intermediate	   filament	  
Vimentin	  and	  α-­‐SMA.	  Partial	  positivity	  was	  detected	  in	  CD166	  and	  αSMA	  in	  both	  oAFCs	  and	  oALCs.	  
Isotype	   control	   staining	  did	  not	  produce	  any	   signals.	  Overall	   no	  differences	  between	  oAFCs,	  oALCs	  
and	  oBMSCs	  (n=3)	  could	  be	  detected	  by	  immunohistochemical	  analyses	  on	  a	  qualitative	  level.	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Figure	   3:	   Phenotypic	   characterization	   of	   isolated	   oAFCs	   and	   oALCs.	   Immunohistological	   analyses	  of	   representative	  paired	  oAFCs	   (n=3;	  
animal	  4.1,	  6.1	  and	  7.2)	  and	  oALCs	  (n=3;	  animal	  4.1,	  6.1	  and	  7.2)	  revealed	  positive	  expression	  of	  common	  MSC	  markers	  CD29,	  CD44,	  Stro4	  
and	  partial	   expression	  of	   CD166	   (Phalloidin	   in	   red,	  Dapi	   in	   blue	   and	   respective	   antibody	   in	   green).	   Positive	   expression	  of	  Vimentin	   and	  
αSMA	  show	  a	  myogenic,	  mesodermal	  phenotype	  of	  the	  cells.	  No	  phenotypic	  differences	  to	  standard	  oBMSCs	  (n=3;	  animal	  D2,	  D3	  and	  D4)	  
were	  detected.	  Scale	  bar	  =	  10	  μm.	  
	  
Therefore,	   in	   order	   to	   further	   quantify	  MSC	   stem	   cell	  marker	   expression	   levels	   and	   to	   also	   detect	  
differences	  between	  the	  three	  cell	  sources	  quantitatively,	  flow	  cytometry	  analyses	  for	  the	  same	  set	  
of	   markers	   were	   conducted	   at	   passage	   3-­‐4	   (Figure	   4).	   Again	   positive	   expression	   of	   CD29,	   CD44,	  
CD166	   and	   STRO-­‐4	   was	   found	   in	   oAFCs	   (n=3),	   oALCs	   (n=3)	   and	   control	   oBMSCs	   (n=3)	   (with	   no	  
expression	  of	  CD11b)	  (Figure	  4a).	  Notably,	  oAFCs	  and	  oALCs	  were	  paired	  and	  derived	  from	  the	  same	  
fetus	  for	  flow	  cytometry	  analyses.	  No	  statistically	  significant	  differences	  in	  the	  percentage	  of	  positive	  
cells	  concerning	   the	  expression	  of	  CD11b,	  CD29,	  CD44	  and	  STRO-­‐4	  could	  be	  detected	  between	  the	  
three	  cell	  sources	  (Figure	  4b,	  all	  P’s	  >0.05).	  CD166	  positive	  cells	  were	  more	  abundant	  in	  the	  fetal	  cell	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sources	   (oAFCs	   and	   oALCs)	   than	   in	   adult	   oBMSC	   control	   cells.	   In	   contrast	   median	   fluorescence	  
intensity	  ratios	  (MFIR)	  of	  the	  common	  MSC	  markers	  showed	  high	  heterogeneity	  between	  the	  three	  
paired	  animal	  samples	  analyzed	  (Figure	  4c).	  However,	  a	  reduced	  MFIR	  of	  common	  MSC	  markers	  was	  
observed	   in	   oALCs	  when	   compared	   to	  oAFCs	   from	   the	   same	  mother	   animal	   and	   fetus	   (Figure	   4d).	  
This	  could	  be	  better	  appreciated	  when	  calculating	   the	  ratio	  of	  MFIR	  of	  oAFC/oALC	  samples	   for	   the	  
following	   ovine	   MSC	   markers	   CD29	   (mean	   ratio=2.4),	   CD44	   (mean	   ratio=1.4)	   and	   STRO-­‐4	   (mean	  
ratio=3)	  (Figure	  4e).	  	  
These	   results	   demonstrate	   a	   higher	   expression	   of	   MSC	   surface	   markers	   per	   single	   cell	   in	   oAFC	  
compared	   to	   paired	   oALC	   samples	   (even	   if	   the	   overall	   percentages	   of	   cell	   populations	   with	   MSC	  
marker	  expression	  were	  equal	  in	  oAFCs	  and	  oALCs).	  Contrary	  to	  human	  cells,	  positive	  expression	  of	  
the	  following	  established	  set	  of	  markers	  –	  CD29,	  CD44,	  CD166	  and	  STRO-­‐4	  –	  defines	  MSC	  origin	  in	  the	  
ovine	  animal	  model	  19,49.	  	  
In	  addition,	  trilineage	  differentiation	  into	  the	  adipogenic,	  osteogenic	  and	  chondrogenic	  lineages	  was	  
proven	   for	   oAFCs	   (n=3),	   oALCs	   (n=3)	   and	   oBMSCs	   (n=3).	   However,	   high	   inter-­‐individual	   variances	  
were	  evident	  and	  successful	  differentiation	  had	  to	  be	  assessed	  by	  direct	  comparison	  to	  the	  control	  
set-­‐up	   (Figure	   5).	   	   In	   particular,	   osteogenic	   differentiation	   resulted	   in	   a	  weak	   Alzarin	   Red	   staining	  
even	  if	  clear	  different	  to	  the	  control	  set-­‐up.	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Figure	   4:	   Mesenchymal	   stem	   cell	   marker	   expression	   of	   isolated	   oAFCs	   and	   oALCs.	   Expression	   of	   common	   ovine	   MSC	   markers	   was	  
confirmed	  by	  flow	  cytometry	  with	  positive	  expression	  of	  CD29,	  CD44,	  and	  STRO-­‐4,	  partial	  expression	  of	  CD166	  and	  no	  expression	  of	  CD11b	  
in	  paired	  oAFCs	  (n=3;	  animal	  4.1,	  6.1	  and	  7.2)	  and	  oALCs	  (n=3;	  animal	  4.1,	  6.1	  and	  7.2).	  oBMSCs	  served	  as	  a	  control	  cell	  source	  (n=3;	  animal	  
D2,	  D3	  and	  D4).	  (a)	  Flow	  cytometry	  gating	  strategy	  after	  exclusion	  of	  dead	  cells.	  No	  differences	  could	  be	  detected	  between	  oAFCs,	  oALCs	  
and	  control	  oBMSCs	  (b)	  in	  the	  percentage	  of	  positive	  cells	  of	  all	  analyzed	  surface	  markers	  as	  well	  as	  (c)	  the	  median	  fluorescence	  intensity	  
ratio	  (MFIR)	  due	  to	  high	  interpatient	  differences.	  (d)	  However,	  a	  reduced	  MFIR	  was	  observed	  in	  oALCs	  compared	  to	  paired	  oAFCs	  from	  the	  
same	  fetus.	  Dotted	  red	  line	  displays	  the	  mean	  of	  control	  oBMSCs.	  (e)	  The	  ratio	  >1	  of	  oAFC/oALC	  underlines	  the	  higher	  expression	  of	  MSC	  
markers	  in	  oAFCs.	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Figure	  5:	  Multilineage	  differentiation	  potential	  of	  isolated	  oAFCs	  and	  oALCs.	  The	  capacity	  of	  oAFCs	  (n=3),	  oALCs	  (n=3)	  and	  oBMSCs	  (n=3)	  
to	  differentiate	  into	  adipogenic,	  osteogenic	  and	  chondrogenic	  lineages	  was	  demonstrated	  by	  positive	  staining	  with	  Oil	  Red	  O,	  Alzarin	  Red	  S	  
and	  Alcian	  Blue	  PAS.	  The	  upper	  squares	  represent	  stained	  controls.	  Scale	  bar	  =	  100	  μm.	  
	  
3.2.3.3	  PLURIPOTENCY-­‐RELATED	  GENE	  EXPRESSION	  OF	  oAFCs	  versus	  oALCs	  
The	   expression	   of	   OCT4,	   STAT3	   and	   NANOG	   was	   qualitatively	   shown	   with	   immunofluorescence	  
stainings	   of	   representative	   cell	   lines	   of	   each	   cell	   group	   (Figure	   6).	   Higher	   expression	   of	   all	  
pluripotency-­‐related	   markers	   has	   been	   detected	   for	   fetal	   oAFCs	   (n=3)	   and	   oALCs	   (n=3)	   in	   direct	  
comparison	  to	  control	  oBMSCs	  (n=3).	  Ovine	  endothelial	  cells	  (oECs)	  served	  as	  control	  cells	  to	  verify	  
the	  specificity	  of	  the	  particular	  staining	  and	  did	  not	  express	  any	  of	  the	  analyzed	  pluripotency-­‐related	  
markers	  (data	  not	  shown).	  	  
To	  quantify	  the	  differences	  in	  expression	  of	  genes	  involved	  in	  the	  maintenance	  of	  pluripotency,	  qRT-­‐
PCR	   analyses	   for	  OCT4,	   STAT3,	   NANOG,	   SOX2	   and	  REX1,	   at	   early	   (p1	   =	   passage	   1)	   and	   late	   (p4	   =	  
passage	  4)	  passages,	  were	  performed	  (Figure	  7).	  Significantly	  higher	  expression	   (p	  <	  0.05)	  of	  OCT4,	  
STAT3,	  NANOG	  and	  REX1	  was	  found	  in	  oAFCs	  (n=9)	  compared	  to	  oALCs	  (n=9)	  from	  the	  same	  offspring	  
at	  p4	  (Figure	  7a,	  d,	  g,	   j,	  m).	  No	  significant	  difference	  was	  detected	  for	  SOX2	   (p=0.09).	  At	  p1,	  only	  a	  
tendency	  of	  higher	  expression	  in	  oAFCs	  could	  be	  observed	  for	  OCT4,	  STAT3,	  NANOG	  and	  SOX2,	  but	  
with	   no	   statistically	   significant	   differences	   (Figure	   7a,	   d,	   g,	   j,	   m).	   	   Given	   these	   results	   with	   no	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significant	   differences	   at	   p1,	   the	   observation	   of	   a	   decreasing	   heterogeneity	   of	   cell	   populations	  
following	   further	   expansion	   might	   be	   of	   particular	   interest.	   REX1	   revealed	   a	   tendency	   of	   higher	  
expression	   in	  oALCs	   in	  p1	  (p=0.07),	  which	  could	  reflect	  a	  substantially	  higher	  expression	  of	  Rex1	  at	  
early	   gestational	   ages	   (gestational	   age	   group	   1).	   Unpaired	   standard	   oBMSCs	   (n=3)	   served	   as	   a	  
baseline	  MSC	  source	  for	  direct	  comparison.	  	  
By	   pairing	   each	   oAFC	   cell	   line	   with	   the	   corresponding	   oALC	   cell	   line	   from	   the	   same	   offspring,	   a	  
significantly	   reduced	   expression	   of	   pluripotency-­‐related	   genes	   in	   oALCs	   becomes	   evident	   at	   p4	  
(Figure	   7b,	   e,	   h,	   k,	   n).	   To	   further	   analyze	   the	   gestational	   age	   dependency	   of	   pluripotency-­‐related	  
gene	   expression,	   three	   gestational	   age	   groups	   have	   been	   established	   based	   on	   the	   CRL	   (n=3	   per	  
group).	   However,	   qRT-­‐PCR	   revealed	   no	   gestational	   age	   dependency	   in	   the	   expression	   of	   OCT4,	  
STAT3,	   NANOG	   and	   SOX2	   (Figure	   7c,	   f,	   i,	   l,	   o).	   Interestingly,	   higher	   REX1	   expression	   levels	   were	  
observed	  in	  oALCs	  at	  gestational	  age	  group	  1	  compared	  to	  gestational	  age	  group	  2	  and	  3.	  
Figure	   6:	   Phenotypic	   characterization	   of	   pluripotency-­‐related	   stem	   cell	   markers	   of	   isolated	   oAFCs	   and	   oALCs.	   Immunohistological	  
analyses	  of	  representative	  paired	  oAFCs	  (n=3)	  and	  oALCs	  (n=3)	  	  (Phalloidin	  in	  red,	  Dapi	  in	  blue	  and	  respective	  antibody	  in	  green)	  revealed	  
positive	  expression	  of	  the	  pluripotency-­‐related	  markers	  OCT4,	  STAT3	  and	  NANOG.	  In	  direct	  comparison	  to	  oBMSCs	  (n=3)	  higher	  expression	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Figure	   7:	   Quantitative	   real	   time	   PCR	   of	   pluripotency-­‐related	   stem	   cell	   markers	   of	   isolated	   oAFCs	   and	   oALCs.	  Genes	   involved	   in	   the	  
maintenance	  of	  pluripotency,	  including	  OCT4	  (a),	  STAT3	  (d),	  NANOG	  (g),	  SOX2	  (j)	  and	  REX1	  (m),	  revealed	  positive	  expression	  at	  early	  (p1)	  
and	  late	  (p4)	  passages	  in	  paired	  oAFCs	  (n=9)	  and	  oALCs	  (n=9).	  Significant	  higher	  expression	  was	  detected	  in	  oAFCs	  at	  p4	  in	  OCT4,	  STAT3,	  
NANOG	   and	  REX1	   (a,	   e,	   h,	   n)	   (p<0.05),	   given	   a	  more	   heterogenous	   cell	   population	   than	   shortly	   after	   harvest	   (p1).	   Unpaired	   standard	  
oBMSCs	  (n=3)	  served	  as	  a	  source	  of	  standard	  MSCs	  for	  direct	  comparison.	  An	  interpatient	  reduced	  expression	  in	  oALCs	  compared	  to	  paired	  
oAFCs	  was	  detected	   (b,	  e,	  h,	   k,	  n).	  No	  gestational	  age	  dependency	   in	   the	  expression	  of	  pluripotent	   stem	  cell	  markers	  was	   found	   for	  all	  
analyzed	  genes	  (c,	  f,	  i,	  l,	  o)	  (1:	  gestational	  age	  group	  1;	  2:	  gestational	  age	  group	  2;	  3:	  gestational	  age	  group	  3)	  (n=3	  per	  cell	  source	  for	  each	  
gestational	  age).	  *	  =	  p<0.05	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3.2.4	  DISCUSSION	  
The	   present	   study	   aimed	   at	   addressing	   the	   origin	   of	   the	   broadly	  multipotent	   stem	   cell	   fraction	   in	  
amniotic	  fluid	  by	  the	  use	  of	  the	  ovine	  developmental	  model,	  which	   is	   frequently	  used	  as	  an	   in	  vivo	  
model	   for	   studying	  prenatal	   disease	  and	   fetal	   therapeutic	   applications	  prior	   to	  human	   clinical	   use.	  
However,	  one	  major	  difference	   to	   the	  human	  anatomy	   is	   the	   retention	  of	  an	  allantoic	   fluid	   cavity,	  
which	  enabled	  us	  to	  derive	  samples	  of	   fetal	   fluid	  and	  cells	   from	  two	  separate	  extraembryonic	   fluid	  
compartments	   from	   the	   same	  animal.	   In	   this	  manner	   cells	  deriving	   from	   the	  efferent	  urinary	   tract	  
and	   the	   allantoic	   fetal	   adnexa	   (released	   into	   the	   allantoic	   fluid	   compartment)	   can	   directly	   be	  
compared	  to	  those	  deriving	  from	  the	  fetal	  skin,	  gastrointestinal,	  respiratory	  tracts	  and	  amniotic	  fetal	  
adnexa	  (released	  into	  the	  amniotic	  fluid	  compartment).	  In	  the	  light	  of	  several	  pre-­‐clinical	  studies	  also	  
investigating	   amniotic	   fluid	   stem	   cell-­‐based	   therapies	   in	   this	   animal	  model	   1-­‐6,46,	   these	   differences	  
may	  have	  to	  be	  taken	  into	  account	  in	  future	  trials	  focusing	  on	  a	  pure	  harvest	  of	  amniotic	  fluid	  only.	  
However,	  in	  the	  presented	  study,	  this	  embryological	  difference	  enabled	  us	  to	  derive	  samples	  of	  fetal	  
fluids	   and	   cells	   from	   both	   extraembryonic	   fluid	   cavities	   from	   the	   same	   animal	   and	   compare	   the	  
expression	  of	  pluripotency-­‐related	  markers	  between	  both	  cell	  types,	  including	  oAFCs	  and	  oALCs,	  over	  
the	  entire	  duration	  of	  gestation.	  
In	   this	   regard	   the	   present	   strictly	   paired	   analyses	   of	   ovine	   fetal	   fluid-­‐derived	   cells,	   revealed	  
significantly	   higher	   pluripotency-­‐related	   gene	   expression	   in	   oAFCs	   than	   in	   oALCs,	   though	   showing	  
similar	  cellular	  phenotypes.	  Significantly	  higher	  expression	  has	  been	  detected	  by	  qRT-­‐PCR	  for	  OCT4,	  
STAT3,	  NANOG	  and	  REX1,	  whereas	  only	  a	  tendency	  for	  higher	  SOX2	  was	  found.	   Interestingly,	  SOX2	  
expression	  has	  been	  associated	  with	  neural	  induction	  and	  enhanced	  neural	  differentiation	  52,	  even	  in	  
preselected	  SOX2	  expressing	  AFSC	  53,	  implying	  that	  in	  the	  present	  study	  only	  a	  small	  portion	  of	  neural	  
progenitor	  cells	  have	  been	  detected	  in	  both	  fetal	  fluids	  analyzed.	  In	  the	  ovine	  preclinical	  model	  the	  
expression	  of	   several	   pluripotency-­‐related	   genes	  has	  been	   reported	   in	   amniotic	   fluid-­‐derived	   cells,	  
including	   NANOG	   6,11,46,54-­‐56,	   SOX2	   6,46,54-­‐56,	   OCT4	   6,46,55-­‐57,	   TERT	   46,54-­‐57	   and	   STAT3	   11,	   and	   further	  
underlines	  that	  the	  ovine	  broadly	  multipotent	  cell	  compartment	  shows	  a	  similar	  expression	  pattern	  
to	  the	  human	  counterpart	  38,39,53,58-­‐64.	  	  
In	   humans,	   AFSC	   genes	   being	   involved	   in	   the	   undifferentiated	   state	   of	   cells	   have	   received	   major	  
attention	   given	   that	   AFSCs	   are	   thought	   to	   represent	   an	   “intermediate	   stage”	   between	  pluripotent	  
stem	  cells	  and	  lineage-­‐restricted	  adult	  stem	  cells	  and	  ultimately	  can	  reacquire	  pluripotency	  through	  
reprogramming	  more	   easily	   41-­‐44.	   AFSCs	   can	   form	   three-­‐dimensional	   embryoid	   bodies,	  which	  were	  
positive	  for	  alkaline	  phosphatase	  and	  expressed	  specific	  genes	  of	  ESCs	  59.	  Therefore,	   the	  presented	  
results	  suggest	  that	  the	  cells	  with	  higher	  expression	  of	  selected	  markers	  representing	  hallmark	  genes	  
of	   pluripotency,	   and	   thus	   broad(er)	   differentiation	   potential,	   originate	   rather	   from	   the	   fetus	   itself	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(including	   skin,	   respiratory	   and	  gastrointestinal	   tract)	   or	   the	  extra-­‐embryonic	   amniotic	   tissues.	   The	  
allantoic	   fluid	   cavity,	   being	  mainly	   composed	   of	   fetal	   urine,	   seems	   to	   contain	   a	   cell	   compartment	  
with	   significantly	   lower	   pluripotency-­‐related	   gene	   expression	   suggesting	   that	   the	   urogenitary	   tract	  
may	  not	  be	  the	  primary	  source	  of	  broadly	  multipotent	  cells,	  contrary	  to	  the	  speculation	  of	  previous	  
reports	  65-­‐67.	  	  
In	  humans,	  urine	  becomes	  evident	  in	  the	  amniotic	  fluid	  at	  week	  8	  of	  gestation,	  given	  that	  the	  urethra	  
is	   fully	   developed	  and	   the	   fetal	   kidneys	  became	   functional	   23.	   In	   the	   second	  half	   of	   gestation	   (~25	  
weeks)	   the	   production	   of	   amniotic	   fluid	   is	   predominately	   based	   on	   fetal	   urine	   (~300ml/kg	   fetal	  
weight/day	  or	  600-­‐1200ml/day	  near	  term)	  and	  secretion	  of	  oral,	  nasal,	  tracheal	  as	  well	  as	  pulmonary	  
fluids	   (~60	   to	   100ml/kg	   fetal	   weight/day)	   23.	   Consequently,	   urine	   represents	   a	   possible	   abundant	  
source	  of	  stem	  cells.	  A	  population	  of	  stem	  cell-­‐like	  cells	  has	  also	  been	  recently	  described	   in	  human	  
adult	   urine	   displaying	   MSC	   markers	   68	   and	   feasibility	   of	   using	   these	   cells	   for	   tissue	   engineering	  
applications	  has	  been	  demonstrated	  69-­‐71.	  Previous	  studies	  described	  a	  heterogeneous	  cell	  population	  
in	  amniotic	  fluid	  where	  ultimately	  a	  wide	  spectrum	  of	  different	  cellular	  origins	  has	  been	  proposed,	  in	  
particular	   the	   fetal	   skin,	   urinary,	   gastrointestinal	   and	   respiratory	   tracts	   as	  well	   as	   extra-­‐embryonic	  
membranes.	   Few	   studies	   have	   described	   subpopulations	   of	   progenitor	   cells	   committed	   to	   specific	  
lineages	  or	  prone	   to	  differentiate	  easily	  under	  appropriate	  culture	  conditions,	   including	   renal-­‐	   65-­‐67,	  
pancreatic-­‐	   72	   and	  neuronal-­‐	   73	  progenitors.	   In	  particular,	   renal/podocyte	  precursors	  are	   suggesting	  
the	   urogenital	   tract	   as	   the	   possible	   source	   of	   amniotic	   fluid	   (stem)	   cells	   65-­‐67.	   On	   the	   other	   hand	  
human	  AFSCs	  derived	  from	  early	  gestational	  periods	  have	  shown	  to	  express	  ubiquitously	  Keratin-­‐8,	  
suggesting	   an	   epithelial	   origin	   of	   the	   cells	   53.	   However,	   conclusive	   evidence	   is	   missing	   so	   far	   and	  
further	  research	  is	  necessary	  to	  investigate	  the	  origin	  of	  broadly	  multipotent	  stem	  cell	  component	  in	  
particular.	  
Besides,	  the	  higher	  expression	  of	  pluripotency-­‐related	  genes,	  oAFCs	  also	  exhibit	  a	  higher	  proliferative	  
capacity	   in	  a	  direct,	  paired	  comparison	  to	  oALCs,	  which	  would	  be	  in	  line	  with	  their	  higher	  stem	  cell	  
characteristics	   reported	   above.	   Particularly	   at	   higher	   passages	   increased	  proliferation	   capacities	   of	  
oAFCs	   were	   observed,	   where	   ultimately	   a	   more	   morphologically	   homogenous	   cell	   population	  
became	   evident	   in	   both	   cell	   types	   analyzed,	   in	   agreement	   with	   previous	   studies	   74.	   The	   authors	  
suggest	   that	   stem	   cell-­‐like	   cells	   are	   enriched	   over	   progressive	   passaging	   through	   selected	  
proliferation	  medium	  towards	  a	  more	  homogenous	  population,	  which	  further	  underlines	  the	  higher	  
pluripotency-­‐related	  gene	  expression	  pattern	  at	  later	  passages	  (p4)	  compared	  to	  early	  passages	  (p1)	  
reported	  here.	  Immunofluorescence	  and	  flow	  cytometry	  stainings	  verified	  a	  mesodermal,	  myogenic	  
phenotype	   of	   isolated	   fetal	   cells,	   with	   higher	   expression	   of	   common	  MSC	  markers	   per	   single	   cell	  
(measured	  with	  MFIR)	  in	  oAFCs	  compared	  to	  oALCs.	  Selected	  MSC	  markers	  differ	  from	  the	  ones	  used	  
with	  human	  MSCs	  given	   interspecies	  differences.	  They	  have	  previously	  been	  described	   to	  uniquely	  
Amniotic	  fluid	  MSC	  	  
126	  
characterize	  ovine	  BMSCs	   for	   future	   translational	   studies	   involving	   this	  animal	  model	   19,49.	  Besides,	  
one	  needs	  to	  emphasize	  the	  limited	  amount	  of	  well	  established	  markers	  in	  the	  ovine	  model	  and	  the	  
necessity	   for	   better	   standardized	   protocols	   for	   future	   clinical	   studies	   implying	   the	   ovine	  
developmental	   model.	   This	   interspecies	   difficulty	   was	   also	   observed	   in	   the	   multilineage	  
differentiation	   of	   ovine	   fetal	   cells,	   even	   if	   their	   multilineage	   differentiation	   potential	   could	   be	  
positively	   confirmed.	   Nevertheless,	   this	   study	   for	   the	   first	   time	   uniquely	   provides	   I)	   a	   systematic	  
comparative	  analysis	  of	   fetal	   fluid	   cells	   from	  both	   cavities,	   the	  amnion	  and	   the	  allantois,	   II)	   paired	  
analysis	   of	   AFCs	   and	   ALCs	   from	   the	   same	   offspring,	   and	   III)	   quantitative	   information	   on	   the	  
pluripotency-­‐related	  gene	  expression	  over	  gestation.	  Initial	  studies	  on	  the	  isolation	  of	  fetal	  fluid	  cells	  
have	   been	   performed	   in	   canine	   75	   and	   feline	   76	   models,	   proving	   the	   principal	   feasibility	   of	   ALC	  
isolation	  with	   a	   differentiation	   potential	   and	   surface	  marker	   expression	   equivalent	   to	  multipotent	  
MSCs	  from	  the	  amniotic	  fluid.	  However,	  oALCs	  have	  not	  been	  broadly	  characterized	  so	  far	  and	  solid	  
evidence	   for	   their	   stem	   cell	   nature	   is	  missing.	   In	   particular,	   the	   expression	  of	   pluripotency-­‐related	  
genes	  has	  not	  been	  analyzed.	  Furthermore,	  strictly	  paired	  quantitative	  analyses	  between	  AFCs	  and	  
ALCs	   were	  missing	   and	   non-­‐paired	   analyses	  may	   neglect	   the	   substantial	   inter-­‐individual	   variances	  
also	  detected	  in	  the	  present	  study.	  	  
In	  spite	  of	  the	  differences	  between	  oAFCs	  and	  oALCs,	  the	  present	  study	  did	  not	  find	  any	  gestational	  
age	  dependent	  differences	  of	   cellular	  phenotype,	  proliferation	  and	   the	  expression	  of	  pluripotency-­‐
related	   markers.	   So	   far	   most	   studies	   on	   human	   AFSCs	   used	   cells	   from	   the	   second	   trimester	   of	  
gestation,	  as	   routine	  amniocenteses	   in	  human	  are	  usually	  performed	  between	  14	  and	  26	  weeks	  of	  
pregnancy	   77.	   Nevertheless,	   several	   studies	   have	   demonstrated	   that	   human	   AFSCs	   can	   also	   be	  
successfully	  isolated	  at	  first	  42,60	  and	  third	  61,78	  trimester	  of	  gestation.	  In	  agreement	  with	  our	  results,	  
comparable	  cellular	  phenotypes	  have	  been	  observed	  in	  human	  AFSCs	  isolated	  in	  the	  second	  or	  third	  
trimester	  of	  gestation,	  including	  expression	  of	  OCT4	  and	  NANOG	  61,78.	  	  
However,	  Moschidou	  et	  al.	  illustrated	  that	  cells	  isolated	  from	  the	  first	  trimester	  of	  gestation	  express	  
a	   larger	   number	   of	   organ	   specific	   genes,	   suggesting	   a	   more	   undifferentiated	   state	   of	   cells	   60.	   As	  
development	   proceeds,	   cells	   from	   the	   second	   trimester	   do	   not	   express	   the	   complete	   pattern	   of	  
pluripotent	   factors	   anymore	   and	   become	  more	   committed	  with	   a	   limited	   differentiation	   potential	  
42,60,61.	  Also	  when	   isolating	  circulating	  CD34+	  hematopoietic	  progenitors	  cells	  and	  multipotent	  stem	  
cells	   from	   the	   human	   umbilical	   cord	   blood,	   the	   frequency	   and	   immature	   pool	   of	   cells	   showed	   a	  
decrease	   towards	   the	   later	   stages	  of	   pregnancy	   79,80.	  However,	   in	   the	  present	   study,	   the	   complete	  
pattern	   of	   pluripotency-­‐related	   genes,	   including	  OCT4,	   NANOG,	   STAT3,	   SOX2	   and	  REX1,	   showed	   a	  
consistent	   expression	   independent	   of	   the	   developmental	   stage	   at	   which	   cells	   were	   harvested.	   In	  
addition,	  also	  no	  morphological	  phenotype	  tendency	  could	  be	  assigned	  to	  a	  certain	  gestational	  age,	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all	   three	  morphological	   phenotypes	  were	   equally	   distributed	   and	   abundant	   at	   every	   stage	   of	   fetal	  
development.	  	  
These	   results	   suggest	   that	  cells	  with	  high	  pluripotency-­‐related	  gene	  expression	  seem	  to	  be	  equally	  
abundant	   within	   the	   amniotic	   fluid	   over	   the	   entire	   duration	   of	   gestation.	   Consequently,	   amniotic	  
fluid	  harvest	  for	  regenerative	  applications	  may	  also	  be	  performed	  shortly	  before	  or	  directly	  at	  birth,	  
to	   minimize	   any	   risk	   of	   amniocentesis	   for	   the	   fetus	   in	   cases	   were	   no	   diagnostic	   amniocentesis	   is	  
necessary.	  A	   single	   study	   focusing	  on	   the	  analysis	  of	  human	  amniotic	   fluid	  obtained	  at	   the	   time	  of	  
elective	  cesarean	  delivery	  also	  reported	  expression	  of	  Oct-­‐4,	  however	  the	  analysis	  was	  limited	  to	  this	  
single	  pluripotency-­‐related	  factor	  only	  81.	  Further	  research	  on	  human	  amniotic	  fluid	  samples	  pre-­‐	  and	  
perinatally	  seems	  mandatory	  to	  confirm	  these	  findings	  and	  to	  establish	  amniotic	  fluid	  as	  a	  potential	  
perinatal	  cell	  source.	  
In	  conclusion,	  the	  presented	  data	  suggest	  that	  the	  expression	  of	  pluripotency-­‐related	  genes	  of	  cells	  
derived	   from	   the	   fluid	   directly	   surrounding	   the	   fetus	   is	   substantially	   higher	   than	   the	   one	   of	   cells	  
derived	  from	  the	  efferent	  urinary	  tract.	  These	  findings	  suggest	  that	  the	  cells	  expressing	  the	  highest	  
stem	  cell	  characteristics	  may	  originate	  from	  the	  fetus	  itself	  (e.g.	  the	  fetal	  skin,	  the	  respiratory	  or	  the	  
gastrointestinal	   tract).	   Interestingly,	   contrary	   to	   previous	   reports	   on	   human	   cord	   blood	   79,80,	   no	  
significant	  decrease	  of	  the	  pluripotency-­‐related	  gene	  expression	  was	  noted	  over	  pregnancy,	  implying	  
that	  even	  at	  the	  end	  of	  pregnancy,	  AFSCs	  with	  high	  differentiation	  potential	  may	  be	  isolated.	  These	  
findings	  will	  have	  to	  be	  confirmed	  by	  future	  studies	  in	  humans,	  at	  least	  as	  far	  as	  the	  major	  ethical	  and	  
medical	  restrictions	  allow	  for	   it.	  However,	   if	  confirmed,	  these	  findings	  may	  have	  major	   implications	  
for	  harvesting,	  banking	  and	  usage	  of	  AFSCs	  for	  future	  therapeutic	  applications.	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Tissue	   engineered	   scaffolds	   have	   emerged	   as	   a	   promising	   solution	   for	   heart	   valve	   replacement	  
because	  of	  their	  potential	  for	  regeneration.	  However,	  traditional	  heart	  valve	  tissue	  engineering	  has	  
relied	   on	   resource-­‐intensive,	   cell-­‐based	   manufacturing,	   which	   increases	   cost	   and	   hinders	   clinical	  
translation.	   To	   overcome	   these	   limitations,	   in	   situ	   tissue	   engineering	   approaches	   aim	   to	   develop	  
scaffold	  materials	  and	  manufacturing	  processes	  that	  elicit	  endogenous	  tissue	  remodeling	  and	  repair.	  
Yet	  despite	  recent	  advances	   in	  synthetic	  materials	  manufacturing,	  there	  remains	  a	   lack	  of	  cell-­‐free,	  
automated	  approaches	  for	  rapidly	  producing	  biomimetic	  heart	  valve	  scaffolds.	  Here,	  we	  designed	  a	  
jet	   spinning	   process	   for	   the	   rapid	   and	   automated	   fabrication	   of	   fibrous	   heart	   valve	   scaffolds.	   The	  
composition,	   multiscale	   architecture,	   and	   mechanical	   properties	   of	   the	   scaffolds	   were	   tailored	   to	  
mimic	   that	   of	   the	   native	   leaflet	   fibrosa	   and	   assembled	   into	   three	   dimensional,	   semilunar	   valve	  
structures.	  We	  demonstrated	   controlled	  modulation	   of	   these	   scaffold	   parameters	   and	   show	   initial	  
biocompatibility	  and	  functionality	  in	  vitro.	  Valves	  were	  minimally-­‐invasively	  deployed	  via	  transapical	  
access	  to	  the	  pulmonary	  valve	  position	  in	  an	  ovine	  model	  and	  shown	  to	  be	  functional	  for	  15	  h.	  Long-­‐
term	  follow	  up	  of	  1-­‐month	  in	  vivo	  revealed	  low	  cellular	  infiltration	  into	  the	  heart	  valve	  scaffolds	  and	  





Experimental	  contributions	  (Kehl	  D	  only):	  
Establishment	  of	  suture	  layout,	  storage	  conditions	  and	  sterilization	  of	  valves	  for	  in	  vivo	  implantation.	  
Integration	   of	   electrospun	   valves	   into	   self-­‐expandable	   nitinol	   stent	   and	   suturing	   under	   sterile	  
conditions.	   Adaptation	   of	   the	   crimping	   procedure	   and	   subsequent	   crimping	   analysis	   of	   the	   valves	  
(suture	  retention,	  macroscopic	  valve	  geometry).	  Preparation	  and	  coordination	  of	   JetValve	  scaffolds	  
for	   in	   vivo	   implantation	  and	  explanation.	  Crimping	  of	  heart	   valves	  before	   in	   vivo	   implantation	   into	  
minimal	   invasive	  delivery	  device.	  Post	  mortem	  macroscopic	  analysis	  of	  engineered	  valves,	   including	  
explant	   photography,	   paraffin	   embedding,	  microtome	   cutting	   and	  microscope	   histological	   analysis	  
(such	   as	   H&E,	   Masson	   Trichom	   etc.).	   Isolation	   of	   native	   ovine	   pulmonary	   heart	   valve	   and	   their	  
characterization	   for	   comparative	   analyses.	   Evaluate	   cellular	   infiltration	   and	   in	   vivo	   functionality	   of	  
implanted	  heart	  valves	  based	  on	  histological	  analyses	  and	  in	  vivo	  echocardiography.	  	  
	  
Experimental	  contributions	  (Kehl	  D,	  together	  with	  co-­‐authors)	  
Design	   input	   for	  building	  automated	  spinning	  process	  and	  storage	  evaluation.	  Evaluation	  of	   in	  vivo	  
functionality	  of	  implanted	  heart	  valves	  based	  on	  echocardiography.	  
	  
Non-­‐experimental	  contributions	  (Kehl	  D	  only):	  
Coordination	   of	   in	   vivo	   implantation	   procedures.	   Amendment	   of	   ethical	   permission	   for	   in	   vivo	  
implantation.	   Maintaining	   data	   exchange	   with	   collaborating	   partners	   in	   Boston	   by	   writing	   and	  
summarizing	  in	  vivo	  findings/data.	  Reviewing	  manuscript.	  
	  
Steps	  contained	  in	  the	  published	  work	  (without	  personal	  contribution	  of	  Kehl	  D)	  
Design	  of	  jet	  spinning	  process	  for	  the	  mandrel-­‐based	  manufacturing	  of	  heart	  valve	  scaffolds.	  Mandrel	  
scaling	   and	   customization.	   Definition	   of	   composition	   (fiber	   diameter	   and	   orientation,	   scaffold	  
porosity),	   multiscale	   architecture	   and	   mechanical	   properties	   of	   electrospun	   heart	   valves.	   Scaffold	  
batch	   process	   capability	   based	   on	   scaffold	   stiffness	   and	   biohybrid	   composition.	   In	   vitro	   cellular	  
infiltration	   studies	   of	   valvular	   interstitial	   cells	   into	  heart	   valve	   leaflet	   and	   conduit	   scaffold.	   In	   vitro	  
functional	   testing	   of	   engineered	   heart	   valves	   in	   a	   pulse	   duplicator	   system.	   In	   vivo	   implantation	   of	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4.1.1	  INTRODUCTION	  
Historically,	   heart	   valve	   tissue	   engineering	   has	   relied	   on	   cell-­‐based	   manufacturing	   to	   build	   living	  
tissues	  in	  vitro	  1.	  In	  this	  approach,	  cells	  are	  seeded	  onto	  scaffolds	  and	  conditioned	  in	  bioreactors	  that	  
mimic	  the	  physiological	  conditions	  (pressures	  and	  flows)	  of	  the	  native	  valve	  2,3.	  The	  conditioned	  cells	  
remodel	   the	   scaffold	   in	   order	   to	   produce	   a	   microenvironment	   that	   mimics	   the	   complex	   spatial	  
organization,	  mechanical	  properties,	  and	  biochemical	  composition	  of	  the	  native	  leaflet	  extracellular	  
matrix	   (ECM)	   4.	   These	   scaffold/tissue	   constructs	   are	   complex	   biomaterials	   designed	   to	   elicit	  
immunological	   mechanisms	   that	   drive	   tissue	   regeneration	   5.	   In	   recent	   attempts	   to	   improve	  
translation	  of	  tissue	  engineered	  valvular	  scaffolds,	  storage	  has	  been	  made	  possible	  by	  decellularizing	  
6-­‐8	  conditioned	  scaffolds,	  which	  can	  be	  recellularized	  prior	  to	  9	  or	  after	  implantation	  10.	  Although	  this	  
strategy	   has	   shown	  promise	   as	   both	   a	   functional	   and	   regenerative	   approach,	   these	   “off-­‐the-­‐shelf”	  
valvular	  scaffolds	  can	  take	  months	  and	  cost	  thousands	  of	  dollars	  to	  produce	  using	  manual	  and	  non-­‐
standardized	   manufacturing	   techniques.	   Fabrication	   steps	   including	   cell	   sourcing/isolation	   11	   and	  
cell/scaffold	  conditioning	  12,13	   in	  heavily	  regulated	  GMP	  environments	  are	  complex	  and	  may	  require	  
the	  patient	  to	  take	  immunosuppressive	  therapies	  if	  foreign	  biologics	  14	  or	  non-­‐degradable	  materials	  
are	   used.	  As	   a	   result	   of	   the	  manufacturing	   time,	   cost,	   and	   inherent	   potential	   for	   product	  material	  
variability	  15,	  the	  translation	  of	  tissue	  engineered	  heart	  valves	  to	  the	  clinic	  remains	  limited	  16,17.	  	  
In	   situ	   heart	   valve	   tissue	   engineering	   is	   a	   simplified	   method	   for	   permanent,	   regenerative	   valve	  
replacement	  18.	  In	  this	  approach,	  the	  scaffold	  is	  designed	  to	  promote	  endogenous	  mechanisms	  that	  
drive	   tissue	   formation	   and	   remodeling	   once	   implanted	   10,17.	   The	   manufacturing	   process	   must	  
therefore	  be	   capable	  of	  producing	   scaffolds	   that	  both	  modulate	   the	  direction	  of	  blood	   flow	   in	   the	  
heart	   immediately	   upon	   implantation	   and	   recapitulate	   aspects	   of	   the	   microenvironment	   of	   the	  
native	  valve	  ECM	  with	  the	  goal	  of	  promoting	  endogenous	  remodeling	  19.	  To	  achieve	  this,	  numerous	  
materials	   fabrication	   techniques	   such	   as	   fiber	   electrospinning	   20	   and	   force	   spinning	   21,	   hydrogel	  
molding	   22,	   and	   3D/bioprinting	   23	   have	   been	   developed	   to	   fabricate	   biomimetic	   valvular	   scaffolds,	  
each	   with	   unique	   building	   advantages.	   The	   nanoscale	   resolution	   of	   fiber	   production	   systems,	   the	  
simplicity	   of	   hydrogel	   material	   properties	   manipulation,	   and	   the	   customizable	   global	   designs	  
achievable	  with	  3D	  printing	  each	   recapitulate	   central	  of	   aspects	  of	   valvular	   architecture.	  However,	  
new	   biomaterials	   manufacturing	   techniques	   achieving	   both	   high	   resolution	   and	   degree	   of	  
customization	   remain	  needed	   to	  mimic	   1)	   the	   anisotropic	   architecture	  of	   the	   valvular	   ECM,	  2)	   the	  
stiffness	   of	   the	   leaflet	   to	   withstand	   systolic	   and	   diastolic	   loading,	   and	   3)	   incorporate	   native	   ECM	  
proteins	   to	   allow	   for	   cellular	   attachment	   and	   infiltration	   13,24.	   Easy	   manipulation	   of	   these	  
manufacturing	   parameters	   will	   be	   necessary	   to	   tailor	   the	   complex,	   and	   still	   yet	   to	   be	   fully	  
understood,	  remodeling	  response	  over	  time.	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In	   this	   study,	   we	   introduce	   a	   cell-­‐free	   manufacturing	   technique	   for	   the	   rapid	   production	   of	  
biomimetic	  semilunar	  heart	  valvular	  scaffolds	  (JetValves).	  JetValves	  were	  manufactured	  in	  a	  two-­‐step	  
mandrel	   collection	   process	   which	   enabled	   facile	   shape	   and	   size	   customization.	   By	   varying	   the	  
biohybrid	   composition	   and	   manufacturing	   collection	   parameters	   of	   JetValves,	   the	   multiscale	  
architecture,	   mechanical	   properties	   and	   biochemistry	   of	   the	   scaffold	   fibers	   were	   engineered	   to	  
recapitulate	   those	   of	   the	   native	   valve	   leaflet	   fibrosal	   ECM	   (ovine).	   The	   controlled	   and	   automated	  
fabrication	   of	   JetValves	   enabled	   seamless	   and	   rapid	   production	   (minutes	   from	   raw	   material	   to	  
product)	  allowing	  for	  the	  implementation	  of	  quality	  control	  standards	  to	  ensure	  scaffold	  consistency	  
prior	   to	   use.	   JetValves	   demonstrated	   acute	   durability	   and	   basic	   functionality	   in	   vitro	   as	   well	   as	  
biocompatibility/competency	   in	  vivo	  upon	  minimally	   invasive	  implantation	  into	  an	  ovine	  pulmonary	  
valve	  model.	   The	   JetValve	   fabrication	   process	  may	   thus	   provide	   a	   versatile	   platform	   for	   the	   rapid	  
production	  of	  tissue	  engineered	  heart	  valve	  scaffolds.	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4.1.2	  MATERIAL	  AND	  METHODS	  
4.1.2.1	  JETVALVE	  MANDREL-­‐BASED	  MANUFACTURIN	  PROCESS	  
Tri-­‐leaflet	   valvular	   scaffolds	   (JetValves)	  were	   three-­‐dimensionally	  manufactured	   by	   the	   cumulative	  
collection	  of	   force-­‐extruded	   fibers	   onto	   custom	   sized	  mandrels.	   A	   two-­‐step	   collection	  process	  was	  
used	  via	  automation	  of	  the	  Rotary	  Jet	  Spinning	  system	  (aRJS,	  Fig.	  1a)	  21,25	  controlled	  by	  a	  customized	  
LabVIEW	   interface	   for	   the	   first	   time	   (National	   Instruments,	   v12.0.1f4).	   First,	   the	   leaflet	   cusps	  were	  
spun	   by	   the	   collection	   of	   fibers	   onto	   a	   rotating	   semilunar	   valve	   leaflet	   shaped	   mandrel	   (male-­‐
mandrel)	   cyclically	   translating	   through	   the	   fiber	   extrusion	   plane.	   Leaflets	   were	   subsequently	  
separated	  by	  the	  removal	  excess	  fiber	  accumulation	  on	  the	  top	  of	  the	  leaflet	  shaped	  mandrel	  with	  a	  
scalpel.	  By	  the	  addition	  of	  a	  shielding	  mandrel	  (female-­‐mandrel)	  over	  the	  leaflet	  mandrel	  and	  further	  
fiber	  deposition,	  the	   leaflets	  were	  seamlessly	  spun	   into	  a	  fibrous	  conduit	  to	  produce	  the	  semilunar	  
valve	  within	  a	  vessel	  structure	  (Fig.	  1b,	  Supplemental	  video	  1).	  Once	  dried,	  removal	  of	  Teflon	  or	  3D	  
printed,	   Teflon-­‐coated	   collection	   mandrels	   from	   either	   end	   of	   the	   fibrous	   conduit	   was	   possible	  
without	  disrupting	  its	  structure.	  
	  
Figure	  1:	  Main	  Automated	  Rotary	  Jet	  Spinning	  of	  JetValves.	  (a)	  CAD	  representation	  of	  the	  automated	  Rotary	  Jet	  Spinning	  system	  (aRJS).	  
(b)	  A	  two-­‐step	  mandrel	  collection	  system	  was	  used	  consisting	  of	   (1)	  a	   leaflet	  mandrel	  and	  (2)	  shielding	  mandrel.	   (c)	  At	  a	  30	  k	  RPM	  fiber	  
extrusion	   rate,	   4%	   w/v	   P4HB/Gelatin	   biohybrid	   solutions	   had	   decreased	   fiber	   diameter	   but	   increased	   percent	   scaffold	   porosity	   as	   a	  
function	  of	  decreasing	  polymer	   content	   (N	  =	  6	  production	   runs	  per	   condition,	  *p	  <	  0.5).	   (d)	   Stress	   vs	   strain	  plots	  of	  60/40	  P4HB/Gelatin	  
blends	  compared	  to	  native	  leaflet	  cusps	  up	  to	  20%	  strain	  (blue	  circumferential	  (C),	  red	  radial	  (R)	  fiber	  alignment;	  N	  =	  6	  production	  runs	  per	  
condition,	  N	  =	  5	  native	  leaflets;	  *p	  <	  0.5).	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4.1.2.2	  JETVALVE	  FABRICATION	  FOR	  STRUCTURAL	  AND	  FUNCTIONAL	  TESTING 
Poly-­‐4-­‐hydroxybutyrate	   (P4HB,	   Tepha	   Inc.,	   TephaFLEX)/gelatin	   (from	   porcine	   skin,	   strength	   300;	  
Sigma,	   G2500)	   “biohybrid”	   (synthetic-­‐polymer/protein)	   solutions	   of	   varied	   composition	  
(P4HB/Gelatin;	   100/0,	   80/20,	   60/40,	   40/60,	   and	   20/80)	   were	   stirred	   for	   12	   hr	   at	   4%	   w/v	   in	  
hexfluoroispropanol	  (HFIP,	  Oakwood	  Chemical,	  003409).	  A	  small	  amount,	  0.2%	  w/v,	  of	  polyglycolide	  
(PGA,	   Sigma,	   457620)	   was	   added	   to	   each	   solution	   for	   compositional	   comparison	   to	   previously	  
published	  valvular	  scaffolds	  6,7,9;	  the	  effect	  of	  PGA	  on	  scaffold	  mechanics	  and	  structure	  were	  assumed	  
to	  be	  negligible,	   therefore	   compositions	   are	  henceforth	   referred	   to	   as	   P4HB/Gelatin.	  After	  mixing,	  
solutions	   were	   individually	   pumped	   into	   the	   rotating	   reservoir	   of	   the	   aRJS	   at	   5.0	  ml/min	   through	  
polyfluoroalkoxy	   alkane	   tubing	   (Saint-­‐Gobain,	   TSPF35-­‐0125-­‐031-­‐50)	   using	   an	   automated	   syringe	  
pump	  (Harvard	  Apparatus,	  703007).	  The	  reservoir	  of	  the	  aRJS	  was	  machined	  from	  stainless	  steel	  to	  
ensure	   structural	   stability	  at	  high	   speeds	  and	   rotated	  at	  30k	  RPM	  (motor:	  Nakanishi,	  EM-­‐3080J)	   to	  
extrude	   solution	   jets	  within	   a	   horizontal	   “fiber	   extrusion	  plane.”	   Solution	   jets	  were	   extruded	   from	  
two	  360	  μm	  diameter	  orifices	  drilled	  horizontally	  into	  the	  bottom	  of	  the	  reservoir.	  Fibers	  ranging	  in	  
diameter,	  porosity	  and	  stiffness	  were	  produced	  by	  varying	  the	  biohybrid	  solution	  (Fig.	  1c	  and	  Fig,	  1d),	  
similar	   to	   previous	   RJS	   hybrid	   materials	   [25],	   and	   collected	   onto	   semilunar	   valve	   shaped	   rotating	  
mandrels	  as	  described	  above.	  Mandrels	  were	  rotated	  at	  3k	  RPM	  at	  0º,	  22.5º,	  or	  45º	  relative	  to	  the	  
horizontal	   as	   they	   vertically	   translated	   through	   the	   fiber	  extrusion	  plane	  at	  10	   cm/s	   (linear	  motor:	  
Misumi,	  LX20).	  JetValve	  scaffolds	  manufactured	  for	  ovine	  implantation	  were	  30	  mm	  in	  diameter	  and	  
composed	  of	  60/40	  P4HB/Gelatin;	  30	  ml	  of	  solution	  were	  spun	  to	  form	  the	  leaflets	  and	  40	  ml	  were	  
spun	   to	   form	  the	   remainder	  of	   the	  conduit.	  8	  mm	  wide	  sample	  strips	  were	  cut	   from	  either	  end	  of	  
each	  JetValve	  scaffold	  for	  measuring	  batch	  process	  capability	  of	  JetValves	  prepared	  for	  implantation.	  
	  
4.1.2.3	  MANDREL	  SCALING	  AND	  CUSTOMIZATION	  
JetValve	   mandrels	   were	   custom-­‐drawn	   and	   scaled	   using	   computer	   aided	   design	   software	  
(Solidworks,	   2015)	   and	   milled	   from	   Teflon	   for	   implantation	   (Proto	   Labs)	   or	   3D	   printed	   in	   Rigid	  
Opaque	   photopolymer	   for	   rapid	   scaling	   (Blue,	   Stratasys,	   Object30	   Printer).	   Leaflet	   and	   shielding	  
mandrels	  were	  readily	  scaled	  from	  30	  mm	  (ovine,	  implantation	  model	  used	  in	  this	  study)	  to	  3	  mm	  to	  
produce	   JetValves	  of	   various	   sizes;	   750	  μm	   in	  diameter	   (~mouse	   sized)	  mandrels	   could	  also	  be	  3D	  
printed	   and	   spun	  onto	   to	   form	  miniature	   JetValves.	   (Fig.	   2a).	   Sinuses	  were	   added	   to	   the	   shielding	  
mandrel	   to	   produce	   aortic	   valve	   relevant	   geometries	   using	   the	   same,	   two-­‐step	   mandrel	   spinning	  
method	  of	  fabrication	  described	  above.	  A	  “Sinus	  Cylinder”	  for	  housing	  “Sinus	  Cartridges”	  comprised	  
the	  shielding-­‐female	  mandrel	  and	  allowed	   for	   seamless	  sinus	  bulge	   incorporation	   into	   the	   JetValve	  
with	  easy	  mandrel	  removal	  via	  breakdown	  of	  the	  cylinder-­‐cartridge	  assembly	  once	  dried	  (Fig.	  2b).	  	  







Figure	   2:	   JetValve	   mandrel	   scaling	   and	   customization.	   (a)	   Digital	  
photograph,	  (left)	  of	  3D	  printed	  shielding	  (upper	  row)	  and	  leaflet	  (lower	  
row)	   JetValve	  mandrels	   and	   scaffolds	   ranging	   from	  30	  mm	   to	  3	  mm	   in	  
diameter.	  Scanning	  electron	  microscope	   images,	   (right)	  of	  miniaturized	  
JetValve	   mandrels	   and	   scaffold,	   750	  μm	   in	   diameter.	   (b)	   Shielding	  
mandrel	   modification	   for	   JetValve	   scaffolds	   with	   sinus	   bulges.	   The	  
shielding	   mandrel	   was	   compartmentalized	   into	   individual,	   symmetric	  
sinus	   component	   “inserts”	   which	   could	   be	   fixed	   to	   a	   housing	   sinus	  
“core,”	  (left).	  Mandrels	  were	  removed	  from	  scaffolds	  without	  disrupting	  
the	  structure,	  digital	  photographs	   (right),	  by	  removing	  the	  connections	  
of	  the	  core	  and	  inserts.	  
	  
4.1.2.4	  FIBER	  DIAMETER	  AND	  SCAFFOLD	  POROSITY	  
Scanning	  electron	  microscopy	   (SEM)	  and	   ImageJ	   software	   (NIH,	   v1.48s)	  were	  used	   to	  measure	   the	  
fiber	   diameter	   and	   percentage	   porosity	   of	   JetValve	   scaffolds	   of	   varied	   biohybrid	   composition	  
(P4HB/Gelatin;	  100/0,	  80/20,	  60/40,	  40/60,	  and	  20/80;	  n=6	  production	  runs	  per	  biohybrid	  condition).	  
Samples	  were	  sputter	  coated	  in	  5	  nm	  of	  platinum/palladium	  (Quorum	  Technologies,	  EMS	  300TD)	  to	  
avoid	   charge	   accumulation	   and	   scaffold	  deformation/melting	  during	   SEM	   imaging.	  A	   field	   emitting	  
electron	   microscope	   was	   used	   to	   image	   samples	   (Zeiss,	   FESEM	   Ultra	   Plus)	   at	   15	   kV	   with	   a	   high	  
efficiency	  secondary	  electron	  detector,	  1.75k	  magnification	  for	  fiber	  diameter	  and	  1k	  magnification	  
for	  porosity	  images.	  Using	  ImageJ,	  10	  fiber	  diameter	  regions	  of	  interest	  (ROIs)	  were	  taken	  per	  sample	  
using	   the	   linear	   measuring	   tool	   and	   one	   porosity	   ROI	   was	   taken	   per	   sample	   using	   thresholding	  
percentage	  (percent	  porosity:	  fiber	  vs.	  non-­‐fiber).	  	  
	  
4.1.2.5	  SCAFFOLD	  AND	  TISSUE	  BIAXIAL	  MECHANICAL	  PROPERTIES	  
JetValve	   scaffolds	  of	   varied	  biohybrid	   composition	   (P4HB/Gelatin;	  100/0,	  80/20,	  60/40,	  40/60,	   and	  
20/80)	   were	   equibiaxially	   loaded	   to	   determine	   low	   (0-­‐10%)	   and	   high	   (10-­‐20%)	   strain	   stiffness	  
measurements	   in	   comparison	   to	   freshly	   harvested	   ovine	   pulmonary	   leaflets.	   8x8	   mm	   scaffold	  
samples	  (n=6	  production	  runs	  per	  biohybrid	  condition)	  and	  8x8	  mm	  native	  leaflet	  samples	  (n=5,	  cut	  
from	  cusp	  centers)	  were	  loaded	  onto	  5x5	  mm	  mounting	  tines	  of	  a	  biaxial	  tensile	  tester	  equipped	  with	  
Biodegradable	  scaffolds	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2.5	   N	   load	   cells	   (CellScale,	   BioTester)	   26.	   Loaded	   samples	   were	   submerged	   in	   a	   phosphate	   buffer	  
saline	   (PBS,	   Thermo	   Fisher,	   10010023)	   bath	   at	   37ºC	   to	   simulate	   hydration	   and	   temperature	  
conditions	   in	   vivo.	   Each	   sample	   was	   first	   preconditioned	   equibiaxially	   at	   a	   strain	   rate	   of	   5%	   per	  
second	  to	  2%	  strain	  4	  times	  to	  ensure	  complete	  hydration	  of	  the	  scaffold	  or	  tissue.	  Next,	  each	  sample	  
was	  loaded	  equibiaxially	  at	  a	  strain	  rate	  of	  5%	  per	  second	  to	  20%	  strain	  4	  times.	  Force/displacement	  
measurements	  and	  images	  were	  recorded	  throughout	  the	  test	  at	  15	  Hz;	  stress	  vs.	  strain	  plots	  were	  
then	   generated	   from	   these	   measurements	   and	   the	   original	   dimensions	   of	   the	   samples	   (i.e.	  
thickness/length	   in	   each	   direction,	   parallel	   and	   perpendicular	   to	   fiber/ECM	   orientation).	   Stiffness	  
moduli	  were	   calculated	   as	   the	   slope	   to	   the	   stress	   vs.	   strain	   curves	   in	   the	   respective	   low	   and	   high	  
strain	   regimes.	   To	   test	   the	  effect	  of	   collection	  angle	  on	  both	   conduit	   and	   leaflet	   stiffnesses,	  60/40	  
blends	   were	   collected	   at	   0˚,	   22.5˚,	   and	   45˚	   (n=6	   from	   3	   production	   runs	   per	   angle)	   and	   biaxially	  
tested	  as	  described	  above.	  
	  
4.1.2.6	  SCAFFOLD	  FIBER	  AND	  TISSUE	  ORIENTATION	  
The	   fiber	   orientation	   of	   60/40	   P4HB/Gelatin	   JetValve	   leaflet	   and	   conduit	   samples	   collected	   at	   0º,	  
22.5º,	   or	   45º	   (n=3	   production	   runs	   per	   condition)	   were	   compared	   to	   that	   of	   decellularized	   ovine	  
pulmonary	  valve	   leaflets	   (n=7	   leaflets).	  Freshly	  harvested	  pulmonary	   leaflets	  were	  decellularized	   in	  
1%	  sodium	  dodecyl	  sulfate	  (SDS,	  Sigma,	  L6026)	  for	  4	  days.	  After	  decellularization,	  leaflets	  were	  rinsed	  
in	  ultra-­‐pure	  water	  (Thermo	  Fisher,	  10977-­‐015)	  then	  dehydrated	  in	  serial	  ethanol	  washes	  (30%,	  50%,	  
70%,	  90%,	  3x	  100%)	  for	  5	  min	  each	  (EtOH,	  VWR,	  64-­‐17-­‐5).	  Dehydrated	  leaflets	  were	  then	  dried	  using	  
a	  critical	  point	  drier	  (Tousimis,	  931	  Series	  SAMDRI)	  and	  sputter	  coated.	  SEM	  images	  of	  scaffolds	  and	  
decellularized	  tissue	  were	  taken	  as	  described	  above	  from	  five	  regions	  encompassing	  the	  whole	  area	  
of	  the	  leaflet	  (scaffold	  and	  native)	  and	  five	  regions	  along	  the	  length	  of	  the	  conduit.	  SEM	  images	  were	  
analyzed	   with	   custom	   made	   ImageJ	   and	   Matlab	   software	   to	   calculate	   the	   orientational	   order	  
parameter	  (OOP),	  a	  quantitative	  measure	  of	  the	  degree	  of	  fiber	  orientation	  within	  a	  scaffold/tissue.	  
In	  brief,	  foreground	  pixels	  were	  assigned	  the	  orientation	  of	  the	  local	  neighborhood	  using	  a	  structure	  
tensor	   method;	   then,	   the	   set	   of	   all	   orientations	   was	   summed	   assuming	   they	   represented	   the	  
directions	   of	   vectors	   of	   unit	   magnitude.	   The	   result	   is	   a	   number	   that	   goes	   from	   0,	   for	   perfectly	  
random	  set	  of	  orientations,	  to	  1	  for	  perfectly	  aligned	  foreground	  pixels	  27,28.	  	  
	  
4.1.2.7	  SCAFFOLD	  SHELF	  LIFE	  
X-­‐ray	   photoelectron	   spectrometry	   (XPS,	   Thermo	   Scientific,	   K-­‐Alpha	   XPS,)	   was	   used	   to	   evaluate	  
freshly-­‐spun	   and	   hydrated	   JetValve	   scaffold	   composition	   in	   time.	   8x8	   mm	   pieces	   of	   60/40	  
P4HB/Gelatin	  scaffolds	  were	  hydrated	  in	  1	  L	  of	  ultra-­‐pure	  water	  and	  stored	  in	  an	  incubator	  at	  37ºC	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for	   up	   to	   1	  week.	   Hydrated	   samples	  were	   removed	   from	   the	  water	   bath	   every	   24	   hr	   with	   sterile	  
forceps	  and	  were	  dried	  for	  12	  hr	  under	  vacuum,	  after	  which	  their	  composition	  was	  evaluated	  using	  
the	   XPS	   system	   (n=3	   production	   runs/XPS	   measurements	   per	   time	   point,	   0-­‐7	   days).	   Briefly,	   each	  
sample	  was	  etched	  for	  30	  seconds	  at	  500	  eV	  (medium)	  to	  remove	  any	  surface	  debris	  that	  may	  have	  
accumulated	  during	  sample	  preparation	  and	  was	  survey	  scanned	  over	  a	  400	  μm2	  spot	  size.	  Gelatin	  
ratiometric	  content	  was	  estimated	  based	  upon	  the	  measured	  presence	  of	  nitrogen	  in	  the	  sample	  and	  
the	   amount	   of	   solvent	   (HFIP)	  was	   estimated	  based	  upon	   the	  measured	  presence	  of	   fluorine,	   each	  
normalized	  to	  the	  element's	  percentage	  within	  the	  respective	  molecule.	  Under	  the	  assumption	  that	  
sample	  purity	  was	  maintained	  throughout	  the	  hydration,	  drying,	  and	  etching	  process,	  P4HB	  content	  
was	   estimated	   as	   the	   remaining	   scaffold	   percentage	   non-­‐gelatin	   or	   solvent.	   Additionally,	   8x8	  mm	  
pieces	  of	  60/40	  scaffolds	  incubated	  under	  the	  same	  conditions	  (n=3	  production	  runs)	  were	  biaxially	  
tested	   as	   described	   above	   to	   directly	   determine	   changes	   in	   stiffness	   due	   to	   the	   same	   hydrated	  
storage	  conditions.	  	  
	  
4.1.2.8	  CELLULAR	  INFILTRATION	  STUDIES	  
In	   vitro	  cellular	   infiltration	   studies	  using	  porcine	   valvular	   interstitial	   cells	   (VICs)	  were	   conducted	   to	  
determine	  the	  potential	  of	  JetValve	  scaffolds	  to	  support	  tissue	  growth	  as	  defined	  by	  cell	  penetration.	  
Porcine	  VICs	  were	  isolated	  and	  statically	  grown	  on	  60/40	  P4HB/Gelatin	  scaffolds	  for	  48hr	  as	  recently	  
described	   29,	   1	   week,	   and	   2	   weeks	   to	   determine	   the	   degree	   of	   cellular	   infiltration	   in	   time.	   60/40	  
leaflet	  and	  conduit	  scaffolds	  (n=6	  production	  runs	  per	  condition)	  were	  produced	  as	  above	  with	  the	  
addition	  of	  5	  μl/ml	  of	  0.2	  μm	  red	  fluorescent	  FluoSpheres	  (Invitrogen,	  F8810)	  added	  to	  the	  pre-­‐spun	  
solution	   for	   scaffold	   visualization	   during	   microscopy.	   VICs	   were	   isolated	   from	   freshly	   harvested	  
porcine	  hearts	  using	  collagenase	  (Blood	  Farms	  Inc.,	  Groton,	  MA;	  in	  compliance	  with	  FDA	  guidelines)	  
and	  seeded	  onto	  8x8	  mm	  sections	  of	   leaflet	  and	  conduit	   scaffolds	  at	  200k	  cells/cm2.	  At	  each	   time	  
point,	  scaffold/VIC	  tissues	  were	  fixed	  in	  4%	  paraformaldehyde	  (Electron	  Microscopy	  Sciences,	  15710)	  
and	  0.5%	  Triton	  100-­‐X(Sigma,	  T8787)	   in	  PBS	  for	  15	  min.	  Samples	  were	  then	  rinsed	  3x	   in	  PBS	  for	  10	  
min	  each	  and	  stored	  at	  4˚C.	  To	  prepare	  for	  imaging,	  samples	  were	  incubated	  for	  1	  hr	  with	  5	  μl/ml	  of	  
4',6-­‐Diamidino-­‐2-­‐Phenylindole,	   Dihydrochloride	   (DAPI,	   Invitrogen,	   D1306)	   in	   PBS	   to	   stain	   the	   VIC	  
nuclei.	   Samples	  were	   then	   rinsed	  with	   PBS	   3x	   for	   15	  min	   each	   to	   remove	   residual	   DAPI	   stain	   and	  
mounted	  between	  25	  mm	  diameter	  coverslips.	  200x200	  μm	  z-­‐stacks	  from	  the	  surface	  of	  the	  scaffold,	  
identified	  by	   coplanar-­‐focused	   FluorSpheres	   and	  DAPI	   stained	  nuclei,	   to	   the	   center	  of	   the	  deepest	  
penetrating	  nuclei	  within	  the	  scaffold	  were	  taken	  using	  a	  Zeiss	  LSM	  7	  LIVE	  confocal	  microscope.	  The	  
distance	   from	  the	  surface	  of	   the	   scaffold	   to	   the	  deepest	  penetrating	  nuclei,	   i.e.	   thickness	  of	   the	  z-­‐
stack,	  was	  used	   to	  measure	   cell	   infiltration	  depth	  and	  visualized	  using	  Zen	   lite	  2.3	   software	   (Zeiss,	  
SP1).	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4.1.2.9	  SCAFFOLD	  BATCH	  PROCESS	  CAPABILITY	  
The	   Batch	   Process	   Capability	   30	   (±3	   times	   the	   variance)	   was	   used	   to	   evaluate	   the	   manufacturing	  
accuracy	   and	   precision	   of	   aRJS	   produced	   60/40	   P4HB/Gelatin	   JetValves	   (n=16	   valves)	   for	  
implantation.	   For	   fiber	   diameter,	   the	   upper	   control	   limit	   (UCL)	   was	   set	   at	   1.2	   μm	   and	   the	   lower	  
control	  limit	  (LCL)	  was	  set	  at	  0.8	  μm	  based	  upon	  previously	  published	  tissue	  engineered	  scaffolds	  6,7,9.	  
As	   scaffold	   porosity	   is	   a	   function	   of	   fiber	   diameter	   using	   the	   aRJS	   manufacturing	   technique	   and	  
JetValve	   input	  materials,	   the	  UCL	  was	  set	  at	  50%	  and	   the	  LCL	  was	  set	  at	  30%	  given	   the	  achievable	  
range	   and	   reproducibility	   of	   the	   manufacturing	   process.	   All	   stiffness	   measurement	   control	   limits	  
were	   based	   upon	   the	   measured	   stiffnesses	   of	   freshly	   harvested	   pulmonary	   leaflets:	   low	   strain	  
stiffness	  in	  the	  parallel	  fiber	  direction	  control	  limits	  ranged	  from	  0-­‐10	  MPa,	  low	  strain	  stiffness	  in	  the	  
perpendicular	   fiber	   direction	   control	   limits	   ranged	   from	   0-­‐1	  MPa,	   and	   high	   strain	   stiffness	   in	   the	  
parallel	   and	   perpendicular	   fiber	   directions	   control	   limits	   ranged	   from	   0-­‐20	   MPa.	   For	   scaffold	  
thickness,	  sample	  strip	  thicknesses	  ULC	  was	  set	  at	  600	  μm	  and	  the	  LCL	  was	  set	  at	  250	  μm	  to	  ensure	  
scaffolds	  were	   thin	   enough	   to	   be	   crimped	   consistently	   but	   not	   too	   thin	   as	   to	   lose	   structure	   once	  
crimped	  and/or	  loaded	  in	  vivo.	  Protein	  content	  was	  taken	  as	  the	  relative	  amount	  of	  P4HB	  to	  gelatin	  
in	  the	  scaffold	  as	  measured	  by	  comparing	  the	  peak	  height	  of	  the	  carbonyl	  stretch	  peak	  at	  1720	  cm-­‐1	  
(indicative	  of	  P4HB)	  to	  the	  amide	  I	  peak	  at	  1645	  cm-­‐1	  (indicative	  of	  gelatin)	  using	  Fourier	  Transform	  
Infrared	  Spectroscopy	   (FTIR)	   25;	   the	  protein	  content	  UCL	  was	  set	  at	  2.5	  and	   the	  LCL	  set	  at	  0.5.	  The	  
scaffold	   fiber	   orientation	   was	   measured	   using	   the	   OOP	   based	   upon	   the	   OOP	   measured	   in	  
decellularized	  native	  tissue	  as	  described	  above;	  the	  OOP	  UCL	  was	  set	  at	  0.8	  and	  the	  LCL	  was	  set	  at	  
0.375.	  	  
	  
4.1.2.10	  IN	  VITRO	  FUNCTIONAL	  TESTING	  
Preliminary	  evaluation	  of	  JetValve	  functionality	  using	  an	  in	  vitro	  pulse	  duplicator	  system	  (Vivitro	  Labs,	  
Pulse	   Duplicator)	   was	   conducted	   to	   ensure	   the	   integrity	   of	   the	   scaffold	   leaflet	   design	   under	  
physiologic	   pressures	   and	   flows	   31.	   60/40	   JetValves	   were	   anchored	   into	   30	   mm	   diameter	   nitinol	  
stents	   with	   5-­‐0	   suture	   (Ethicon,	   black	   monofilament)	   and	   continuously	   loaded	   for	   48	   hr	   under	  
pulmonary	  pressure	   conditions	   (n=3	   JetValve	   flow	   trials).	  A	   FDA	  waveform	  at	  70	  beats	  per	  minute	  
was	   applied	   to	   the	   pulse	   duplicator’s	   150	   ml	   silicon	   ventricle;	   distal	   compliance	   chambers	   were	  
adjusted	   to	   achieve	   pulmonary-­‐like	   pressures	   across	   the	   JetValve	   during	   diastole	   with	   a	   cardiac	  
output	  of	  2.2	   L/min	   (valve	  diameter,	  beat	   rate,	  and	  cardiac	  output	  within	   the	   ranges	  of	  previously	  
reported	  ovine	  measurements	  7,32).	  Ventricular	   (proximal	   to	  the	  JetValve)	  and	  arterial	   (distal	   to	  the	  
JetValve)	   pressures	   and	   intravalvular	   volumetric	   flow	   rates	  were	  measured	   at	   48	   hr	   at	   a	   sampling	  
rate	  of	  256	  samples	  per	  cycle.	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4.1.2.11	  IN	  VIVO	  IMPLANTATION	  DEPLOYMENT	  AND	  FUNCTIONAL	  TESTING	  
60/40	   JetValves	  were	   implanted	   into	   the	  orthotopic	   pulmonary	   valve	  position	  of	   ovine	  models	   for	  
deployment	  and	  acute	  functional	  testing	  via	  transapical	  access	  (Fig.	  3a),	  a	  delivery	  technique	  recently	  
shown	  to	  be	  a	  viable	  implantation	  method	  for	  tissue	  engineered	  heart	  valves	  7.	  The	  ethics	  committee	  
(ZH151_2013,	  Zürich,	  Switzerland)	  approved	  the	  study	  in	  compliance	  with	  the	  Guide	  for	  the	  Care	  and	  
Use	  of	   Laboratory	  Animals,	  published	  by	   the	  National	   Institutes	  of	  Health	   (NIH	  publication	  No.	  85-­‐
23).	  After	  a	   right	   sided	   thoracotomy,	   the	  pericardium	  was	  opened	  and	   the	   right	  ventricle	   (RV)	  was	  
exposed,	  before	  it	  was	  punctured	  using	  needle	  through	  purse-­‐string	  sutures.	  Next,	  a	  guide	  wire	  was	  
introduced	   into	  the	  RV	  and	  placed	   into	  the	  main	  pulmonary	  artery	  under	   fluoroscopic	  control.	  The	  
scaffold	  loaded	  implantation	  catheter	  was	  introduced	  into	  the	  RV	  over	  the	  wire	  and	  placed	  over	  the	  
native	   pulmonary	   valve.	   Optimal	   positioning	   was	   controlled	   by	   contrast	   angiography,	   before	   the	  
scaffold	  was	  delivered	  under	   fluoroscopic	  control.	  After	   full	  delivery	  of	   the	  scaffold	  a	   final	  contrast	  
angiography	  was	  done	  to	  ensure	  optimal	  positioning,	  instant	  functionality	  and	  complete	  exclusion	  of	  
the	  native	  pulmonary	  valve	  (Supplemental	  videos	  2	  and	  3).	  The	  delivery	  device	  was	  removed,	  the	  RV	  
was	   closed	   with	   the	   purse-­‐string,	   and	   the	   thoracotomy	   was	   closed.	   Finally	   trans-­‐esophageal	  





Figure	   3:	   JetValve	   catheter-­‐based	   deployment	   and	   crimping.	   (a)	   Transcatheter	  delivery	   involved	   fixing	   the	   scaffold	   in	   a	   self-­‐expanding	  
nitinol	   stent,	   transapical	   placement	   via	   entry	   through	   the	   right	   ventricle	   (RV),	   positioning	   via	   a	   guide	  wire	   system,	   deployment	   of	   the	  
stented	  scaffold	  over	  the	  native	  leaflets,	  and	  retraction	  of	  the	  catheter	  through	  the	  ventricle.	  Radial	  pressure	  of	  the	  released	  stent	  held	  the	  
valve	  scaffold	  in	  place	  between	  the	  RV	  and	  pulmonary	  artery	  (PA),	  over	  the	  native	  valve	  leaflets.	  (b)	  Crimping	  of	  anchored	  JetValves	  from	  
the	  30	  mm	  fully	  extended	  conformation	  to	  the	  fully	  crimped	  9	  mm	  conformation	  to	  accommodate	  implantation.	  
	  
For	  the	  acute	  situation	  (n=4),	  functionality	  measurements	  were	  taken	  after	  15	  hr	   in	  vivo	  and	  valves	  
were	  subsequently	  explanted	  for	  visual	  inspection	  of	  structural	  integrity	  and	  H&E	  staining.	  The	  15	  hr	  
evaluation	   time	   point	   was	   used	   to	   test	   the	   stability	   of	   valve	   functionality	   after	   the	   stresses	   of	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minimally	   invasive	   delivery	   on	   the	   JetValve/stent	   construct.	   For	   the	   chronic	   situation	   (n=3),	  
functionality	   measurements	   were	   taken	   after	   1	   month	   in	   vivo.	   The	   scope	   of	   this	   study	   was	   to	  
determine	   if	   the	   JetValve	  manufacturing	   technique	   and	  biohybrid	  materials	   introduced	  here	   could	  
produce	  a	  scaffold	  able	  to	  sustain	  the	  rigors	  of	  a	  minimally	  invasive	  implantation	  method	  and	  enable	  
host	  cellular	  infiltration.	  
For	  minimally	   invasive	   deployment,	   JetValves	  were	   crimped	   from	   30	  mm	   in	   diameter	   to	   9	  mm	   in	  
diameter	   and	   loaded	   into	   the	   implantation	   catheter.	   Stress	   minimization	   during	   crimping	   was	   a	  
critical	   design	   concern	   because	   of	   the	   non-­‐woven	   micro-­‐structure	   of	   the	   scaffold	   and	   resulting	  
potential	  susceptibility	  to	  suture	  and	  shear-­‐induced	  tearing.	  To	  test	  capacity	  for	  crimping,	  JetValves	  
were	  anchored	  into	  nitinol	  stents	  via	  suture	  and	  pneumatically	  crimped	  from	  30	  mm	  (fully	  extended,	  
adult	  ovine	   size)	   to	  9	  mm	   (fully	   crimped)	  at	  45	  psi.	   Leaflet	   shape	  and	   thickness	  were	  optimized	   to	  
ensure	  a	  “swirling”	  fold	  during	  the	  crimping	  process	  that	  minimized	  the	  stresses	  on	  the	  leaflets	  and	  
leaflet-­‐conduit	  sutured	  anchor	  points	  (Fig.	  3b).	  
	  
4.1.2.12	  STATISTICAL	  ANALYSES	  
All	  statistical	  analyses	  of	  data	  were	  done	  using	  SigmaPlot	  software	  (v12.0,	  Systat	  Software	  Inc.);	  the	  
sample	  size	  “n”	  used	  for	  statistical	  analyses	  are	  reported	  in	  the	  respective	  methods	  sections	  2.3-­‐2.10	  
above.	   Data	   analyses	   of	   variance	   were	   done	   using	   the	   One-­‐Way	   ANOVA	   test	   (for	   fiber	   diameter,	  
porosity,	   stiffness,	   and	   cell	   infiltration	   depth)	   or	   the	   Two-­‐Way	   ANOVA	   test	   (for	   scaffold	   fiber	  
anisotropy	  ‘OOP’).	  Pairwise	  multiple	  comparison	  procedures	  
Chapter	  4.1	  	   	  
145	  
4.1.3	  RESULTS	  
4.1.3.1	  JETVALVE	  BIOHYBRID	  STRUCTURE	  AND	  MECHANICS	  
Fiber	  diameter	  and	  porosity	  33,34	  are	  structural	  scaffold	  parameters	  that	  contribute	  to	  the	  degree	  of	  
endogenous	   cellular	   attachment	   and	   infiltration	   during	   the	   remodeling	   process.	   To	   control	   these	  
parameters,	   scaffolds	   were	   composed	   of	   biohybrid	   blends	   of	   poly-­‐4-­‐hydroxybutyrate	   (P4HB)	   and	  
gelatin,	   i.e.	   denatured	   collagen,	   which	   is	   the	   primary	   structural	   component	   of	   valve	   leaflets.	   By	  
varying	   the	   biohybrid	   concentration	  within	   the	   scaffold,	   fiber	   diameter	   25	   and	   alignment	   could	   be	  
controlled	  to	  approximate	  that	  of	  the	  native	  valve	  ECM.	  We	  mixed	  high	  molecular	  weight	  P4HB	  (MW	  
~450	   kDa)	   with	   gelatin	   (MW	   ~50-­‐100	   kDa)	   to	   control	   solution	   viscosity	   and	   consequently	   fiber	  
diameter	   21,35.	   By	   decreasing	   P4HB	   content,	   fiber	   diameter	   could	   be	   reduced	   (range:	   100/0	   1.28	   ±	  
0.39	  μm	  to	  20/80	  680	  ±	  0.19	  nm)	  to	  achieve	  a	  higher	  porosity	  (range:	  100/0	  41.59	  ±	  1.58%	  to	  20/80	  
55.51	  ±	  2.38%)	  within	  the	  construct	  (Fig.	  1c).	  	  
As	   in	   the	   native	   valve	   structural	   fibrosa,	   fibers	   were	   primarily	   oriented	   in	   the	   circumferential	  
direction	  of	  the	  scaffold	  leaflets	  to	  withstand	  transvalvular	  loading	  during	  diastole	  while	  the	  high	  Mw	  
of	  the	  P4HB	  and	  non-­‐woven	  mesh	  structure	  would	  allow	  for	  elastic,	  radial	  stretching	  during	  systole.	  
The	   continuous	   deposition	   of	   fibers	   onto	  mandrels	   angled	   0˚,	   22.5˚,	   and	   45°	   relative	   to	   the	   fiber	  
extrusion	   plane	   produced	   circumferential	   alignment	  within	   JetValve	   ECM	   [29]	   (native	  OOP:	   0.49	   ±	  
0.06,	   0˚	   JetValve	   Leaflet	   OOP:	   0.51	   ±	   0.03,	   22.5˚	   JetValve	   Leaflet	   OOP:	   0.57	   ±	   0.03,	   45˚	   JetValve	  
Leaflet	   OOP:	   0.53	   ±	   0.04,	   Fig.	   4a).	   However,	   fiber	   anisotropy	   within	   the	   conduit	   portions	   of	   the	  
JetValve	   constructs	   was	   significantly	   reduced	   although	   consistent	   for	   all	   angles	   of	   collection	   (0˚	  
JetValve	  Conduit	  OOP:	   0.25	   ±	   0.04,	   22.5˚	   JetValve	  Conduit	  OOP:	   0.23	   ±	   0.04,	   45˚	   JetValve	  Conduit	  
OOP:	  0.25	  ±	  0.04,	  Fig.	  4a).	  Because	  fiber	  anisotropy	  varied	  spatially	  within	  JetValves,	  we	  asked	  how	  
collection	  angle	  influenced	  scaffold	  packing	  density	  or	  porosity	  in	  the	  leaflet	  versus	  conduit	  portions	  
of	   the	   constructs.	   For	   JetValve	   leaflets,	   increasing	   collection	   angle	   decreased	   scaffold	   porosity,	   a	  
trend	   that	  was	  observed	   for	   JetValve	  conduits	  as	  well,	  although	  not	   statistical	   (Fig.	  4b).	  For	  0˚	  and	  
22.5˚	  collection	  angles,	  leaflet	  porosities	  were	  increased	  by	  ~10%	  compared	  to	  conduit	  porosities	  of	  
leaflets,	   recapitulating	   the	   load	   bearing,	   collagen-­‐rich	   fibrosa	   layer	   of	   the	   native	   valve	   the	   same	  
angle;	  however,	   leaflet	  and	  conduit	  porosities	  reached	  similar	  values	  when	  scaffolds	  were	  collected	  
at	  45˚.	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Figure	   4:	   JetValve	   leaflet/conduit	   anisotropy	   and	   porosity.	   (a)	   JetValve	   leaflet	   anisotropy	   was	   comparable	   to	   native	   anisotropy,	   as	  
indicated	  by	  OOP,	  and	  was	  significantly	  more	  anisotropic	  than	  the	  conduit	  for	  each	  collection	  angle.	  Colorized	  SEM	  images,	  right,	  indicate	  
local	  fiber	  direction,	  (R)	  indicates	  radial	  direction	  and	  (C)	  indicates	  circumferential	  direction	  (N	  =	  3	  production	  runs	  per	  condition	  and	  N	  =	  7	  
native	  leaflets,	  *p	  <	  0.5	  comparing	  leaflet	  vs.	  conduit).	  (b)	  Representative	  SEM	  images	  of	  JetValve	  leaflet	  and	  conduit	  scaffold	  collected	  at	  
45°	   (scale	  bar	  500	  μm).	  Porosity	  of	   leaflets	  and	  conduits	  as	  a	   function	  of	  collection	  angles	   (N	  =	  3	  production	  runs	  per	  condition,	  *p	  <	  0.5	  
comparing	  angles	  and	  #p	  <	  0.5	  comparing	  leaflet	  vs	  conduit	  for	  a	  given	  angle).	  Data	  presented	  as	  mean	  ±	  s.e.m.	  
	  
Recapitulating	   the	   bulk	   anisotropy	   of	   the	   native	   leaflet	   fibrosa	   and	   varying	   fiber	   biohybrid	  
composition	  allowed	  for	  control	  of	  the	  bulk	  biaxial	  stiffness	  of	  the	  JetValve	  leaflets.	  The	  mechanical	  
properties	  of	  the	  valvular	  leaflets	  determines	  the	  stress	  and	  strain	  fields	  within	  the	  tissue	  during	  the	  
cardiac	  cycle,	  ultimately	  enabling	   their	   functionality	   34,36.	  Accordingly,	  elastic,	   fibrous	  scaffolds	  such	  
as	   JetValves	   should	   be	   designed	   to	   mimic	   these	   mechanical	   properties	   to	   ensure	   optimal	  
functionality	   in	   flow	   37.	   We	   therefore	   designed	   the	   stretch-­‐dependent,	   biaxial	   stiffness	   of	   our	  
scaffolds	  to	  recapitulate	  that	  of	  the	  native	  leaflet	  ECM.	  The	  P4HB/Gelatin	  ratio	  of	  fibers	  governed	  the	  
biaxial	   stiffness	  of	   the	  bulk	  scaffold	  at	  both	   low	  (0-­‐10%)	  and	  high	   (10-­‐20%)	  strains	   (Fig.	  5a).	  At	   low	  
strain,	  in	  the	  primary	  (circumferential)	  axis	  of	  fiber	  alignment,	  scaffold	  stiffness	  ranged	  from	  505.52	  ±	  
61.72	  kPa	  (40/60)	  to	  5.12	  ±	  0.82	  MPa	  (100/0)	  vs.	  643.23	  ±	  215.76	  kPa	  (native);	  in	  the	  perpendicular	  
(radial)	  axis	  of	   fiber	  alignment,	   scaffold	  stiffness	   ranged	   from	  211.91	  ±	  31.32	  kPa	   (40/60)	   to	  4.33	  ±	  
0.16	  MPa	  (100/0)	  vs.	  501.41	  ±	  74.72	  kPa	  (native).	  At	  high	  strain,	  in	  the	  primary	  (circumferential)	  axis	  
of	   fiber	   alignment,	   scaffold	   stiffness	   ranged	   from	   1.16	   ±	   0.11	   MPa	   (40/60)	   to	   34.47	   ±	   1.54	   MPa	  
(100/0)	   vs.	   3.33	   ±	   0.45	  MPa	   (native);	   in	   the	   perpendicular	   (radial)	   axis	   of	   fiber	   alignment	   scaffold	  
stiffness	  ranged	  from	  338.38	  ±	  44.31	  kPa	  (40/60)	  to	  13.89	  ±	  0.75	  MPa	  (100/0)	  vs.	  1.49	  ±	  0.40	  MPa	  
(native).	   Only	   when	   the	   P4HB/Gelatin	   ratio	   of	   fibers	   was	   reduced	   to	   60/40	   or	   40/60	   did	   scaffold	  
stiffness	   approximate	   that	   of	   the	   native	   leaflet	   in	   both	   strain	   regimes	   in	   the	   primary	   and	  
perpendicular	  axes	  of	  fiber	  alignment.	  JetValves	  were	  not	  crosslinked	  resulting	  in	  scaffold	  fibers	  that	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began	  to	  stick	   to	  mandrels	  at	  ≥60%	  gelatin	  content;	  we	  therefore	  used	  60/40	  P4HB/Gelatin	  blends	  
for	   further	   functional	   testing.	   Because	   collection	   angle	   spatially	   affected	   scaffold	   anisotropy	   and	  
porosity,	  we	  asked	  if	  stiffness	  values	  were	  also	  influenced	  by	  collection	  angle.	  Biaxial	  stiffness	  values	  
generally	   decreased	   as	   a	   function	   of	   increasing	   collection	   angle	   (Fig.	   5b	   and	   Supplemental	   Fig.	   1).	  
Likely	  due	  to	   increased	  packing	  during	   fiber	  collection,	  conduit	  stiffnesses	  were	   found	  to	  be	  higher	  






















Figure	   5:	   JetValve	   biaxial	   stiffness	   as	   a	   function	   of	  
biohybrid	   composition,	   collection	   angle,	   and	  
location.	  (a)	  Increasing	  protein	  percentage	  within	  the	  
biohybrid	   ratio	   of	   spun	   scaffolds	   decreased	   the	   low	  
strain	  (0–10%)	  and	  high	  strain	  (10–20%)	  biaxial	  global	  
stiffness	   of	   scaffolds	   (N	  =	  6	   production	   runs	   per	  
condition,	   N	  =	  5	   native	   leaflets;	   *p	  <	  0.5,	   data	  
presented	   as	   mean	  ±	  s.e.m.	   (b)	   Conduit	   samples	  
comprised	  of	  60/40	  P4HB/Gelatin	  blends	  were	  stiffer	  
than	   corresponding	   collection	   angle	   leaflet	   samples	  
for	   both	   low	  and	  high	   strains	   (N	  =	  6	   production	   runs	  
per	   conditions;	   *p	  <	  0.5	   between	   leaflet	   and	   conduit	  
stiffness	  for	  the	  same	  collection	  angle,	  data	  presented	  
as	  mean	  ±	  s.e.m.).	  
	  
	  
4.1.3.2	  JETVALVE	  SURFACE	  BIOCHEMISTRY	  AND	  HYDRATED	  SHELF	  LIFE	  
Because	   JetValve	   biohybrid	   scaffolds	   were	   physically	   blended,	   the	   compositional	   effects	   of	   not	  
crosslinking	   and	   hydrating	   of	   the	   scaffold	   were	   further	   analyzed	   due	   to	   the	   time	   required	   for	  
minimally	   invasive	   surgical	   delivery	   preparation.	   To	   prepare	   for	   stent	   anchoring	   and	   crimping,	  
JetValves	  were	  hydrated	   resulting	   in	  more	  pliable	   fibers.	  Because	   the	   scaffold	  protein	  content	  was	  
not	  crosslinked,	  once	  hydrated	  the	  shelf-­‐life	  of	  the	  scaffold	  would	  be	  limited	  due	  to	  passive	  gelatin	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diffusion	   from	  the	  surface	  of	   the	   fibers.	  Using	  FTIR,	   initial	   relative	  protein	  content	  within	   JetValves	  
was	  measured	  by	  comparing	  the	  height	  of	  the	  carbonyl	  stretch	  peak	  (1720	  cm-­‐1,	  indicative	  of	  P4HB)	  
with	  those	  of	  the	  amide	  I	  and	  amide	  II	  peaks	  (1645	  and	  1535	  cm-­‐1	  respectively,	  indicative	  of	  gelatin,	  
Fig.	  6a)	  25.	  The	  60/40	  P4HB/Gelatin	  scaffold	  blend	  was	  chosen	  as	  it	  most	  closely	  mimicked	  the	  leaflet	  
structural	   and	   mechanical	   design	   criteria	   described	   above	   while	   maintaining	   constant	   polymer	  
crystallinity	  and	  therefore	  a	  predictable	  degradation	  profile	  over	  a	  range	  of	  manufacturing	  spinning	  






Figure	   6:	   Shelf	   life	   composition	   and	   stiffness	   of	  
JetValves.	   (a)	   Initial	   protein	   content	   and	   P4HB	  
crystallinity	   was	   measured	   by	   comparing	   carbonyl	  
stretch	   and	   amide	   FTIR	   absorbency	   peak	   heights.	   (b)	  
Neither	   protein	   content	   nor	   polymer	   crystallinity	   were	  
affected	  by	  fiber	  extrusion	  spin	  speed;	  Biohybrid	  blends	  
of	   60/40	   P4HB/Gelatin	   exhibited	   stable	   relative	  
crystallinity	   for	   all	   spin	   speeds	   compared	   to	  
compositions	   with	   higher	   synthetic	   polymer	   content	  
(N	  =	  3	   production	   runs	   per	   condition).	   (c)	   Ratiometric	  
(XPS)	   hydrated	   scaffold	   content	   over	   the	   course	   of	   1	  
week.	  Inset:	  trace	  amounts	  of	  bound	  HFIP	  solvent	  were	  
detected	   upon	   hydration	   (N	  =	  3	   production	   runs).	   (d)	  
The	   biaxial	   mechanical	   properties	   of	   1	   week	   hydrated	  
scaffolds	   compared	   to	   those	   of	   fresh-­‐spun	   scaffolds	  
(N	  =	  3	   production	   runs	   per	   condition;	   blue	   represents	  
circumferential	   (C),	   red	   represents	   radial	   (R)	   fiber	  
alignment;	  data	  presented	  as	  mean	  ±	  s.e.m.).	  
	  
The	  as-­‐spun,	  dry	  composition	  of	  the	  60/40	  JetValve	  blend	  was	  measured	  to	  be	  58.43	  ±	  2.30%	  P4HB,	  
39.85	  ±	  1.86%	  gelatin,	  and	  0.44	  ±	  0.4%	  HFIP.	  Once	  hydrated,	  the	  surface	  gelatin	  composition	  of	  the	  
scaffold	   increased	  to	  56.42	  ±	  0.81%	  but	  returned	  to	  43.48	  ±	  0.89%	  after	  7	  days	   in	  pure	  water	  (XPS,	  
Fig.	  6c).	  As	  fibers	  within	  the	  scaffold	  were	  hydrated,	  uncrosslinked	  and	  therefore	  chemically	  unbound	  
gelatin	   first	   diffused	   to	   the	   fiber	   surface,	   then	   into	   the	   surrounding	   water.	   Additionally,	   the	   HFIP	  
content	   decreased	  by	  nearly	   half	   (0.26	   ±	   0.07%)	   after	   1	   day	   in	  water	   suggesting	   that	   the	   residual,	  
bound	  solvent	  was	  only	  present	  in	  trace	  amounts	  once	  hydrated.	  The	  shelf	  life	  of	  the	  hydrated	  60/40	  
JetValves	  was	  therefore	  approximatively	  1	  week,	   the	  timeframe	  within	  which	  JetValve	  composition	  
stayed	  within	   60/40	   to	   40/60	   P4HB/Gelatin	   composition	  with	   stiffness	   similar	   to	   as-­‐spun	   scaffolds	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4.1.3.3	  IN	  VITRO	  CELLULAR	  INFILTRATION	  
JetValve	   composition	   was	   designed	   to	   be	   an	   approximation	   of	   previously	   published,	   tissue	  
engineered	   valves	   that	   exhibited	   cellular	   infiltration	   and	   extensive	   regeneration	   via	   endogenous	  
repair	   mechanisms	   6,7,9,33,38.	   Although	   composed	   of	   similar	   materials	   to	   those	   tissue	   engineered	  
products	  previously	  investigated,	  we	  asked	  if	  the	  rapid	  and	  non-­‐biological	  manufacturing	  of	  JetValve	  
scaffolds	   allowed	   for	   cellular	   infiltration	   and	   if	   this	   integration	   varied	   spatially	   throughout	   the	  
construct.	  Primary	  harvest	  porcine	  VICs	   infiltrated	   leaflet	  portions	  of	  60/40	   JetValve	  scaffold	   faster	  
than	  conduit	  portions	  of	  the	  scaffold	  by	  one	  week	  in	  culture	  (Fig	  7a;	  infiltration	  depth	  Leaflet:	  14.52	  ±	  
1.16	   μm	   compared	   to	   Conduit:	   11.09	   ±	   0.81	   μm).	   However,	   by	   two	   weeks	   in	   culture,	   infiltration	  
depth	  for	   leaflet	  and	  conduit	  sections	  were	  similar	  (Leaflet:	  27.17	  ±	  3.56	  μm	  compared	  to	  Conduit:	  






Figure	  7:	  In	  vitro	  valvular	  interstitial	  cell	  (VIC)	  infiltration.	  (a)	  VICs	  infiltrated	  the	  JetValve	  leaflet	  portion	  of	  scaffolds	  in	  greater	  abundance	  
than	   conduit	   portions	   by	   1	   week;	   by	   2	   weeks,	   infiltration	   depth	   evened	   at	   ∼25–26	  μm	   from	   the	   scaffold	   surface	   (N	  =	  6	   production	  
runs/tissues	  per	  condition,	  *p	  <	  0.5	  between	  like	  scaffold	  areas	  in	  time,	  #p	  <	  0.5	  between	  leaflet	  and	  conduit	  at	  the	  same	  time	  point;	  data	  
presented	  as	  mean	  ±	  s.e.m)	  (b)	  Representative	  three	  dimensional	  reconstructions	  of	  VIC	  nuclei	  within	  the	  JetValve	  scaffold	  (red	  indicates	  
nuclei	  of	  cells	  on	  the	  scaffold	  surface,	  while	  blue	  indicates	  the	  nuclei	  of	  cells	  that	  have	  penetrated	  into	  the	  scaffold,	  all	  images	  in	  isometric	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4.1.3.4	  aRJS	  MANUFACTURED	  JETVALVE	  BATCH	  PROCESS	  CAPABILITY	  
In	   order	   to	   evaluate	   scaffold	   quality	   and	   fabrication	   reproducibility,	   essential	   for	   eventual	   clinical	  
translation	   15,	  we	   implemented	  standard	   industrial	  manufacturing	  process	  controls	  based	  upon	  the	  
JetValve	   design	   criteria	   described	   above.	   We	   accomplished	   this	   by	   analyzing	   the	   structural,	  
mechanical,	   and	   biochemical	   batch	   process	   capability	   (CP)	   of	   each	   scaffold	   as	   a	   measure	   of	   both	  
manufacturing	   accuracy	   and	   precision	   30.	   Batch	   CP	   specifications	   were	   held	   to	   standard	   precision	  
values	  of	  ±3	  times	  the	  batch	  parameter	  variance,	  ensuring	  that	  over	  99%	  of	  scaffolds	  within	  a	  passing	  
batch	  were	  within	   specification.	   Despite	   laboratory-­‐scale	   batch	   sizes	   (≤4),	  manufacturing	   achieved	  
higher	   than	   70%	   batch	   acceptance	   rate,	   which	   was	   increased	   to	   100%	  with	   the	   addition	   of	   small	  
batch	  correction	  factors	  39.	  	  
	  
4.1.3.5	  IN	  VITRO	  AND	  IN	  VIVO	  JETVALVE	  FUNCTIONAL	  TESTING	  
JetValve	   functionality	   was	   evaluated	   both	   in	   vitro	   and	   in	   vivo.	   Preliminary	   evaluation	   of	   scaffold	  
function	   using	   an	   in	   vitro	   pulse	   duplicator	   system	   was	   conducted	   to	   ensure	   the	   integrity	   of	   the	  
scaffold	  leaflets	  under	  physiologic	  pressures	  and	  flows.	  JetValves	  were	  continuously	  loaded	  for	  48	  hr	  
under	   pulmonary-­‐like	   conditions,	   maintaining	   scaffold	   structural	   integrity	   and	   exhibiting	   a	  
regurgitant	   fraction	   of	   30.24	   ±	   2.07%	   during	   diastolic	   closing	   (Fig.	   8a).	   In	   vivo	   studies	   were	   then	  
conducted	   to	   determine	   if	   1)	   JetValve	   scaffolds	   could	   be	   delivered	   using	   a	   minimally	   invasive	  
method,	   2)	   if	   the	   as-­‐spun,	   acellular	   scaffolds	  would	   be	   immediately	   functional	   upon	   implantation,	  
and	   3)	   if	   the	   scaffold	   design	  was	   biocompatible	   (i.e.	   non-­‐thrombogenic).	   JetValves	  were	   delivered	  
transapically	   into	   the	   native	   pulmonary	   valve	   position	   in	   an	   ovine	  model	   for	   15	   hr	   as	   a	   proof-­‐of-­‐
concept.	   Implanted	   scaffolds	   revealed	   acute	   functionality	   as	   sufficient	   leaflet	   motion	   and	   good	  
coaptation	   area	   were	   observed	   with	   non/minor	   regurgitation	   fraction	   on	   echocardiography.	  
Transvalvular	  pressure	  gradients	  across	  the	  valve,	  <2mmHg,	  were	  also	  comparable	  to	  native	  leaflets	  
during	  systole	  (Fig.	  8b,	  Echo:	  Supplemental	  videos	  4	  and	  5;	  Doppler:	  Supplemental	  videos	  6	  and	  7).	  
Gross	   examination	   and	   histological	   analyses	   done	   at	   the	   time	  of	   explantation	   revealed	   competent	  
valves	  with	  pliable	  and	  intact	  leaflets.	  No/minor	  thrombus	  formation	  and	  initial,	  what	  appears	  to	  be	  
neutrophil	   infiltration	  on	  the	  scaffold	  surface	  were	  observed	  (Supplemental	  Fig.	  3)	   indicative	  of	  the	  
acute	  safety	  and	  compatibility	  of	  JetValve	  scaffolds.	  	  




Figure	  8:	  In	  vitro	  and	  in	  vivo	  functionality.	  (a)	  Top:	  digital	  photographs	  from	  arterial	  view	  of	  mounted	  JetValves	  during	  systole	  and	  diastole	  
at	  48	  h	  (dotted	  lines	  highlight	  the	  JetValve	  leaflet	  and	  conduit	  edges).	  Bottom:	  flow	  through	  the	  JetValve	  reached	  ∼175	  ml/s	  during	  peak	  
systole	  with	  complete	  valve	  closure	  during	  diastole	  (∼30%	  regurgitant	  fraction,	  ∼10	  mmHg	  transvalvular	  pressure).	   (b)	  Top:	  distal	  three-­‐
dimensional	   echocardiography	   revealed	   complete	   leaflet	   opening	   and	   closing	   during	   systole	   and	   diastole	   respectively	   at	   15	  h.	   Bottom:	  	  
Doppler	   imaging	   showed	   unrestricted	   blood	   flow	   through	   the	   JetValve	   leaflets	   during	   systole	   and	   complete	   closure	   with	   minor	  











Supplemental	   Figure	   3:	   Histological	  
examination	   of	   explanted	   JetValves	   at	   15	   hr	  
post-­‐implantation.	   JetValves	   explanted	   15	   hr	  
after	   implantation	   revealed	   no/minor	  
thrombus	   formation	   on	   the	   intact	   leaflets.	  
Hematoxylin	   and	   eosin	   (H&E)	   staining	   of	  
explanted	   JetValves	   showed	   limited	   scaffold	  
infiltration	   of	   circulating	   immune	   cells	   (scale	  
bars:	   10	   mm	   pulmonary	   view,	   20	   mm	   cross	  
sectional	  view,	  2	  mm	  cross	  sectional	  histology,	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Long-­‐term	  in	  vivo	  implantation	  of	  1	  month	  revealed	  several	  complications	  as	  to	  the	  suture	  retention	  
(n=1)	   and	   migration	   of	   the	   stent	   (n=2).	   Migration	   was	   due	   to	   either	   size-­‐mismatch	   of	   the	   ovine	  
pulmonary	   annulus	   with	   the	   implanted	   stent	   size	   or	   inaccurate	   placing	   during	   the	   implantation	  
procedure	  due	  to	  the	  implantation	  device.	  This	  unintentional	  migration	  enabled	  functionality	  of	  the	  
native	  ovine	  valves,	  consequently	   leading	  to	   less/no	   loading	  of	  the	   implanted	  heart	  valve	  scaffolds.	  
Leaflet	   motion	   was	   limited	   to	   single	   loaded	   leaflets,	   resulting	   in	   no	   coaptation	   and	   overall	  
functionality	  of	  implanted	  scaffolds	  (Fig.	  unpublished	  1).	  Hemodynamic	  loaded	  leaflets	  were	  thin	  and	  
pliable,	  whereas	  no	  loading	  resulted	  in	  thickening	  of	  the	  scaffold	  by	  tissue	  accumulation	  and	  leaflet	  
attachment	   to	   the	   vessel	  wall.	   Therefore,	   only	   hemodynamic	   loaded	   leaflets	   of	   two	   implantations	  
were	   evaluated	  on	   cellular	   infiltration	   and	   endogenous	   tissue	   formation	  by	   cross	   examination	   and	  




Unpublished	   figure	   1:	   Evaluation	   of	   explanted	   Jetvalves	   after	   1	   month	   post-­‐implantation.	   JetValves	   revealed	   no	   functionality	   and	  
coaptation	  of	   the	  heart	  valve	   leaflets	   in	  vivo	  given	   functional	  native	   leaflets	  on	  top.	  Hemodynamic	   loaded	   leaflets	  were	  thin	  and	  pliable	  
with	   regular	   motion	   as	   detected	   by	   echocardiography.	   Endogenous	   tissue	   formation	   (green)	   was	   found	   on	   the	   surface	   of	   implanted	  
material	   (violet)	  with	   limited	   integration	  as	  demonstrated	  by	  Masson	  Goldner	  staining.	   (scale	  bars:	  1cm	  in	  cross	  examination	  pictures	  of	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In	  comparison	  to	  native	  ovine	  heart	  valve	  leaflets,	  recruitment	  of	  host	  cells	  was	  limited	  to	  the	  surface	  
layer	  of	  the	  hemodynamic	  loaded	  leaflet	  scaffolds	  (Fig.	  unpublished	  2).	  Low	  degree	  of	  repopulation	  
was	  also	  found	  in	  the	  hinge	  and	  wall	  regions	  of	  all	  implanted	  scaffolds,	  which	  usually	  is	  repopulated	  
faster	   and	   independently	   from	   hemodynamic	   loading.	   Overall	   implanted	   leaflet	   scaffolds	   did	   not	  
possess	   an	   endothelial	   cell	   layer	   (CD31	   positive	   cells),	   which	   is	   essential	   for	   an	   anti-­‐thrombotic	  
behavior	   of	   the	   scaffold.	   No	   elastic	   fibers	   (Von	   Giesson-­‐Elastin,	   VG-­‐EL),	   intermediate	   filaments	  
(Vimentin,	  Vim)	  and	  collagen	  depositions	  (Masson	  Goldner,	  MG)	  were	  found	  in	  the	  central	  region	  of	  
the	   implanted	   scaffolds.	   Calcifications	   (Von	   Kossa,	   VK)	   and	   enhanced	   attraction	   of	   alpha-­‐smooth	  
muscle	  actin	  positive	  cells	  (αSMA)	  were	  not	  detected.	  A	  portion	  of	  endogenous	  tissue	  was	  found	  on	  
the	  surface	  of	  hemodynamic	   loaded	  scaffolds,	  however	   its	   integration	  with	   the	   implanted	  material	  
was	  low	  and	  resulted	  in	  easy	  delamination	  (Fig.	  unpublished	  1).	  This	  accumulation	  of	  tissue	  resulted	  
in	  an	  overall	   valve	   thickness	  extending	   the	  original	  material	   implanted.	  Histological	  analyses	  at	   the	  
time	  of	  explantation	  further	  revealed	  low	  degradation	  of	  electrospun	  scaffold	   in	  comparison	  to	  the	  
originally	  implanted	  60/40	  P4HB/Gelatin	  scaffold.	  
	  
	  
Unpublished	  figure	  2:	  Histological	  examination	  of	  explanted	  JetValves	  at	  1	  month	  post-­‐implantation.	  Explanted	  JetValve	  leaflets	  revealed	  
limited	  recruitment	  of	  host	  cells	  with	  low	  endogenous	  tissue	  formation	  compared	  to	  native	  ovine	  leaflets.	  Infiltrating	  cells	  were	  only	  found	  
on	  the	  surface	  layer	  of	  implanted	  scaffold	  (CD31	  =	  platelet	  endothelial	  cell	  adhesion	  molecule;	  VG-­‐EL	  =	  Von-­‐Giesson	  Elastin;	  MG	  =	  Masson	  
Goldner;	  Vim	  =	  Vimentin;	  VK	  =	  Von	  Kossa;	  aSMA	  =	  alpha-­‐smooth	  muscle	  actin).	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4.1.4	  DISCUSSION	  
In	   this	   study,	  we	  present	   a	   novel	  method	  of	  manufacturing	   valve	   replacements	   containing	   leaflets	  
with	   fibrosal-­‐like	   fiber	   alignment	   and	   global	   semilunar	   valve	   structure	   in	   minutes.	   This	   level	   of	  
throughput	   is	   an	   improvement	   in	   time	   to	   manufacture	   relative	   to	   previously	   reported	   mandrel-­‐
based,	   fibrous	   valve	   fabrication	   techniques	   40,41.	   Slow	   solution	   infusion	   rates	   (≤2	   ml/hr)	   and	  
grounded-­‐mandrel	  collection	  speeds	  (≤1	  RPM)	  have	  resulted	  in	  production	  times	  ranging	  from	  1.5	  hr	  
40	  to	  over	  3.5	  hr	  41	  per	  scaffold	  using	  comparable	  electrospinning	  methods.	  By	  increasing	  infusion	  and	  
fiber	  collection	  rates	  by	  two	  and	  three	  orders	  of	  magnitude	  respectively,	  we	  were	  able	  to	  produce	  30	  
mm	  diameter	  JetValves	  in	  less	  than	  fifteen	  minutes.	  JetValve	  production	  times	  can	  be	  compared	  to	  
those	   achievable	   with	   3D	   printing	   techniques	   42,43;	   however,	   3D	   printing	   still	   remains	   unable	   to	  
produce	  the	  spatial	  resolution	  of	  nano/micro-­‐fiber	  production	  platforms.	  Similarly,	  hydrogel	  and	  soft-­‐
polymer	   molding	   and	   patterning	   techniques	   for	   engineering	   heart	   valves	   have	   been	   limited	   to	  
feature	   resolutions	   within	   tens	   to	   hundreds	   of	   microns	   44-­‐47	   and	   often	   require	   hours	   to	   days	   for	  
fabrication	   due	   to	   gelation/layer	   bonding	   times.	   In	   comparison,	   we	   were	   able	   to	   achieve	   fiber	  
resolution	   ranging	   from	   hundreds	   of	   nanometers	   to	  microns	   by	   varying	   solution	   composition	   and	  
collection	   in	   order	   to	   rapidly	   recapitulate	   the	   size	   scale	   and	   anisotropy	   of	   the	   native	   fibrosa	   ECM	  
layer	  of	  the	  valve.	  	  
Scaffold	   biochemical	   and	   mechanical	   properties	   are	   critical	   for	   guiding	   tissue	   regeneration	   and	  
macro-­‐scale	   leaflet	   functionality	   48,49.	  Accordingly,	   the	  bulk,	  biaxial	   stiffness	  of	   JetValve	   leaflets	  was	  
engineered	   to	   match	   that	   of	   native	   tissue	   similar	   to	   previously	   reported	   ‘off-­‐the-­‐shelf’	   cell-­‐based	  
manufactured	   valve	   scaffolds	   7,9	   but	   without	   the	   need	   for	   long	   culture	   and	   in	   vitro	   conditioning.	  
JetValve	  stiffness	  values	  were	  an	  order	  of	  magnitude	  smaller	  than	  previously	  reported,	  as-­‐spun	  off-­‐
the-­‐shelf	  fibrous	  scaffolds	  50	  and	  commercially	  available	  ‘stiff’	  bioprosthetic	  valves	  (single	  versus	  tens	  
of	  megapascals)	  51.	  This	  was	  made	  possible	  by	  the	  inclusion	  of	  uncrosslinked	  gelatin	  in	  the	  biohybrid	  
JetValve	   fibers	   and	   varying	   the	   collection	   angle	   on	   the	   aRJS	   system.	   Despite	   not	   crosslinking	  
JetValves,	   exposure	   of	   biohybrid	   fibers	   to	  water	   for	   up	   to	   1	  week	   did	   not	   significantly	   change	   the	  
stiffness	   of	   the	   scaffold.	   During	   this	   period,	   P4HB/Gelatin	   content	   remained	   within	   compositional	  
range	  for	  mimicking	  the	  measured	  native	  tissue	  stiffness	  values.	  This	  length	  of	  hydrated	  shelf	   life	  is	  
comparable	   to	   recent	   fiber/gel	   valvular	   scaffold	   composites	   52	   and	   is	   well	   in	   excess	   of	   the	   time	  
required	   for	   pre-­‐implantation	   procedures:	   on	   the	   order	   of	   hours	   for	   stent	   fixation,	   crimping,	   and	  
surgical	  delivery	  preparation.	  	  
While	  recent	  studies	  have	  begun	  to	  apply	  defined	  standards	   (e.g.	   ISO)	   for	   the	  assessment	  of	   tissue	  
engineered	  heart	  valve	  functional	  performance	  52,53,	  little	  work	  has	  been	  done	  to	  establish	  industrial-­‐
style	   quality	   control	   standards	   for	   tissue	   engineering	   manufacturing	   processes	   and	   products	   54.	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Therefore	  the	  structural,	  mechanical,	  and	  compositional	  scaffold	  design	  parameters	  discussed	  above	  
were	  measured	  and	  evaluated	  for	  each	  JetValve	  prepared	  for	   implantation	  as	  a	  factor	  of	  safety	  for	  
the	   animal	   models	   used.	   The	   automated	   method	   of	   JetValve	   assembly	   and	   simplicity	   of	  
manufacturing	   customization	   enabled	   straightforward	   implementation	   of	  multi-­‐parameter	   process	  
capability	  metrics	  55,56.	  Our	  group	  has	  developed	  similar	  multi-­‐parameter	  quality	  assessment	  indices	  
for	   stem	   cell	   manufacturing	   27,57	   and	   suggest	   that	   the	   same	   can	   and	   should	   be	   done	   for	   tissue	  
engineered	  products	  19.	  We	  envision	  batch	  process	  capability	  and	  other	  quality	  control	  metrics	  may	  
likewise	   be	   applied	   to	   future	   JetValve	   designs	   and	   similar	   automated	   in	   situ	   tissue	   engineered	  
scaffold	  processes	  to	  ensure	  patient	  or	  model	  safety	  prior	  to	  functional	  testing.	  	  
Restoration	   of	   valvular	   functionality	   upon	   implantation	   is	   the	   immediate	   goal	   of	   regenerative	  
scaffolds.	  As-­‐manufactured	  JetValves	  showed	  potential	  as	  functioning	  and	  biocompatible	  valves	  both	  
in	   vitro	  and	   in	   vivo	  after	   crimping	  and	  minimally	   invasive	  delivery.	   Scaffold	   stiffness	  plays	  a	   critical	  
role	  in	  leaflet	  kinematics	  and	  the	  development	  of	  transvalvular	  pressure	  gradients	  during	  systole	  58,59.	  
As	   in	   previously	   proposed	   Polymer/Gelatin	   composite	   models	   for	   achieving	   native	   tissue-­‐like	  
stiffnesses	   60,	   the	   biohybrid	   JetValve	   scaffold	   composition	  was	   tuned	   to	  mimic	   native	   ECM	   leaflet	  
stiffness.	  As	   a	   result,	   transvalvular	   pressure	   gradients	   of	   <2	  mmHg	  were	  observed	   in	   vivo	  which	   is	  
equivalent	   to	   recently	   published	   human	   and	   ovine	   tissue	   engineered	   heart	   valve	   (<5	  mmHg)	   31,53.	  
However,	   in	   vitro	   pulse	   duplicator	   testing	   did	   reveal	   a	   regurgitant	   fraction	   of	   approximately	   30%	  
which	  is	  above	  ISO	  standards	  of	  similarly	  sized	  heart	  valves	  52.	  These	  data	  did	  not	  appear,	  though,	  to	  
fully	  predict	  JetValve	  functionality	   in	  vivo	  where	  rapid	  and	  complete	  leaflet	  coaptation	  and	  minimal	  
closing	   jet	   were	   observed	   with	   echo/doppler	   imaging.	   JetValves	   were	   mounted	   in	   the	   pulse	  
duplicator	   system	   in	   the	   absence	   of	   radial	   loading	   which	   is	   normally	   applied	   in	   vivo	   by	   the	  
surrounding	  tissue	  (pulmonary	  artery	  and	  valve	  annulus).	  This	  resulted	  in	  full	  expansion	  of	  the	  stent	  
and	  may	  explain	  the	  level	  of	  measured	  regurgitation	  in	  vitro.	  While	  these	  data	  do	  not	  necessarily	  give	  
indication	  as	  to	  the	  regenerative	  capacity	  or	  long-­‐term	  functionality	  of	  JetValves,	  they	  do	  support	  the	  
manufacturing	  method	  as	  viable.	  These	  time	  points,	  48	  hr	  in	  vitro	  and	  15	  hr	  in	  vivo,	  indicate	  that	  the	  
JetValve	   manufacturing	   technique	   can	   be	   used	   to	   produce	   a	   working,	   semilunar	   valve	   structure	  
amenable	   to	   minimally	   invasive	   implantation	   with	   acute	   safety.	   Future	   iterations	   of	   the	   JetValve	  
scaffold	   will	   reveal	   which	   compositions	   and	   spinning/collection	   parameters	   will	   be	   necessary	   for	  
long-­‐term	  functionality	  and	  tissue	  regeneration.	  	  
In	   addition	   to	   restoring	   function,	   the	   long-­‐term	   goal	   of	   all	   regenerative,	   in	   situ	   tissue	   engineered	  
scaffolds	   is	   to	   promote	   both	   full	   regeneration	   and	   adaptive	   growth	   of	   the	   target	   tissue.	   Such	  
scaffolds	  should	  serve	  as	  resorbable	  platforms	  onto	  and	  into	  which	  the	  body	  can	  “auto-­‐engineer”	  its	  
own	  replacement	  tissue	  that,	  ideally,	  perfectly	  matches	  healthy	  native	  tissue.	  This	  requires	  intricate	  
engineering	   design	   of	   scaffold	   architectural,	   mechanical,	   and	   biochemical	   properties	   50	   to	   control	  
Biodegradable	  scaffolds	  	  
156	  
time-­‐dependent	   biological	   processes	   including	   cellular	   recruitment,	   inflammation,	   and	   scaffold	  
remodeling	  61.	  Here,	  we	  showed	  that	  60/40,	  as-­‐spun	  JetValves	  supported	  progressive	  VIC	  infiltration	  
and	  tissue	  growth	  at	  least	  in	  vitro,	  suggestive	  of	  their	  potential	  for	  serving	  as	  scaffolds	  for	  long-­‐term	  
endogenous	   tissue	   formation	   in	   vivo.	   However,	   these	   studies	   are	   limited	   and	   it	   is	   likely	   that	   that	  
inclusion	  of	  anti-­‐inflammatory	  agents	  and/or	  growth	  factors	  may	  be	  necessary	  for	  endogenous	  repair	  
mechanism	   to	   be	   activated.	   Inclusion	   of	   these	   factors	   as	   dopants	   is	   possible	   using	   the	   JetValve	  
manufacturing	   method	   without	   significant	   modification	   to	   the	   technique	   or	   time	   to	   production.	  
Growth	  factors	  associated	  with	  development	  such	  as	  transforming	  growth	  factor-­‐β1	  (TGF-­‐β1),	  bone	  
morphogenic	  proteins	  (BMPs),	  and/or	  platelet-­‐derived	  growth	  factors	  (PDGFs)	  may	  be	  incorporated	  
into	   scaffolds	   to	   elicit	   endothelial-­‐to-­‐mesenchymal	   transformation	   (EMT),	   for	   example,	   in	   order	   to	  
populate	   and	   remodel	   the	   scaffold	   55,62,63.	   Additionally,	   recently	   reported	   hybrid-­‐manufacturing	  
techniques	   for	   the	   production	   of	   more	   complex,	   tri-­‐layered	   scaffolds	   have	   been	   developed	   in	   an	  
effort	   to	   better	   mimic	   this	   anisotropic,	   stratified	   structure	   of	   the	   valvular	   ECM	   for	   optimal	  
hemodynamic	   performance	   and	   tissue	   regeneration	   52,64-­‐66.	   The	   JetValve	   production	   platform	   is	  
amenable	   to	   fabrication	   of	   similarly	   layered	   scaffolds	   while	   maintaining	   industrial-­‐like	   scaffold	  
production	   rates	   67-­‐69	   due	   to	   its	   additive	   nature.	   By	   successively	   spinning	   fibrosa,	   spongiosa,	   and	  
ventricularis-­‐like	  layers	  of	  biohybrid	  materials	  with	  mechanical	  properties	  and	  biochemistry	  tailored	  
to	  the	  specific	  ECM	  layers	  of	  the	  valve,	  stratified	  JetValve	  production	  could	  be	  possible.	  	  
We	   further	   propose	   that	   this	   method	   can	   be	   valuable	   for	   the	   fabrication	   or	   other	   fibrous	  
replacement	  organ	   scaffolds	   or	   for	   production	  of	   customized	   scaffolds	   given	   the	   specific	   age,	   size,	  
and	  organ	  or	   organ-­‐part	   needs	  of	   a	   patient	   19.	   Fibrous,	   vascularized	   tissue	   such	   as	  myocardium	  or	  
branching	  blood	  vessels	  may	  incorporate	  vascular	  endothelial	  growth	  factors	  (VEGFs),	  angiopoietins,	  
or	   ephrins	   to	   elicit	   neovascularization	   within	   the	   scaffold	   70.	   Although	   precise	   growth	   factor	  
combinations	  and	  amounts	  needed	  to	  recruit	  tissue	  specific	  cell	  progenitors	  remains	  to	  be	  identified	  
15,71,	   the	   flexibility	   of	   the	   JetValve	   manufacturing	   process	   described	   here	   would	   allow	   for	   easy	  
incorporation	  of	  multiple	  factors	  into	  scaffolds	  to	  promote	  homing	  and	  assembly	  of	  endogenous	  cells	  
and	  tissues.	  Furthermore,	  because	  mandrels	  can	  be	  3D	  printed	  in	  any	  shape,	  scaffolds	  of	  customized	  
anatomy	  may	  be	  spun	  using	  this	  technique:	  combining	  the	  JetValve	  mandrel-­‐based	  spinning	  process	  
with	  the	  idea	  of	  3D	  printing	  patient	  specific	  organ	  geometries	  43,72-­‐74.	  The	  manufacturing	  process	  we	  
present	  here	   is	  well	  suited	  to	  rapidly	  and	  iteratively	  study	  the	  properties	  and	  compositions	  needed	  
for	   fibrous	   scaffold-­‐based	   endogenous	   tissue	   repair	   and	   is	   amenable	   to	   patient-­‐specific	  
customization.	  	  
In	   conclusion,	   we	   have	   introduced	   a	   manufacturing	   process	   for	   the	   rapid	   fabrication	   of	   fibrous,	  
semilunar	  heart	  valve	  scaffolds.	  By	  varying	  manufacturing	  parameters	  such	  as	  solution	  composition,	  
extrusion	  speed,	  and	  mandrel	  size	  or	  collection	  angle,	  functional	  scaffolds	  were	  built	  to	  model	  basic	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native	   valvular	   ECM.	   This	   method	   is	   amenable	   to	   further	   customization	   by	   tuning	   the	   same	  
multiscale	   structural,	   mechanical,	   and	   biochemical	   scaffold	   parameters	   to	   potentially	   match	   the	  
anatomy	  of	  specific	  patients	  and/or	  determine	  which	  values	  of	  these	  parameters	  will	  elicit	  an	   ideal	  
remodeling	   response	  once	   implanted.	   Because	   scaffolds	  were	   fabricated	   three-­‐dimensionally,	   they	  
could	   easily	   be	   incorporated	   into	   stents	   and	   implanted	   minimally	   invasively	   as-­‐spun,	   without	   the	  
need	   for	   post	   processing	   or	   in	   vitro	   preconditioning.	   The	   simplicity	   and	   control	   of	   this	   scaffold	  
manufacturing	   process	   offers	   a	   viable,	   cell-­‐free	   and	   clinically	   translatable	   alternative	   for	   the	  
fabrication	   of	   heart	   valves	   and	   possibly	   other	   fibrous	   organs.	   Therefore,	   first	   long	   term	   in	   vivo	  
functionality	  of	  electrospun	  heart	  valves	  is	  necessary	  before	  safe	  clinical	  translation.	  	  
In	  this	  regard,	  a	  follow	  up	  study	  for	  the	  long-­‐term	  in	  vivo	  evaluation	  has	  been	  initiated.	  Despite	  initial	  
success	  in	  the	  acute	  situation,	  recruitment	  of	  host	  cells	  was	  limited	  to	  the	  surface	  layer	  of	  the	  valve	  
scaffold	   after	   1-­‐month	   post-­‐implantation.	   It	   appeared	   that	   cells	   could	   not	   infiltrate	   the	   implanted	  
scaffold	   to	   form	   endogenous	   tissue.	   In	   contrast,	   previous	   studies	   demonstrated	   fast	   cellular	  
repopulation	   of	   decellularized	   tissue	   engineered	   heart	   valves	   after	   1-­‐month	   implantation,	   with	  
comparable	  cellularity	  of	  the	   leaflets	  to	  that	  of	  native	   leaflets	   6.	  Although	   in	  vitro	   infiltration	  of	  VIC	  
could	   be	   demonstrated	   in	   the	   presented	   study,	   one	   has	   to	   emphasize	   that	   the	   in	   vitro	   cellular	  
infiltration	   was	   limited	   to	   ∼25	   μm,	   which	   overall	   only	   represents	   a	   small	   portion	   of	   the	   surface	  
scaffold	  in	  comparison	  of	  the	  overall	  thickness	  of	  the	  JetValve	  scaffold	  with	  a	  UCL	  of	  600	  μm	  and	  a	  
LCL	  of	  250	  μm.	  Reasons	  as	  to	  the	  limited	  host	  cell	  infiltration	  might	  be	  scaffold	  composition,	  porosity	  
and/or	   pore	   sizes.	   Host	   cells	   interact	   primarily	   with	   chemical	   functional	   groups	   on	   the	   material	  
surface,	  which	  are	  produced	  in	  natural	  extracellular	  materials	  but	  not	  in	  synthetic	  materials	  such	  as	  
P4HB	   75.	   Too	   small	   pore	   sizes	   result	   in	   a	   high	   cellular	   density	   at	   the	   scaffold	   surface,	  whereas	   too	  
large	  pore	  sizes	  decrease	  surface	  area	  and	   limit	  cellular	  attachment	   76.	  Optimal	  pore	  size	  varies	  on	  
the	   tissue	   being	   engineered,	   its	   required	   mechanical	   properties	   and	   the	   different	   cell	   types	  
infiltrating	  it.	  Inclusion	  of	  bioactive	  substances	  has	  shown	  to	  activate	  endogenous	  tissue	  remodeling	  
by	  enhancing	  cell	  attraction	  and	  binding.	  As	  an	  example,	  the	  local	  release	  of	  inflammatory	  cytokines	  
and	   chemokines	   has	   shown	   to	   increase	   host	   cell	   recruitment	   via	   an	   inflammatory	   process	   and	  
determine	  the	  fate	  of	  implanted	  scaffold	  towards	  functional	  tissue	  77.	  Like	  that	  the	  balance	  between	  
tissue	   formation	   and	   scaffold	   degradation	   could	   be	   improved.	   Degradation	   of	   implanted	   scaffold	  
material	  after	  1	  month	  in	  vivo	  was	  limited	  in	  the	  presented	  study.	  Therefore	  exact	  degradation	  rates	  
of	   electrospun	   material	   need	   to	   be	   further	   defined,	   given	   its	   biohybrid	   compositon	   60/40	  
P4HB/Gelatin	  and	  a	  negligible	  amount	  of	  PGA.	  Complete	  resorption	  of	  P4HB	  occurs	  between	  12	  and	  
18	  month	   in	   vivo	   78,	   whereas	   gelatin	   degradation	   alone	   occurs	   rapidly.	   Overall	   further	   studies	   are	  
mandatory	   to	   elucidate	   the	   exact	   underlying	   mechanisms	   of	   tissue	   remodeling	   and	   scaffold	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degradation	   involved.	   In	   particular,	   the	   precise	   role	   of	   engineered	   scaffolds	   with	   respect	   to	   their	  
chemo-­‐attraction	  of	  host	  cells	  and	  tissue	  formation	  has	  to	  be	  assessed.	  
Besides	   further	   optimization	   of	   scaffold	   composition	   for	   better	   recellularization	   and	   remodeling	  
capacities,	   adaptations	   of	   the	   heart	   valve	   design	   are	   required.	   The	   presented	   valve	   geometry	  
represents	  a	  simplified	  flat	  version	  with	  sharp	  transition	  areas	  from	  the	  heart	  valve	  belly	  to	  the	  wall	  
region.	  Integration	  of	  sinuses	  would	  enable	  better	  biomechanical	  load	  of	  the	  leaflets	  and	  ultimately	  
support	   leaflet	   movement	   and	   durability,	   while	   functioning	   as	   a	   washout	   mechanism	   to	   prevent	  
blood	  stagnation	  and	  thrombosis	  79.	  Therefore,	  first	  studies	  are	  recapitulating	  the	  native	  heart	  valve	  
anatomy	  by	  including	  bioengineered	  sinus	  of	  Valsalve	  and	  demonstrating	  initial	   in	  vivo	  functionality	  
in	  the	  aortic	  position	  80.	  However	  another	  anatomical	  structure	  never	  incorporated	  into	  engineered	  
heart	   valves	   are	   ventricular	   papillary	   muscles	   and	   its	   chordea	   tendineae,	   which	   prevent	   valve	  
inversion	  or	  prolapse	  during	  ventricular	  contraction.	  Ultimately	  future	  studies	  will	  need	  to	  evaluate	  
the	   necessity	   and	   advantages	   of	   such	   anatomical	   structures	   in	   the	   functionality	   and	   translation	   of	  
engineered	  heart	  valves.	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5.1	  MSC	  HYPE	  OR	  HOPE?	  
Adult	  MSCs	  were	  first	  identified	  by	  Friedstein	  et	  al.	  in	  the	  1960s	  and	  1970s,	  when	  observing	  a	  group	  
of	   cells	  within	   the	   bone	  marrow	   that	   developed	   into	   fibroblastic	   colony	   forming	   cells	   (CFU-­‐F)	   and	  
could	  differentiate	  in	  vitro	  into	  several	  mesenchymal	  lineage	  cells	  such	  as	  chondrocytes,	  adipocytes,	  
myoblasts	  and	  osteoblasts	  1.	  Since	  then,	  MSCs	  have	  been	  isolated	  form	  almost	  all	  adult	  tissues.	  This	  
includes	   among	   others	   the	   bone	   marrow	   2,	   adipose	   tissue	   3,	   dental	   tissue	   4,	   skin	   and	   foreskin	   5,	  
peripheral	  blood	  6	  and	  vessels	  7.	  Besides	  MSCs	  are	  also	  found	  in	  fetal	  tissues	  and	  fluids,	  such	  as	  the	  
amniotic	   fluid	   8	   and	  membrane	   9,	  placenta	   10	   and	   fetal	  membrane	   10	   and	  umbilical	   cord	  Wharton’s	  
jelly	  11.	  
The	   interest	   in	   MSCs	   for	   clinical	   applications	   has	   constantly	   increased	   since	   the	   last	   decade.	   The	  
advantages	   of	  MSC	   include	   their	   easy	   accessibility,	   extensive	   in	   vitro	   expansion,	   their	  multilineage	  
differentiation	   potential,	   immunomodulation	   and	   secretion	   of	   trophic	   factors	   initiating	   tissue	  
remodeling.	   In	   preclinical	   studies,	  MSCs	   have	   therefore	   shown	   the	   potential	   for	   the	   treatment	   of	  
many	  chronic	  diseases	  such	  as	  neurodegenerative,	  cardiovascular,	  autoimmune	  and	  wound	  healing	  
diseases.	  More	   then	   20	   years	   ago	   Lazarus	   et	   al.	   conducted	   the	   first	   clinical	   trial	   using	   BMSCs	   for	  
lymphomas	  12.	  Since	  then,	  the	  efficacy	  and	  feasibility	  of	  MSC-­‐based	  cell	   therapy	  has	  been	  tested	   in	  
several	  different	  settings	  and	  patients	  suffering	  congenital	  or	  acquired	  diseases.	  Currently,	  there	  are	  
619	  studies	  found	  for	  “Mesenchymal	  Stem	  Cells”	  in	  different	  clinical	  phases	  throughout	  the	  world	  13.	  
The	  amount	  of	  MSC-­‐based	  clinical	  trials	  has	  even	  triplet	  since	  the	  study	  number	  described	  by	  Wang	  
et	  al.	  2012	  14.	  Among	  619	  registered	  trials,	  33	  have	  been	  either	  suspended,	  terminated	  or	  withdrawn.	  
539	  of	  the	  studies	  are	  in	  early	  study	  phases,	  including	  early	  phase	  I,	  phase	  I	  and	  phase	  II.	  Only	  a	  small	  
portion	  is	  registered	  as	  clinical	  phase	  III	  or	  IV.	  Clinical	  trials	  conducted	  with	  MSCs	  did	  only	  show	  mild	  
adverse	  effects,	  given	  evidence	  that	  MSC-­‐based	  therapies	  are	  well	  tolerated	  and	  safe.	  Potential	  late-­‐
side	  effects,	  such	  as	  MSC	  tumorigenic	  potential,	  will	  be	  evaluated	  in	  the	  future	  with	  longer	  follow-­‐up	  
times.	  However,	   the	   overall	   effectiveness	   of	  MSC	   is	   currently	   limited	   to	   graft	   versus	   host	   diseases	  
and	   hematological	   bone	   and	   cartilage	   diseases	   15.	   It	   seems	   as	   if	   beneficial	   effects	   of	   MSC-­‐based	  
therapies	   are	   related	   to	   the	   immunomodulation	   and	   regenerative	   potential	   of	   these	   cells	   15.	  
Nevertheless,	   inflammation	  is	  a	  key	  event	   in	  a	   lot	  of	  pathologies	  and	  therefore	  beneficial	  effects	  of	  
MSC-­‐based	  therapies	  are	  also	  expected	  in	  other	  diseases.	  	  
Before	  clinical	  translation	  the	  following	  points	  need	  to	  be	  addressed.	  First,	  there	  is	  still	  not	  a	  single	  
characterization	  of	  MSC	  available	  limiting	  comparison	  of	  different	  studies	  conducted	  and	  their	  results	  
(see	  paragraph	  5.2).	  We	  are	  still	  far	  from	  defining	  a	  molecular	  signature	  for	  MSC	  from	  different	  tissue	  
sources.	   Secondly,	   the	   mechanism	   of	   action	   of	   MSCs	   is	   still	   not	   fully	   elucidated	   yet.	   It	   has	   been	  
postulated	  to	  be	  based	  on	  the	  secretion	  of	  cytokines	  and	  biologically	  relevant	  molecules	  rather	  than	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direct	   effect	   of	   MSC	   (see	   paragraph	   5.3).	   Processes	   such	   as	   MSC	   survival	   after	   transplantation,	  
modulation	   of	   the	   host	   immune	   system	   and	   MSC	   phenotype	   after	   in	   vivo	   translation	   remain	  
unknown.	  Thirdly,	   suitable	   animal	  models	   are	  necessary	   to	   enable	  more	   accurate	   extrapolation	  of	  
gained	   knowledge	   to	   the	   human	   situation	   and	   finally,	   also	   different	   delivery	   routes	   have	   to	   be	  
critically	  evaluated	  (see	  paragraph	  5.4).	  
	  
5.2	  MSC	  CHARACTERIZATION	  PARAMETERS	  
MSC	   are	   isolated,	   cultured	   and	   characterized	   differently	   among	   laboratories.	   Even	   if	   cultured	   in	  
different	   culture	  media	   supplemented	   with	   varying	   concentration	   of	   serum	   and	   oxygen,	   all	   MSCs	  
exhibit	   the	   minimum	   criteria	   proposed	   in	   2006	   by	   the	   International	   Society	   for	   Cellular	   Therapy	  
(ISCT)16.	   According	   to	   them,	   isolated	   cells	   need	   I)	   to	   be	   plastic	   adherent	   under	   standard	   culture	  
conditions,	   II)	   to	   possess	   specific	   set	   of	   cell	   surface	   markers,	   i.e	   expression	   of	   cluster	   of	  
differentiation	   (CD)105,	   CD90	   and	   CD73	   and	   lack	   of	   expression	   of	   CD14,	   CD34,	   CD45	   and	   human	  
leucocyte	   antigen-­‐DR	   (HLA-­‐DR),	   and	   III)	   to	   differentiate	   in	   vitro	   into	   osteocytes,	   chondrocytes	   and	  
adipocytes	   16.	  The	  goal	  of	   these	   ISCT	  guidelines	  was	   to	  offer	  a	  quality	  control	   for	   researcher	   in	   the	  
field	   of	   MSCs	   and	   to	   decrease	   possible	   experimental	   variability	   and	   increase	   transparency	   of	  
published	  data.	  
However,	   these	   criteria	   still	   enable	   a	   mixed	   population	   of	   cells	   and	   neglect	   the	   tissue	   origin	   of	  
isolated	   cells.	   Tissue-­‐specific	   differences	   can	   be	   maintained	   under	   in	   vitro	   culture	   conditions	   and	  
markers	  may	  vary	  depending	  on	   the	  MSC	   tissue	  source.	  Furthermore,	   ISCT	  criteria	  do	  not	   improve	  
the	  purification	  of	  MSCs	  after	   isolation	  but	  produce	  heterogeneous,	  non-­‐clonal	   cultures	  of	   stromal	  
cells	   containing	   stem	   cells	   with	   different	   multipotent	   properties,	   committed	   progenitors	   and	  
differentiated	  cells	  15.	  In	  particular,	  in	  the	  situation	  were	  MSC	  are	  present	  in	  low	  quantities,	  such	  as	  
the	  bone	  marrow	  with	  only	  0.01%	  to	  0.001%	  17.	   In	  an	  attempt	  to	  further	  increase	  purity	  of	   isolated	  
MSCs,	   positive	   and	  negative	   selection	  markers	  have	  been	   tested.	   Even	   if	   there	   are	   some	   concerns	  
over	  using	  such	  isolation	  strategies	  due	  to	  cross-­‐linking	  of	  antigens	  altering	  cellular	  phenotypes	  and	  
potentially	   activating	   signaling	  pathways,	   increased	   clonogenicity	   compared	   to	   cells	   isolated	  based	  
on	   plastic	   adhesion	   has	   been	   reported	   18,19.	   Clonogenicity	   is	   also	   not	   assumed	   in	   currently	   used	  
trilineage	  differentiation	  assays	  to	  assess	  MSC	  plasticity.	  Differentiation	  into	  adipogenic,	  osteogenic	  
and	  chondrogenic	  lineages	  can	  be	  initiated	  by	  single	  (precursor)	  cells	  within	  the	  heterogeneous	  and	  
mixed	  cell	  population.	  Furthermore,	  in	  vitro	  culturing	  of	  MSCs	  has	  shown	  to	  decrease	  differentiation	  
potential	  20,	  emphasizing	  the	  need	  to	  verify	  MSC	  multipotency	  not	  only	  after	  isolation,	  but	  also	  after	  
been	  passaged	  several	  times.	  In	  the	  presented	  thesis,	  multipotency	  has	  therefore	  been	  evaluated	  at	  
passage	   3-­‐4	   after	   isolation	   in	   all	   donors	   and	   at	   the	   same	   passage	   as	   other	   assays	   have	   been	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performed,	  such	  as	  conditioned	  media	  harvest	  and	  MSC	  characterization	  (see	  chapter	  2	  and	  3).	  Like	  
that	   culture	   differences	   were	  minimized.	   However	   besides	   the	   decline	   in	   their	   multipotency,	   also	  
increased	   probability	   of	  malignant	   transformation	   21,	   decrease	   telomerase	   activity	   22	   and	   changed	  
cellular	   morphology	   have	   been	   described	   on	   long-­‐term	   culture.	   In	   this	   regard,	   also	   markers	   to	  
monitor	  senescent-­‐associated	  changes	  have	  been	  suggested	  for	  a	  better	  MSC	  characterization	  over	  
passaging.	  
In	  addition	   to	  previously	  described	   concerns	  about	   ISCT	  guidelines,	  quantitative	   information	  about	  
the	   expression	   of	   MSC	   surface	   markers	   of	   analyzed	   cells	   is	   not	   obtained.	   This	   is	   essential	   when	  
comparing	   MSC	   lines	   from	   different	   donors	   and	   tissue	   sources.	   Therefore,	   the	   present	   thesis	  
analyzed	   all	   surface	   markers	   using	   multicolor	   flow	   cytometry	   (described	   in	   chapter	   2),	   enabling	  
phenotypic	   single	   cells	   instead	   of	   percentages	  within	   the	   overall	   population.	  Median	   fluorescence	  
intensity	   ratios	   (MFIR)	   allowed	   quantification	   of	   different	   subsets	   of	  MSCs.	   In	   the	   future,	   specific	  
subpopulation	   might	   be	   even	   enriched	   using	   fluorescence-­‐activated	   cell	   sorting.	   A	   potential	   side	  
effect	  of	  sorting	  might	  be	  the	  cross-­‐linking	  of	  surface	  antigens	  or	  other	  molecules	  23.	  Also	  embryonic	  
stem	   cell	   (ESC)	   markers	   are	   used	   to	   characterize	  MSCs.	   Expression	   of	   ESC	   markers	   such	   as	   Oct4,	  
Nanog,	  Sox2	  and	  SSEA-­‐4	  have	  been	  found	  in	  so	  called	  “broadly	  multipotent”	  MSCs	  from	  fetal	  sources	  
such	   as	   the	   amniotic	   fluid	   (described	   in	   chapter	   3.2).	   These	  markers	   have	   also	   been	   qualitatively	  
detected	   in	   MSC	   from	   the	   bone	   marrow,	   adipose	   tissue	   and	   dermis	   24.	   Nevertheless,	   fetal	   MSCs	  
exhibit	   higher	   plasticity,	   faster	   proliferation	   and	   senesced	   later	   in	   culture	   than	   their	   adult	  
counterparts	   25.	   In	   the	   future	   quantifiable	   characterization	   parameters	   are	   therefore	   necessary	   to	  
compare	   the	   primitive	   state	   of	  MSCs	   between	   different	   groups,	   isolation	   protocols,	   tissue	   sources	  
and	  donors.	   It	   seems	  not	  enough	   to	  have	   certain	  markers	  expressed	  without	  any	  prove	   for	  higher	  
plasticity	  and	  possible	  related	  cellular	  features.	  	  
MSCs	  have	  also	  been	  isolated	  form	  several	  animal	  models	  such	  as	  mice,	  pig	  and	  sheep	  and	  are	  used	  
for	   preclinical	   studies	   before	   human	   translation.	   In	   contrary	   to	   the	   human	   situation,	   there	   are	   no	  
established	   minimal	   criteria	   for	   the	   identification	   of	   MSCs	   in	   non-­‐humans.	   Not	   available	   species-­‐
specific	  antibodies	  and	  a	  different	  set	  of	  surface	  markers	  limit	  the	  accurate	  comparison	  to	  the	  human	  
situation	   (described	   in	   chapter	   3).	   This	   would	   not	   only	   enable	   better	   predictions	   of	   safety	   and	  
efficacy	   using	  MSC-­‐based	   therapies,	   but	   also	   open	   novel	   treatment	   strategies	   for	   the	   veterinarian	  
clinic.	  
Taken	  together,	   further	  research	   in	  this	  field	  will	  not	  only	  enable	  a	  better	  defined	  MSC	  population,	  
but	   also	   less	   variability	   between	   documented	   results	   in	   the	   literature	   and	   ultimately	   less	  
contradictory	  data	  and	  a	  better	  clinical	  translation.	  
	  
General	  discussion	  	  
168	  
5.3	  MSC	  SECRETOME	  VERSUS	  CELLS	  
Published	  research	  has	  pointed	  out	  the	  broad	  in	  vitro	  differentiation	  potential	  of	  MSC	  from	  different	  
sources	  into	  all	  three	  lineages	  including	  not	  only	  adipocytes,	  osteocytes	  and	  chondrocytes,	  but	  also	  
cardiomyocytes,	  pancreatic	  cells,	  neuronal	  cells	  and	  hepatocytes	  26.	  However,	  the	  question	  whether	  
in	  vivo	  differentiation	  of	  MSC	  is	  required	  for	  beneficial	  effects	   in	  treated	  patients	  remains	  debated.	  
Initially,	  stem	  cell	  research	  focused	  on	  the	  direct	  differentiation	  of	  MSCs	  into	  intended	  phenotypes.	  
Some	   functional	   improvements	   were	   found	   with	   MSC	   transplantation	   and	   could	   directly	   be	  
attributed	   to	   in	   vivo	   homing	   and	   cell	   differentiation	   26.	   However,	   it	   has	   become	   evident	   that	  
functional	  benefits	  found	  in	  animal	  models	  and	  treated	  patients	  may	  be	  due	  to	  paracrine	  actions	  of	  
introduced	   MSCs	   rather	   than	   cell	   differentiation.	   Cytokines	   and	   biologically	   relevant	   molecules	  
secreted	  by	  MSCs	  exert	  potent	  effects	  on	  other	  cell	  types	   in	  vitro	  and	   in	  vivo	  as	  demonstrated	  by	  a	  
number	   of	   studies	   utilizing	   conditioned	   media	   (CM)	   collected	   from	   different	   MSC	   sources	   27.	  
Paracrine	   factors	   have	   been	   postulated	   to	   influence	   the	   microenvironment	   following	   injury	   by	  
recruiting	  host	  cells	  enabling	  cytoprotection,	  angiogenesis	  and	  endogenous	  regeneration	  of	   injured	  
environment	  in	  an	  inflammation	  mediated	  cellular	  cascade	  (see	  chapter	  1.2).	  
Considering	  clinical	  translation,	  MSC	  CM	  can	  provide	  several	  advantages	  over	  using	  the	  cell	  itself.	  No	  
cells	  means	  there	  is	  no	  risk	  of	  inadequate	  differentiation	  of	  MSCs	  in	  a	  certain	  tissue	  environment,	  as	  
shown	  by	  undesired	  ectopic	  bone	  within	  the	  heart	  of	  MSC-­‐treated	  mouse	  in	  a	  model	  of	  myocardial	  
infarction	  28.	  Further,	  long-­‐term	  in	  vitro	  culturing	  of	  MSC	  are	  not	  necessary	  which	  involves	  high	  costs	  
for	   a	   regulated	   GMP-­‐compliant	   facilities	   to	   expand	   high	   numbers	   of	   cells.	   MSC	   CM	   can	   be	  
manufactured,	   freeze-­‐dried	  and	  transported	  more	  easily.	  Even	   if	   controversially	  debated	  and	  more	  
evidence	   is	  still	  needed,	  several	  studies	  have	  suggested	  chromosomal	  aberrations	  during	   long-­‐term	  
culturing	  of	  MSC,	  which	   subsequently	   enable	  malignant	   neoplastic	   transformation	   29,30.	   This	  would	  
mean	  patient	  treated	  with	  MSCs	  could	  potentially	  promote	  growth	  of	  new	  or	  preexisting	  tumors	  31.	  
Moreover,	   by	   using	  MSC	  CM	   there	   is	   no	   need	   to	  match	   the	   donor	   and	   the	   recipient	   to	   avoid	   any	  
adverse	   immunological	   responses,	   although	   MSC	   are	   unable	   to	   bring	   substantial	   alloreactivity	   by	  
protecting	  them	  against	  natural	  killer	  cell	   lysis	  32.	  However,	  certain	   limitations	  exist	  with	  the	  use	  of	  
MSC	  CM,	  such	  as	  its	  contamination	  by	  animal	  products	  used	  in	  the	  serum.	  Serum	  proteins	  can	  easily	  
bind	  to	  the	  surface	  of	  cells	  and	  subsequently	  be	  part	  of	  the	  CM	  harvested.	  Therefore,	  the	  presented	  
thesis	   (described	   in	   chapter	   2)	   established	   culturing	   conditions	   without	   any	   xenogenic	   factor	  
involved.	   This	   not	   only	   enables	   in	   vitro	   experiments	  with	   human	   immune	   cells,	   but	   also	   increases	  
safety	   for	   possible	   clinical	   evaluation.	   The	   use	   of	   fetal	   bovine	   and	   calf	   serum	   has	   raised	   some	  
concerns	   given	   the	   possibility	   to	   induce	   host	   immune	   reactions	   and	   transmission	   of	   unidentified	  
zoonose	   and	   prions.	   By	   using	   autologous	   or	   allogeneic	   human	   platelet	   lysate	   as	   serum	   substitute	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(described	   in	   chapter	   2)	   for	   in	   vitro	   expansion	   such	   risks	   could	   be	   avoided.	   Finally,	   the	   relative	  
amount	   of	   secreted	   factors	   and	   the	   effective	   functional	   response	   in	   vivo	   need	   to	   be	   evaluated	  
depending	   on	   the	   harvest	   procedure	   and	   clinical	   application.	   This	   is	   often	   neglected	   in	   preclinical	  
studies	  where	  different	  concentrations	  of	  MSC	  CM	  or	  amount	  of	  MSC	  itself	  are	  used	  depending	  on	  
the	   experimental	   assay,	   rather	   than	   equalizing	   it.	   The	   study	   in	   chapter	   2	   has	   therefore	   harvested	  
MSC	  CM	  based	  on	   the	  amount	  of	   incubated	  cells.	  This	  enables	  comparison	  of	  different	  MSCs	  even	  
with	  different	  proliferation	  capacities.	  Hence,	   it	  seems	  important	  to	  consider	  that	  MSC	  CM	  offers	  a	  
cocktail	  of	  both	  stimulatory	  and	   inhibitory	  factors	  and	  that	  the	   interaction	  of	  several	  cytokines	  and	  
biologically	  relevant	  molecules	  might	  sustain	  physiological	  pharmocokinetics	  compare	  to	  the	  deliver	  
of	   single	   factors	   (described	   in	   chapter	   2).	   In	   ischemic	   heart	   diseases,	   single	   cytokine	   therapy	   trials	  
have	  not	  met	  expectations	  underlying	  that	  processes	  such	  as	  regeneration	  may	  need	  simultaneous	  
administration	  of	  multiple	  factors	  at	  different	  concentrations	  to	  act	  synergistically	  33.	  To	  high	  dosages	  




Unpublished	  figure	  1:	  Delivery	  routes	  for	  MSC	  CM	  in	  ischemic	  heart	  diseases	  (e.g	  myocardial	  infarction)	  and	  structural	  heart	  diseases	  (e.g	  
heart	   valve	   diseases).	   Intramyocardial	   or	   systemic	   injections	   is	   predominantly	   described	   for	   ischemic	   heart	   diseases,	   where	   the	  
replacement	  of	  diseased	  heart	  valves	  is	  focusing	  on	  the	  in	  situ	  tissue	  engineering	  approach,	  including	  so	  called	  microcapsules	  for	  defined	  
MSC	   CM	   release.	   Both	   delivery	   routes	   induce	   an	   inflammation-­‐mediated	   cellular	   cascade	   of	   vascular	   remodeling,	   defined	   by	   a	   first	  
monocyte	   attraction	   followed	   by	   a	   second	   vascular	   cell	   attraction	   (smooth	   muscle	   cells	   /	   endothelial	   cells).	   These	   events	   result	   in	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5.4	  MSC	  DELIVERY	  ROUTE	  FOR	  CLINICAL	  APPLICATIONS	  
The	   route	   of	  MSCs	   administrations	   varies	   between	   local	   (e.g	   intramuscular	   or	   subcutaneous)	   and	  
systemic	   (e.g	   intravenous	  or	   intraarterial)	   injections	  or	  by	   the	  use	  of	   synthetic	  and	  natural	   scaffold	  
materials	  as	  a	  carrier.	  In	  this	  regard,	  the	  systemic	  intravenous	  delivery	  route	  shows	  first	  efficacy	  and	  
safety	   in	   preclinical	   models	   and	   in	   preliminary	   clinical	   settings,	   representing	   the	   least	   invasive	  
delivery	  route	  with	  the	  ability	  for	  clinical	  translation	  and	  patient	  compliance.	  However,	   it	  has	  to	  be	  
explored	  whether	  the	  therapeutic	  effects	  of	  systemic	  and	  targeted	  delivery	  can	  be	  further	  refined	  in	  
order	  to	  improve	  MSC-­‐based	  therapies	  in	  the	  future.	  
It	  has	  been	  shown	  that	  regardless	  of	  the	  injection	  route	  only	  1-­‐5%	  of	  administered	  MSCs	  end	  within	  
the	  target	  tissue	  and	  that	  most	  of	  cells	  are	  not	  even	  detectable	  7-­‐14	  days	  post	  administration	  34.	  Thus	  
increasing	   number	   of	   injections	   or	   cell	   concentrations	   seem	   necessary	   to	   increase	   the	   amount	   of	  
MSCs	  within	  the	  injury	  site	  34.	  The	  recruitment	  of	  systemically	  applied	  MSCs	  into	  the	  target	  tissue	  is	  
probably	  due	  to	  chemotactic	  stimuli	  released	  by	  injured	  cells.	  Therefore,	  only	  a	  limited	  time	  window	  
might	  lead	  to	  therapeutic	  effects	  in	  vivo.	  	  
In	  this	  regard,	  the	  combination	  of	  MSC	  or	  MSC	  secretome	  with	  appropriate	  scaffold	  material	  would	  
enable	  a	  more	  targeted	  application.	  Higher	  concentrations	  of	  paracrine	  factors	  released	  by	  MSCs	  can	  
be	   preserved	   in	   a	   local	   microenvironment.	   Various	   biomaterials	   have	   been	   used	   as	   vehicles	   of	  
delivery	   for	  cells	  and	  paracrine	   factors	  as	  well	  as	  a	   scaffold	   for	  extracellular	  matrix	  production	  and	  
tissue	   formation.	   In	   the	   field	   of	   cardiovascular	   in	   situ	   tissue	   engineering	   (see	   chapter	   1.1),	   the	  
inclusion	   of	   bioactive	   substances	   has	   shown	   to	   increase	   host	   cell	   recruitment	   via	   an	   inflammatory	  
process	   and	   enable	   tissue	   formation	   35.	   Aliginate	   particles	   can	   be	   formulated	   into	   porous	   scaffold	  
marices	  as	  delivery	  vehicles	  for	  bioactive	  molecules	  or	  transplanted	  cells	  36.	  This	  strategy	  might	  also	  
improve	   the	   limited	   cellular	   repopulation	   of	   electrospun	   heart	   valves	   described	   in	   chapter	   4	   and	  
further	  support	  a	  faster	  host	  tissue	  formation.	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  Sietä	  bisch,	  mir	  selbstvertraue	  gisch	  und	  (ab	  und	  zue)	  ab	  mine	  PhD	  
Witzli	  lachsch.	  Au	  es	  grosses	  Danke	  a	  dich	  Angi,	  di	  bescht	  Mitbewohnerin	  und	  Fründin	  wos	  git.	  
